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fusion. 
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s.c. subcutaneous 
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Preface 
The progress in the treatment of epilepsy made during recent years is largely 
due to the increased knowledge on the pharmacokinetics of antiepileptic 
drugs. However, the possibilities of this approach have not been fully utilized 
yet. The studies, described in this thesis, investigate how the pharmacokinetic 
and pharmacodynamic knowledge can be applied in clinical practice. This 
approach of antiepileptic drug treatment may be considered as a model for 
other chronic therapies. Due to the fact, that the antiepileptic drugs have been 
monitored in epileptic patients for many years already, a large amount of in-
dividual pharmacokinetic data is available. These data form the base of the 
present approach. 
The thesis is divided into three parts. 
— The first one describes some characteristics of-the epilepsies and their treat-
ment mainly based on literature data. The pharmacokinetics and other rel-
evant properties of the most important antiepileptic drugs are reviewed. 
— In the second part some gaps in our pharmacokinetic knowledge are filled 
up. Special attention is paid to valproic acid, both regarding its distribution, 
metabolism and the interactions with other drugs. It is tried to explain the 
observed discrepancy between the plasma concentrations and the therapeu-
tic effect by one of these processes. 
Attempts to improve pharmacotherapy by application of pharmacokinetic 
knowledge are foredoomed to failure when the dosage forms of the drugs 
applied do not show constant biological availability. Phenytoin is studied in 
this regard as it shows a high risk for bioavailability inequivalences and, due 
to the non-linear kinetics of the drug, small deviations of the effective dose 
may have large consequences in clinical practice. 
— In the third part a treatment protocol is developed, based on the gathered 
knowledge. Its effectiveness is judged by a clinical study, in which the treat-
ment of 135 patients is accompanied by a multidisciplinary team. The 
results of this study are used for further improvement of the handling of 
antiepileptic drugs in individual patients. 
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part one 
introduction 

Chapter 1 
Characteristics of the disease and its treatment 
1.1 History 
Epileptic seizures have been known since early history. Because of their 
bizarre and impressive manifestations they have been ascribed to supernatural 
causes like hostile spirits or punishment by higher beings. Nevertheless epilepsy 
or the 'falling sickness' has been known as a disease for more than 4000 years. 
In the Codex Hammurabi (2080 B.C.) laws are found regarding the marriage 
of epileptic persons and the validity of their court testimony. Various forms 
of epileptic attacks were already recognised by the early Greeks. Many colour-
ful reports of seizures date from this period, some demonstrating excellent 
observation qualities by their detailed descriptions. The term 'epilepsy' was 
first used by Hippocrates (460-357 B.C.) and Aristotle (384-322 B.C.): the 
word means that something falls upon a man, catches him. Other denomina-
tions from the same period are: 'black disease','sacred disease' and 'Herakles' 
disease', the latter because of the resemblance between the seizures and the 
burst of insanity in which Herakles is said to have killed his wife and children 
(Foésius 1588). 
Hippocrates may be considered to have described epilepsy as a clinical entity 
for the first time. Descriptions of many forms of seizures are found in his 
writings or in that of his colleagues and disciples. However, not all types are 
considered epileptic. They recognised what we now call premonitory signs 
(aura) of a threatening attack and even the influence of age and menstruation 
on the appearance of seizures. A wound to the left part of the brain was 
observed to cause convulsions beginning on the right side of the body. This is 
probably the first case report of a symptomatic partial epilepsy. 
One of the first definitions of epilepsy is given by Galen (131-201 A.D.): 'a 
convulsion of the whole body, together with interruption of the leading 
functions' (1ет .т 1945). 
The term 'aura', used to indicate the sensation of the patient immediately 
preceding the clinical attack, is accredited to Galens master Pelops. The Greek 
word meaning 'a breeze' is said to be introduced by one of his patients, trying 
to describe the feeling ascending from leg to head before loosing consciousness. 
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This observation corresponded well with the current theory at that time of a 
vapor, passing from the limbs into the head, as a cause of some epileptic attacks 
(Temkin 1945). 
The ideas of Hippocrates and contemporaries have dominated our knowledge 
of epilepsy for about two thousand years. Their scientific approach to the 
problem of epilepsy was resumed in the seventeenth and eighteenth centuries. 
The well-known description of an epileptic convulsion in the New Testament 
(Mark 9.17), portrays the disease as if it was the devil entered into a person. 
This belief was held for many centuries and does not appear to have been fully 
abandoned yet. Even recently, exorcism has been used for the treatment of 
epilepsy in a still disputed case (Vroon 1978). 
In his Opera Medica (1488), Guainerius recommends as first aid at the 
beginning of an epileptic attack to perform vigorous rubbings or painful 
ligatures on the extremities, in order to prevent the ascent of vapours. It was 
generally thought in that time that the aura indicated the cause and the location 
of the pathological process. It was Paracelsus (1493-1541) who denied these 
Galenical doctrines and in his disputes with Erastus the aura was described as 
the onset of the attack itself rather than its cause for the first time. Charles le 
Pois (1563-1636) was probably the first who stated that all epilepsies are of 
brain origin (Penfield and Jasper 1954). 
Although the form of attack known now as 'petit mal' or 'absence seizure' 
was described by the early Greeks already, it was only recognised as epileptic 
by eighteenth century physicians. The terms 'petit mal' and 'grand mal', which 
are still used frequently in a narrower sense in the characterisation of epileptic 
seizures, were first documented by Esquirol in 1838. This rough differentiation 
between most major and minor attacks, was followed by a more fundamental 
classification, which comes close to some in use today. In his 'Traité de 
l'Epilepsie' Delasiauve (1854) divided epilepsy in the following categories: 
1. essential or idiopathic epilepsy, 
2. symptomatic epilepsy, as a symptom of an appreciable cerebral lesion, 
3. 'sympathetic' epilepsy, due to extracerebral causes. 
His contemporary Herpin (1852) recognised already 39 'grades' of epilepsy. 
'Des accès incomplets d'épilepsie' of the same author, published posthumously 
in 1867, includes the following important statements: ' in the intervals 
between the major attacks there are attacks reduced to their initial symptoms 
or aborted at a period more or less advanced in their course. The onset of 
attacks vary infinitely in different subjects but they are always, or nearly 
always, identical in the same patient'. This means that the attacks of one 
patient vary only in intensity and number but not qualitatively. This statement 
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also illustrates that the view on epilepsy has always been based on the classical 
major seizure until that time. 
The first worker to pay primary attention to the minor attacks was Hughlings 
Jackson (1870). He gave a comprehensive description of the significance of 
focal seizures and the focal onset of generalised seizures. His work became the 
starting point for the study of the localisation of functions within the central 
nervous system. It is difficult to improve his definition of epilepsy as he states: 
'A convulsion is but a symptom, and implies only that there is an occasional, 
an excessive, and a disorderly discharge of nerve tissue ...'. Also the 
idiopathic, generalised seizures, of which grand mal and petit mal, in the 
narrower sense, are the best known examples, are included in his conception 
of focal epilepsy. The type of attack depends on the functional characteristics 
and the localisation of the focus within the brain, the strength of the initial 
discharge and the way it is spread to other brain areas. According to Jackson 
the basic physiological and biochemical disturbances underlying the initial 
excessive discharge are the same in all cases: seizures are just variations at a 
theme. 
The titles of some recent handbooks on epilepsy: 'les Epilepsies' (Gastaut 
1963), 'die Epilepsien' (Janz 1969) and 'the Epilepsies' (Sutherland et al. 1974) 
suggest that there is no single disease epilepsy, but according to the recent 
views rather a group of disorders of different etiology and manifestation. 
which probably involve similar pathophysiological mechanisms. 
The approach of Jackson was continued and further established by Penfield 
and Jasper (1954) and Lennox (1960) who performed outstanding systematic 
studies on the localisation of excessive discharges and the functional anatomy 
of the brain in correlation with clinical epileptic seizures. In their research the 
measurement of electrical cerebral discharges, enabled by the development of 
the electroencephalography (EEG), was of decisive value (Berger 1929). 
According to contemporary concepts the definition of epilepsy by Hughlings 
Jackson cited above is too broad. A more suited formulation reads: 
iEpilepsy is a symptom of excessive paroxysmal discharge of cerebral neurones, 
characterised clinically by discrete episodes, which tend to be recurrent, in 
which there is a disturbance of movement, sensation, behaviour, perception 
and/or consciousness' (modified after Sutherland et al. 1974). 
In ancient times numerous unsuccessful attempts to cure epilepsy have been 
undertaken. Either they were based on the belief that epilepsy had supernatural 
causes or they were largely pure quackery, which often was as horrible and 
mysterious as the epileptic attacks themselves. An excellent example is found 
in Guainerius(1488): 'Also when an epileptic falls, at once kill a dog, and give 
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the gall to the patient in any way that you can. If the one who first sees the 
attack urinates in his own shoe and then stirs it around as if to wash it, then 
gives the urine to the patient to drink, afterwards, the patient will be entirely 
delivered'. On the contrary the same author recommends 'to avoid fear, 
sadness, anger and all disturbances of soul' for interseizure management of 
epilepsy, and this seems to be a real therapeutic measure in some types of 
seizures even today. 
Hippocrates already advised trepanation in cases of head injuries and 
subsequent appearance of seizures. A rational surgical approach has been 
developed since Horsley(1886) and Krause (1912) (Penfield and Jasper 1954). 
Gui Patin ( 1602-1672) was convinced that there was no remedy against epilectic 
seizures and he labeled all 'medicaments' appraised as such as fictions and 
fables. 
Except certain recommendations regarding the way of living, medical treat-
ment of epilepsy only became possible since the introduction of potassium bro-
mide by Samuel Wilks (1859). The use of bromide continued for over 50 years 
before an alternative became available in the use of phénobarbital (Hauptmann 
1912). And a major improvement was made possible by the introduction of 
Phenytoin by Merritt and Putnam in 1938. Since that time, development of 
new antiepileptic drugs has led to the present pharmacotherapeutic armament 
against epilepsy. Pharmacotherapy is still the most important treatment 
modality for the disease. The most recent advance was the fortuitous discovery 
of the anticonvulsant properties of valproic acid (Meunier et al. 1963), 
chemically known since 1881 (Burton). 
Also surgical treatment has made much progress and is indicated in special 
types of focal epilepsy. More recently attention has been drawn to the 
psychological and social accompaniment of epileptic patients. In some 
instances, these can replace other forms of treatment. Biofeedback procedures 
have been tried experimentally and may lead to a new way of treatment 
(Sterman et al. 1974). For the present, however, antiepileptic drug treatment 
is the only possibility in the vast majority of cases. 
1.2 Classification of epilepsy 
Because of the multiform appearance of epilepsy, classification is necessary. 
Since Delasiauve (1854) many attempts have been made to develop a 
classification that orders all types in a logical way and is simple enough to be 
practically applied. Unfortunately, almost all authors in the field of epilepsy 
use their own classification, often a slight modification of an existing scheme, 
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but sometimes a rather new proposal. Epilepsies can be classified on several 
criteria: 
The clinical manifestations of the seizure are perhaps the best accessible 
symptoms. In most classifications, this symptom is often related with EEG 
criteria, preferentially the EEG manifestations of the attack itself. Interictal 
EEG phenomena differ substantially and may be taken as another approach. 
EEG recordings are not only performed to register the pattern and shape of 
electric discharges but also to obtain information on the anatomical localisation 
of the abnormal electric activity in the cerebrum and the degree of spreading. 
Classification on etiology involves the problem of a rather large group of 
epilepsies for which no simple cause can be indicated. As several types occur 
independently of the age of the patient, the same problem is encountered in 
classification on age of onset of epileptic seizures. 
Grouping of epileptic seizures according to their frequency e.g. isolated, 
repeated and prolonged seizures (status epilepticus) has little practical value 
as it can be used retrospectively only. The same holds to a certain extent for 
classification on the basis of the therapeutic response. 
Most classifications combine several of the criteria mentioned. Penfield and 
Jasper (1954) mainly used EEG patterns and localisation. Janz (1969) divides 
epilepsies primarily according to major and minor clinical seizures, the latter 
being ordered to age of onset subsequently. Most classifications, however, 
distinguish between generalised and partial seizures. This can be seen as char-
acterisation of localisation; each group is divided further according to clinical 
and/or electroencephalographical features. 
In order to create some uniformity in the chaos of divergent classifications 
the International League against Epilepsy has proposed an international 
classification (Gastaut 1969), which is now widely accepted. However, many 
names for seizure types, that are fully or partially identical, are still used by 
force of habit. The international classification is not followed universally. 
Sutherland and others (1974) consider it too elaborate for convenient clinical 
application, while its main division cannot be used as a guide in pharmaco-
therapy (Millichap 1972). One of the major problems of this classification is 
that it distinguishes only seizure types. Physicians are confronted not with 
single seizures but with a patient and his individual type of epilepsy, 
characterised by one but often more types of seizures and by accompanying 
problems. The best way to characterise his epilepsy would be to describe all 
criteria mentioned before, using the international classification to denominate 
the clinical seizures (Masland 1969). However, such a multidimensional 
classification would be complex and confusing. Fortunately, not all criteria 
mentioned are independent. Moreover, as one of the major aims of a classifi-
23 
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Table 1.1 Comparison of several classifications of epilepsies and epileptic seizures 
(epilepsy with) 
1. simple partial seizures 
2. benign rolandic seizures 
3 psychomotor seizures 
4. simple partial seizures 
secondarily generalised 
5 psychomotor seizures, 
secondanly generalised 
6. infantile spasms 
7 Lennox syndrome 
8 progressive familial 
myoclonus 
GASTAUT(1969) 
PARTIAL SEIZURES 
- with elementary 
symptomatology 
- with complex 
symptomatology 
- secondarily 
generalising 
GENERALISED SEIZURES 
atonic/akinetic 
seizures 
JANZ(1969) 
EPILEPSY WITH MINOR SEIZURES 
NOT RELATED TO AGE 
(neo)cortical seizures 
psychomotor seizures 
(neo)cortical seizures and 
diffuse/sleep grand mal 
psychomotor seizures and 
sleep/diffuse grand mal 
EPILEPSY WITH MINOR SEIZURES 
RELATED TO ACE 
propulsive petit mal 
myoclonic-astatic 
petit mal 
VAN HEYCOP TEN HAM (1974/76) 
PARTIAL EPILEPSY 
Jackson epilepsy 
mid-temporal epilepsy 
psychomotor epilepsy 
secondarily generalised 
seizures 
SECONDARY GENERALISED 
(ENCEPHALOPATHIC) EPILEPSY 
West syndrome 
Lennox-Gastaut syndrome 
SUTHERLAND ET AL. (1974) 
SYMPTOMATIC EPILEPSY 
focal-cortical seizures 
focal-cortical symptoms 
preceding major seizures 
infantile spasms 
familial myoclonic 
epilepsy 
9 myoclonic epilepsy 
IO petit maJ absences 
11 petit mal absences and 
tomc-clomc seizures 
12 atypical absences 
13 photosensitive epilepsy 
14 pnmanly generalised 
(tonic-)clonic seizures 
15 tonic seizures 
16 unilateral seizures 
17 neonatal convulsions 
18 febnle convulsions 
bilateral massive 
epileptic myoclonus 
absences typical 
-complex 
- atypical 
tomc-clomc seizures 
clonic seizures 
tonic seizures 
UNILATERAL SEIZURES 
impulsive petit ma) 
pyknoleptic petit mal 
pyknoleptic petit mal and 
'Aufwach' grand mal 
non-pyknoleptic petit mal 
(photogeneous/TV epilepsy) 
EPILEPSY WITH MAJOR SEIZURES 
'Aufwach' grand mal 
abortive grand mal 
hemi grand mal 
(occasional seizures) 
PRIMARILY GENERALISED 
EPILEPSY 
myoclonic epilepsy 
absences 
photosensible epilepsy 
Ionic-clonic seizures 
febrile convulsions 
IDIOPATHIC EPILEPSY 
minor seizures 
- myoclonic seizures 
- absences 
• myoclomc-akinetic 
seizures 
- reflex epilepsy 
ma/or seizures 
benign febrile 
convulsions 
The first column shows the authors classification and the terms used in the present work. A more detailed classification is considered 
not to have other therapeutic consequences. 
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cation is to offer directives for treatment and to enable judgement of prognosis, 
only those types of epilepsy which are different in this respect have to be 
distinguished. In our present state of knowledge, at most 18 types of epilepsy 
should be classified for that purpose. In table 1.1, these types are given with 
their place in four classification systems which are still used today and that are 
based on different criteria. 
The classification of the International League (Gastaut 1969), which describes 
seizures according to localisation of cerebral discharges and further to clinical 
and electroencephalographical features, is used by several authors with only 
slight adaptations (Schmidt and Wilder 1968, Eadie and Tyrer 1974, Grant 
1976, Wilder and Ramsay 1976, Jeavons 1977b). Van Heycop ten Ham (1974) 
uses the same system to classify types of epilepsy to a large extent but he 
groups a number of syndromes, of which the infantile spasms and the Lennox 
syndrome are the best known examples, under a separate heading: secondary 
generalised or multifocal epilepsy. Masland (1969) already had entitled the 
same group, encephalopathic epilepsies. Patients with epilepsies belonging to 
this group almost always have severe diffuse organic brain diseases of various 
origin. The EEG is strongly disturbed. Besides major seizures they show a wide 
spectrum of frequent seizures of the atonic, akinetic and myoclonic type that 
are distinguished only with great difficulty. Most patients are mentally retarded 
and their seizures are extremely difficult to control. These characteristics justify 
the classification as a separate group. 
As mentioned before age is an important criterion in the classification of 
Janz (1969) which is followed by most epileptologists in the German language 
(Dreyer 1969, Matthes and Schmutterer 1971). Its clinical application is rather 
simple because epilepsies are divided into only 8 main groups. Within this 
system, each type represents a large group of possible varieties but only minor 
subdivisions are indicated with respect to choice of therapy and estimation of 
prognosis. Janz rejects, as artificial, the subdivision of the 'complex' partial 
seizures by the international classification into those with cognitive, affective, 
psychosensory, and psychomotor symptomatology. His main objection is that 
the symptoms cannot be described in that way. Moreover, symptoms may 
change during the same attack. 
For the choice of antiepileptic treatment, van Heycop ten Ham (1974) does 
not need any subdivision of partial epilepsies as all are treated the same way. 
Most authors however do distinguish between psychomotor and other partial 
seizures and implicate the concomitant appearance of generalised seizures for 
this purpose. Division of epilepsies as to etiology results in a classification with 
great similarities to that of van Heycop ten Ham (Sutherland et al. 1974). Idio-
pathic epilepsies, i.e. without known etiology, correspond largely to the primar-
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ily generalised ones while symptomatic epilepsies mostly result in partial seizures 
if not due to diffuse encephalopathies. 
To exclude possible mistakes a brief characterisation of the 18 types of epi-
lepsy (table 1.1) is given here: 
1. epilepsy with simple partial seizures: 
twiching and/or sensations which remain localised or move along limbs 
(Jacksonian march), or a tonic turn of a part of the body to one side - no 
loss of consciousness - seizures at irregular intervals. 
2. benign rolandic seizures: 
some, predominantly clonic, attacks from the age of 4 — a sharp focus in 
the premotor cortex — most complete recovery during puberty. 
3. epilepsy with psychomotor seizures: 
extremely varied symptoms, from only an aura to complex motor or func-
tional and vegetative disturbances — gradual onset and termination — con-
sciousness usually changed — originating from temporal lobe. 
4. epilepsy with simple partial seizures, secondarily generalised = type I + 
secondary generalisation to a tonic-clonic seizure with loss of conscious-
ness — this occurs in about 50 per cent of all cases. 
5. epilepsy with psychomotor seizures, secondarily generalised = type 3 + 
secondary generalisation — this occurs in about 50 per cent of all cases. 
6. infantile spasms: 
'Blitz-Nick-Salaam Krämpfe', abrupt flexor spasms of arms and upper part 
of the body and nodding of the head — usually beginning in the first year 
of life, up to 3 years — EEG shows hypsarhythmia — mental retardation is 
usual. 
7. Lennox syndrome: 
frequent myoclonic jerks with fall, drop attacks and absences, also tonic-
clonic seizures — onset between 1 and 4 years of age — develops sponta-
neously or from type 6 — chaotic EEG — mental retardation is usual. 
8. progressive familial myoclonus: 
progressive degenerative condition with myoclonic, akinetic and tonic-
clonic seizures accompanied by extrapyramidal and cerebellar symptoms. 
9. myoclonic epilepsy 
in adolescents: 
short bilateral jerks of muscles especially of arms and shoulders — conscious-
ness is maintained. 
in children: 
generalised myoclonic jerks — onset around 3 years of age — no mental re-
tardation. 
10. epilepsy with petit mal absences: 
daily short lapses of consciousness with abrupt onset and end — staring 
look and either minor or no movements — characteristic EEG: symmetri-
cal spike-and-wave complexes at a frequency of 3/sec — onset between 4 
and 11 years of age. 
11. epilepsy with petit mal absences and tonic-clonic seizures = type 10+ tonic-
clonic seizures — this occurs in about 40 per cent of all cases. 
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12. epilepsy with atypical absences: 
brief impairment of consciousness only — less frequent than petit mal ab-
sences - in many cases accompanied by tonic-clonic seizures — EEG less 
regular, spike-and-wave complexes at frequencies, deviating from 3/sec. 
13. photosensitive epilepsy: 
absences similar to petit mal epilepsy and tonic-clonic seizures provoked 
by flickering light or TV. 
14. epilepsy with primarily generalised tonic-clonic seizures: 
no aura — loss of consciousness, short tonic spasm, clonic jerking of the 
whole body, gradually fading away and ending in a comatose phase — often 
drowsiness or sleep afterwards. 
15. epilepsy with tonic seizures: 
tonic spasms, usually flexor of upper limbs and extensor of lower Umbs 
— consciousness retained — not in infants. 
16. epilepsy with unilateral seizures: 
tonic, clonic or tonic-clonic convulsions predominantly on one side, may 
shift to the other side — EEG discharges restricted to contralateral 
hemisphere. 
17. neonatal convulsions: 
collection of various clinical patterns of different etiology - during the 
first weeks after birth - usually with generalised jerking or focal, tonic 
fits. 
18. febrile convulsions: 
tonic-clonic seizures only during episodes of fever in children up to 10 
years, onset usually under 3 years — interval EEG is normal. 
The last two types of convulsions are not found in several classifications. 
They are not always considered to belong to epilepsy. 
Like most biological phenomena, epilepsies or epileptic seizures cannot be 
fully ordered in a systematic way. Each classification therefore contains a group 
of unclassifiable epilepsies. These groups are not comparable among various 
classifications. In daily practice a considerable number of epilepsies will remain 
unclassified moreover because of lack of consistent data. 
1.3 Choice of antiepileptic drugs 
The ideal antiepileptic drug should specifically act on the supposed common 
mechanism in the origin of all epileptic seizures. However, a substance active 
against all seizure types has not been found. The first drugs with antiepileptic 
activity, bromide and phénobarbital, have a rather unspecific dampening action 
on many cerebral functions. These drugs appear to be mainly effective in the 
treatment of primarily generalised seizures. The introduction of phenytoin 
(Merritt and Putnam 1938)enabled the treatment of partial epilepsies. The first 
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really selective anticonvulsants belong to the group of the oxazolidinediones 
of which trimethadione was introduced in 1938. This group of drugs is almost 
exclusively active in petit mal absences and related types of minor, primarily 
generalised, seizures. 
The whole variety of antiepileptic drugs available today is used in almost 
every possible combination in the treatment of the whole scale of seizure 
types. Assessment of the most appropriate drug to treat a certain type of 
seizures is extremely difficult, especially because the outcome will vary inter-
individually. Few studies have been made involving reliable comparisons of 
single drugs in the treatment of a well-defined seizure type. Most information 
is based on comparison of treatment results in different patient groups or on 
the personal experiences and preferences of well-known epileptologists. In 
1971, Coatsworth reviewed 250 clinical studies in order to compare the 
efficacy of antiepileptic drugs. His study revealed that most trials had been 
carried out without sufficient seizure type selection. Moreover, the validity of 
the collected data is open to question. Porter and Решу (1978) repeated his 
effort. Their review included only reliable clinical trials with a clear description 
of seizure type and a well documented study design. Still in many seizure types 
not enough studies fulfilled these requirements to enable conclusions about 
the efficacy of the drugs tested. In those cases, the authors are confined to 
recommendations based on presumed highest efficacy and lowest toxicity. 
Their drugs of choice are given in table 1 .II, together with some previous data 
of other clinicians with a large experience in the field of epilepsy. Fortunately, 
not every seizure type needs a specific medication and the classification can 
be simplified for therapeutic purposes. Omitting those seizures whose extra­
cranial cause can be treated specifically, Janz (1969) needed 8 groups for the 
pharmacotherapeutic classification of epilepsy, Millichap (1969) only 6 and 
van Heycop ten Ham (1976) essentially 4. 
For almost all epilepsies with partial seizures the same drug treatment is 
recommended by many authors. The concomitant occurrence of generalised 
seizures does not influence the choice of drugs. Only Janz (1969) has a 
pronounced preference for phenytoin in the case of both psychomotor and 
generalised seizures. Between epilepsies with simple partial seizures in contrast 
to those with psychomotor seizures only the sequence of the two drugs of 
highest preference appears to differ. Generally phenytoin is recommended in 
the first instance, while carbamazepine is more frequently preferred in psycho­
motor seizures. The role of valproic acid in the treatment of partial seizures is 
promising but more studies are needed to assess its effectiveness compared to 
phenytoin and carbamazepine. Until recently, testing of valproic acid in partial 
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Table 1 .II Recommended drugs for the treatment of several types of epilepsy* 
* Drugs are indicated in order of preference. 
simple partial seizures 
(± sec generalisation) 
psychomotor seizures 
(±sec generalisation) 
infantile spasms 
Lennox syndrome 
myoclonic epilepsy 
petit mal and atypical 
absences 
petit mal absences and 
tomc-clomc seizures 
primarily generalised 
tomc-clomc seizures 
febnle convulsions 
status epilepticus 
JANZ 
(1969) 
pnmidone 
Phenytoin 
carbamazepine 
carbamazepine . , 
pnmidone 
nitrazepam 
ACTH 
phénobarbital 
ethosuximide 
ACTH 
tnmethadione 
pnmidone 
ethosuximide 
phénobarbital 
tnmethadione 
ethosuximide 
+ phénobarbital 
ethosuximide 
+ pnmidone 
pnmidone . 
phénobarbital ' 
Phenytoin 
paraldehyde 
phénobarbital 
Phenytoin 
diazepam 
EADIEANDTYRER 
(1974) 
Phenytoin 
phénobarbital 
carbamazepine 
sulthiame 
ACTH 
pyndoxine 
nitrazepam , . 
diazepam 
clonazepam 
ethosuximide 
tnmethadione 
ethosuximide 
+ Phenytoin 
ethosuximide 
+ phénobarbital 
Phenytoin 
phénobarbital 
carbamazepine 
phénobarbital 
diazepam 
amylobarbital 
Phenytoin 
I ) with secondary generalisation Phenytoin 
phenytom + carbamazepine 
Phenytoin + primidone 
2) recommended for 'Aufwach Grand Mai', 
m the case of 'Schlaf Grand Mai' phenytom 
pnmidone 
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V HEICOPTENHAM 
(1974/76) 
Phenytoin 
carbamazepine 
valproic acid 
nitrazepam 
diazepam 
clonazepam 
phenytom 
carbamazepine 
valproic acid 
valproic acid 
ethosuximide 
tnmethadione 
valproic acid 
ethosuximide 
+ phénobarbital 
ethosuximide 
+ carbamazepine 
valproic acid 
carbamazepine 
phénobarbital 
Phenytoin 
phénobarbital 
JEAVONS 
(1977) 
carbamazepine 
phenytom 
carbamazepine 
phenytom 
phenetunde 
ACTH 
nitrazepam 
clonazepam 
valproic acid 
nitrazepam 
clonazepam 
acetazolamide 
valproic acid 
clonazepam 
valproic acid 
ethosuximide 
valproic acid 
ethosuximide 
+ carbamazepine 
carbamazepine 
valproic acid 
phenytom 
valproic acid 
phénobarbital 
diazepam 
paraldehyde 
PORTER AND PENRY 
(1977) 
phenytom 
carbamazepme 
valproic acid 
carbamazepine 
phenytom 
valproic acid 
ACTH 
valproic acid 
ethosuximide 
valproic acid 
ethosuximide 
+ phenytom 
valproic acid 
phenytom . 
carbamazepme 
valproic acid 
3) for acquired types, 
ш the case of hereditary origin ethosuximiae 
tnmethadione 
4) not distinguished between primarily and secondarily generalised tomc-clonic 
seizures 
31 
epilepsies has been confined almost exclusively to cases refractory to the latter 
drugs (Finder et al. 1977). 
In infantile spasms, treatment with ACTH or corticosteroids during a limited 
period is recommended almost unanimously. The benzodiazepines, especially 
nitrazepam, are the most obvious alternative. The Lennox-syndrome is difficult 
to control and the strongly varying recommendations for drug treatment may 
reflect the helplessness of the physician concerned and the flicker of hope in 
cases of relief. Valproic acid, nitrazepam or clonazepam may be tried first ac-
cording to the most recent recommendations. 
Myoclonic seizures occur in a variety of epileptic disorders and classification 
problems predominate in this group. Even the pure 'myoclonic epilepsy' with 
bilateral myoclonic jerks as the main seizure type has not the same meaning 
for every author. Jeavons (1977a) even distinguishes two types depending on 
the age of occurrence. The average age of his 'myoclonic epilepsy of childhood' 
is three years while its adolescent counterpart begins around puberty. The latter 
type may benefit from nitrazepam, clonazepam or sometimes oral contracep-
tives. In a subsequent article the same author indicates valproic acid as drug of 
choice in myoclonic epilepsy in children (Jeavons et al. 1977). Eadie and Tyrer 
(1974) recommend to treat myoclonic and akinetic seizures with benzodiaze-
pines when acquired but to use anti-petit mal drugs when of hereditary origin. 
Although valproic acid may be preferred because of fewer side effects, a con-
trolled comparison between this drug and clonazepam in myoclonic epilepsies 
would be of great value. Only Lance and Anthony (1975) reported 2 cases of 
familial myoclonus epilepsy, which improved when clonazepam was replaced 
by valproic acid. 
For the treatment of petit mal absences, more or less specific drugs are 
available and the views in this respect are very similar. The group of oxalolidine-
diones of which trimethadione was the first and most known representative, 
has been largely replaced by the succinimides, especially ethosuximide. In 
recent years, valproic acid has proved to be equally effective. Combined petit 
mal absences and tonic-clonic seizures are treated with a combination of two 
drugs each effective against one type of seizures. As valproic acid acts against 
both types this drug maybe sufficient on its own (vanHeycop ten Ham 1976, 
Porter and Penry 1978). Which drug should be used in combination with etho-
suximide appears to depend on personal preferences. Almost any possible 
combination is used. As ethosuximide is supposed to provoke or to worsen 
tonic-clonic seizures, many authors recommend the addition of a drug against 
these seizures in the treatment of pure petit mal absences. However, there is 
no scientific proof for the negative effect of ethosuximide on tonic-clonic 
seizures. 
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In many instances it is difficult to distinguish between primarily generalised 
and secondarily generalising tonic-clonic seizures. Therefore this ambiguity 
sometimes troubles the recommended therapy. For instance, the recommen-
dation of Porter and Penry (1978) is based on all generalised tonic-clonic 
seizures. One of the most characteristic properties of phenytoin is thought to 
be the prevention of spreading of localised discharges, which explains its high 
effectiveness in partial seizures. On closer investigation, most phenytoin 
responsive tonic-clonic seizures appear to be secondary to a partial defect. 
Janz (1969) divides the major seizures according to the time of the day into 
'Schlaf-', 'Aufwach-' or 'diffuses Grand Mai'. According to his experience the 
'sleep'-seizures, that are frequently observed in patients with psychomotor 
seizures, are best treated with phenytoin or primidone but not with phéno-
barbital. On the contrary, the 'awakening' seizures, which predominantly occur 
in patients with seizures belonging to the petit mal quintet (minor primarily 
generalised seizures), respond most favourably to phénobarbital or primidone. 
In the remaining diffuse variant, the three drugs are almost equally effective. 
During recent years, phénobarbital has lost its predominant position even in 
the treatment of primarily generalised tonic-clonic seizures. Valproic acid seems 
to be a good substitute in most cases. The use of carbamazepine in this type 
of epilepsy is also promising, although most information is based on the treat-
ment of tonic-clonic seizures, that have not been further specified. Phenytoin 
would not be a drug of choice in the primarily generalised form as it may 
provoke absences (van Heycop ten Ham 1976). 
Febrile convulsions are not always found in classifications of epilepsy. 
Because they may be recurrent and can be treated with antiepileptic drugs they 
are included here. Prevention of high fever by antipyretics or antibiotics in 
threatening illness is perhaps the best remedy. In cases with a high risk of re-
currence chronic prevention with phénobarbital or valproic acid may be rec-
ommended. 
In dealing with epilepsy, status epilepticus will inevitably be encountered. 
Seizures succeed each other with such a frequency that the patient does not 
regain normal function in between. With the possible exception of partial status 
and absence status, this situation must be urgently terminated as longer 
duration considerably worsens the prognosis. The treatment of status epilepti-
cus requires deliberate, massive application of an antiepileptic drug. Paraldehyde 
still seems to be one of the most effective and safe ways of treatment (New 
Zeal. Med. J. 1974, Jeavons 1977b). Because of its unpleasant physical prop-
erties its use is rather limited. The benzodiazepines are much more popular. 
Diazepam and more recently clonazepam are usually administered intravenous-
ly for this purpose. The intravenous application of phenytoin has some prac-
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tical limitations but may be equally effective. Choice of drug will depend on 
the history of the patient i.e. his medication, and personal experience of the 
physician. 
Two types of epilepsy have not been included in this survey because they 
usually do not require treatment. 
In photosensitive epilepsy seizures can be prevented by taking some precau-
tions especially in watching television. If drug treatment is necessary valproic 
acid is recommended (Jeavons and Harding 1970, Jeavons 1977b). Benign 
rolandic seizures may be treated with carbamazepine but the usually limited 
number of seizures during the whole course of the disease necessitates treat-
ment in only a few cases (van Heycop ten Ham 1976, Jeavons 1977b). Neonatal 
seizures are generally treated with phénobarbital, probably because there is 
still little experience with the other antiepileptic drugs in neonates (Grant 
1976, Jeavons 1977b). 
The treatment of unilateral or tonic seizures is usually not distinguished from 
that of the primarily generalised tonic-clonic seizures. Only Wilder and Ramsay 
(1976) recommend dextroamphetamine or methylphenydate in a special type 
of tonic seizures. These drugs however are not recognised as antiepileptic drugs 
any more and no further attention will be paid to their possible application. 
According to Millichap (1972) phenytoin is particularly effective against tonic 
seizure patterns, having little or no effect on clonic elements. 
1.4 Prognosis in epilepsy 
Many disciplines dealing with epilepsy have been concerned with prognosis, 
both from the social point of view as well as from the point of therapeutic 
possibilities. Here, prognosis can be interpreted in several ways: it may repre-
sent the natural course of the disease in untreated patients. In many instances 
a good prognosis means that the disease is easily controlled by therapeutic 
measures, especially drug treatment. It may also be considered in terms of risk 
of recurrence of seizures after a defined period of complete control by anti-
epileptic drugs and consecutive withdrawal of therapy. A fourth meaning of 
prognosis deals with the social handicap, with which the epilepsy burdens a 
patient. Some literature data will be reviewed here in which these four types 
will be included. 
Prognosis in epilepsy appears to depend on a large number of factors of 
which seizure type is an important one. Many proposed factors are highly cor-
related to certain seizure types: for instance age of onset, mental retardation, 
the occurrence of status epilepticus, a detectable organic etiology, abnormalities 
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in neurologic examination and the familial occurrence of epilepsy (Strobos 
1959). For the natural course of the disease - if not of extracranial etiology -
the seizure type and the age of onset are the most predominant prognostic 
factors (Janz 1969, Rodin 1972). Age is not only related to seizure type; in par-
tial epilepsies for instance it is clearly related to the most probable cause of the 
disease (Sutherland et al. 1974). For judgement of the chances of therapeutic 
control, the frequency of seizures and their duration before onset of therapy 
are also important (Strobos 1959)Rodm 1972). Discontinuation of antiepilep-
tic drug treatment offers special problems and it will be discussed later in more 
detail (chapter 9). In this case the recurrence of seizures appears to be influen-
ced also by the age at discontinuation of treatment and the normalisation of 
the EEG pattern (Holowach et al. 1972,011er Daurella and Marquez 1972). In 
all instances however the type of epilepsy appears to be a predominant factor 
in prognosis. An estimation of its influence can be obtained from table 1 .HI. 
For some types of epilepsy, Janz (1969) gives detailed estimations of the 
spontaneous course for each year after onset. He clearly distinguishes between 
cases with only minor seizures and those in which major seizures join from 
the beginning or appear as later complications. The overall cure rate appears 
to be only small for many types. 
The improvement that can be expected by drug treatment may be derived 
from the figures of Strobos (1959) and Rodin (1972). The first author arranged 
a large group of patients according to the degree of control of seizures and to 
the type of epilepsy. His classification was based on EEG criteria and will not 
fully correspond with the one used here. Table l.III shows his numbers for 
complete control for at least 1 or 2 years, depending on original seizure 
frequency. Rodin (1972) reviewed a large number of studies on this topic and 
gave average values for several degrees of seizure control found in clinical trials 
and less controlled 'case reports' respectively. Study design appeared to influ-
ence the outcome considerably. Especially the duration of follow-up is crucial. 
The same holds for the consequences of discontinuation of treatment. For 
instance, for the petit mal absences, which are generally believed to be the 
most benign type of epilepsy, Oiler Daurella and Marquez (1972) have found 
a recurrence of seizures in up to 80 per cent of cases when the follow-up period 
is extended over 20 years. In this study antiepileptic drugs were only withdrawn 
after 10 years of freedom from seizures. Their findings are comparable to data 
of Janz (1969), who observed freedom from seizures in 20 per cent of his 
patients, 20 years after onset of the petit mal absences. Most authors however 
are more optimistic. Remission rates after at least 4 years of freedom from 
seizures and consecutive reduction of treatment are given by Holowach et al. 
(1972) (table 1 .III). The percentages indicated are obtained in a period of 5-12 
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(epilepsy with) 
simple partial 
seizures 
(secondarily 
generalising) 
psychomotor 
seizures 
(secondarily 
generalising) 
infantile spasms 
Lennox 
syndrome 
petit mal 
absences 
(+ tonic-clonic 
seizures) 
NATURAL COURSE 
more propitous than 
psychomotor seizures 
50% + ton.clon.seizures 
20 years after onset: 
10% cured 
50% + ton.clon.seizures 
10 years after onset: 
10% cured 
40% + ton.clon.seizures 
20% died 
5 years after onset: 
30% cured 
30% + ton.clon.seizures 
10 years after onset: 
15% cured 
45% + ton.clon.seizures 
5% died 
50% + ton.clon. 
seizures 
at the age of 20: 
50% cured 
at the age of 30: 
75% cured 
SEIZURE CONTROL 
BY DRUG 
TREATMENT 
100%/lyr 50%/2yr 
51% 
26% 
19% 
..(-58)%* 
17(-39)% 
38(-57)% 
RECURRENCE 
AFTER DRUG 
WITHDRAWAL 
53% 
25% 
12% 
23% 
23% 
33% 
48% 
29% 
43% 
5% 
NEED FOR 1 
INSTITUTION-
ALISATION 
3% 1 
4% 
9% 
50% 
1 
1% 
7% 
atypical absences 
prim, generalised 
ton clon.seizures 
unilateral 
seizures 
febnle 
convulsions 
1 
83% + ton.clon .seizures 
33% single convulsion 
50% 2-5 convulsions 
15% chronic epilepsy 
JANZ 
(1969) 
at the age of 10 
90% cured 
10% chronic 
epilepsy 
SUTHERLAND 
et al. 
(1974) 
17% 
STROBOS 
(1959) 
30(-55)% 
RODIN 
(1972) 
8% 
12% 
HOLOWACH 
et al. 
(1972) 
29% 
44% 
OLLER-
DAURELLA 
(1977) 
22% 
JANZ 
(1972) 
Table 1 III Prognosis of several types of epilepsy 
Percentages refer to the number of patients who show the indicated result The course of the disease without treatment is 
indicated as natural course 
The second segment gives figures for complete control of seizures for more than one year and over 50% reduction of seiz-
ures, maintained for 2 years of treatment (*numbers within parentheses are results from case reports) 
Recurrence rates are indicated for cases of complete withdrawal of antiepileptic drugs after freedom from seizures for at least 
4 and 5 years respectively 
The last column gives the number of patients from a large outpatient population who had to be temporarily or permanently 
institutionalised 
years after complete drug withdrawal. They may be compared to the data of 
Oiler Daurella and Marquez (1972) who withdrew medication after 5 years of 
complete seizure control. The average follow-up period in his study was 10 
years after the time of control of seizures. This data must be interpreted with 
care with respect to overall prognosis, as in certain seizure types very few cases 
fulfil the condition of several years of freedom from seizures. 
An interesting aspect of social prognosis is considered by Janz (1972): how 
severely a person is handicapped by his type of epilepsy and related problems 
may be derived from the percentage of patients that needs temporary or per-
manent institutionalisation in a specialised epilepsy clinic (table 1 .III). Psycho-
motor seizures in combination with generalised major seizures appear to take 
an exclusive position in this respect, especially because of psychiatric compli-
cations. Stevens and Portland (1966) however doubt the special relationship 
between psychomotor epilepsy and psychiatric problems. The similar age 
distribution of psychosis and this type of epilepsy may be responsible for the 
relatively high coincidence. Epilepsy with psychomotor seizures, the most 
common type of epilepsy as it accounts for about one third of all cases, involves 
still more problems as it appears to react poorly on antiepileptic drug therapy. 
In recent years growing attention has been paid to less dramatic social conse-
quences of epilepsy. For instance, impairment of school or work achievement 
and behavioural disturbances appear to depend to some extent on seizure type 
(Kriz 1978,Zollner-Breusch 1978). 
The natural course of benign rolandic seizures is already enclosed in its name. 
During puberty generally complete recovery is observed (Lehrman and Kivity 
1975). Pure photosensitive epilepsy is also benign in most cases and seldom 
needs drug treatment. However, photosensitivity may also occur in other types 
of epilepsy. 
The progressive familial myoclonus on the other hand is a disease entity with 
a bad prognosis. Seizures are accompanied by dementia and cerebellar and 
extrapyramidal symptoms, all signs of adegenerative process (Sutherland et al. 
1974). On the prognosis of myoclonic epilepsy and neonatal convulsions rela-
tively little information is available. Myoclonic epilepsy without detectable 
brain damage would have a reasonably good prognosis. According to Janz 
(1969) seizure frequency may remain constant for years with sporadic occur-
rence of a tonic-clonic seizure. 
Neonatal convulsions are often signs of gross underlying neurological damage. 
Survival in these cases is not frequent. Babies who survive, expecially those 
who were affected by only one series of convulsions, have a good chance to 
remain free from seizures (Sutherland et al. 1974). 
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1.5 Conclusion 
From the collected data it may be concluded that classification of epilepsy 
gives some leads for therapeutic or prognostic aims. The 18 types of epilepsy 
distinguished here have their own characteristics in this respect. Based on the 
present knowledge a more detailed classification does not appear to allow 
more specific choice of antiepileptic drug treatment or a more reliable prog-
nosis. The question why different patients with the same type of epilepsy are 
best treated with different drugs, remains to be clarified. When solutions for 
this type of problems have been found, a more detailed classification is 
plausible. 
Prognosis in individual cases remains extremely difficult.The figures presented 
do not allow reliable predictions in almost any seizure type. For that reason, 
all efforts should be made in trying to control epileptic seizures unless treat-
ment becomes worse than the disease itself. Reduction or discontinuation of 
treatment should be taken into account after several years of control of seizures 
provided no serious risk factors are present. 
Reviewing recommendations on first choice treatment of the various types 
of epilepsy, the limited number of useful drugs is striking. According to the 
presented data, the vast majority of epilepsies can be well treated with carba-
mazepine, phenytoin and valproic acid. This is even more pronounced when 
the relative frequencies of the different types are taken into account. For that 
reason most attention will be paid to these three drugs in the present work. At 
the second stage the benzodiazepines (clonazepam, diazepam and nitrazepam), 
ethosuximide, phénobarbital and ACTH are recommended. Phénobarbital is 
loosing its predominant position but is still used in over 65 per cent of 
patients nowadays (Guelen and Johannessen 1977). It is thereby still the mos' 
frequently used antiepileptic drug. Consequently also some aspects of this drug 
will get special attention. 
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Chapter 2 
Characteristics of the antiepileptic drugs 
2.1 Chemical classification 
Since the introduction of phénobarbital a considerable number of drugs with 
antiepileptic activity has been developed. They can be divided into 9 groups 
according to chemical structure. Within each group the pharmacological prop-
erties of the different substances vary mainly quantitatively. The most im-
portant compounds of each group are given in table 2.1. Some structural 
formulas are shown in figure 2.1. 
Table 2.1 Chemical classification of antiepileptic drugs * 
YEAR OF 
INTRODUCTION 
1912 
1938 
1946 
1951 
1951 
1954 
1961 
1964 
1967 
FIRST COMPOUND 
phénobarbital 
Phenytoin 
trimethadione 
phensuximide 
phenacemide 
acetazolamide 
diazepam 
carbarn azepine 
valproic acid 
GROUP 
barbiturates 
hydantoines 
oxazolidine-
diones 
succinimides 
phenyl-
ace tylurea's 
sulphonamides 
MOST IMPORT ΛΝΤ 
COMPOUNDS 
phénobarbital 
primidone 
Phenytoin 
trimethadione 
ethosuximide 
pheneturide 
acetazolamide 
sulthiame 
benzodiazepines diazepam 
dibenzazepines 
branched fatty 
acids 
nitrazepam 
clonazepam 
carbamazepine 
valproic acid 
* For each group the most important compounds and the year of introduction of the 
first representative are given. 
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Figure 2.1 
Structural formulas of the most important antiepileptic drugs. 
2.2 Anticonvulsant spectra in animal models 
All compounds marketed as antiepileptic drug appear to protect mice from 
seizures evoked by maximal electroshock and/or subcutaneous pentetrazole 
(Millichap 1969, Krall et al. 1978). In the last ten years a large number of 
experimental models of epilepsy have been applied in the testing of known and 
potential antiepileptic drugs. The techniques used involve cerebral or systemic 
application of chemical agents or electrical current in intact animals, local 
lesions of cerebral cortex, the sensory precipitation of convulsions in suscepti­
ble species or strains, abrupt withdrawal of certain compounds, and experiments 
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with parts of organs or tissue cultures even at the subcellular level. The pre-
dictive value of these models with respect to the efficacy in certain human 
types of epilepsy is rather limited. As the pathophysiology of the epilepsies 
still remains unclear an identical animal model can only be found by accident. 
YetMillichap (1969) found some correlations between laboratory results and 
clinical efficacy of the antiepileptic drugs available at that moment. All drugs 
which control generalised tonic(-clonic) seizures are effective against the maxi-
mal electroshock seizures in mice and rats. Drugs which control partial or 
generalised clonic seizures in patients protect mice from clonic experimental 
seizures whether they are induced by pentetrazole or, for instance, by cortical 
application of penicillin. Most drugs effective against petit mal absences are 
active against pentetrazole seizures but it is not a specific characteristic as 
acetazolamide does not obey the rule. Infantile myoclonic seizures would only 
be controlled by drugs with an exceptionally high potency against pentetrazole 
seizures. 
Woodbury (1972) reviewed the results with a larger number of experimental 
models and he attached predictive value to several of these models. Since that 
time carbamazepine and valproic acid have been introduced. Both have a 
broad spectrum of antiepileptic activity in man. In table 2.II, their activities 
in what are probably the most valuable animal models, are compared with 
other important drugs (Swinyard 1964, Millichap 1969, Woodbury 1972, 
Koella et al. 1976). The degree of effectiveness is judged from ED^Q values in 
comparison with other tests and with toxic dosages. The value of the tests in 
the prediction of antiepileptic activity in man as indicated by Woodbury (1972) 
appears not to be restricted by the data available until now. 
Predictive value for effectiveness in generalised tonic-clonic seizures may be 
attributed to the tonic extensor component of the maximal electroshock test 
in mice (MES), post-tetanic potentiation in spinal cord of cats and prevention 
of seizure discharge spread in tests with local lesions of the cerebral cortex. In 
the latter tests, drugs effective against primarily generalised tonic-clonic seizures 
probably also prevent the focal discharge. Experimental models that predict 
drugs effective in petit mal absences are the pentetrazole test in mice (s.c), the 
photomyoclonus in the Papio papio monkey and the CC^-withdrawal seizures 
in rats. Acetazolamide, also used as a diuretic, has been considered as the drug 
of first choice in this type of epilepsy for several years but it is ineffective in the 
pentetrazole test (Millichap 1969). Perhaps, the carbonic anhydrase inhibitors 
are not effective in this test because of their alternative mechanism of action. 
Ethosuximide is very effective in this test but, on the contrary, it is ineffective 
in the maximal electroshock test (Millichap 1969). Unfortunately, these drugs 
have not been tested extensively in other models. 
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Table 2.II Efficacy of antiepileptic drugs in experimental models of epilepsy 
MODEL 
maximal electroshock test in mice 
(tonic extensor component) 
pentetrazole test in mice (s.c.) 
(clonic convulsions) 
photomyoclonus in Papio papio monkey 
CCU-withdrawal seizures in rats 
6 Hz electroshock test in mice 
post-tetanic potentiation in the 
spinal cord of the cat 
focus in cerebral cortex (caused by 
freezing, alumina gel, penicillin) 
in rat/cat/monkey/rabbit 
- focal discharges 
- spreading of discharges 
hippocampal after-discharges in cats 
2 
a. 
** 
** 
.3 
a. 
.S 
о 
с 
ν 
.с 
CL 
2 с 
с ~ 
*** highly effective 
** effective 
* moderately effective 
- not effective 
High efficacy corresponds to a low EDJQ in the prévention of seizures or abnormal 
electrical discharges. 
Models with some specificity for partial epilepsies have been developed during 
recent years. There is still little agreement on definitively predictive tests. 
However, for psychomotor seizures the following models are potentially useful: 
low frequency electroshock test (6 Hz EST) in mice and the hippocampal after-
discharges, induced by electrical stimulation. Experience with focal lesions in 
the temporal lobe is also promising (Woodbury 1972, Koella et al. 1976). 
Cobalt or alumina lesions in cerebral cortex are thought to resemble simple 
partial seizures. 
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For effectiveness against myoclonic seizures an exceptionally high potency 
against pentetrazole seizures would be required. As valproic acid, to which 
activity against myoclonic seizures is attributed, does not show such outstanding 
results in this test, the high anti-pentetrazole activity maybe better considered 
as a common characteristic of the benzodiazepines, which were the most 
effective drugs in myoclonies at the moment of this statement (Millichap 1969). 
Following the correlations between experimental models and clinical efficacy 
given above, animal experiments lead to the following classification of anti-
epileptic drugs: 
effective against: 
generalised tonic-clonic seizures: phénobarbital, phenytoin 
(less pronounced: valproic acid, primidone, carbamazepine). 
petit mal absences: trimethadione, valproic acid, phénobarbital 
(less pronounced: ethosuximide, benzodiazepines), 
psychomotor seizures: phenytoin, carbamazepine 
(less pronounced: valproic acid), 
simple partial seizures: carbamazepine, phénobarbital, primidone, 
myoclonic epilepsy: benzodiazepines 
With the exception of phénobarbital in some seizure types this classification 
reasonably corresponds to that given in the previous chapter, which was based 
on clinical efficacy studies. Apparently phénobarbital has such a non-specific 
depressive effect on the central nervous system that all models are influenced. 
Valproic acid and carbamazepine, the representatives of new chemical classes 
of antiepileptic drugs, appear to fit well in the scheme for predictive values of 
experimental epilepsy models designed before they became available. This adds 
some value to the predictions. As long as the basic mechanisms of human epi-
lepsies and the experimental models have not been proven to be similar, the 
value of the models must be carefully examined for each new antiepileptic 
drug however. 
2.3 Mechanisms of action 
Many efforts have been made to elucidate the mechanisms involved in the 
origin of epileptic seizures and the mechanisms of action of drugs, used to 
prevent the clinical manifestations. These studies are hampered by the com-
plexity of the intact brain. It is hardly possible to change only one parameter 
in this system. Due to the existence of many compensatory regulations it is 
difficult to relate the ultimate effect with the primary stimulus. Experiments 
with small brain elements are oversimplifications of the complex brain activi-
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ties. Nevertheless this type of research has brought an enormous advance of 
knowledge on brain functions and dysfunctions. Several effects of antiepileptic 
drugs have been recognised that may be related to their pharmacotherapeutic 
activity. However, discrimination between primary and secondary effects is 
difficult. Some of the supposed mechanisms of action will be reviewed shortly. 
No effort will be made to relate them with each other. 
Electrophysiological mechanisms 
All antiepileptic drugs are able to decrease brain excitability. Most of the 
compounds stabilise the neuronal membrane, which is reflected by higher 
threshold values for neuronal discharge or reduced post-synaptic potentials 
(Woodbury 1969). Also the threshold for the generation of after-discharges, 
following short repetitive electrical stimulations, is elevated in several brain 
regions (Boyer 1966, Patry and Naquet 1971, Julien and Hollister 1975). 
Phenytoin appears to have unique properties, in that it inhibits post-tetanic 
potentiation. This phenomenon, facilitates synaptic transmission of high-
frequency neuronal discharges (Esplin 1957, Julien and Hollister 1975). This 
mechanism may be the basis of the main effect, attributed to the drug; Pheny-
toin appears to prevent spreading of epileptic discharges rather than to depress 
the epileptic focus itself (Louis et al. 1968). Moreover phenytoin has been 
shown to increase the firing rate of cerebellar Purkinje cells, which have an 
inhibitory output onto several cerebral nuclei (Cabreéis 1970, Julien 1972). 
Electrolyte balance 
The neuronal membrane potential is largely determined by the electrolyte 
composition of the intracellular and extracellular fluid. Active transport of 
sodium ions from the inside to the external fluid and of potassium ions in the 
opposite direction by the so called 'sodium pump', is one of the most important 
mechanisms to restore the resting membrane potential after depolarisation. 
Many antiepileptic drugs appear to lower the intracellular sodium concentration 
(Pincus et al. 1970). The resulting hyperpolarisation stabilises the neuronal 
membrane. Conflicting results have been obtained in studies on the influence 
of antiepileptic drugs on the sodium pump (Woodbury 1969, Formby 1970, 
Escueta and Appel 1972, Ayala 1977). Selective permeability changes of 
neuronal or glia cell membranes have also been found, especially for potassium 
ions (Prichard 1972, Woodbury 1978). Some anticonvulsants are likely to 
cause an extracellular acidosis which influences ion transport and membrane 
polarisation. This effect is not limited to the carbonic anhydrase inhibitors 
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but is also brought about by, for instance, the oxazolidinediones (Butler et al. 
1966). 
In recent years growing attention has been paid to the role of calcium ions 
in the release of neurotransmitters. Several antiepileptic drugs appear to inhibit 
calcium influx into the presynaptic terminals (Escueta 1977, Kmjevic 1977). 
Synaptic transmitters 
Antiepileptic drugs have been shown to influence cerebral concentrations of 
some transmitter substances or their breakdown products. Interpretation of 
such data is difficult. Both increased and decreased synaptic transmission may 
be accompanied by an increase of the transmitter content of brain tissue. Due 
to the existence of large, inactive pools of transmitters, the significance of the 
observed changes may be low. In animals showing epileptic discharges, the 
lowered seizure frequency could account for altered transmitter turnover. 
Reports on changes in the cholinergic system are scarce and conflicting (Frey 
1969, Woodbury 1969, Costa and Greengard 1975). Reynolds et al. (1975) 
found higher concentrations of 5-hydroxy-indoleacetic acid and homovanillic 
acid, the breakdown products of 5-hydroxy-tryptamine (serotonine) and 
dopamine respectively, in cerebrospinal fluid of patients treated with anti-
epileptic drugs. Also noradrenaline appears to play a role in the anticonvulsive 
effect (Meyer and Frey 1973). 
In recent years considerable attention has been paid to possible mechanisms, 
in which gamma-aminobutyric acid (GABA) plays an important role. This 
substance functions as an inhibitory transmitter in mammalian brain (Roberts 
et al. 1960, Curtis 1968, Meldrum 1975). GABA appears to be involved, at 
least partially, in the pharmacological activity of valproic acid (Godin et al. 
1969,Simleretal. 1973). 
In comparison with the other antiepileptic drugs valproic acid has a totally 
different chemical structure (see fig. 2.1). Corresponding pharmacological 
effects could probably throw light on common mechanisms of antiepileptic 
activity. Valproic acid resembles GABA in steric configuration. Ferrandes et 
al. (1974) suggest the drug may act as an antagonist for the enzyme GABA-
transaminase. Also other antiepileptic drugs appear to increase brain GABA 
concentrations (Saad 1970, Saad et al. 1972). On the mechanism of this effect 
conflicting observations have been made. In some studies, no influence on 
GABA-transaminase could be observed (Sawaya et al. 1975, Anlezark et al. 
1976). Moreover the significance of this enzyme for inactivation of GABA is 
doubted as it is found only intercellulary (Meldrum 1975). Probably re-uptake 
of GABA is more important in this respect (Harvey 1976). 
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GABA is formed from glutamic acid by glutamic acid decarboxylase. This 
enzyme is inhibited by some convulsants. Many antiepileptic drugs, with the 
exception of phenytoin and phénobarbital, appear to antagonise this inhibition 
(Hirano 1967, Löscher and Frey 1977). Lust et al. (1976) found an inverse 
relationship between GABA and cyclic GMP concentration in mouse cerebellum 
after administration of valproic acid. Reviewing the effects of several con-
vulsants and anticonvulsants the change in cerebellar cyclic GMP appeared to 
be a common effect, while only some of the compounds influenced GABA 
concentrations. 
Other mechanisms 
Interference with brain energy supply has been mentioned as a possible anti-
convulsant mechanism. Some antiepileptic drugs appear to reduce oxygen 
consumption probably by impairment of oxidative metabolism (Godin et al. 
1969, Spector 1972). On the other hand, glucose transport into brain appears 
to be facilitated (Nahorski 1972). Both increased energy consumption, needed 
for fast repolarisation of firing neurones, and reduced metabolic activity, 
leading to decreased neurotransmitter synthesis, may fit well into hypothetical 
anticonvulsant mechanisms. 
Phenytoin and phénobarbital lower blood and cerebrospinal folic acid con-
centrations. Folic acid and its derivatives are highly epileptogenic when they 
are brought into the central nervous system. Experimental evidence has been 
accumulated that folic acid is involved in several essential biochemical reactions 
in the brain (Hommes and Obbens 1972, Hommes et al. 1979). 
Taurine, an amino acid which occurs naturally in nervous tissue, has attracted 
much attention during the last few years (Huxtable and Barbeau 1976). It 
appeared to possess inhibitory properties (Curtis and Watkins 1965). Taurine 
has been applied successfully in experimental and human epilepsy (van Gelder 
1972, Mutani et al. 1975). As more information became available, the relative 
concentrations of several amino acids and related compounds, including 
glutamine, glutamic acid, GABA, taurine and aspartic acid appeared to be 
related to increased susceptibility for epileptic seizures. The complex inter-
relations are the subject of ongoing research (van Gelder 1978). 
Conclusions 
Without any doubt, several of the mentioned pharmacological effects of anti-
epileptic drugs are secondary to others. All observations are small pieces of a 
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huge puzzle. The Symposium on the Mechanisms of Action of Antiepileptic 
Drugs, held at St. Louis, Missouri, november 1977, brought together much of 
the present knowledge. A comprehensive synthesis of the various observations 
and hypotheses could not be found yet. One or a limited number of primary 
sites of action may be compatible with the results obtained. Although much 
has been learned about the central nervous system, functioning normally and 
abnormally, it is too early to reach an overall insight into the mechanisms 
which lead to epileptic seizures and their prevention. Without this knowledge, 
little will be clarified about the mechanisms of action of antiepileptic drugs. 
2.4 Quantitation of antiepileptic drugs in body fluids 
The first analyses of antiepileptic drugs in blood plasma used spectrophoto-
metric methods usually requiring several extraction steps (Butler 1952, Dill et 
al. 1956). The methods were based either on the U.V. absorption of the drugs 
themselves or these substances were transformed chemically to obtain higher 
specific extinctions or better specificity. In general, these methods are highly 
susceptible to interference by other compounds. A major advance in the 
specificity of analysis were the chromatographic techniques, Thin Layer Chro-
matography (TLC), Gas Liquid Chromatography (GLC) and High Pressure 
Liquid Chromatography (HPLC). Until recently GLC has been the most 
popular technique for the determination of antiepileptic drugs. Possibly, it 
will be replaced by HPLC. The latter method enables a more specific detection 
and decomposition problems are less frequently encountered. However, inter-
ference from other drugs or biogeneous substances is possible. Most methods 
have been checked for these interferences. In many chromatographic aSsay 
methods, it is possible to quantitate several drugs in one run, which is an 
advantage as polypharmacy in epilepsy is very common. Several excellent 
reviews on analysis methods for antiepileptic drugs have been published (Dijk-
huis 1975, Kellaway and Petersen 1976, Pippenger et al. 1978). 
Recent developments in immunological techniques permit the production 
of drug-specific antibodies. Immunological reactions may be combined with 
the measurement of radioactivity or enzyme activity. Due to high sensitivity 
and specificity of the resulting methods extraction and purification of samples 
is hardly necessary. Although radioimmunoassays for some antiepileptic drugs 
have been available for several years, immunological determination of these 
drugs first became popular after the development of the Enzyme Multiplied 
Immunoassay Technique (Rubenstein et al. 1972, Tichelaar et al. 1973). This 
method is based on the enzymatic activity of drug-labeled enzymes, which com-
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pete with the drug to be analysed, for binding with the specific antibody. The 
enzyme activity of the drug-enzyme complex is lost by binding to the antibody. 
The remaining enzyme activity is proportional to the amount of drug in the 
sample and may be measured photometrically in the mixture of sample and 
reagents directly. As the method is extremely rapid and requires no special 
provisions its share in the analysis of antiepileptic drugs is growing rapidly. 
Beside the required careful performance of these analyses related to the 
microscale work, specificity is the major theoretical disadvantage of the im-
munoassays. Compounds with related chemical structures and the metabolites 
of the drug itself, may interfere with the analyses. For instance (para-hydroxy-
phenyl)-phenyl-hydantoin (HPPH), the main metabolite of phenytoin, is bound 
by the antibody of the phenytoin assay to a considerable degree. Moreover, 
this degree of cross-reactivity may vary among different reagent batches (fig. 
2.2). Under normal circumstances the HPPH concentrations in patient plasma 
are low compared to those of phenytoin (Albert et al. 1974a, Jusko 1976). 
However, in cases of impaired renal function or in children higher values have 
been found (Bochner et al. 1973, Rane and Wilson 1976). In blood plasma 
almost all HPPH is present as glucuronide. In the EMIT-assay the glucuronide 
® 
r-EMIT phenytoin assay cross-reactivity for HPPH 
25 phenytoin equivalents 
mg/1 
20_ ,·· 10% cross-reactivity 
2Ö0mg/l HPPH 
FigUre 2
·
2
 JB> 
Specificity of ЕМІТ^ antiepileptic drug assay antibodies. The response for 
several concentrations of the metabolite (parahydroxy-phenyl)-phenyl-hydan-
toin (HPPH j in plasma in the phenytoin assay is indicated' the degree of cross-
reactivity appears to depend on the batch of reagents (EO2, FO¡, GO2). 
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crossreacts to a lower degree than the free compound. Wide experience with 
the EMIT - antiepileptic drag assays in comparison with chromatographic tech-
niques has proven the validity of the method in normal practice (Pippengeret 
al. 1975, Schmidt et al. 1976, Schobben and van der Kleijn 1977, Schottelius 
1978). 
Analyses in other body fluids than blood may be carried oui using the same 
techniques. Quantification in urine or cerebrospinal fluid is rarely indicated. 
Salivary concentrations may be useful. For most antiepileptic drugs these 
concentrations approximate the concentration of unbound drug in blood 
plasma (Blom and Cuelen 1977). Unce the individual ratio between salivary 
and plasma concentration has been established, saliva can be used for monito-
ring purposes. Especially when frequent sampling is necessary, this may be 
advantageous. 
Analysis of plasma and saliva samples, obtained simultaneously, may provide 
information on protein binding. This information may be clinically important 
as protein binding may be considerably influenced by concomitant drugs and 
intercurrent diseases. Plasma concentrations of unbound drug are thought to 
correlate better with therapeutic or toxic effects than total plasma concentra-
tions (Booker and Darcey 1973). 
Drug analyses are mainly performed in body fluids as these media are readily 
accessible and a representative sample can be obtained. Ideally the concentra-
tion of the drag at the site of action should be measured but these places are 
inaccessible for sampling. In a real steady state situation these concentrations 
will be proportional to the total amount of drag in the body. The plasma con-
centration is considered to reflect this amount. In steady state tissue concen-
trations will only rarely correlate better with the pharmacological effect. 
However, particular binding phenomena can only be quantitated this way. 
Tissues generally contain more interfering substances than the usual sample 
materials. Therefore extraction procedures are more elaborate. Brain concen-
trations of antiepileptic drugs have been determined, both in animal studies 
and in human material, obtained by surgery (Waddel and Butler 1957, Firemark 
et al. 1963, Sherwin et al. 1976, Harvey et al. 1977, Hulshof et al. 1977). 
Until now these studies have not led to new views as the results largely cor-
respond to those expected, when the physico-chemical properties of the drugs 
are taken into account. For acute administration the rate of penetration into 
different brain areas deserves special attention. In the search for the mechanism 
of action of the antiepileptic drugs, information on the presence or accumu-
lation of the drug in question or its metabolites in brain tissue is of great im-
portance. 
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2.5 Pharmacokinetics 
The anticonvulsant spectra of the antiepileptic drugs are important in the 
choice of therapy, while other properties will dominate their handling. In acute 
or short time treatment, factors such as rate of absorption and of distribution 
and initial side effects are important. Usually, treatment of epilepsy involves 
chronic suppression of seizures. In that case, the ultimate bioavailability, the 
dose/blood level ratio, the chronic toxicity and drug interactions overrule the 
former properties. Most of the characteristics mentioned, have been reviewed 
by others (Woodbury et al. 1972, Eadie and Туrer 1974, Morselli 1977,Richens 
1977, Dam 1978, Guelen and van der Kleijn 1978). Only those data which are 
pertinent to the present work, will be summarised here. 
Pharmacokinetic data presented here are based on the assumption of a steady 
state situation during chronic treatment. In general the rate of elimination of 
a drug dQ
e
i/dt is proportional to the concentration in the body: 
Ύ - *·° o) 
The proportion is represented by the total body clearance V. This relationship 
holds for all compartment models. The clearance often is a constant factor, 
but this is not necessarily the case as will be shown below. 
During chronic administration a drug usually accumulates in the body until 
a steady state situation is reached. Then the part of the dose, which reached 
the general circulation, compensates for the loss by elimination during each 
dosage interval: 
f.D = V.J c.dt = V .cü . At (2) 
о 
where: f = biological availability 
D= maintenance dose (mg) per dosage interval At (hours) 
c ^ = average plasma concentration over a dosage interval at steady 
state (mg/1) 
V = total clearance (1/hr) 
For most antiepileptic drugs the apparent biological half-life (tM) is large in 
comparison with the usual dosage interval. Consequently plasma concentrations 
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fluctuate over only a narrow range and the concentration at any time may be 
chosen to represent the average steady state concentration. With shorter half-
lives plasma concentrations will vary widely between dosages, depending on 
absorption and elimination rates. Although c^" is difficult to estimate in cli­
nical practice, a stable plasma concentration can be simulated by proper choice 
of fixed sampling times (fig. 2.5). The clearance value, derived from these plasma 
concentrations, is a fictive one and can be applied only to the chosen sample 
moment. 
For simplification purposes the biological availability is assumed to be com­
plete (f= 1.0). 
Rearranging equation (2) enables the calculation of the clearance directly 
from the steady state plasma concentration: 
D . D 
V = or V = (3) 
A t
· ^
 Δ 1
· ^
B W 
where: V' = relative clearance (1 .hr"1 .kg"1 ) 
BW = body weight 
Following this method Cuelen and van der Kleijn (1978) obtained clearance 
values from a large number of patients, whose plasma concentrations have been 
determined. Average values and a number of variables which influence the V' 
value are given in their study. 
In the case that the body may be regarded as a single compartment there is a 
simple direct relationship between the clearance and the elimination rate, 
which on tum is inversely proportional to the biological half-life: 
* ' = ke|.Vd· (4) 
where к ι is the reciprocal time constant for elimination, includingboth excre­
tion and metabolism, and \ß is the apparent volume of distribution in steady 
state, relative to the body weight (1/kg). 
Most frequently the parameters are related to the total plasma concentration. 
In that case, the volume of distribution may be simply defined as the total 
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amount of drug in the body, divided by the plasma concentration. As only 
the free fraction of the drug in blood is available for distribution into the 
tissues, differences in protein binding may influence the Vf value to a large 
extent. 
Clearance and distribution volumes are calculated on the assumption of total 
bioavailability of the drugs. In order to obtain the true total clearance, the 
obtained values are multiplied by the actual fraction of the dose (f), which 
reaches the general circulation. This fraction may be determined by comparison 
of intravenous and oral dosage. Comparison of the area under the plasma con­
centration/time curve after single doses is frequently used to measure 'f' (cf. 
fig. 3.6). In chronic dosage the area under the curve (AUC) during one dosage 
interval or the average steady state plasma concentrations are used for the 
same purpose. The chronic model is used predominantly for the determination 
of relative bioavailabilities of different oral dosage forms. 
Information on the absorption rate of drugs is often limited to the average 
time of peak plasma concentration. However, its significance also depends on 
the elimination rate, and in chronic dosage peak concentrations are reached 
earlier for drugs that accumulate. More reliable data are obtained when the 
pharmacokinetic model is extended to include an exponential absorption 
process. As the absorption rate of solutions is usually fast, dissolution of the 
drug overrules the total absorption process. This holds for solid dosage forms, 
suspensions and for drugs which precipitate after administration. In the phar­
macokinetic model absorption rate is characterised by the rate constant for 
absorption (к
а
ь 8) or the, inversily proportional, half-life for absorption ( ^ а ь 8 ) . 
In non-linear kinetics the clearance concept indicated above, may still be 
applied, but the clearance is no longer a constant. More complicated methods 
are necessary to calculate bioavailability. Phenytoin is eliminated by a non­
linear process: the clearance depends on the plasma concentration of the drug. 
The pharmacokinetic model will be described in the section on phenytoin. 
Interactions between antiepileptic drugs will receive brief mention in the 
following sections as more attention will be paid to this subject later (chapters 
5 and 10). 
2.6 Phénobarbital 
Pharmacokinetics and metabolism 
Phénobarbital is notorious for its long biological half-life, 53-140 hours in 
adults. Therefore it can be given once daily without risk of large variations 
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in total amount of drug in the body. The average clearance value is 5.3 ± 1.6 
ml.hr"1.kg"1 (Guelen and van der Kleijn 1978). In children higher values are 
to be expected, depending on their age (cf. chapter 5). Changes of both the 
elimination rate and the volume of distribution contribute to the differences of 
clearance. The half-lives of phénobarbital in infants and children vary between 
20 and 80 hours. The relative apparent volume of distribution may range 
between 0.5 and 1.5 1/kg up to ages of 2 years while older children show 
approximate adult values of 0.50-0.60 I/kg (Morselli 1977). It is unlikely that 
differences in protein binding are responsible for the total difference in distribu-
tion volume. Values in adults fluctuate around 50 per cent while in newborns 
about 40 per cent of the drug is bound to plasma protein. Relative amounts 
of body water and fat probably have a larger influence on the distribution 
volume. 
Clearance values may also be altered by concomitantly administered drugs. 
As phénobarbital is an enzyme inducer in itself, enhancement of elimination 
by other drugs seldom occurs except by alkalinisation of the urine. For 
example, phenytoin, valproic acid and carbamazepine appear to lower 
clearance values, probably by inhibition of, or competition for the hydroxyla-
ting enzymes in liver (Morselli 1975, Flachs et al. 1977, Schobben et al. 1977, 
Windorfer and Sauer 1977, Guelen and van der Kleijn 1978). 
About 50 per cent of administered phénobarbital is metabolised. The main 
metabolite is p-hydroxy-phenobarbital, which is excreted by the kidneys, 
about half as such and the rest as glucuronide. 20-35 per cent of phénobarbital 
is excreted unchanged in the urine. The pharmacological activity is predomi-
nantly attributed to the unchanged drug (Butler 1956). 
Routes of administration 
After oral dosage phénobarbital is almost completely absorbed, with a peak 
plasma concentration after 2-18 hours (Maynert 1972, Strandjord and Johan-
nessen 1977). Absorption is faster in infants and children (Morselli 1977). 
The drug may be administered intravenously or by intramuscular injection 
as a solution of its sodium salt. Absorption from intramuscular administration 
appears to be complete and relatively rapid: peak concentrations are reached 
within 1-4 hours (Morselli 1977, Strandjord and Johannessen 1977). Phénobar-
bital also appears to be completely absorbed from rectal suppositories: in one 
patient we found exactly the same steady state plasma concentration on oral 
and rectal administration. No information is available on the rate of rectal 
absorption. 
In mice and cats, phénobarbital has been shown to enter the central nervous 
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system only slowly (Butler 1950, Domek et al. 1960). This property throws 
doubts upon the use of phénobarbital in status epilepticus and the acute pre-
vention of febrile convulsions. When also in man penetration into the brain is 
the limiting step, the usefulness of phénobarbital in status epilepticus and in 
the acute prevention of febrile convulsions is questionable. Rectal administra-
tion to ensure fast absorption does not alter the case very much. 
Plasma concentration and effect 
Many authors mention a 'therapeutic plasma concentration range' for phéno-
barbital. Values vary from 15-25 mg/1 to 20-50 mg/1 (Eadie and Tyrer 1974, 
Kutt and Penry 1974, Richens 1976, Wilder and Ramsay 1976, Guelen et al. 
1977). All these values may have been derived from undocumented experience 
but are likely to be ultimately based on the classical study by Buchthal et al. 
(1968) in 11 patients with generalised tonic-clonic seizures. They observed 90 
per cent reduction in EEG paroxysms at phénobarbital plasma concentrations 
varying from 3-22 mg/1. Several patients had seizures at plasma concentrations 
of 2-4 mg/1 and no more at 10-30 mg/1 during an observation period of only 1 
month. As half of the patients had an average seizure frequency of once a 
month this follow-up period is rather short. Moreover phénobarbital concen-
trations were not at steady state during most observations. 
On the relation between plasma concentration and side effects, more data 
are available. Most side effects are related to the aspecifìc depression of the 
central nervous system. Initially drowsiness may occur, but tolerance to this 
effect develops quickly (Butler et al. 1954). Again, at higher plasma levels 
drowsiness, sedation and ataxia may occur. Buchthal and Svensmark (1959) 
already observed that drowsiness after intoxications with phénobarbital disap-
peared at plasma concentrations of 20-50 mg/1. Although clear consciousness 
is observed at plasma concentrations of 80 mg/I in some patients, mental 
slowness and ataxia have been reported at levels from 30 mg/1 (Plaa and Hine 
1960, Kutt and Penry 1974). Therefore, Buch thai and Lennox-Buchthal (1972) 
judged the therapeutic plasma concentrations to be between 10 and 25 mg/1. 
Schmidt and Janz (1977) tried to distinguish effective plasma concentrations 
according to the severity of the epilepsy. After several years of control of 
seizures, epilepsies may have become mild and therefore would require lower 
antiepileptic drug levels for control. Unfortunately most of their data on 
phénobarbital plasma concentrations were obtained from patients treated 
with primidone. Judging only the plasma concentration of derived phénobar-
bital would deny the antiepileptic effect of primidone itself, which is still 
open to discussion. The only patient in their study who became free from 
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seizures on phénobarbital alone did so at a plasma concentration of 35 mg/1 
compared to 3 mg/1 before control. Baruzzi et al. (1977) withdrew antiepilep-
tic medication fora limited period in some patients. The plasma concentration 
at which the seizure frequency was increased by more than 100 per cent was 
considered as 'critical'. After re-administration, seizure frequency returned to 
the normal level as soon as the critical level was reached. In three patients 
critical phénobarbital values appeared to be 6, 14 and 15 mg/1 respectively. In 
newborn children, effective plasma concentrations between 12 and 20 mg/1 
are indicated (Jailing 1975). Febrile convulsions appear to be prevented by 
phénobarbital levels above 15 mg/1 (Faer^ et al. 1972). Probably, this is the 
only study in which a therapeutic level of phénobarbital is documented in a 
sufficient number of patients. 
Children may tolerate high concentrations of phénobarbital without evidence 
of toxic effects but lowering concentrations from 45-50 mg/1 to 15-20 mg/1 
appeared to improve markedly psychomotor performance in 8 infants (Morselli 
1977). One case of respiratory depression in an acutely overdosed newborn 
child was observed at a plasma concentration of 22 mg/1 in our experience. 
There is no documented evidence that adults need higher phénobarbital con-
centrations than children. Yet the average phénobarbital plasma concentration 
in 3000 patients appeared to be 31.8 ± 4.5 mg/1 (Guelen et al. 1975). 
Also at concentrations appropriate for the control of seizures, mental perfor-
mance may not be optimal (Hutt et al. 1968) and deterioration at school is 
not uncommon. Sometimes, in children irritability and hyperactivity occurs, 
while in aged people confusion is observed. Perceptual motor behaviour 
appeared to be impaired at plasma concentrations below 20 mg/1 in volunteers 
during a 3-week treatment (Hutt et al. 1968). It is not sure that the same holds 
for chronic use as development of tolerance to the initial side effects is usual. 
Side effects like blood dyscrasia, osteomalacia, and coagulation disturbances 
are apparently not dose-related. They have been reported infrequently. The 
occurrence of severe hypersensitivity reactions is rare. 
Concluding, it may be stated that sufficient data on therapeutic concentra-
tions for phénobarbital are lacking. The lowest well documented effective 
concentration appears to be 6 mg/1 in one patient (Baruzzi et al. 1977). Severe 
dose-related side effects below 30 mg/1 are rare. Complementary data will be 
given in chapter 8. 
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2.7 Primidone 
Pharmacokinetics and metabolism 
From the pharmacological point of view, primidone is a complex substance 
as it is metabolised to phénobarbital and phenylethylmalonamide (ΡΕΜΑ), 
which are found in man in concentrations equal to or above those of primidone 
itself. In animal studies, ΡΕΜΑ has proven to possess anticonvulsant properties 
of its own and to potentiate the effects of phénobarbital (Gallagher et al. 1970, 
Gallagher and Baumel 1972). The anticonvulsant activity of primidone itself, 
is difficult to test as it is inevitably accompanied by its two active metabolites. 
After oral administration to man, peak primidone concentrations are found 
0.5-9 hours later (Gallagher and Baumel 1972). In man the drug has been used 
only sporadically by any other way of administration. For that reason, bio-
availability is unknown. Zavadil and Gallagher (1976) administered a single 
dose of primidone by intravenous injection, but did not compare their results 
with oral administration. In three patients without any anticonvulsant medi-
cation, they found half-lives between 14 and 16 hours. In 7 patients, treated 
with several antiepileptic drugs including primidone, values between 4.5 and 
11 hours were found. The relative volume of distribution appeared to vary 
between 0.5 and 1.0 1/kg. The drug is notbound to plasma proteins and there-
fore cerebrospinal fluid and saliva concentrations almost equal those in plasma 
(Schmidt and Kupferberg 1975, Blom and Cuelen 1977). 
ΡΕΜΑ is rapidly formed from primidone as it is already present 1-2 hours 
after the first primidone intake. Its half-life may vary between 30 and 50 
hours (Gallagher and Baumel 1972, Zavadil and Gallagher 1976). Therefore, 
ΡΕΜΑ will accumulate during chronic treatment up to plasma concentrations 
of the same order as those of primidone itself. Phénobarbital is only found 
after several days of primidone treatment. Despite its slow formation, phéno-
barbital concentrations are higher than those of primidone in steady state in 
most cases, due to its very long half-life. In combined treatment with other 
antiepileptic drugs about 40 per cent of the dose of primidone is excreted un-
changed in urine, about 30 per cent as ΡΕΜΑ and only a few per cent as 
phénobarbital (Zavadil and Gallagher 1976). 
Interactions 
The relative concentration of phénobarbital compared to that of primidone 
may be considerably changed by concomitant drugs. The susceptibility of 
primidone for drug interactions may be seen from data of Cuelen et al. (1975) 
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who found a relative clearance of 30.9 ±1.9 ml.hr .kg in 10 patients on primi-
done alone, while the value of 63.7 ± 37.8 ml.hr"1.kg was obtained in a large 
population with random comedication. According to Windorfer and Sauer 
(1977) nitrazepam causes a significant fall of primidone concentrations, while 
clonazepam exerts the opposite effect. This discrepancy has not been explained 
yet. Phenytoin and carbamazepine appear to lower primidone levels and to 
increase phénobarbital plasma concentrations by induction of primidone 
metabolism (Fincham et al. 1974, Reynolds 1975). Even primidone itself or 
the derived phénobarbital is likely to exert similar effects (Zavadil and Gal-
lagher 1976, Windorfer and Sauer 1977). This would result in an increasing 
phenobarbital/primidone plasma concentration ratio during a prolonged period 
after onset of primidone treatment. On primidone monotherapy, phenobarbi-
tal/primidone ratios between 1 and 2 are usual, in combination with other 
antiepileptic drugs values between 2 and 5 are most frequently found, and 
even higher in children (Fincham et al. 1974, Reynolds 1975). 
Plasma concentration and effect 
The only effects which can be definitively attributed to primidone itself, 
are early toxic symptoms such as pronounced sedation, nausea and diplopia 
that have been observed after a first dose of 500 mg (Gallagher and Baumel 
1972). Other side effects of primidone are very similar to those seen during 
phénobarbital treatment. Several authors doubt the intrinsic antiepileptic effect 
of primidone and therefore consider it merely as an alternative way of admin-
istration of phénobarbital (pro-drug). The synonym 'luminal-de-luxe' originates 
from these circles (van Hey cop ten Ham 1974). Others prefer primidone above 
phénobarbital, because it would be superior in certain seizure types ^ specially 
in psychomotor seizures (Janz 1969, Booker 1972, van Heycop ten Ham 1974, 
Sutherland et al. 1974, Wilder and Ramsay 1976). 
The effectiveness of primidone and/or ΡΕΜΑ can only be demonstrated in 
controlled studies where phénobarbital and primidone are used in a cross-over 
design and dosages are adapted to ensure identical phénobarbital plasma con-
centrations in both periods. Such a study by Olesen and Dam (1967) in 19 
patients did not reveal a significant difference between both treatnu^nts. 
However, in some case reports, primidone has appeared to be superior to 
phénobarbital alone, but it is uncertain whether primidone itself, ΡΕΜΑ or 
still unknown metabolites are responsible for these effects (Pippenger 1975, 
Rowan et al. 1975). 
As the effectiveness of primidone has not been proven, verdicts on the thera­
peutic plasma concentrations are very risky. In the literature, some data are 
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given, varying from 8-10 mg/1 to 7-15 mg/1 (Wilder and Ramsay 1976, Guelen 
et al. 1977). Booker (1972) found no improvement of seizure control by in-
creasing plasma concentrations over 10 mg/1, while major side effects are 
unusual below this level. Several authors do not measure primidone plasma 
concentrations at all but adjust doses on the basis of plasma concentrations of 
derived phénobarbital (Sutherland et al. 1974, Schmidt and Janz 1977). 
If primidone and ΡΕΜΑ would have a spectrum of antiepileptic activity iden­
tical to that of phénobarbital or no activity at all, there would be no indication 
for the use of primidone. However, animal studies suggest that both compounds 
have specific anticonvulsant properties (Gallagher et al. 1970, Baumel et al. 
1973). If this is true for human epilepsy, the appropriate applicability is still 
limited. When primidone is combined with one or more of the usual antiepilep-
tic drugs the phenobarbital/primidone plasma concentration ratio is almost 
always increased significantly. Consequently, the phenobaibital-effect over-
rules the specific effects of primidone or ΡΕΜΑ; ΡΕΜΑ levels appear to be 
closely correlated to primidone levels (Gallagher and Baumel 1972). If primi­
done is used it should be preferentially given as a single drug. Because of the 
pharmacologically complex situation with three possible active compounds 
whose ratios are highly susceptible to interactions, Windorfer et et. (1975) 
even advise against the use of primidone at all. 
2.8 Phenytoin 
Phenytoin is undoubtedly the most extensively studied antiepileptic drug. Its 
efficacy has been proven sufficiently (Lund 1974a, Reynolds et al. 1976, Porter 
and Penry 1978). Unfortunately, the drug has several properties which hamper 
its proper use. 
— The metabolism of phenytoin is saturable which causes a disproportionate 
rise of plasma concentrations when the dose is increased. Therefore the dif­
ference between therapeutic and toxic doses may be small. 
— Toxic plasma concentrations are very close to those attained at therapeutic 
doses or even overlap one another. 
— The clinical picture in overdosage and subtherapy may be difficult to dis­
tinguish as the well known side effects such as nystagmus and ataxia do not 
occur always, and seizure frequency may even increase at toxic plasma con­
centrations (Levy and Fenichel 1965, Lascelles et al. 1970, Grant 1976). 
— The saturable metabolism and also the high protein binding make phenytoin 
very susceptible to interactions with other drugs and to intercurrent diseases. 
— The poor solubility of phenytoin at pH values found in vivo, causes bioavail-
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ability problems. Phenytoin is considered a drug with high risk for product 
bioavailability inequivalence (Committee on drug product selection 1973). 
Pharmacokinetics and metabolism 
In man, phenytoin is largely metabolised to (para-hydroxy-phenyl)-phenyl-
hydantoin (HPPH), which is rapidly eliminated, almost exclusively as the glu-
curonide (Butler 1957). HPPH, which may accumulate in cases of renal impair­
ment, is practically devoid of anticonvulsant activity (Butler 1957, Letten et 
al. 1971). The conversion of phenytoin into HPPH appears to be saturable. 
This means that above a certain dose, or plasma concentration, only a fixed 
amount of the drug can be metabolised per unit of time (cf. metabolism of 
ethanol). Therefore the apparent half-life of phenytoin varies with plasma 
concentration. 
This has been demonstrated in single dose experiments and after termination 
of chronic or subchronic treatment (Arnold and Gerber 1970, Gerber and 
Wagner 1972, Atkinson and Shaw 1973, Garretson and Jusko 1975). 'Half-
life' values between 9 and 122 hours have been reported (Richens 1975). 
Houghton and Richens (1974) measured phenytoin half-lives during steady 
state by administration of a tracer dose. They reported a good correlation 
between half-life and steady state concentration both interindividually and in 
the same subject. A rough estimation of phenytoin 'half-life' for the average 
patient may be found as 1.5 χ plasma concentration (тф) + 10 hours. This 
relation also implies that the attainment of steady state after onset of treatment 
will take more time at higher dosages; in fact this had already been observed 
by Svensmark et al. (1960). Kutt et al. (1964) reported the disproportionate 
rise in steady state concentration at dose increments, for the first time. 
The characteristics of phenytoin kinetics mentioned here can be described 
by a capacity-limited elimination model using the Michaelis-Menten equation, 
derived from enzyme kinetics. At the same time, a small part of the drug will 
be eliminated by a first order process e.g. the renal excretion of the unchanged 
drug. Beside HPPH, some other metabolites have been discovered, but quanti­
tatively they play only a minor role (Borgä et al. 1972, Chang and Glazko 
1972). 
As pointed out before the clearance of phenytoin is not a constant parameter, 
but depends on the concentration of the drug. In the case of simultaneous 
capacity-limited and first order elimination the following equation is obtained 
(van Ginneken et al. 1974): 
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v=v1 (1- fo)+ fo-тіЧс m (6) 
where : Vj = the clearance constant at low plasma concentrations (apparently 
first order elimination) 
f0 = the fraction of the clearance, that proceeds via the capacity-
limited process, at low plasma concentrations 
k^ = apparent Michaelis-Menten constant, equal to the plasma con­
centration at which 50 per cent of the metabolising enzyme is 
occupied (mg/1) 
From data of Jusko et al. (1976) on single intravenous dose experiments in 
volunteers, can be derived that f is greater than 0.998. This means that the 
contribution of the first-order elimination pathway can be neglected and the 
kinetics of phenytoin can be easily described by elimination via a single meta-
bolic route (f = 1.0). 
Equation (6) then reduces to: 
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(mg/hr). In a steady state situation during chronic treatment the amount of 
drug eliminated during one dosage interval equals the amount of the mainten­
ance dose: 
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max 
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 k
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s s
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(8) 
Just like for clearance calculations the bioavailability is assumed to be com­
plete (f = 1.0). Deviations from this ideal situation will be reflected by the 
V
m a x
 value. In order to estimate the real maximum rate of metabolism, the 
obtained values will have to be multiplied by the bioavailability factor. Rear-
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ranging equation (8) then yields: 
D/At. k
m 
sT = — ^т- (9) 
V -DMt max ' 
In a number of studies the model described here has been shown to be useful 
for the description of the kinetics of phenytoin in man (Atkinson and Shaw 
1973, Garretson and Jusko 1975, Richens and Dunlop 1975, Martin et al. 
1977). The relation between dose and plasma concentration is now determined 
by two independent constants, instead of one clearance value. 
Several methods have been developed to calculate phenytoin dosages when 
adjustment is wanted. Richens and Dunlop (1975) made a nomogram for this 
purpose, based on an average к value. Martin et al. (1977) developed a 
nomogram, based on a joint estimation of k
m
 and V
m a x
 as close as possible 
to the population average from a single steady state plasma concentration. 
Ludden et al. (1976) developed a graphical method to determine individual 
k
m
 and V
m a x
 values from steady state plasma concentrations at two or more 
dosage levels. They linearised the exponential relation between dose and plasma 
concentration by plotting dose versus dose divided by plasma concentration: 
DMt Vmax 1 
. DMt (10) 
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m
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 or the desired dose can be simply read from such a graph. An 
even more simple graphical method hasbeen published by Mullen (1978). Both 
methods are shown in figure 2.3. When plasma concentrations at only two 
dosage levels are known, the latter method may be preferred because of its 
simplicity. When more data are available the 'Ludden-plot' is thought to give 
a better survey. A mathematical approach for dose corrections based on the 
same principle is given by Guelen and van der Kleijn (1977). 
No statistical data on k_ and V_1„v values and the factors that influence m max 
them are available. In literature values fork
m
 range from 1.5-25.3 mg/1 while 
relative V
m a x
 values vary between 0.20 and 0.68 mg.hr1 .kg"1 (Mawer et al. 
1974, Jusko et al. 1976,Martin étal. 1977,Guelen andvan derKleijn 1978). Addi-
tional data are presented in chapter 10. The apparent volume of distribution 
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has been calculated at 0.49-1.21 1/kg in adults (Atkinson and Shaw 1973, 
Mawer et al. 1974, Jusko et al. 1976). 
Phenytoin kinetics have been studied less frequently in children. Available 
data suggest that the same Michaelis-Menten model as used in adults is valid, 
however with a faster elimination (Garretson and Jusko 1975, Nolte and Briig-
mann 1975). Larger interindividual differences than in adults have been 
reported. Several factors, possibly responsible for this variation, have been 
put forward: lower к values than in adults, inefficient absorption or even 
partial absorption defects (Borofsky et al. 1973, Garretson and Jusko 1975, 
Morselli 1977). 
Apparent plasma half-lives ranging from 1.2-66 hours have been reported 
(Wilder et al. 1973, Curless et al. 1976). On the distribution volume almost 
no information is available. 
Interactions 
Rough indications of the clearance of phenytoin and the influence of age 
and concomitantly administered drugs can be obtained from the data of Cuelen 
and van der Kleijn (1978). They have analysed a great number of patient data 
on the assumption of linear kinetics. Their results point to an effect of age 
similar to that for phénobarbital. It would be worthwhile to know to what 
extent the к the V value, protein binding or the volume of distribution 
III ΙΙΙαΛ 
contribute to the overall effect. 
The same uncertainties apply to the drug interactions. Many authors have 
provided qualitative data on the rise or decrease of phenytoin steady state 
plasma concentrations when combined with other drugs (Buchthal and Svens­
mark 1971, Hansen et al. 1971, Vajda et al. 1971, Gram et al. 1977, Richens 
1977, Windorfer and Sauer 1977). Some combinations appear to give conflict­
ing results. For instance carbamazepine and phénobarbital appear to lower 
phenytoin plasma concentrations by enzyme induction (Kristensen et al. 
1969, Garretson and Dayton 1970, Hansen et al. 1971, Rizzo et al. 1972). 
However, when phénobarbital is given in high dosages phenytoin elimination 
appears to be impaired, probably by competition for the oxidative enzyme 
systems (Kutt 1972a, Wilson and Wilkinson 1973, Richens 1977). When such 
effects are averaged for a large group of patients receiving the drug combination 
under study, only small changes in average clearance will be found (Guelen 
and van der Kleijn 1978). Those values indicate in what direction plasma con-
centrations will change in most cases. 
In order to enable quantitative prediction of individual effects, individual 
data will have to be gathered taking into account the plasma concentration of 
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dose and steady state concentrations of phenytoin-
daily dose (mg) 
Vmax 32¿mg/day 
Km¿ 0 m g / l , 
mg /day 
-τ 1 1 г-—г2-
20 ¿0 60 15 ю 
daily dose ( l/day) 
Τ" 
5 0 5 
plasma cone ( mg/l ) 
plasma cone 
(patientMHç 20yrs.40kg) (-Ludden c4 al, Lancet 1976, 307 ) — ( -Mullen et al, Clin Pharmacol Therap.23(1978)228 ) 
Figure 2.3 
Example of the non-linear relationship of daily dose and steady state plasma concentration of Phenytoin. Two 
methods are shown to linearise the relation. For further explanation see text. 
the affecting drug. Possibly also, the concentration of the drug affected and 
the age of the patient may influence the resulting degree of interaction. An 
impression of results obtained by this way will be given in chapter 10. 
Protein binding 
Phenytoin appears to be about 90 per cent bound to plasma proteins (Lunde 
et al. 1970). This implies that disturbances of protein binding may cause a 
drastic change in free phenytoin concentrations. In uremic patients and in 
newborns, protein binding may be lowered to 75 per cent (Odar-Cederlöf and 
Borgâ 1974, Morselli 1977). Other drugs may displace phenytoin from its 
binding sites. Probably the interaction with valproic acid is exerted in this 
way (Patsalos and Lascelles 1977). 
The increased concentration of free drug may have several consequences. 
More drug is available for distribution resulting in higher tissue/plasma concen-
tration ratios. The same pharmacological effect may be observed at lower total 
plasma concentrations. At the same time, more drug is available for metabolism 
and direct excretion processes. Normally, this would lead to lowered total plasma 
concentrations. However, when the metabolising enzymes are largely saturated 
already, as may be the case at the usual phenytoin levels, impaired elimination 
may be the result (Woodbury and Swinyard 1972). Indeed, both increased 
and lowered phenytoin plasma concentrations have been observed after addi-
tion of valproic acid (Gram et al. 1977, Windorfer and Sauer 1977). 
Phenytoin also appears to be bound to tissue elements to a great extent. At 
equilibrium, brain concentrations are higher than total plasma concentration 
(Harvey et al. 1977). After intravenous injection of phenytoin to several 
animal species maximal brain concentrations are rapidly reached (Noach et al. 
1958,Firemarketal. 1963). 
Routes of administration 
Phenytoin is administered orally in the form of capsules, tablets and suspen-
sions, both of the free acid and the sodium salt. In the Netherlands, predomi-
nantly tablets of the sodium salt, and less frequently of the calcium salt, are 
used. Bioavailability of these dosage forms has hardly been studied. In view of 
the risk for bioavailability inequivalence of phenytoin preparations, chapter 6 
will be dedicated to the oral administration with special emphasis on the bio-
availability of the Dutch preparations. 
Due to the poor solubility of phenytoin at physiological pH, the drug precipi-
tates at the site of injection after intramuscular administration. Subsequent 
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absorption is extremely slow but appears to be nearly complete Kostenbauder 
et al. (1975) found that after 40 hours 20 per cent still had to be absorbed. 
Willenski and Lowden (1973) reported even slower disappearance from rabbit 
muscle. They observed large crystals of phenytoin and disrupted muscle fibres 
on histological examination of the injection site Short time substitution of 
intramuscular for oral administration without significant change in plasma 
concentration was thought possible by Wilder and Ramsay (1976) They gave 
1 5 times the normal dose by the intramuscular way for 1 week Due to the 
delayed absorption, oral administration was restored at half the old dose for 
the first week 
Rectal administration of phenytoin does not appear to be sensible After ad-
ministration of suppositories containing phenytoin sodium, no phenytoin was 
found in blood (Meijer and Kalff 1975) 
Plasma concentration and effect 
Both therapeutic and side effects have been correlated with plasma concen-
trations in a great number of studies. In 1959, Buchthal and Svensmark re-
ported that of 12 patients with generalised tomc-clonic seizures at phenytoin 
plasma concentrations below 10 mg/1, 11 became free from seizures after in-
creasing the dose, resultmg m plasma concentrations between 10 and 50 mg/1. 
In a group of outpatients the level of 10 mg/1 also appeared to be crucial A 
significant reduction of seizure frequency was observed in 79 per cent of the 
patients with concentrations above 10 mg/1, but only in 25 per cent of those 
below this level Side effects had not been reported at plasma concentrations 
below 14 mg/1, and serious ones had only been seen above 30 mg/1 
Dose-related side effects of phenytoin are quite characteristic in most pa-
tients, as is the order of appearance with increasing plasma concentrations 
Kutt et al. (1964) observed nystagmus at plasma concentrations of 15-31 
mg/1, while ataxia most frequently dominates the clinical picture between 27 
and 41 mg/1 According to their experience, plasma concentrations of 40-58 
mg/1 were accompanied by mental changes such as lethargy and confusion. 
They even found a good correlation between the degree of nystagmus and 
plasma concentration 
On the basis of experience up to that moment, Kutt (1972b) indicated the 
plasma concentration range between 10 and 20 mg/1 as a good initial goal for 
therapeutic effect These values have been cited since as the therapeutic range 
m many publications (Lascelles et al 1970, Eadie and Tyrer 1974, Richens 
1976). However, broader and narrower ranges have been reported 10-30 mg/1 
(Kutt and Penry 1974), 3-20 mg/1 (Deonna et al. 1975) and 12-15 mg/1 (van 
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der Kleijn et al. 1975). There are indications that children may benefit from 
lower plasma concentrations (Kutt and Penry 1974, Rane and Wilson 1976). 
However, results from a number of clinical studies suggest that the reverse 
may be true: also in adults, plasma concentrations below 10 mg/1 may be 
sufficient. In table 2.III these results have been summarised. If dose increments 
brought improved or total seizure control both pre-existing plasma concentra-
tions (subtherapeutic) and therapeutic concentrations have been given. 
Suppression of seizures by antiepileptic drugs is not an all or nothing process. 
In a beautifully designed prospective study, Lund (1974a) increased Phenytoin 
dosages in 32 patients with generalised tonic-clonic convulsions with intervals 
of one year. The first increment reduced the average seizure frequency from 
5.8 to 4.1 convulsions a year while the plasma concentration increased from 
6.1 ±2.9 mg/1 to 11.7 ± 3.3 mg/1. The second increment, that produced plasma 
concentrations of 15.0 ± 2.5 mg/1, again caused a marked decrease of seizure 
frequency to an average of 1.6 per year. In some individual cases Lund and 
Alván (1975) could demonstrate a reversed linear correlation between plasma 
concentration and seizure frequency. 
As mentioned already, the relation between phenytoin plasma concentration 
and the occurrence of side effects has been established more clearly. Serious 
acute side effects at plasma concentrations below 30 mg/1 have not been re-
ported frequently. However,in chronic use, psychomotor slowing and intellec-
tual deterioration may be disturbing consequences of the therapy. Such effects 
have been demonstrated in patients with average plasma concentrations of 15 
mg/1 (Reynolds and Travers 1974). In children, phenytoin toxicity is often 
overlooked as early symptoms are often absent or strongly deviating from the 
toxicity pattern in adults (Patel and Chrichton 1968). Buchanan and Allen 
(1971) found ataxia at plasma concentrations with an average of only 11.9 
mg/1, while nystagmus was first observed at higher levels. Toxic effects of 
phenytoin may also appear in an unexpected manner: Lascelles et al. (1970) 
found a significant decrease in seizure frequency when they lowered dosages 
in 18 patients with phenytoin concentrations over 25 mg/1. This paradoxical 
effect has also been observed by others (see table 2.HI). 
Reviewing the data available, a wide range of plasma concentrations may be 
therapeutic. Even a concentration of 1 mg/1 has appeared to be associated with 
control of seizures in one patient (Feldman and Pippenger 1976), while the 
desired effect had not been reached until the plasma concentration was in-
creased from 18 to 21 mg/1 in another case (Schmidt and Janz 1977). Plasma 
concentrations between 5 and 25mg/lappear to be effective in over 80 per cent 
of the patients. Individual therapeutic or toxic concentrations seem to be 
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Table 2.Ill Phenytoin plasma concentrations and therapeutic or side effects 
Literature sources 
Buchthal and Svensmark 1959 
Kuttetal 1964 
шкагі 1969 
bscelles et al. 1970 
Lund et al 1971 
Borofsky et al. 1972* 
Borofsky et al. 1973· 
Lund 1973 
Reynolds and Travers 1974 
Troupin and Ojemann 1975 
Nolte et al. 1975* 
Windorfer et al. 1975· 
Richens 1976 
Reynolds et al. 1976 
Feldman and Pippenger 1976 
Schmidt and Janz 1977 
plasma concentrations (mg/I) 
subtherapeutic 
10 
2-11 
recurr." 5 
recurr. 5 
recun. 2-3 (2) 
0 
10 
0 
4 8-18 
therapeutic 
10-50(12)° 
12-34(40) 
5(18) 
6-20(10) 
9-13(2) 
10(10) 
10-20(6) 
10-20(7) 
09-15(11) 
3-23(15) 
side effects 
slight/serious 
14 30 
15 27 
20 29 
1440 
24-60 
24 40 
20 
16 
increased 
convulsions 
19(1) 
25(18) 
40-53 (6) 
32-36 (2) 
recurrence of seizures when the plasma concentration was lowered below this level. 
the numbers between parentheses indicate the number of patients involved. 
* Data of Borofsky et al. (1972), Borofsky et al. (1973), Notte et al. (1975) and Windorfer 
et al. (1975) refer to children. 
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reasonably constant (Jensen and Grynderup 1966, Borofsky et al. 1973) 
The large intenndividual differences have been attributed to several causes 
differences in protein binding may influence the amount of drug available at 
the site of action (Booker and Darcey 1973) Comedicationmay also influence 
the distribution of phenytoin (Hulshof et al 1977, Patsalos and Lascelles 
1977) For instance, folic acid and phenytoin have rather complex interactions 
at several levels (Reynolds 1973,Hommes et al 1979) Long-term antiepileptic 
drug therapy may lead to folic acid deficiency (Houben et al 1971) When folic 
acid is given, phenytoin plasma concentrations appear to decrease (Olesen and 
Jensen 1970,Baylisetal 1971) In rats, ten Berge (1975) has found a significant 
increase in phenytoin brain/plasma concentration ratios after injection of folic 
acid In this respect we made a remarkable observation in some epileptic patients 
with very low folic acid plasma concentrations They were treated with 15 mg 
folic acid daily while other medication was kept constant The decrease in pheny-
toin plasma concentration was accompanied by an increase in saliva concen-
tration of the drug (fig 2 4). This observation suggests that folic acid may 
decrease phenytoin protein binding Such a mechanism deserves further at-
tention as it may explain the observed interactions. 
For additive effects or potentiation of antiepileptic drugs at the receptor 
level as far as the therapeutic effect is considered there is little scientific proof 
(Richens 1977) However, forthe combination of phénobarbital and phenytoin, 
Sherwin et al (1976) have found additive effects in the prevention of electro-
shock convulsions in rats,both regardingbrain concentration and dose/response 
relationships 
Intenndividual differences in drug sensitivity and severity of the epilepsy to 
be treated may probably account for many of the differences in effective 
plasma concentrations (Lund 1974a, Schmidt and Janz 1977) 
Other side effects 
Many side effects have been attributed to antiepileptic drug treatment Be-
cause of the widespread polypharmacy it is often difficult to ascribe the ob-
served effects to a single drug However, in many instances most phenomena 
may be caused by phenytoin Besides the dose-related effects already men-
tioned, idiosyncratic reactions and long-term compbcations have been observed, 
whose relation with plasma concentration is unclear or has not been proven 
Well-known phenytoin side effects include gingival hyperplasia, especially in 
children, hypocalcaemia, folic acid deficiency, sometimes resulting in megalo-
blastic anaemia, and coagulation defects, especially in newborns of mothers 
treated with the drug (Gardner et al 1962, Reynolds 1973, Richens 1976, 
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Figure 2.4 
Influence offolic acid supple non in a case of deficiency The patient was treated 
with 375 mg Phenytoin, 800 mg carbamazepine, ¡50 mg phénobarbital 
and 900 mg sodium valproate daily throughout the period shown Initially 
Phenytoin plasma concentrations were significantly decreased, while saliva 
concentrations were increased Carbamazepine plasma concentrations were also 
lowered. The changes appear to be transient 
Dam 1978) Phenytoin is also highly suspected of being teratogenic, which is 
manifested most frequently in cleft palate and related abnormalities (Eadie 
and Tyrer 1974, Janz 1975, Richens 1976). 
2.9 Carbamazepine 
During the last ten years, experience with carbamazepine has increased sub-
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stantially, both in its clinical applications and in experimental work. Regarding 
its chemical structure, the substance is quite different from the classical anti-
epileptic drugs (fig. 2.1). Consequently, the drug has several exclusive proper-
ties. Being a lipophilic neutral compound, the distribution of the drug in the 
body is fast and rather uniform, once it has been absorbed. Due to the poor 
water solubility the latter process is crucial. Carbamazepine is a strong enzyme 
inducer, thereby influencing its own metabolism to a substantial degree. 
Pharmacokinetics and metabolism 
In human volunteers the gastrointestinal absorption of carbamazepine appears 
to be slow. Peak plasma concentrations have been observed after 3-18 hours. 
During chronic treatment absorption seems to be faster. However, the plasma 
concentration course is often so irregular that no absorption peak is observed 
(Morselli et al. 1975a). As the drug has not been given to man by the intra-
venous route the bioavailability is not known. Comparison of the usual tablets 
with a suspension in sorbitol revealed no bioavailability differences in chronic 
use (Morselli et al. 1975a). In single-dose experiments, Levy et al. (1975) found 
a higher plasma curve area using a solution of the drug in propyleneglycol. 
Similar results were obtained by Gerard et al. (1972). Due to the poor solubility 
of the drug, tablet formulation differences are likely to influence rate and 
amount of absoiption. Differences between two tablet preparations have been 
found by Pynnönen et al. (1978) in single dose studies. In chronically treated 
patients, Kauko and Tammisto (1974) found significant differences between 
the same preparations, but in the reverse order. After oral intake of labeled 
carbamazepine, about 20 per cent was found in the faeces (Faigle and Feldmann 
1975). At least a part of this amount had been resorbed initially. Bioavailability 
of the usual tablet is estimated at 70-90 per cent (Pippenger et al. 1978). 
As only carbamazepine tablets are available, the drug has rarely been given 
to patients by other than the oral route. Meijer and Kalff (1975) reported a 
case where the drug was given by suppository for 16 days without significant 
change in the steady state plasma concentration. 
In single dose experiments half-lives between 19 and 55 hours have been 
found, after chronic medication these values are reduced to 14-27 hours 
(Eichelbaum et al. 1975, Faigle et al. 1976, Pitlick et al. 1976). Half-life re-
duction of 10-50 per cent in 3 weeks of treatment has been observed (average 
35 per cent). Pitlick et al. (1976) developed a model for prediction of plasma 
concentrations based on an exponential increase of the elimination time con-
stant. Its applicability has not yet been proven in clinical practice. Half-life 
72 
of induction in three volunteers ranged between 2.4 and 6.4 days, indicating 
that maximal induction is reached after 10-30 days (Levy and Lane 1978). The 
results of a similar study by Gérardin et al. (1976) do not correspond with this 
model: after an increase of the elimination rate during the first few days of 
treatment a plateau was reached, but after two weeks a renewed acceleration 
of elimination could be observed. In 13 volunteers, Pynnönen et al. (1977) 
did not find significant reduction of half-life after 4 weeks of treatment with 
100 mg twice daily. Therefore, auto-induction appears to be dose-dependent. 
Handling of carbamazepine in clinical practice is even more complex as addi-
tional induction by other drugs is likely: in epileptic patients treated with phéno-
barbital and/or phenytoin concomitantly, carbamazepine half-lives between 8 
and 11 hours have been found (Cereghino et al. 1973, Troupin et al. 1974, 
Westenberg et al. 1978). 
Clearance values of carbamazepine are increased synchronously with the re-
duction in half-life. If no precautions have been made to exclude data at sub-
maximal induction, large standard deviations will be found in average clearance 
values. Cuelen et al. (1975) reported a mean relative clearance of 132 ± 68 
ml.hr .kg for patients treated only with carbamazepine. Within several weeks 
after onset of treatment clearance values between 50 and 100 ml.hr'1.kg"1 are 
usual. These values may increase with time up to 150 ml.hr Jcg on carba-
mazepine alone and even over 200 ml.hr"1 Jcg"1 when combined with phéno-
barbital and/or phenytoin. The degree of induction is stressed by the clearance 
values found after a single dose in volunteers: 11-26 ml.hr"1 Jcg"1 (Morselli et 
al. 1975b, Pynnönen et al. 1977). The dramatic auto-induction necessitates a 
gradual increase of dosage during the first months of treatment, in order to 
maintain the clinical improvement that is often observed during the first week. 
Even a fourfold increase of the initial effective dose may be necessary some-
times. An example is shown in figure 2.5. Also, the elimination of other drugs 
will be accelerated. However, the effects of carbamazepine on the plasma con-
centrations of other drugs are ambiguous. After addition of carbamazepine to 
an existing therapy with phenytoin or phénobarbital, increased plasma con-
centrations of the latter drugs may be observed initially. 
From single oral dose studies the apparent volume of distribution has been 
calculated on the assumption of complete absorption. In 4 volunteers values 
between 0.88 and 1.861/kg have been reported (Eichelbaum et al. 1975). Data 
from Levy et al. (1975)lead to an average volume of 0.85 1/kg in 6 volunteers, 
while Pynnönen et al. (1977) found 0.99 1/kg in 13 cases. Carbamazepine 
appears to be bound to plasma proteins for 70-90 per cent (Morselli et al. 
1975b, Christiansen and Dam 1977, Johannessen et al. 1977). Concentrations 
in saliva and cerebrospinal fluid appear to correlate well with plasma concen-
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trations, both averaging 25 per cent of plasma concentration (Blom and Guelen 
1977, Johannessen etal. 1977, Westenberg et al. 1978). Because of the constant 
ratio for one individual saliva samples can be used to monitor carbamazepine 
in patients. 
The metabolism of carbamazepine has been partially elucidated (Faigle and 
Feldmann 1975). Carbamazepine-10, 11-epoxide, which is present in blood 
plasma at concentrations from 10-80 per cent of the carbamazepine concen-
tration, is the most important metabolite (Eichelbaum et al. 1976, Rane et al. 
1976). In animal experiments the epoxide has shown anticonvulsant activity 
almost equal to that of carbamazepine itself (Frigerio and Morselli 1975, 
Faigle et al. 1977). On its effectiveness in man no data are available. Most 
investigators report a poor correlation between plasma concentrations of car-
bamazepine and its epoxide (Eichelbaum et al. 1976,Johannessenetal. 1977). 
This may be partly explained by the short half-life of the epoxide. After dis-
continuation of long term treatment, the plasma curves suggest elimination 
half-lives of the epoxide between 5 and 20 hours (Morselli et al. 1975b). 
However, as the metabolite is still being formed, the real half-life might be as 
small as 1-2 hours (Westenberg et al. 1978). Using only early morning blood 
samples. Rane et al. (1976) found a significant influence of other drugs on 
the epoxide/carbamazepine ratio. Drugs such as phénobarbital and phenytoin 
double this ratio. Westenberg et al. (1978) confirmed these results. At the 
same time they found a 50 per cent reduction of the carbamazepine half-life. 
Side effects 
Carbamazepine sometimes gives rise to gastrointestinal complaints which are 
usually transient. Common dose-related side effects include diplopia, drowsi-
ness, nystagmus and ataxia. Also idiosyncratic reactions like jaundice, aplastic 
anaemia and rashes have been reported. Thrombocytopenia, that was seen by 
colleagues recently in two patients, has rarely been reported in literature 
Figure 2.5 
Treatment record from the clinical study, described in chapter 7. Patient L.H. 
(female, 21 years) suffering from a partial, secondarily generalising epilepsy. 
The number of major (black) and minor (white) seizures per half month are 
indicated. Note the decrease of the carbamazepine plasma concentration at 
several dose levels and the difference between the initial and the final daily 
dosage, which produce almost the same plasma concentrations. The influence 
of valproic acid on phénobarbital plasma concentrations in relation to dose is 
also remarkable. 
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(Pearceand Ron 1968, Karpatkin 1971, Jensen 1972,Sanabriaet al. 1976). A 
transient decrease in platelet count has been observed more frequently 
(Cereghino et al. 1974). Recently a few cases of water intoxication have been 
detected (Stephens et al. 1978). Like phenytoin.carbamazepineis understudy 
for chromosomal damage (Herha and Obe 1976). 
Carbamazepine is believed to lack sedative properties, common to most other 
antiepileptic drugs. Replacement of these drugs by carbamazepine often leads 
to improved behaviour and learning abilities (Marjerrison et al. 1968, Dalby 
1975, Trimble 1977). It is generally felt that carbamazepine has rather positive 
effects on behaviour (Bird et al. 1966, Cereghino et al. 1974,Diehl and Werner 
1975). However, for the intrinsic so-called 'psychotropic' effect of carbama-
zepine there is no definitive proof yet (Rett 1976, Henriksen 1977). 
Plasma concentration and effect 
At the time carbamazepine was introduced as an antiepileptic drug, con-
siderable interest had already arisen in plasma concentration monitoring of 
antiepileptic drugs. However, analytical problems hampered its application in 
early clinical studies (Gérardin and Hirtz 1976). Schneider (1975) performed 
a clinical study on 170 patients with psychomotor attacks. Carbamazepine 
was added to the existing antiepileptic medication. In those patients, who 
reached complete control of seizures the average plasma concentration was 
5.9 ±2.7 mg/l;over 50 percent reduction of seizures was observed at 4.6 ±2.2 
mg/1, while the group of patients with less or no improvement had plasma con-
centrations of 2.6 ± 1.5 mg/1. Carbamazepine was estimated by a spectrophoto-
metric method in samples taken before the morning intake of the drug. The 
plasma concentration at which side effects occurred, could be sharply defined 
in individual cases. Values ranged from 5.9-22.1 mg/1 in 10 patients.The thera-
peutic range was estimated 6.5 ± 3.0 mg/1. 
Cereghino (1975) mentions only an 'expected range' between 3 and 12 mg/1 
as a useful guide in therapy, based on literature data and his own experience 
(Cereghino et al. 1974). Provocation of seizures has been described in acute 
overdosage of carbamazepine. Troupin and Ojemann (1975) describe this para-
doxical phenomenon in chronic treatment at plasma concentrations over 20 
mg/1. According to their data, side effects below 7 mg/1 are rare and slight, 
while serious toxicity is only observed at levels over 15 mg/1. In contrast, Mei-
nardi (1972) had already encountered side effects at plasma concentrations of 
1.5 mg/1 in some patients. 
Dam et al. (1977) measured carbamazepine and its epoxide metabolite sep-
arately in 132 patients, whose seizure frequency was being recorded. Carbama-
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zepine caused an improvement in seizure control in 113 cases at an average 
plasma concentration of 5.2 mg/1 for the parent drug. In cases of high and 
low epoxide concentrations, the former caused by interaction with phéno-
barbital or phenytoin, the carbamazepine concentrations related with clinical 
improvement were not different. 
Despite the growing number of clinical studies in which plasma concentrations 
are monitored, views still differ on the therapeutic plasma concentrations of 
carbamazepine: while Morselli et al. (1976) suppose that plasma concentrations 
between 7 and 12 mg/1 tend to display a better therapeutic response, Shorvon 
et al. (1977) take 4-8 mg/1 as the optimum range. The fact that the latter 
authors used this range in previously untreated patients, may be important. 
Mehta (1977) and Feely (1977) both reported effective carbamazepine plasma 
concentrations in individual patients. Combining their data, 30 patients became 
free from seizures or experienced only occasional seizures while on carbama-
zepine monotherapy at plasma concentrations varying from 1.4-12 mg/1. The 
mean values for both studies differ significantly: 8.6 ± 3.0 mg/1 (n= 14) and 5.5 ± 
1.8 mg/1 (n= 16) respectively. The first study largely concerned cases of temporal 
lobe epilepsy while both primarily and secondarily generalised epilepsies occur-
red equally in the second one. However, it is improbable that this will explain 
the difference found. The assay methods for carbamazepine may have been of 
different specificity or the moment of sampling may have been different. Un-
fortunately, no methods are specified. 
Apparently, therapeutic plasma concentrations strongly vary among individ-
uals for carbamazepine. Factors responsible for this variation are unknown 
at the moment. Reviewing the literature data available, about 80per cent of 
the patients who benefit from carbamazepine will do so at plasma concentra-
tions between 3 and 10 mg/l. 
2.10 Valproic acid 
The pharmacological properties of valproic acid, chemically known since 
1881, have been discovered serendipitiously by Meunier et al. (1963). Its chemi-
cal structure is different from all other antiepileptic drugs. The same holds 
for many properties of this compound. When it was first introduced in France 
in 1967 relatively little was known of these properties. In 1978, the drug has 
been admitted to the United States, but still, only scarce information on metab-
olism and mechanism of action is available. The resemblance to endogeneous 
substances tempers research in this field. 
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Pharmacokinetic properties 
After oral administration, sodium valproate is rapidly absorbed with maximal 
plasma concentrations after 0.5-5 hours (Loiseau et al. 1975, Meijer and Kalff 
1975, Richens et al. 1976, Mortel and Frank 1976, Brachet-Liermain and 
Démarquez 1977). Absorption generally is complete (Klotz and Antonin 
1977, Perucca et al. 1978b). After intravenous administration, the plasma 
concentration course can be described with an open-two compartment model. 
After a large oral dose, a biphasic curve can be observed (Vree and van der 
Kleijn 1977b). However, after oral intake, the first distribution phase is gener-
ally overlooked. In cases of repeated administration its influence on steady state 
levels is slight. Therefore, many authors described the pharmacokinetics of 
the drug in man according to the open-one compartment model, even after 
intravenous administration (Perucca et al. 1978a). Also, in infusion experi-
ments in dogs and monkeys this model appeared to be valid (Schobben and 
van der Kleijn 1974, Schobben et al. 1977). 
In six children, half-lives of 8-11.7 hours have been reported while in one 
adult 15.3 hours have been found (Schobben et al. 1975). These observations 
have been confirmed by many others (Loiseau et al. 1975, Johannessen 1977, 
Wulff et al. 1977). Values ranged from 8-15 hours. Brachet-Liermain and Dé-
marquez (1977) were able to determine valproic acid half-lives in young 
children. From 2 months of age they found values between 7 and 14 hours, 
nearly identical to adult values. In children under two months, higher values 
were common, even up to 67 hours in a premature newborn. In older children 
larger relative clearance values are found than in adults (Cuelen and van der 
Kleijn 1978). Probably also a decrease in relative distribution volume with 
increasing age contributes to these differences. 
In a group of epileptic patients treated with a combination of several anti-
epileptic drugs Richens et al. (1976) found half-lives of only 3.8-8.3 hours 
after a single dose of valproic acid. However, only plasma concentration values 
up to 9 hours after drug intake were used for calculation of these parameters. 
After a single intravenous dose of valproic acid given to volunteers and epilep-
tic patients the same differences in half-lives have been observed by Perucca 
et al. (1978b). Like Richens and colleagues they found differences in distribu-
tion volume between both groups: 0.147 ± 0.0041/kg for the volunteers and 
0.175 ± 0.025 1/kg for the epileptic patients. The small distribution volume of 
valproic acid may be partially explained by its high plasma protein binding. 
Values between 84 and 95 per cent have been found for the protein bound 
fraction. Binding appeared to decrease at higher plasma concentrations (Klotz 
and Antonin 1977, Wulff et al. 1977, Taburet and van der Kleijn 1977). Dis-
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placement of valproic acid from plasma proteins by other antiepileptic drugs 
might offer an explanation for the larger volume of distribution in epileptic 
patients. 
pH conditions appear to influence the distribution volume of the drug. Vree 
and van der Kleijn (1977b) calculated the parameters for a two-compartment 
model in two volunteers, who took a single dose under acidic and alkaline 
conditions: urine was maintained atpH 5.5-6.0by regular intake of ammonium 
chloride or at pH 7.0-7.5 by sodium bicarbonate. Under alkaline conditions 
the volumes for both compartments are lower. The values for the apparent 
volume of the second compartment under acidic conditions appear to corres-
pond to those found by Klotz and Antonin (1977) without pH control. The 
volume of the first compartment seems to be more sensitive to pH differences. 
This may be explained by a shift in the degree of ionisation of valproic acid in 
blood. For a drug with a pKa of 4.9, a change of the physiological pH from 
PLASMA CONCENTRATIONS OF DI-N-PROPYLACETATE IN CHILDREN 
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Figure 2.6 
Plasma concentrations of sodium valproate in 4 children during and after sub-
chronic administration. Note the apparent steady state concentrations, which 
were obtained by blood sampling exactly 2 hours after drug intake (from 
Schobben et al. 1975). 
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7.4 to 7.3 results in a 25 per cent change in concentration of the undissociated 
acid. Consequently, distribution through lipoid membranes will be enhanced 
and more drug will accumulate at sites, where pH is less influenced by acidosis. 
In view of the smaller degree of ionisation in acidic urine renal excretion will 
be impaired. Indeed longer half-lives are found under acidic conditions. 
Sustained release preparations 
Due to the short half-life, considerable fluctuations in plasma concentration 
will occur. Therefore, it is difficult to choose a moment for blood sampling in 
order to obtain a representative plasma concentration. Strict adherence to 
fixed medication and sampUng times could not avoid variations of ± 20 per 
cent in 'steady state' plasma concentrations of patients on chronic therapy 
(fig. 2.6). Data of Loiseau et al. (1975) and Wulff et al. (1977) clearly illustrate 
the extremely irregular daily fluctuations of plasma concentration, that may 
be partly explained by prolonged absorption due to food intake and delayed 
plasma concentration 
sodium 2-PP (mg/l ) 
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Figure 2.7 
Fluctuations of valproate plasma concentrations in 38 patients. The concen­
trations of two samples, taken with an interval of 2-5 hours, are compared. 
Thick lines connect mean values. The drug is taken three times daily (arrows). 
For further explanation see text (from Schobben et al. 1977). 
80 
stomach emptying. But even in monkeys with a constant intravenous infusion 
of valproic acid fluctuations in plasma concentration of even 50 per cent have 
been observed. A day and night-rhythm is likely to be present (Levy et al. 
1977b). Duplicate samples taken with an interval of several hours may provide 
more reliable information (fig. 2.7). Decay of plasma concentration between 
2 and 5 hours after the morning intake usually reflects the individual half-life, 
while samples taken during the afternoon often reveal delayed absorption 
after the usual hot meal (Schobben et al. 1977). Probably the fasting concen­
tration is the most reliable guide. The influence of food intake was also 
demonstrated by Meinardi et al. (1975): in two volunteers the velocity and 
the extent of absorption after a single dose of sodium valproate appeared to 
be reduced by a solid breakfast, when compared to intake on an empty 
stomach. 
In order to avoid the extreme fluctations in plasma concentration, sustained 
release dosage forms have been developed. We have tested two of these prepa­
rations in vitro: 
A (Depakine® retard, Labaz, the Netherlands) and 
В (Propymal®, Chemische Industrie Katwijk, the Netherlands). 
Dissolution curves are presented in fig. 2.8. Surprisingly, the dissolution pat­
tern could be accurately described with a simple exponential function. Disso­
lution half-lives appeared to amount 0.3, 1.2 and 3.5 hours for the normal 
tablet (Depakine®, Labaz) and preparations A and В respectively. 
Preparation A has been compared with the plain tablet by Kalff et al. (1976). 
Dosage frequency could be reduced from 3 to 2 times a day without causing 
larger fluctuations in plasma concentration. Their experiments were simulated 
using the dissolution rate constants found in vitro in a sequential pharmacoki­
netic model (fig. 2.9). Similar results were obtained. The second preparation 
was tested by Reekers-Ketting et al. (1975). The ratio between the concentra­
tions in plasma, 2 and 8 hours after drug intake, diminished from 1.71 ± 0.34 
to 0.94 ± 0.12 in 4 patients when they changed from the normal tablet to 
preparation В each 8 hours. In theory a ratio of 1.50 and 0.91 respectively 
would have been expected. 
Also precursors of valproic acid have been tested in order to obtain a gradual 
supply of the drug. The amide of valproic acid is commercially available (De-
pamide®, Labaz). In man, this substance appears to be completely metabolised 
to valproic acid. Plasma concentrations fluctuate less than on administration 
of the free acid (Loiseau et al. 1975, Meijer and Kalff 1975). The ester of 2-
propyl-pentanol and valproic acid, of which the alcohol moiety is also trans­
formed into the drug by oxidation, appeared to produce very flat plasma 
curves in monkey, but the substance was rather toxic (Reekers-Ketting et al. 
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Figure 2.8 
Dissolution of sodium valproate from two preparations with sustained release 
in comparison with the normal tablet (Depakine®). The upper part of the 
figure shows the amounts dissolved for each sample moment, the lower part 
the fractions, which still have to dissolve. The release of the drug may be 
described by a first order process. 
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Figure 2.9 
Plasma concentrations of sodium valproate in a fictive patient (V^ = 14 I) 
treated with different preparations: three times daily two plain tablets (600 mg) 
at 8 a.m., 1 p.m. and 6 p.m. or two times daily three tablets of preparation A 
or В (900 mg) at 8 a.m. and 8 p.m. The pharmacokinetic model used is shown 
in the upper part. Dissolution rates are taken from fig. 2.8. 
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1975). The triglyceride of valproic acid has been tried in human volunteers 
(Meijer and Kalff 1975). 
Besides the sustained release formulations enteric coated tablets have also 
been introduced. Their aim was to prevent the gastrointestinal side effects, 
which occur frequently, especially when initiating therapy. Enteric coating 
brought only partial relief (Kalff et al. 1976). The enteric coated forms showed 
similar absorption patterns as the normal tablet, after a delay of 2-3 hours. No 
significant differences in bioavailability have been observed between all tested 
formulations (Kalff et al. 1976, Jordan et al. 1977, Oelkers et al. 1977). Only 
Johannessen et al. (1978) have found a significant difference in bioavailability 
between a tablet and a solution product of the same brand. 
Plasma concentration and effect 
Another consequence of the short half-life is the rapid attainment of a 
'steady state' condition after onset of treatment. Equilibrium is normally 
reached within 48 hours. In contrast, the onset of the clinical effect is general-
ly observed after several weeks of treatment (Jeavons and Clark 1974, Lance 
and Anthony 1975). However, some animal studies showed a relation between 
valproic acid concentration and pharmacological effect in acute experiments. 
In mice the maximal protection against pentetrazole and audiogenic seizures 
seems to coincide with the highest valproate concentrations in plasma and 
brain (Simler et al. 1968, Ferrandes 1972, Lacolle and Baisse 1972, Ciesielski 
et al. 1975). Unfortunately the anticonvulsive effect and drug concentrations 
have been measured in different experiments. Moreover, the use of radioactively 
labeled valproic acid and the subsequent assay for total radioactivity results 
in combined concentrations of the drug and its metabolites. 
Lacolle et al. (1978) determined concentrations of unchanged valproic acid 
and compared them with anticonvulsant activity in mice. Because of the dif-
ferences in time course, they denied a direct relation between plasma or cere-
bral concentration and the protection against pentetrazole seizures. In fact, 
they found a high correlation between log concentration and effect (fig. 2.10). 
In contrast, the protection against maximal seizures caused by mercaptopro-
pionic acid was sustained much longer. 
During their experiments with valproic acid in the photosensitive baboon 
Papio papio, Patry and Naquet (1971) had distinguished a short-lasting effect 
on EEG paroxysms and myoclonies during intermittent photic stimulation, 
and a longer lasting prevention of after-discharges and generalised convulsions. 
Lockard et al. (1977) also observed dual effects in their long-term infusion 
experiments in monkeys with an alumina focus. Seizure frequency appeared 
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Correlation between brain or plasma concentration of valproic acid and anti­
convulsive effect in single dose experiments in mice. Data are taken from 
Lacolle et al. (1978), who doubted a direct relationship. The pharmacological 
response is highly correlated with log concentration. 
to be decreased immediately, but this effect was transient. A permanent re­
duction in seizure frequency has been observed, only after attainment of a 
plasma concentration of 150 mg/1, preceded by 4 weeks at lower concentra­
tions. After discontinuation of drug administration, there was a significant 
carry-over effect during the next two weeks and even a rebound increase in 
seizure frequency during the fourth week. The severity of seizures had been 
85 
decreased from the beginning and remained so until several weeks after discon-
tinuation of treatment. Lockard and Levy (1976) tried to explain these obser-
vations by the assumption that valproic acid exerts its pharmacological effect 
via a series of biochemical processes. Accumulation or exhaustion of certain 
compounds will be effected only gradually. 
Also in epileptic patients, the lack of correlation between plasma concentra-
tion and antiepileptic effect has been demonstrated, both in acute and chronic 
administration. In six epileptic patients, sensitive to intermittent photic stimu-
lation, Rowan et al. (1978a) observed a marked decrease of sensitivity after a 
single dose of valproic acid. The maximal effect occurred 1-6 hours after the 
maximal plasma concentration of valproic acid (average time-lag 2.4 hours). 
In patients chronically treated with valproic acid, 24-hour EEG monitoring 
and frequent blood sampling did not reveal an immediate temporal relationship 
between the amount of paroxysmal EEG activity and plasma concentrations 
(Rowan et al. 1978b). However, in some patients the reduction of EEG 
paroxysmal activity and clinical seizures appeared to be related to the average 
steady state plasma concentration of the drug. Another study of valproic acid 
with frequent EEG monitoring in patients with petit mal absences, revealed 
that a significant reduction in the three-per-second spike-and-wave complexes 
was apparent after an average treatment period of 3 weeks (Zagnoni 1977). A 
clinical study on the effect of valproic acid on tardive dyskinesia also revealed 
significant carry-over effects, often during two weeks (Linnoila et al. 1976). 
Jeavons et al. (1977) reported efficacy in epileptic children after 1-3 weeks of 
treatment. 
The lack of relation between plasma concentration and effect, at least tem-
porally, may be explained in three different ways: 
1. As already suggested by Lockard and Levy (1976) a delay in effect may be 
caused by indirect action via biochemical processes. 
2. Valproic acid may be the active substance itself but it only slowly penetrates 
the site of action. 
3. A metabolite with a longer half-life time of elimination, which will accumu-
late for that reason, may be responsible for the pharmacological effect. 
All three hypotheses can explain the slow onset of effect in chronic treatment, 
the time-lag between maximum valproic acid concentrations in plasma or even 
in brain and maximal effect, and the carry-over effects after discontinuation 
of treatment. 
Since Godin et al. (1969) observed an increase of GABA in rat brain after 
administration of valproic acid, many efforts have been made to explain the 
anticonvulsive effect of the drug by its influence on the metabolic pathway of 
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GAB A. All biochemical changes, after administration of valproic acid, which 
have been studied in this respect, show a time course that is directly related 
to the kinetics of the parent drug: for instance local concentrations of GABA, 
cyclic GMP and activities of glutamic acid decarboxylase, GABA-transaminase 
and succinylsemialdehyde dehydrogenase (Lacolle and Baisse 1972, Simler et 
al. 1973, Lust et al. 1976, Lacolle et al. 1978). Explanation of the sustained 
action of valproic acid by means of these pathways therefore remains difficult 
at the present time. 
The second and third hypotheses may be tested by studies on metabolism 
and regional brain distribution of valproic acid. Relatively little information 
was available on these subjects a few years ago. Our experiments and results 
from other research groups will be dealt with in detail in chapters 3 and 4. 
In addition to all data on the slow onset of therapeutic effect of valproic 
acid, one report must be mentioned on the decreasing efficacy with time. 
Mortier and Michaelis (1975) have observed a recurrence of myoclonic seizures 
in three patients with subacute sclerotising panencephalitis after several weeks 
of treatment. After three weeks of abstinence, sensitivity had returned to the 
initial level. Onset of activity, in these cases, was observed within three days 
of treatment. These observations have yet not been explained. 
Unexpectedly, valproic acid has appeared to be effective in some cases of 
status epilepticus, in which the usual approach with several drugs had brought 
no relief. In 3 documented cases, the status ended within 5 days (Manhire and 
Espir 1974, Vajda et al. 1977). Another case responded already after several 
hours, however with some temporary relapses (Barnes et al. 1976). The drug 
had been administered by gastric tube, as enemas or in suppositories. Since, 
Vajda et al. (1978b) treated 6 cases of status epilepticus with suppositories of 
sodium valproate, in doses of 200-800 mg at 6-hour intervals. In 5 patients a 
complete control of seizures was obtained. A marked reduction of seizures 
was seen after 24 hours already. However, the control of seizures may not be 
definitely attributed to valproic acid on its own. All cases were, unsuccess-
fully, treated with other antiepileptic drugs as well. Five of the six patients of 
Vajda et al. (1978b) recieved sufficient doses of phenytoin; an increase of the 
unbound fraction in plasma by valproic acid, might offer an alternative expla-
nation for the rapid recovery in these cases. 
Routes of administration 
In man, there is little experience with other routes of administration than 
oral. In two of the cases of status epilepticus mentioned above, the rectal 
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administration was replaced by oral treatment without obvious change of 
plasma concentrations (Vajda et al. 1978b). 
Intravenous administration has also been used in epileptic patients but no 
reports on its therapeutic application have been published. 
Interactions 
In view of the strongly fluctuating plasma concentration of valproic acid in-
fluences on elimination or distribution by other drugs are unlikely to be detec-
ted in routine practice. Animal experiments demonstrated clearly that elimin-
ation may be increased by enzyme induction (Vree et al. 1977b). Several obser-
vations suggest that the same holds for epileptic patients (Richens et al. 1976, 
Zagnoni 1977, Perucca et al. 1978b). The significance of this interaction can-
not be judged, as long as uncertainty exists on the antiepileptic activity of val-
proic acid itself rather than its metabolite(s). Valproic acid influences protein 
binding and elimination of several drugs. Details will be given in chapter 5. 
Side effects 
Gastrointestinal side effects have already been mentioned. They are especially 
frequent in children (± 15 per cent). In general, these effects occur at the on-
set of treatment and are transient. However, in some studies, gastrointestinal 
complaints have been observed at high dosages that had been built up gradual-
ly (Lance and Anthony 1975, Bachmanet al. 1977). Van Duijn and Beckmann 
(1975) reported vomiting in cats even after parenteral administration of the 
drug. Lambert et al. (1966) have observed vomiting in one epileptic patient 
after rectal administration of the amide of valproic acid. Therefore local irri-
tation of the gastrointestinal mucosa, will probably not be the only mechanism 
of these effects. Sustained release and enteric coated preparations brought only 
partial relief for the same reason. 
Drowsiness or sedation is usually caused by the interaction with other anti-
epileptic drugs or sedatives and may be attributed to the drug itself in only a 
few cases (Noronha and Bevan 1976). Replacement of other antiepileptic drugs 
by valproic acid often leads to marked improvements in mood and alertness 
(Kugler et al. 1973, Haigh and Forsyth 1975). A positive psychotropic action 
has also been attributed to the drug itself (Beaudouin and Claden 1971) but 
no significant positive results have been obtained in studies, especially designed 
to measure these effects (Herbaut 1972, Sommeibeck et al. 1977). 
A prolonged bleeding time has been attributed to valproic acid in several 
cases, mostly accompanied by thrombocytopenia (Sutor and Jesdinski-Buscher 
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1974, Winfield et al. 1976). Withdrawal of the drag is not always necessary; 
up to now the condition has been reversible in all cases. Also loss of hair on 
the head and face has been reported (Jeavons and Clark 1974, Lance and 
Anthony 1977). Valproic acid has been observed to be teratogenic in rabbit, 
rat and mouse (Nixon 1976, Whittle 1976). As yet there are no indications for 
the same effect in man, but only 8 pregnancies on valproic acid have been re-
ported in the literature (Espir et al. 1976, Knop et al. 1976, Whittle 1976). 
Routine monitoring of plasma concentrations 
Several factors throw doubt on the significance of valproic acid plasma con-
centration determination for routine practice. The irregular, large fluctuations 
in plasma concentration have already been mentioned. Even concentrations 
before the morning intake of the drug may fluctuate over 20 per cent in the 
same patient (Mortel and Frank 1976, Wulff et al. 1977). Whether valproic 
acid is the active substance or metabolites are responsible for the therapeutic 
effect is only of minor importance: in steady state, metabolite concentrations 
will be related to the concentration of the parent drug. 
Therapeutic plasma concentrations of valproic acid are not known. Meinardi 
et al. (1974) reported plasma concentrations between 20 and 150 mg/1 in 46 
patients who improved on valproic acid. However, the drug was added to the 
existing medication and in view of the marked influence valproic acid may 
exert on plasma concentrations of phénobarbital for instance, no conclusion 
can be drawn from these data. Vajda et al. (1978a) have suggested a tentative 
therapeutic range. From their results it may be concluded that some patients 
improved when the plasma concentration was raised from below 50 mg/1 to 
the 50-100 mg/1 range. Controlled clinical trials with valproic acid alone or 
with control of plasma concentrations of concomitant drugs have been carried 
out (Haigh and Forsyth 1975, Gram et al. 1977). However, plasma concentra-
tions of those patients who responded well, have not been reported. 
As no serious dose-related side effects have been reported, there is almost no 
need for plasma concentration determinations in routine practice. Poor com-
pliance will be detected only when the patient does not take the drug at all. 
In view of the large fluctuations of plasma concentration, the daily dose of 
valproic acid per kilogram body weight is probably a better measure of the 
average amount of drug in the body than the actual plasma concentration. 
Further evidence in support of this view, is presented in chapter 8. 
89 
2.11 Ethosuximide 
In the treatment of petit mal absences, the succinimides have largely replaced 
the oxazolidinediones, because drugs from the latter group showed frequent 
side effects. Among the succinimides, ethosuximide is used preferentially. 
Phensuximide and methsuximide are less effective and have only short half-lives 
in man (Glazko and Dill 1972). However, methsuximide is demethylated to 
form a metabolite with a much longer half-life (Kupferberg et al. 1977). 
After oral administration, ethosuximide is promptly and efficiently absorbed. 
Plasma half-life values between 49 and 66 hours have been found (Buchanan 
et al. 1973). Consequently plasma concentrations are very stable. In children, 
half-lives around 30 hours have been reported. The apparent volume of distribu-
tion is about 0.62 1/kg (Buchanan et al. 1973). The drug is little bound to 
plasma proteins. Concentrations in cerebrospinal fluid and in saliva are almost 
equal to the plasma concentration(Blom and Cuelen 1977). It is generally agreed 
that ethosuximide kinetics almost ideally follow the open-one compartment 
model. Patel et al. (1975) have tested this model in monkeys extensively. 
However, diurnal rhythms in plasma concentration were obvious during con-
tinuous linear infusion (Levy et al. 1977b). Smith et al. (1979) found a non-
linear relationship between steady state plasma concentration and dose in 
several patients. An explanation for their observation has not yet been found, 
but first-pass metabolism might be responsible. However, in the monkey ex-
periments of Patel et al. (1975) no proof was found for this hypothesis: with 
increasing dose, bioavailability appeared to be slightly enhanced, but at the 
same time the fraction excreted unchanged in urine, appeared to decrease. 
Relative clearance values appeared to amount 19.9 ± 8.4 ml.hr"1 .kg"1 in457 
patients with various comedication (Guelen and van der Kleijn 1978). Buchanan 
et al. (1975) reported values between 8.9 and 23.3 in 9 children. According 
to Sherwin (1978), children between 3 and 10 years of age need 1.5 times the 
adult dose per kilogram body weight to reach the same plasma concentrations. 
Data are scarce on interactions of ethosuximide with other drugs in man. Smith 
et al. (1979) did not find a significant influence of most antiepileptic drugs in 
46 patients. 
As less than 25 per cent of the dose is found unchanged in urine ethosuximide 
is largely metabolised. Several metabolites have been identified in human urine 
(Chang et al. 1972, Preste et al. 1974). For the time being the therapeutic 
effect is attributed to ethosuximide itself. Ethosuximide is almost always given 
orally. However, Meijer and Kalff( 1975) reported successful rectal administra-
tion of ethosuximide capsules. 
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Plasma concentration and effect 
As true petit mal absences are always accompanied by characteristic EEG 
phenomena and fit frequency is high enough to enable its estimation in one 
recording session, the degree of control in this type of epilepsy can be easily 
quantitated. In some studies this has been correlated with plasma concentra-
tions of ethosuximide. Penry et al. (1972) noted a significant decrease of 
absence frequency in 18 patients with ethosuximide plasma concentrations 
between 36 and 104 mg/1. This effect was evident already after one week of 
treatment. Several weeks later, the duration of the absences appeared to de-
crease. The 9 patients with over 95 per cent of control of absences, had plasma 
concentrations between 41 and 89 mg/1. Sherwin and Robb (1972) monitored 
plasma concentrations in a group of 117 patients with a known history of petit 
mal absences. Of these patients 63 were clinically free from absences for at 
least 3 months at plasma concentrations between 5 and 250 mg/1; 93 per cent 
of this group had plasma concentrations over 40 mg/1. In a limited group of 
patients, the same authors measured the degree of control at two dose levels. 
In 3 patients with plasma concentrations of 67, 70 and 86 mg/1 only further 
dose increase brought control of absence attacks. The lowest level associated 
with complete control in this group was 37 mg/1. Sherwin (1978) presented 
one well documented case in which both EEG paroxysms and clinical absences 
were markedly reduced at a plasma concentration of 22 mg/1, and had com-
pletely disappeared at 42 mg/1. 
Reviewing the reported data, it may be concluded that in more than 80 per 
cent of the patients effective ethosuximide concentrations can be expected 
between 40 and 90 mg/l. 
Sherwin et al. (1973) demonstrated that monitoring of ethosuximide plasma 
concentrations, used to improve compliance and to ensure plasma concentra-
tions over 40 mg/1 in all patients, did increase the number of patients that are 
completely controlled from 47 to 61 per cent. 
Side effects such as tiredness, headache and dizziness appear to be dose-
related. However, plasma concentrations as high as 168 mg/1 have been found 
without signs of toxicity. In some patients, an increase of seizure frequency 
has been reported at high plasma concentrations. Side effects, apparently not 
dose-related, include gastric disturbances and reactions of the skin and the he-
matopoietic system (Buchanan 1972). Also disturbances of behaviour may 
occur (Sherwin 1978). 
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Figure 2.11 
Structural formulas of the benzodiazepine derivatives discussed in this chapter. 
2.12 Benzodiazepines 
Benzodiazepines are widely used as tranquiUizers, hypnotics and muscle 
relaxants. In epilepsy the three compounds, shown in figure 2.11, are some-
times used. Diazepam is one of the drugs of choice in the treatment of status 
epilepticus. Moreover it has frequently been used as adjuvant in the chronic 
treatment of epilepsy. Nitrazepam is especially effective in some juvenile types 
of epilepsy. Clonazepam appears to be a very potent anticonvulsant, effective 
against several seizure types. 
Benzodiazepines are extensively metabolised and many metabolites are phar-
macologically active (Garattini et al. 1973). The benzodiazepines are very 
lipophilic; despite a high protein binding rapid accumulation takes place into 
the brain. When not in steady state, considerable redistribution into body fat 
is usual (vanderKleijnetal. 1977b). Xhe use of the benzodiazepines in epilepsy 
is limited, by the development of tolerance. The antiepileptic effects of several 
members of this class of compounds appear to decrease both in the treatment 
of status epilepticus and in chronic therapy (Mattson 1972). This tolerance is 
unlikely to be explained by induction of metabolism or by metabolite effects 
(van der Kleijn et al. 1977b). 
Diazepam 
Absorption of diazepam after oral administration is generally rapid and com-
plete. Maximal plasma concentrations are usually obtained within one hour 
(de Silva ^óó.Kaplanetal. 1973). After intravenous administration a triphasic 
plasma concentration curve is observed (Kaplan et al. 1973, Agurell et al. 
92 
1975). The initial decrease of the concentration is rapid. Therefore, in the 
treatment of status epilepticus, it will be necessary to give a second dose after 
30 minutes to 1 hour in many cases (Dreyer 1969). 
The diazepam solution, suited for intravenous administration, may also be 
given by rectum. Maximal plasma concentrations are then reached within 10 
to 20 minutes; a resorption of 80 per cent has been found in two children 
(Agurell et al. 1975). However, the solvent is irritating and may cause 
haemorrhage. Efforts to develop a solvent for the benzodiazepines which is 
non-irritative, prevents decomposition and releases the drug quickly and com-
pletely, has not been successful so far. Recently, a ready-for-use micro-enema 
has been introduced (Stesolid^, Dumex). However, its composition appears 
to be identical to that of the i.v. solution. Administration of diazepam by 
suppositories in emergency treatment appears to have little sense: maximum 
plasma concentrations are only attained after 1-3 hours. Moreover, the amount 
absorbed strongly depends on the suppository base (Arnold 1975, Kan to 
1975). Also intramuscular administration yields varying results, apparently 
related to the injection place and technique; peak plasma concentrations have 
been reported between lOminutes and 4hours after injection (Ferngren 1974, 
Agurell et al. 1975, Gamble et al. 1975). 
The terminal half-life of diazepam may vary between 20 and 40 hours (van 
der Kleijn et al. 1971, Kaplan et al. 1973). Approaching chronic treatment as 
a linear infusion in a one-compartment model, van der Kleijn et al. (1971) 
found relative distribution volumes between 0.74 and 0.97 1/kg in 4 patients. 
Kaplan et al. (1973) analysed plasma concentration curves after intravenous 
administration according to a three-compartment model and found total 
distribution volumes of 1.6-2.1 1/kg. In view of the accumulation of diazepam 
in adipose tissue, this high figure is quite realistic. The difference in distribution 
volumes may be explained by the moment of sampling. In the first study, 
samples have been taken 1 hour after oral drug intake. Peak plasma concen-
trations will overestimate the average steady state level. When diazepam is to 
be used chronically,clearance values around 40 ml.hr .kg may be expected. 
However, when the drug is combined with enzyme inducing antiepileptic drugs, 
higher values are often found. 
The acute effects of diazepam can undoubtedly be attributed to the drug 
itself. During chronic treatment, metabolites will accumulate. The most im-
portant metabolite, desmethyldiazepam, has a half-life of 30-100 hours (van 
der Kleijn et al. 1971, Kaplan et al. 1973, Post et al. 1977). This compound 
may even reach higher plasma concentrations than the parent drug, especially 
when enzyme inducing drugs are given concomitantly (van der Kleijn et al. 
1977b). This may be a disadvantage as a mood depressant effect has been attri-
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buted to desmethyldiazepam in man (Dasberg 1975). In studies in cats, des-
methyldiazepam appeared to be a weak agonist and its slow accumulation might 
be responsible for some tolerance to diazepam (Bamett and Fiore 1971). The 
widespread use of diazepam as adjunct in antiepileptic drug therapy will poss-
ibly have tobe reconsidered. Other metabolites of diazepam are oxydiazepam 
and oxazepam. Both compounds are marketed as ataractic drugs. 
Diazepam is widely used as drug of first choice in the treatment of status 
epilepticus(Dreyerl969, New Zeal. Med.J.1974,Femgren 1974). Care should 
be taken of depression of cardiac and respiratory functions. Diazepam may 
potentiate similar effects of barbiturates, and especially when high amounts 
of such compounds are present serious problems have been reported (Bell 
1969, Dreyer 1969). 
Little information is available on the effective plasma concentrations of 
diazepam. In some individual cases, values between 150 and 330 ng/ml have 
been correlated with clinical efficacy (Femgren 1974, Agurell et al. 1975). As 
some of the concentrations have been determined after acute administration, 
care should be taken in the interpretation of these values. A simple relation 
between plasma concentration and the concentration in brain can be expected 
only in steady state. According to Dasberg et al. (1974), plasma concentrations 
of 400 ng/ml are necessary for anti-anxiety effects. 
Nitrazepam 
Due to the low effective dosages and corresponding plasma concentrations 
analytical problems have dominated the investigations after the pharmacoki-
netic properties of nitrazepam. Sufficiently sensitive and specific assay methods 
have been developed only recently. After oral administration 50-90 per cent 
is absorbed. The plasma half-life of the drug has been reported to vary from 17 
to 25 hours. The distribution volume approximates 1.5-2.51/kg (Rieder 1973). 
During chronic treatment, the most important metaboUtes, the 7-amino-
nitrazepam and 7-acetamido-nitrazepam are found in plasma in amounts com-
parable to those of the parent compound (Rieder and Wendt 1973). Data on 
the pharmacological properties of these substances are minimal. However, it is 
unlikely that they are effective, in view of the properties of the corresponding 
metabolites of clonazepam. The relation between plasma concentration and 
antiepileptic effects has not been extensively investigated. On occasional use 
as hypnotic agent, plasma concentrations between 50 and 80 ng/1 are associated 
with transitions between sleeping and waking (Rieder 1973). 
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Clonazepam 
Clonazepam has marked anticonvulsant properties, in comparison with other 
effects common to most benzodiazepines. It is the most potent antiepileptic 
drug available today. Analytical problems are even greater than with nitraze-
pam. Half-lives between 31 and 42 hours have been reported after two weeks 
of treatment in volunteers (Berlin and Dahlström 1975). Knop et al. (1977) 
measured a half-life of only 13 hours in two patients, treated with other anti-
epileptic drugs concomitantly. Values for the relative distribution volume 
ranged from 1.6-3.2 l/kg(Knop et al. 1975). Clearance values are between 100 
and 250 ml.hr Jcg in most epileptic patients (Knop et al. 1977). Usually 
lower values have been found in volunteers (Eshenhof 1973). Therefore, the 
drug appears to be sensitive to enzyme induction by other antiepileptic drugs. 
After oral administration, the drug appears to be absorbed completely. Clona-
zepam is extensively metabolised. Its metabolite pattern is quite similar to 
that of nitrazepam. The 7-ammo derivative appears to be the main metabolite. 
It is not pharmacologically active. In man, small amounts of the 7-acetamido 
and З-ОН-7-nitro metabolite have been found (Eshenhof 1973, Knop et al. 
1975). 
Several clinical studies including monitoring of plasma concentrations have 
been carried out. Plasma concentrations between 25 and 70 ng/ml would be 
most frequently associated with therapeutic success (Dreifuss et al. 1975). Side 
effects are common. Drowsiness and lethargy may occur in 80 per cent of 
patients at the onset of therapy. Ataxia is also frequently observed, probably 
caused by the muscle relaxant effect of the drug. Acute withdrawal has led to 
status epilepticus in several cases (Edwards 1974). Side effects and withdrawal 
symptoms appear to occur more frequently in patients with high plasma con­
centrations of metabolites (Hvidbergand Sjö 1975,Knop et al. 1977). In view 
of the enzyme inducing properties of most antiepileptic drugs, it might be 
sensible to use the drug as monotherapy whenever possible. 
Besides its application in the chronic treatment of some juvenile forms of 
epilepsy and in myoclonies, clonazepam appears to be suited for the treatment 
of status epilepticus. Several authors prefer it to diazepam (van Huffelen and 
Magnus 1976, Lagenstein and Iffland 1977). Lower doses appear to be equally 
effective and may cause less side effects. 
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2.13 Objectives of further investigations 
Among the properties of antiepileptic drugs described above, the clearance 
and the effective plasma concentration appear to be the most vital parameters 
in chronic therapy. When these parameters could be predicted in a reliable 
manner, appropriate drug dosage would not longer be a problem. Clearance 
and concentration data reported above vary too widely for this purpose. There-
fore attempts are undertaken to increase the probability of successful prediction 
in individual cases. 
Several factors have been identified, which influence the clearance value. 
When clearance data are classed according to such factors, more reliable values 
are obtained. Non-linear kinetics also contribute to the variability of the 
clearance, and two, or more, independent constants will take its place. On such 
parameters still little information is available. Reliable average values and 
quantitative data on interfering factors are needed in order to attain the 
mentioned aims. In the third part of this work methods will be indicated to 
obtain such data. At the same time, the application of the pharmacokinetic 
information is evaluated. From individual effective plasma concentrations 
guidelines for dosage are derived. 
As clearance values in epileptic patients are calculated on the assumption of 
complete bioavailability, deviations from this ideal situation will increase the 
variability of the results. Phenytoin is highly suspected for product bioavail-
ability inequivalences. Therefore some current preparations of this drug are 
investigated (chapter 6). 
Knowledge on pharmacokinetics and metabolism of valproic acid is still 
scarce. Moreover the therapeutic effects of the drug appear not to be correlated 
with plasma concentrations at steady state. In the next three chapters new 
information on distribution, metabolism and interactions of valproic acid is 
provided. An attempt is undertaken to explain the discrepancy between 
plasma concentration and effect by the discovered properties. 
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pharmacokinetics 

Chapter 3 
Distribution of valproic acid 
3.1 Introduction 
Information on distribution of valproic acid is scarce (Eymardet al. 1971). 
As the distribution of a drug will influence the onset, intensity and time course 
of the pharmacological effect, the metabolism and excretion, such information 
is of fundamental importance in the study of these processes. The chemical 
structure of valproic acid is strongly deviating from those of the other antiepi-
leptic drugs. Therefore similarities of regional brain distribution arc of special 
interest, in view of a possible common mechanism of action. The distribution 
of valproic acid is studied by autoradiography in order to visualise the whole 
body distribution and the possible accumulation of the drug and its metabolites 
in certain brain areas. The latter process might explain the lack of correlation 
between the plasma concentrations and the clinical effects. At the same time, 
an attempt is made to define the appropriate mathematical model, which de-
scribes the pharmacokinetics of the drug, including distribution. 
Valproic acid has a small apparent volume of distribution. In man, most re-
ported values range from 0.15-0.20 l/kg (Schobben et al. 1975, Richens et al. 
1976, Klotz and Antonin 1977, Perucca et al. 1978b). This seems to suggest a 
rather restricted distribution, as the blood plasma and the rapid exchangeable 
body water already account for this volume. However, the high protein bind-
ing capacity is largely responsible for the low figure. Based on free plasma 
concentrations the apparent volume of distribution would be about ten times 
larger. However, the volume parameter is merely a mathematical entity and 
has no direct anatomical meaning. 
Physical distribution can be visualised by means of whole body autoradio-
graphy as shown below. This technique enables only the detection of the sum 
of the parent drug and its metabolites. As valproic acid is extensively meta-
bolised, radioactive metabolites may contribute to the distribution pattern to 
a considerable extent. The position of the labeled atom in the valproic acid 
molecule determines which metabolites will be radioactive. By the use of 
carboxy-labeied and side-chain-labeled valproic acid the influence of certain 
metabolites might be discovered. l-'^C-valproic acid was made available. The 
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3-14C-analogue was synthctised for this purpose. 
3.2 Materials and methods 
Chemicals 
1- C-valproicacid,l mCi/mmole, was kindly supplied by Dr. H.J. Kupferberg, 
National Institute of Neurological and Communicative Disorders and 
Stroke, Bethesda, Maryland, USA. 
3- C-valproic acid, 1.30 mCi/mmole, synthesis described in appendix 1. 
Instagel® and Soluene 350® were obtained from Packard-Becker, the Nether-
lands. 
All other reagents were analytical grade and were obtained from Merck, Darm-
stadt, Germany. 
Mice experiments 
To 16 Swiss mice (20 to 25 g), 200 ßCi/kg of 1-'^C-valproic acid was injected 
via the tail vein. A solution of 8.20 mg of sodium valproate per ml of water, 
corresponding to 20 дСі/тІ was used. Survival times ranged from 1 minute to 
24 hours (see fig. 3.1 and 3.2). For further details, see Schobben and van der 
Kleijn(1974). 
Monkey experiments 
A. A newborn male rhesus monkey (Macaca mulatta) of 415 g body weight 
was given a rapid injection of about 50 цСі valproic acid, specific activity 
405 цСіІ mmole. The animal was sacrificed 10 minutes after the injection, 
and was used for whole body autoradiography (Schobben et al. 1977). 
B. A male squirrel monkey (Saimirí) of 500 g was given 220 дСі of l - ^ C -
valproic acid by constant rate infusion over 90 minutes. The infusion fluid 
contained 1.50 mg of sodium valproate per ml, corresponding to 3.67 μα/ 
ml, and was given at an infusion rate of 4.0 ml/hr into the femoral vein. 
By means of a catheter into the opposite femoral artery blood samples 
were taken at regular intervals. The animal was sacrificed after 90 minutes. 
For further details, see Schobben et al. (1977). 
C. 254 AiCi 1 -'^С-valproic acid was given by intravenous infusion during 4.0 
hours to a female squirrel monkey of 820 g, which was in the last phase of 
pregnancy (Schobben et al. 1978). The infusion fluid consisted of 7.35 mg 
sodium valproate per ml saline solution, corresponding to 21.2 ßCA ^ C / m l , 
and was infused at a constant rate of 3.0 ml/hr. Blood samples were taken 
at intervals of 10-15 minutes. During the experiment the animal was kept 
under light halothane anaesthesia. After the infusion the foetus was taken 
from the mother by caesarian section and was sacrificed 15 minutes after 
termination of the infusion. The survival period of the mother was 15 
minutes longer. 
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D . A l year old male squirrel monkey (home breed, Central Animal Laboratory, 
Faculty of Medicme, Catholic University of Nijmegen), body weight 431 g, 
was given a constant rate infusion, containing 178 ßCi of 3-'^C-valproic 
acid{side-chain-labeled),oveT 9 25 hours The infusion fluid contained 13 7 
mg/ml of sodium valproate, corresponding to 10 3 MG/ml ^4C, in distilled 
water The infusion was given at a rate of 1 87 ml/hr. 
E. A similar experiment was performed, using a marmoset monkey (Calhthnx 
jacchus), body weight 330 g The infusion, containing 12 4 mg sodium val-
proate per ml, corresponding to 13 8 μ Ο l^C/ml (side-chain-labeled), was 
given at a constant flow rate of 1 16 ml/hr for 8 85 hours 
Both animals (D + E) were kept under light halothane anaesthesia and 
wereartificially respirated by means of a Keuzekamp pump, connected to a 
tracheal tube The infusion was given via a cánula in the femoral vein 200-
300 μΐ blood samples were taken via a cánula in the femoral artery at regular 
intervals, as indicated in figures 3 5 and 3 6. 
Autoradiography 
Whole body autoradiography was carried out according to the Uli berg method, 
as described by van der Kleijn (1969) After the chosen survival period the 
animals were killed — under deepened anaesthesia — by submersion into 
isopentane, cooled with solid carbon dioxide to -80oC The animals were stored 
at -20 0C The whole body was embedded in a 5 % carboxymethylcellulose gel 
of 0oC and frozen again. By means of a PMV 450 special microtome (PMV, 
Stockholm, Sweden), whole body sections of 30 /im thickness were made, at-
tached to Scotch tape 810 After freeze-drying at atmospheric pressure the 
sections were brought onto a Structunx D7FW rontgen film (Agfa-Gevaert). 
Exposure took place at -15GC during 3 weeks to 3 months After development 
positive prints were made, which are shown in figures 3 1 , 3 2 and 37-3 13 
White areas correspond to the presence of radioactivity. 
Tissue analysis 
From the body moieties, left after sectioning, parts of organs or tissues were 
removed, weighed and homogenised in saline solution (Schobben and van der 
Kleijn 1974, Schobben et al. 1977) Homogenates were used for determmation 
of total radioactivity, for GLC analysis of valproic acid and for TLC screening 
of radioactive metabolites (see chapter 4) 
Total radioactivity was determined by liquid scintillation counting (LSÇ) 
weighed quantities of tissue or homogenate were dissolved in Soluene 350®, 
decolourised with hydrogen peroxide and mixed with Instagel® Counting 
was performed in a Hewlett Packard Tncarb scintillation spectrophotometer 
Quenching corrections were made by the external standard method 
0 5 or 2 0 ml of the tissue homogenates were acidified with 12N sulphuric 
acid and extracted with 200 μΐ of chloroform, containmg cyclohexane car-
boxylic acid (internal standard) Homogenates of corresponding blank tissues 
from rats were spiked with valproic acid for calibration purposes GLC analysis 
was performed accordmg to Vree et al (1976) 
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Figure 3.1 
Whole body autoradiograms of 1-^C-valproic acid in mice during the first 15 
minutes after rapid i.v. administration of 200 ßCi/kg body weight. White areas 
correspond to the presence of radioactivity. Initially large amounts of radio-
activity are present in blood and liver. Later on, high concentrations are found 
in the kidneys, urine bladder, gall bladder, small intestine and nasal septum 
(from Schobben and van der Kleijn 1974). 
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Figure 3.2 
Whole body autoradiograms of 1-^C-valproic acid in mice. 20 minutes to 12 
hours after rapid i.v. injection. Note the accumulation of radioactivity in the 
olfactory bulb, in contrast with the rapid overall disappearance from the 
body (from Schobben and van der Kleijn 1974). 
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Plasma analysis 
Heparinised blood samples were centrifugea at 4000 rpm. 20-50 μΐ samples 
of plasma were mixed with Instage]®and assayed by LSC. 50-100 pi plasma 
were diluted with blank plasma up to 200 μΐ. These quantities were analysed 
for valproic acid by GLC according to the method of Vree et al. (1976). 
3.3 Distribution in mice 
Autoradiography shows the distribution of valproic acid and its labeled meta­
bolites (Schobben and van der Kleijn 1974). After intravenous injection of 
1-^c-valproic acid into mice a rapid distribution appears to occur (fig. 3.1). 
Already after 1 minute, maximal penetration is observed in several organs.There 
appears to be a relatively high radioactivity in blood and the liver (fig. 3.2). 
However, overall elimination is rapid. In the brain, much lower amounts of ra­
dioactivity are found. Elimination from the brain appears to parallel the disap­
pearance from blood during the first hour after injection (fig. 3.3). The half-
life for radioactivity is estimated at 20 minutes. Whole brain concentrations 
are about 30 per cent of those in blood, but initially an overshoot may be ob­
served: up to 5 minutes after injection the brain concentration is over 40 per 
cent ofthat in blood. A similar phenomenon was observed in cats by van Duijn 
et al. (1977)'. Relatively high levels of radioactivity appear tobe also present in 
the skin and hair follicles. 
After several minutes radioactivity is found in the gall bladder and in the kid­
ney; this is followed by labeling of urine and the intestines. Although radio­
activity is found in the small intestines already after several minutes, it is first 
seen in the large intestines, in smaller quantities, after several hours. This ob­
servation points towards a reabsorption of the drug or of its metabolites. In­
deed, Eymard et al. (1971) have demonstrated the existence of enteric cycling 
of radioactivity. The most important pathway of elimination appears to be via 
urine. From bile and urine, only small fractions of radioactivity could be ex­
tracted by organic solvents (Schobben and van der Kleijn 1974). This indicates 
that the radioactivity found there, is largely represented by metabolites of val­
proic acid, which are more polar than the drug itself. 
The distribution of radioactivity in the brain is rather homogeneous. However, 
the white matter fibre tracts of the cerebellum appear to be more intensively 
labeled (cf. Meinardi et al. 1975). This is observed already after 2 minutes. The 
penetration into thin-myelinated white matter structures may be considered 
remarkably fast. Phenytoin is known to penetrate the brain quickly; however, 
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blimination of total ^C-activity from blood and several tissues of mice, du­
ring the first hour after rapid ι ν injection of 200 ßCi/kg 1-^C sodium val-
proate (dipropyl-acetate) The semiloganthmic curves are almost linear and 
parallel After an initial overshoot, the radioactivity in brain is about one third 
of that in blood (from Schobben and van der Kleijn 1974) 
in cats, the white matter concentrations did not surpass those in grey matter 
before 3 hours after administration (Firemark et al 1963) 
A remarkable accumulation of radioactivity is fouçd in the olfactory bulb 
The maximal amount is reached after about 2 hours and the disappearance is 
very slow This phenomenon might be of pharmacological importance The ol-
factory bulb contains high amounts of GABA After administration of valproic 
acid GABA is significantly increased in this area (Simler et al 1976) Ciesielski 
et al (1975) suggested a relation between the activity of the enzyme GABA-
transammase and the accumulation of valproic acid in several brain regions, 
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such as the nucleus caudatus and the cerebellum. Mack et al. (1975) have de-
monstrated a very high efficacy of valproic acid against the 'mouse killing be-
haviour' of rats, when the drug was injected into the olfactory bulb directly. 
GABA given in the same way had an identical effect. In contrast to GABA the 
effect of valproic acid had a delay time of 30 minutes, but it lasted much longer. 
The olfactory bulb also appears to play a role in the anticonvulsant effect of 
valproic acid: Ueki et al. (1977) demonstrated that the protection of the drug 
against electroshock- and pentetrazole convulsions in mice was almost com-
pletely abolished by ablation of the olfactory bulb. Several other antiepileptic 
drugs did not show such effects, while the anticonvulsant activity of several 
benzodiazepines appeared to be enhanced. 
As will be discussed in the next chapter, a part of the radioactivity after ad-
ministration of carboxy-labeled valproic acid might represent carbonate, 
formed by decarboxylation of the drug. However, preliminary results of similar 
experiments with S-'^C-labeled valproic acid do not indicate significant differ-
ences. 
3.4 Distribution in monkeys 
Plasma kinetics 
In a previous experiment, after intravenous injection into a squirrel monkey, 
first order elimination of valproic acid was observed (Schobben et al. 1977). 
However, concentrations were followed over only 30 minutes. During intra-
venous infusion for 90 minutes the plasma concentrations found could be fit-
ted to the equation of a one-compartment model, although the apparent volu-
me of distribution tended to increase with time when calculated from the con-
centration of each sample. Half-lives of 60-70 minutes were found. The vali-
dity of the pharmacokinetic model is rigorously put to the test by the present 
infusion experiments over several of these half-lives. 
During the first hour of the infusion, the plasma concentrations appeared to 
fit the simple model. However, a steady state was not reached within the ex-
pected period and plasma concentrations seemed to rise almost in a log-linear 
proportion to time (fig. 3.4 and 3.5). Such curves could indicate non-linear ki-
netics. Although capacity-limited elimination has been demonstrated for some 
structurally related compounds, elimination curves of valproic acid over a wide 
range of plasma concentrations did not indicate corresponding properties (Cue-
len et al. 1977, Schobben et al. 1977, Vree et al. 1977a). Diminished protein 
binding at higher plasma concentrations will influence the distribution volume 
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Figure 3.4 
Sodium valproate concentration and total ^C-activity in plasma during first 
order i.v. infusion of 1-^C-valproic acid in a pregnant squirrel monkey. The 
valproate plasma concentrations have been fitted to equation (2). Concentra-
tion a corresponds to AJOLT and b to B/ßT respectively. The steady state con-
centration (c ) equals a + b. The indicated half-lives for the a- and ß-phase 
correspond to In 2/a and In 2/ß. 
and, by consequence, the clearance of the drug. This had been suggested by 
Levy et al. (1977a) to explain the increase of clearance with increasing dose in 
their long-term infusion experiments in rhesus monkeys. Protein binding stu-
dies of Potratzand Schulz (1976) revealed a total binding capacity of 190mg/l 
plasma. The offered explanation does not seem to be applicable in the present 
case, as in one monkey the log-linear increase of the plasma concentration oc-
curs between 50 and 100 mg/1. The observed curves appear to be accurately 
described by the sum of two exponential terms. This is consistent with a two-
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Figure 3.5 
Plasma concentrations of valproic acid and one of its metabolites (y-valprolac-
tonej in a squirrel monkey during a 9-hour constant rate i.v. infusion of the 
З-І^С labeled drug. Curves for total plasma ^C-activity (open circles) and 
valproate concentration (black dots) cannot be distinguished. The curve has 
been fitted to equation (2). 
compartment pharmacokinetic model. After a bolus injection of a dose D, the 
concentration in the central compartment at time t (cj ^0j) is given by: 
с
ІЬо1 = А.е-а1 + В .
е
^ (1) 
When the same dose is given by a constant rate intravenous infusion over in­
fusion time T, the concentration course during infusion (ci ¡ f) is described by 
the following equation: 
108 
' í inf40Nboldt=Aa-e*V£(l-e-<») (2) 
From the plasma concentration data Α/αΤ, B/0T, α and β were determined 
by graphical and regression analysis. 
These values were used to calculate the parameters for the two-compartment 
open model (Wagner 1971): 
Слі/· ι 
| k l 3 
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У 
k21 
2 
J 
c t 
wh( 
D 
T k l 3 V d 
; r e V l -
 D 
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.at a - k 1 3 
a-0 a-ß 
d k i i _ ^ ( A + B) 
. ^ (3) 
Aß-
к j2 and k2i can be calculated from: a + β = kj2 + ^21 + ' ' ІЗ 
α.β = к 1 з . k2 1 
ci = concentration in compartment 1 at time t (= plasma concentration) 
D = total dose, infused at constant rate over infusion period Τ (t<T) 
= apparent volume of compartment 1 vá 
'13 = rate constant for elimination 
^12' ^21 = r a t e c o n s t a n t s for transport between compartments 1 and 2 
The calculated parameters are given in table 3.1. Instead of the volume of com-
partment 1, the fictive total distribution volume (V^
 ss) is given, related to the 
body weight of the animals: 
'dss =
 v à ( 1 + ^ ) (4) 
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Table 3.1 Pharmacokinetic parameters of valproic acid in monkeys 
infusion time 
Τ 
squirrel 
monkey 
4hr 
9.25 hr 
marmoset 
monkey 
8.9 hr 
infusion rate 
sodium valproate 
D.T-'.BW1 
(mg-min-1 .kg-1) 
fictive 
distribution 
volume 
Vd'ss 
O/kg) 
1 
0.45 1.68 
0.99 0.52 
0.73 0.66 
rate constants 
k12 k21 k 13 
(min-1) 
0.04252 0.00752 0.00887 
0.05245 0.01005 0.00797 
0.01481 0.00385 0.00533 
The model appeared tobe applicable also in the marmoset monkey (fig. 3.6); 
distribution appeared tobe slower than in the squirrel monkeys. The high value 
for the volume of distribution in the 4-hour infusion experiment concerns a 
pregnant monkey. The gain of body fluid during pregnancy may be responsible 
for this figure. 
In order to study the distribution, relevant for the therapeutic use, a steady 
state situation should be reached. In view of the /3-phase found for elimination 
with a half-life of 10 hours for the squirrel monkey and 13 hours for the mar­
moset monkey, this situation has not been reached in the present experiments. 
Therefore, changes in distribution pattern after longer infusion periods may 
be expected. From the ratio between kj2 and k2i the relative amounts in com­
partment 1 and 2 can be estimated. As the second compartment may contain 
4-6 times the amount in the first compartment, the second phase may signifi­
cantly influence overall distribution. Long-term infusion experiments may also 
definitively prove the validity of the two-compartment pharmacokinetic 
model: the apparent exponential increase of plasma concentrations observed 
over several hours must approach the predicted steady state level. 
Beside valproic acid, metabolites also appear to accumulate in plasma, as may 
be concluded from the difference between the plasma concentration curves for 
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Valproic acid concentration and total ^C actmty in plasma during a 9-hour 
constant rate infusion m a marmoset monkey The concentrations of the meta­
bolite γ ι alprolactone are also indicated The \alproic acid concentrations have 
been fitted to equation (2) For further explanation see figure 3 4 
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Table 3 II Abbreviations used in monkey autoradiograms 
BF 
BL 
BM 
brach conj. 
CA 
CC, corp call 
cereb 
CH.chopt 
CoA.comm ant 
coll 
CST 
eye m 
ΠΙ term. 
GB 
GP 
grey cort 
hip 
HY 
I 
к 
L 
lemn 
LI 
lig flav 
brown fat 
blood 
bone marrow 
brachium 
conjunctivum 
nucleus caudatus 
corpus callosum 
cerebellum 
optic chiasma 
commissura 
antenor 
colhculus 
infenor/supenor 
cisterna 
eye muscles 
filum terminale 
gall bladder 
globus pallidus 
grey cortex 
hippocampus 
hypothalamus 
intestines 
kidney 
liver 
lemniscus 
large intestine 
ligamentum 
flavum 
LU 
MC 
nucí caud. 
nucí dent. 
olf.bulb 
ped cereb. 
pit 
oesoph. 
PO 
put. 
S 
SC, spin cord 
SG.salivgl. 
SI 
SM 
τ 
ΤΗ 
thai 
trolf 
V 
ventr 
vert 
UB 
umb cord 
Ut 
lungs 
myocardium 
nucleus caudatus 
nucleus dentatus 
olfactory bulb 
pedunculus 
cerebelli 
pituitary gland 
oesophagus 
pons 
putamen 
stomach 
spinal cord 
salivary gland 
small intestine 
skeletal muscle 
testis 
thymus 
thalamus 
tractus 
olfactonus 
vein 
ventricle 
vertebrae 
unne bladder 
umbilical 
cord 
uterus 
Figure 3 7 
Whole body autoradiograms of l-'4C-valproic acid in a pregnant squirrel mon­
key, foetus and placenta, after 4 hours constant rate ι ν infusion of 77 4 μΟ 
hr , kg'1 to the mother The foetus was taken from the mother by caesanan 
section Survival times after termination of the infusion are indicated Both in 
mother and foetus large amounts of radioactivity are found in blood, liver, 
kidney and small intestine Note the marked accumulation in the yellow liga­
ments in the adult monkey and in the penosi layer of the foetal bones (from 
Schobben et al 1978) 
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valproic acid and for total radioactivity (fig. 3.4 and 3.6). However, in the case 
of the 9-hour infusion to a squirrel monkey no difference between the curves 
could be detected. The cause for this exception is not known. Perhaps, the dis­
tribution of radioactivity in this animal can be attributed largely to unchanged 
valproic acid. The metabolite (γ-valprolactone) curves will be discussed in the 
next chapter. 
Whole body autoradiography 
Whole body autoradiography in squirrel monkeys after constant rate infusion 
of labeled valproic acid showed a limited distribution, comparable to that found 
in mice. The general distribution after 90 minutes, 4 hours and 9 hours infusion 
respectively was very similar (cf. Schobben et al. 1977, Schobben et al. 1978). 
No significant differences of distribution were found between the compounds, 
labeled in the carboxy-group or in the propyl-side-chain. The abbreviations used 
in figures 3.7-3.13 are explained in table 3.II. 
High levels of radioactivity are present in blqod, liver and kidney. Large quan­
tities appear to be excreted in urine and bile (fig. 3.7). Bile flow appeared to 
cause the amounts of radioactivity in the intestinal contents. In a newborn rhe­
sus monkey, 10 minutes after i.v. injection of labeled valproic acid, almost no 
radioactivity in the bile and the intestinal lumen was observed (fig. 3.9). Even 
after long-term infusion the large intestines contain smaller amounts of radio­
activity than have been observed in mice. This observation may also be ex­
plained by an extremely slow intestinal motility under the experimental con­
ditions. Only in one animal, significant radioactive faecal excretion has been 
found (fig. 3.8). 
There isa marked accumulation of radioactivity in the yellow ligaments. This 
has been observed for several antiepileptic drugs, and for other drugs as well 
(vanderKleijn et al. 1977a). This phenomenon is ascribed toa high affinity of 
these drugs for elastine (van der Kleijn et al. 1972). Its significance is not clear 
yet. 
Placental passage has been studied in an almost full-term pregnant squirrel 
monkey (fig. 3.7). A very similar distribution of radioactivity is found in mother 
and foetus. However, there appears to be a remarkable labeling of the periost 
layer of all parts of the foetal skeleton. This might be related to the teratoge­
nic effects of valproic acid, which have been reported in animal studies (Whittle 
1976). In rabbit especially, abnormalities of the axial skeleton have been ob­
served, in rat predominantly the lumbar vertebrae were effected. These effects 
have been attributed to late ossification (Nixon 1976). Schäfer and Kettner 
(1974) have suggested that the loss of hair, observed in some patients on val-
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proie acid therapy, might be associated with teratogenicity. In the present study 
high amounts of radioactivity are also found in the skin and hair follicles. This 
is even more pronounced in the marmoset monkey (fig. 3.8). 
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Figure 3.8 
Whole body autoradiograms of S-'^C-valproic acid in a squirrel and a marmo-
set monkey after 9 hours of constant rate i.ν. inßusion. A corresponding limit-
ed distribution pattern is found in both species. The high radioactivity in stom-
ach and oesophagus is caused by reflux of intestinal fluid. After the long-
term infusion applied here also the large intestine and, in one case, the faeces 
appear to be radioactively labeled. Especially in the marmoset monkey the 
skin appears to contain large amounts of radioactivity. 
115 
Figure 3.9 
Whole body autoradiogram of a newborn rhesus monkey, 10 minutes after a 
rapid i.v. injection of about 120 ßCi/kg I-'^ С-valproic acid. Note the rapid 
penetration into various organs and the relatively high brain radioactivity. For 
further explanation see text. 
In a newborn rhesus monkey, the periost was not labeled as clearly, but a sur­
vival period of only 10 minutes may be too short for accumulation (fig. 3.9). 
In this animal, the teeth pulp, the eye and ligaments within the lumbar verte­
brae appear to be labeled quickly. Also the amount of labeled material in the 
brain is relatively high. The grey matter is more active than the white matter. 
Probably, this can be based on the differences in blood supply. A similar, al­
though more pronounced, initial labeling of grey matter structures had been 
observed for diazepam (van der Kleijn and Wijffels 1971). 
Quantitative data on distribution of radioactivity, obtained by tissue analy­
sis, are indicated in table 3.III. 
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Table 3 III Tissue distribution of radioactivity in squirrel monkey 
Tissue 
blood 
brain 
liver 
bile 
intestinal contents 
kidney 
unne 
muscle 
relative ^ C activity* 
after 114 hours 
100 
30 
104 
1705 
32 
after 4 hours 
100 
26 
246 
6375 
3341 
400 
2622 
33 
after 9 25 hours 
100 
32 
114 
2562 
989 
91 
650 
* dpm per gram of tissue is related to whole blood radioactivity (= 100%) 
As the relative amount of radioactivity in brain tissue does not change with 
increasing infusion time, no general accumulation in brain tissue appears to take 
place The high values for the 4-hour experiment are due to the rapid decline 
of plasma concentration during the 30 minutes survival period after the discon-
tinuation of the infusion 
GLC analysis showed that almost all radioactivity was represented by free 
valproic acid in blood and muscle In contrast, only a few per cent of radio-
activity was present as such m bile and unne In the intestinal contents wide 
differences were found This may be related to the site of sampling and the 
storage conditions valproic acid glucuronide will easily hydrolyse under alka-
line conditions 
Regional bram distribution 
Brain distribution in squirrel monkey appears to change with increasing infu-
sion times After 90 minutes, the distribution is rather homogeneous, but, as 
in the mouse, the white matter fibre tracts of the cerebellum are clearly more 
labeled Also in the postenor lobe of the cerebrum, white matter appears to 
contain a higher amount of radioactivity (fig 3 10) 
After 4hours, the picture appears tobe reversed now in all brain regions the 
grey matter is more labeled (fig 3 11) Moreover marked amounts of radio-
activity appear to have accumulated in the olfactory bulb and the postenor lobe 
of the pituitary gland After 9 hours of infusion a more differentiated pattern 
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is observed, but in the cerebellum white matter activity predominates again (fig. 
3.12). The presence in the cerebellum, which is shown by most other antiepi-
leptic drugs (Cuelen and van der Kleijn 1978) is considered of importance for 
the antiepileptic effects: the cerebellum has an inhibitory and regulatory influ-
ence on many brain activities. As blood supply is better for grey matter, in-
itially higher concentrations in these areas are to be expected. White matter con-
tains more proteins and phospholipids, and therefore will have a higher affinity 
for most antiepileptic drugs (Harvey et al. 1977). For those reasons a shift from 
grey to white matter could be explained. Perhaps the use of the side-chain-
labeled valproic acid in the 9-hour infusion has played a role. This will still not 
explain the difference between the two shorter experiments. 
The amount of metabolites present might offer an explanation. In the last 
plasma samples taken during infusion, valproic acid appeared to account for 85 
per cent of total radioactivity in the shortest experiment, and for 67 per cent 
Figure 3.10 
Autoradiogram of l-'^C-valproic acid in squirrel monkey brain after constant 
rate i.v. infusion of 440 ßCi/kg body weight during 1.5 hours. Note the high 
radioactivity in the cerebellar fibre tracts and in the white matter of the pos-
terior lobe (from Schobben et al. 1977J. 
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after 4 hours. During the 9-hour infusion no differences between total radio-
activity and valproic acid could be detected, suggesting slight metabolism in the 
animal. As will be shown in the next chapter, the highest metabolite content 
in brain was found after the 4-hours infusion. Therefore the observed differen-
ces might be explained by a preference of the - more hydrophilic — meta-
bolite(s) for grey matter structures, while the distribution of radioactivity after 
the longest infusion may be mainly attributed to unchanged valproic acid. 
In view of the long terminal half-life of the drug, found in the present experi-
ments, steady state still has not been reached. Nevertheless, after 9 hours some 
differentiated distribution becomes visible. The accumulation in the olfactory 
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Figure 3.11 
Autoradiogram of 1-^C-valproic acid in squirrel monkey brain after 4 hours 
of infusion. Brain of the monkey shown in figure 3.4. A marked accumulation 
of radioactivity is found in the olfactory bulb and in the posterior lobe of the 
pituitary gland. In contrast to figure 3.10. now the grey matter structures in 
the cerebellum and the cerebral hemispheres appear to contain higher amounts 
of radioactivity than white matter. Metabolites are held responsible for the 
difference. 
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Figure 3.12 
Autoradiograms of З-'^C-valproic acid in squirrel monkey brain. Six sagittal 
sections of the brain of the squirrel monkey shown in figure 3.8. The monkey 
was sacrificed after a constant rate infusion of 413 ßCi/kg body weight during 
9.25 hours. High amounts of radioactivity are found in the blood vessels, the 
surroundings of the vascular plexuses and the olfactory bulb. Some structures 
contrast with their surroundings by a higher radioactivity : the cerebellar fibre 
tracts, the nucleus dentatus and the pedunculi cerebelli, the putamen and the 
nucleus caudatus. 
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bulb, which appears to be specific for valproic acid, is also found in monkeys. 
The pronounced accumulation in the posterior lobe of the pituitary gland, 
which has been observed in the 4-hour experiment, is not significant any lon­
ger. Again, this may be due to the use of another label, or to the degree of me­
tabolism. Besides the fibre tracts in the cerebellum, their extensions into the 
cerebrum, the pedunculi cerebelli, also appear to accumulate radioactivity. The 
nucleus dentatus, one of the basal nuclei in the cerebellum, is also labeled. The 
corpus striatum, the colliculi, the commissura anterior and the optic chiasma 
appear to be more labeled than their surroundings. Experiments of still longer 
infusion times are needed to ascertain whether the observed differentiation in 
brain distribution may lead to significant accumulation during chronic treat­
ment. Radioactivity in the pia mater may be ascribed to the blood vessels and 
the elastine present within this membrane. Within the cerebrum not only the 
blood vessels are striking by their high radioactivity, but also the surroundings 
of the vascular plexuses. 
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Figure 3.13 
Autoradiogram of З-'^C-vaiproic acid in marmoset monkey brain, after linear 
infusion of399ßCijkgbody weight during 8.85 hours. Note the marked radio-
activity in the olfactory bulb and the pituitary gland. Other brain areas show 
less contrast than was found in squirrel monkey. 
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In the marmoset monkey, brain distribution is less pronounced than in the 
squirrel monkey, but essentially the same areas contain more radioactivity (fig. 
3.13). 
3.5 Conclusions 
Distribution of valproic acid appears to be rapid, but rather limited. In mice, 
maxima] concentrations are reached within 1 minute after intravenous injec­
tion in many organs. Penetration into brain is also rapid, even into the less ac­
cessible white matter. Renal excretion appears to be the most predominant way 
of elimination. Also in bile large amounts are excreted, but reabsorption is like­
ly. In bile and urine mainly metabolites are found, which are less lipophilic than 
the parent drug. 
The one-compartment open model, which has been successfully applied pre­
viously to the description of the pharmacokinetics of valproic acid in monkeys, 
is not applicable to the present data. The plasma concentration curves obtained 
during constant rate infusion to squirrel and marmoset monkeys over several 
hours, appear to fit a bi-exponential function. Two phases with strongly devi­
ating half-lives are found: 10-30 minutes for the α-phase and 10-13 hours for 
the j3-phase. Infusion experiments over several j3-phase half-lives will be neces­
sary to obtain a steady state distribution, at least for the parent drug. Such ex­
periments also may definitely prove the validity of the chosen two-compart­
ment model. As the amount of the drug in the second compartment may ac­
count for the largest fraction of the total body content, the distribution pat­
tern will be different after longer infusion periods. However, no gross differ­
ences in total body distribution have been observed after 1.5 hours and 9 hours 
of infusion. 
Valproic acid appears to cross the placental barrier freely. Distribution in 
mother and foetus was nearly identical. The high concentration of the drug in 
the periost layer of the developing foetus may be related to teratogenicity which 
has been found in animal studies. Loss of hair, which has been reported in pa­
tients, may be related in a similar way to the accumulation in the skin and hair 
follicles. 
The average brain concentration of radioactivity is approximately 30 percent 
of that in blood. Regional brain distribution is much more diffuse than that 
of other antiepilcptic drugs, but it may become more differentiated after pro­
longed infusion. A remarkable, slow accumulation of radioactivity is observed 
in the olfactory bulb, both in mice and monkeys. The marked role of GABA 
in this structure may be of interest in this respect. Because of their structural 
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resemblance, valproic acid might be bound to receptors or enzymes, which 
normally react with G ABA Also, the accumulation in the corpus striatum, 
which is rather specific for valproic acid, may be related to the activity of the 
GABA-system in this area Higher affinity of the drug for the fibre tracts, 
basal nuclei and peduncuh of the cerebellum and for the collicuh may be con-
sidered as similarities with other antiepileptic drugs (Guelen and van der Kleijn 
1978) 
Results of the present squirrel monkey experiments suggest that the meta-
bolites of valproic acid have a bram distribution, almost opposite to that of the 
parent drug Predominant labeling of grey matter structures was observed in 
one animal In this monkey, metabolites accounted for the highest percentage 
of total brain radioactivity found until now 
Synthesis of 3-^C-vdlproic acid yielded a product of sufficient specific activ-
ity and purity However, no significant differences of distribution in compari-
son to the compound labeled in the carboxy-group, have been found 
The results of the present study offer some arguments in support of the hy-
pothesis of a gradual accumulation of valproic acid at the site of action, put 
forward to explain the late onset of the therapeutic effect 
— Autoradiography showed a gradual development with increasing infusion 
times, from a rather uniform brain distribution into a pattern with more 
contrasting areas 
— The unchanged drug, rather than its metabolites, is likely to be responsible 
for the late distribution phenomena, as an almost opposite distribution pat-
tern was obtained in the presence of considerable amounts of metabolite 
— The pharmacokinetic model, chosen to explain the observed concentration 
curves, involves a slow accumulation of the drug in a peripheral compartment 
Complementary arguments will be given in the next chapter 
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Chapter 4 
Metabolism of valproic acid 
4.1 Introduction 
The late onset of the therapeutic effect of sodium valproate, following the 
start of treatment, is not compatible with the short half-life of the drug. One 
of the possible explanations is the accumulation of a metabolite, which is 
responsible for the pharmacological effect. Although some metabolites have 
been identified during recent years, the elimination pathways of valproic acid 
have not been fully elucidated. It was the aim of the present study to provide 
some quantitative data on the metabolism of valproic acid in several animal spe­
cies, and in epileptic patients. 
In the search for metabolites only a limited number of analytical detection 
methods are suitable because of the physico-chemical properties of the drug and 
related compounds. Gas chromatography can be considered the only possibility 
for unlabeled material. One of the greatest drawbacks of this approach is the 
vast number of closely related substances with similar properties naturally oc­
curring in body fluids. Therefore, it is not surprising that the first data on the 
extent of metabolism of the drug have been obtained by the use of the radio-
actively labeled compound. The present study started from a similar approach. 
4.2 Materials and methods 
Chemicals 
l-'^C-valproic acid, 1 mCi/mmole was kindly supplied by Dr. HJ. Kupferberg, 
National Institute of Neurological and Communicative Disorders and 
Stroke, Bethesda, Maryland, USA. 
3-^C-valproic acid, 1.30 mCi/mmole, synthesis described in appendix 1. 
γ-valprolactone, δ-valprolactone and 2-propyl-3-pentenoic acid, syntheses 
described in appendix 2. 
/3-glucuronidase, 4 x 1 0 ° units/g, was obtained from Sigma. 
Instagel® and Soluene 350® were obtained from Packard-Becker, the Nether­
lands. 
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All other reagents were analytical grade and have been obtained from Merck, 
Darmstadt, Germany. 
Май balance study in macaca monkey 
An eight years old malt rhesus monkey (Macaca mulatta), body weight 7.9 
kg, was given a rapid intravenous injection containing 289 mg of 3-^C sodium 
valproate, corresponding to 92.0 μ€ί l^C ij, 6.6 ml distilled water. Subse­
quently an intravenous infusion of physiological saline 20 ml/hr was given 
for 6 hours. The animal was kept under light anaesthesia by inhalation of 
nitrous oxide 3 1/min and oxygen 1 l/min, and the intravenous injection of 
120 mg of pentobarbital for induction of anaesthesia and 60 mg 6 hours later. 
Respiration was maintained by means of a Keuzekamp pump (Loosco) and a 
tracheal cuff tube at 20 inhalations per minute. During the first 6 hours 
expiratory air was sucked through 100 ml of aminoethanol, which was replaced 
each hour. 1 ml sample of each fraction was mixed with 4 ml of water and 10 
ml of Instagel®. Radioactivity was determined by liquid scintillation counting 
(LSC). 2 ml heparinised blood samples were taken by means of a catheter in 
the femoral artery at intervals increasing from 2 minutes up to 30 minutes 
until 6 hours after injection. Urine fractions were collected by means of a 
bladder catheter. 
After 6 hours, nitrous oxide and saline infusion were discontinued, tracheal 
tube, arterial and venous lines and urine catheter were removed and the animal 
was left in a metabolic cage for one week. Blood samples were taken at larger 
intervals as indicated in fig. 4.9. Urine and faeces were collected regularly up 
to 5 days after injection. 
100 μΐ blood samples were used for LSC after pretreatment with Soluene 
350®. Blood samples were centrifuged at 3000 г.p.m. Also ΙΟΟμΙοί each plasma 
sample were mixed with Instagel® for LSC. Valproic acid and metabolites 
were analysed as indicated. 100 μΐ of each urine fraction were also assayed for 
total radioactivity. Urine samples were further analysed for valproic acid and 
metabolites after treatment with ^-glucuronidase. All collected faeces fractions 
were homogenised in water and fractions were assayed for total radioactivity 
after pretreatment with Soluene 350®. Total amount and excretion rate of 
radioactivity were calculated for each aminoethanol, urine and faeces fraction. 
After one week the experiment was repeated. The injection now consisted 
of 293 mg 1-14C of sodium valproate corresponding to 81.2 дСі ^ C in 5.8 
ml distilled water. Collection of expiratory air and frequent blood sampling 
was now proceeded during 7 hours. Two more doses of 60 mg pentobarbital 
were given. 
Other animal experiments 
The experiments with labeled valproic acid in squirrel and marmoset monkeys 
are described in chapter 3. 
The infusion experiment in a dog after 3 weeks of maintenance treatment 
with carbamazepine and valproic acid is described in chapter 5. 
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Routine patient samples 
Plasma samples from 30 epileptic patients, obtained for routine monitoring 
of antiepileptic drugs including valproic acid, were analysed for valproic acid, 
7-valprolactone and metabolite III Seven patients were treated with valproate 
alone, the remaining 23 patients were treated with one or two additional anti-
epileptic drugs Phénobarbital, Phenytoin and carbamazepine were the most 
frequently used concomitant drugs Sodium valproate doses ranged from 6-70 
mg/kg daily Most samples had been taken about three hours after the morning 
administration of the drug In 5 patients 2 samples were available, one taken 
just before the morning mtake and one 2-3 hours later 
Discontinuation of valproate treatment m epileptic patients 
Patient Ρ Η (male, 18 years, 63 kg) had been treated with 1500 mg sodium 
valproate,225 mg Phenytoin sodium and 600 mg carbamazepine daily for several 
months Because of serious continuing myoclonies, valproic acid was replaced 
by clonazepam, 6 mg daily Blood samples were taken at 8, 42, 45, 71, 94 
and 185 hours following the last dose of sodium valproate. 
Patient J S (male, 14 years, 80 kg) had been treated with 3 χ 300 mg sodium 
valproate alone f or 6 weeks Because of lack of effect valproate was replaced by 
phenytom 75 mg daily at once Blood samples were obtained daily during one 
week Sodium valproate treatment was discontinued on the third day Samples 
one and two were taken at 12 00 and 17 30 o'clock respectively, the medication 
instruction being equal doses at 8, 12 and 18 o'clock The remammg samples 
were taken 5, 29, 53, 77 and 98 hours after the last dose 
Samples were analysed for valproic acid and metabolites. 
Analysis of valproic acid 
Valproic acid in blood plasma and unne was determmed accordmg to Vree 
et al (1976) Urine was assayed both directly and after alkaline or enzymatic 
hydrolysis 0 5 ml of urine and 0 5 ml of 4 N sodium hydroxide were heated 
at 9 0 1 for 1 hour, 0 5 ml of unne, 0 1 ml of 0 2 N acetic acid, 0 5 ml of 0 1 
M potassium dihydrophosphate solution and 50 jul buffer containing 20 000 
units /3-glucuronidase were incubated at 3 7 1 overnight Plasma or urine 
calibration samples were treated identically 
Screening of unne for metabolites 
Urine samples of patients and animals treated with valproic acid were hydro-
lysed with alkali Chloroform extracts were analysed on a coupled gas chroma-
tograph/mass spectrometer Mass spectra of each peak were recorded A Hewlett 
Packard 5710A gas Chromatograph was provided with a 1 80 m χ 3 mm I D 
glass coiumn, packed with 5 % FFAP on Gaschrom Q, 60-80 mesh (Chrompack, 
Middelburg, the Netherlands) Column temperature was increased from 1 ΙΟ­
Ι 70 0C at a program rate of 47mm The column outlet was coupled directly 
or by a membrane separator to a Hewlett Packard 5982A quadrupole mass 
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spectrometer. Camer gas was helium 20 ml/min. for the electron ionisation 
mode and methane ± 30 ml/min. in the chemical ionisation mode to achieve 
a methane pressure of 2 χ 10"^ torr. Electron ionisation was achieved at 70 
eV; chemical ionisation at 300-390 eV. The ionisation chamber temperature 
was held at 110 C. Total-ion chromatograms were recorded on a Hewlett 
Packard 7130A recorder. By means of a Hewlett Packard 18634A Multiple 
Ion Detection System single ion chromatograms were obtained at m /e = 143, 
171, 183 (M.W. 142 + 1,+ 2 9 , + 41), 145, 173, 185 (M.W. 1 4 4 + l , + + 2 9 , 
+ 41) and 161 (M.W. 160 + 1) in the chemical ionisation mode and at m /e = 
100 and 102 (loss of СзН^) in the electron ionisation mode. Detector gain: 
high, x6. Amplification: gain 10 - 100, span 1-5. Mass spectra were recorded 
by means of a Datagraph 5-154 light beam oscillation recorder,scan speed 200 
mass units/sec from m7e 0 to 300. 
Quantitative assay for valproic acid and metabolites 
In a nipple tube 0.2 ml of plasma or tissue homogenate was mixed with 100 
μΐ of ethanol, containing 10 ng of cycloheptane carboxylic acid (internal 
standard), 2 drops of 12 N sulphuric acid and 100 μΐ of chloroform. To 0.2 ml 
of urine 2 drops of 12 N sulphuric acid and 100μ1 of chloroform, containing 
10 ng of cycloheptane carboxylic acid, were added. This mixture was shaken 
on a Vortex-mixer for 15 seconds and centrifuged for 10 minutes at ЗОООг.р.т. 
2 μΐ of the chloroform layer were injected into the coupled GC/MS instrument. 
The GC oven was programmed from 160-190 0C at 47min. Single ion chroma­
tograms were recorded at m+/e = 143. Attenuation: gain 1000 + 100, span 1. 
Peak height ratios were correlated with concentrations. 
Calibration samples were prepared by dilution of a stock solution with blank 
plasma or urine. The stock solution consisted of equal parts of 1% sodium val­
proate in water and an ethanolic solution containing 100 mg of 2-propyl-3-
pentenoic acid and 10 mg of 7-valprolactone in 100 ml. In order to estimate 
the extraction efficiency tissue homogenates were analysed a second time, af­
ter incubation with added standard amounts of valproic acid and of γ-valpro-
lactone approaching the amounts of these substances, that had been found in 
the first analysis. 
Concentrations of valproic acid and metabolites greater than 20 mg/1 could 
be quantitated by GLC with flame ionisation detection (F.I.D.). This method 
was employed for dog urines. 0.2 ml of urine, both without and after treat­
ment with j3-glucuronidase, was acidified with two drops of 12 N sulphuric 
acid and was extracted with 100 μΐ of chloroform, containing 50 ng of cyclo­
heptane carboxylic acid. The mixture was shaken and centrifuged, and 2 μΐ of 
the chloroform layer were injected into a gas Chromatograph with F.I.D. de­
tector. Apparatus and column were identical to those mentioned for GC/MS 
analysis. Nitrogen was used as carrier gas at 30 ml/min. Hydrogen and air sup­
ply were set at 30 ml/min. and 150 ml/min. respectively. The analysis was 
operated isothermally at 150 CC. 
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Radio-chroma tograp hy 
Amounts of body fluids or tissue homogenates corresponding to 5 χ 10"* -
2x10-' dpm were acidified with 12 N sulphuric acid, and were shaken with 
200 μΐ of chloroform on a Vortex-mixer. After centrifugation at 4000 r.p.m. 
during 15 minutes, as much as possibleof the chloroform 1ауег(50-150д1) was 
transferred to a precoatedTLC plate, silicagel F (Merck, Darmstadt, Germany). 
After development with acetone,methanol, benzene,ammonia 25% (5:2:2:1) 
over 150 mm the radioactive spots were detected with a Desaga scanner (type 
12-2/LB2031). 
4.3 Metabolites in rats 
After oral administration of ^C-carboxy-labeled valproic acid to rats, Ey-
mard et al. ( 1971 ) have detected an important excretion of radioactivity in bile 
and urine. By means of thin layer chromatography they found 6 different radio­
active components in the bile. By implantation of a bile cánula in the gut 
of a second rat they were able to demonstrate enterohepatic cycling. This was 
confirmed by Kukino et al. (1972), who reported a biliary excretion of 40-60 
per cent of the administered radioactivity, while normally only 10 per cent was 
found in faeces. About 70 per cent of the dose was recovered from urine and 
10-20 per cent appeared to be expired in the form of labeled CO2. Bile and 
urine contained both free and conjugated valproic acid, the major part in the 
form of a glucuronide. In vitro experiments showed that the formation of 
labeled CO2 took place in the mitochondrial fraction of liver homogenates. In 
view of the dependency on oxygen and certain coenzymes the authors sugges-
ted j3-oxidation as a metabolic pathway. 
Kuhara and Matsumoto (1974) demonstrated the excretion of 2-prapyl-
glutaric acid and probably 5-hydroxy-valproic acid in rat urine. In this way they 
proved the ω-oxidation pathway. A few years later the presence of 3-oxo-vaI-
proic acid, a product of ß-oxidation, was made plausible (Matsumoto et al. 
1976). The authors proposed a hypothetic metabolic scheme for valproic acid, 
involving both β-, ω- and (<ij-l)-oxidation. 
The formation of labeled CO2 described above was interpreted as a cleavage of 
the 3-oxo metabolite to propionyl-coenzyme A and pentanoyl-coenzyme A, 
which is further broken down to propionyl-coenzyme A and acetyl-coenzyme 
A. Propionyl-coenzyme A is carboxylated and further converted into succinyl-
coenzyme A, which enters the Krebs cycle. In this way the complete valproic 
acid molecule might be catabolised to form carbon dioxide. 
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Figure 4.1 
Sodium valproate concentration (GLC) and total '^C-activity in plasma of a 
dog, treated with 50.8 mg/kg of the 1-^C labeled drug, corresponding to 2.56 
ßCi/kg, by i.v. infusion for 205 min. The interrupted lines are the residuals of 
'^C-activity and the concentration of the unchanged drug, representing the 
sum of metabolites. Note the slow elimination of total radioactivity (from 
Schobben and van der Kleijn 1974). 
4.4 Isotope dilution experiments in dogs and monkeys 
Kinetic studies in dogs, combining determination of unchanged valproic acid 
and of total radioactivity in blood plasma after administration of the labeled 
drug, have provided the first information on the presence of metabolites within 
the body. In the dog, a substantial difference between elimination half-life of 
valproic acid and total radioactivity was found (fig. 4.1) (Schobben and van 
der Kleijn 1974). Half-lives of 1 and 17.6 hours respectively suggest accumula-
tion of metabolites up to plasma concentrations exceeding those of the parent 
drug. 
In monkeys however smaller differences between unchanged drug and radio-
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activity were found. Plasma concentrations determined in autoradiography ex-
periments in squirrel monkeys up to survival periods of 4 hours, revealed half-
lives for valproic acid between 61 and 74 minutes, according to a single compart-
ment model. Total radioactivity was eliminated with a half-life of 100-113 
minutes (Schobben et al. 1977, Schobben et al. 1978). 
Surprisingly, during a 9-hour infusion to a squirrel monkey no significant 
amounts of metabolites have been detected: plasma curves for valproic acid 
and total radioactivity appeared to coincide completely (fig. 3.5). As has been 
shown in the previous chapter the concentration curves could be fitted to a bi-
exponential function. Due to the unexpectedly long terminal elimination half-
life, plasma concentrations had risen to an exceptional high level (800 mg/1). 
Maybe metabolic pathways are impaired at these concentrations. When the ex-
periment was repeated in a marmoset monkey, a similar difference between 
total radioactivity and the unchanged drug in plasma was observed, as in the 
earlier experiments (fig. 3.6). 
4.S Urinary excretion 
More concrete data on the amount of valproic acid that is subjected to metab-
olism, may be obtained from analyses of urine. Both in man and several ani-
mal species usually less than one per cent of the dose is excreted unchanged. 
Heating with alkali or treatment with ^ -glucuronidase liberates important quan-
tities of valproic acid. In human urine, both methods yielded different amounts 
of the free drug, suggesting that the glucuronide as well as other conjugates are 
excreted (Vree and van der Kleijn 1977b). The nature of the other conjugates 
has not been clarified yet. Treatment with sulfatase did not increase valproic 
acid concentrations (Regazzi Sonora et al. 1979). Gompertz et al. (1977) 
rejected the possibility of glycine conjugation. Among the remaining alternatives 
conjugation with glutamine is most probable. Vree and van der Kleijn (1977b) 
demonstrated that the amount of conjugates was dependent on dose and urinary 
pH. Including extreme conditions in this respect 15-80 per cent of a single dose 
could be recovered from urine. As bioavailability of the drug appears to be 
complete and autoradiography experiments indicate that by far the greatest 
amount of radioactivity is excreted by the renal pathway, search for urinary 
metabolites has been undertaken in several laboratories. 
By means of radio-chromatography the existence of several metabolites has 
been clearly demonstrated. After 4 hours infusion of l-'^C-labeled valproate 
into a squirrel monkey, the urine yielded at least 7 radioactive compounds 
(Schobben et al. 1978). After alkaline hydrolysis and TLC separation 5 spots 
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2-PROPYL-PENTANOATE-CARBOXY-4C IN SQUIRREL MONKEY 
Τ L С-separation of radioadive compounds 
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Figure 4.2 
Distribution of metabolites in squirrel monkey after 4 hours i.v. infusion of 
l-l^c-valproic acid. Radioscans of acidic extracts of body fluids and tissue 
homogenates after TLC separation. The Rf-value of valproic acid corresponds 
topeakC, the Rt of 2-propyI-glutaric acid corresponds topeakA. E represents 
about 35% of total brain radioactivity (from Schobben et al. 1978). 
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Table 4.1 Tissue distribution of valproic acid and metabolites 
blood 
brain 
liver 
bile 
intestine 
kidney 
urine 
total 
valproic acid 
JUg/g 
50 
10 
69 
4560 
2190 
219 
1940 
% of total 14C-activity 
peak С 
(= VPA) 
81 
63 
78 
96 
97 
93 
90 
peak A 
1 
1 
1 
peakD 
3 
1 
1 
1 
peak E 
19 
37 
19 
2 
1 
7 
8 
were detected (fig. 4.2). By two-dimensional TLC, spot С and E appeared to 
consist of two components each. Peak С from the scan mainly corresponds to 
valproic acid. Because of its low migration, peak A probably represents a 
dicarboxylic acid. It has the same Rf-value as 2-propyl-glutaric acid, that has 
been proven to be one of the urinary metabolites of valproic acid (Kuhara and 
Matsumoto 1974). The most interesting metabolite, however, is represented 
by peak E as this substance also appears to occur in blood and brain tissue. 
This radioactive spot was also present when alkaline urine was extracted. 
Therefore, the substance is not a free carboxylic acid. From analogous 
assays, the relative amounts of several radioactive compounds have been esti­
mated for several organs and body fluids (table 4.1). In this table, the total val­
proate concentrations are also indicated. In blood and brain tissue, the same 
concentrations of valproic acid were found before and after hydrolysis. These 
results suggest that the drug occurs only in the unconjugated form. 
GLC screening of urine from patients treated with valproic acid and from ani­
mal experiments revealed some drug specific peaks (fig. 4.3). Metabolite I ap­
peared to be present consistently in urine from patients and monkeys after 
valproate treatment. The second metabolite gave much more difficulty because 
of its low concentrations and because separation from valproic acid has been 
successful only under optimal analysis conditions. Depending on column and 
flow conditions the peak could be observed just before or just after the peak of 
valproic acid. Metabolite III was found in dog urine. Coupled gas liquid chro-
matography/mass spectrometry (GC/MS)led to the surprising discovery that all 
three metabolites had a molecular weight of 142. Rigorous screening of urine of 
patients with GC/MS revealed that more substances with the same molecular 
weight are often present, but their association with valproic acid treatment 
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Figure 4.3 
Valproic acid (2-PP) and three metabolites in the urine of an epileptic patient, 
beagle dog and squirrel monkey. GLC chromatograms of acidic urine extracts, 
obtained by flame ionisation detection. The internal standard is cyclohexane 
car boxy lie acid. 
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could not be established with certainty. Also the radioactive spot E from the 
thin layer chromatograms mentioned above appeared to contain substances 
with the molecular weight of 142, probably identical to metabolite I and II. 
Since this discovery, attempts have been undertaken to obtain these substances 
by synthesis and to develop quantitative assay methods. 
4.6 Possible valproate metabolites 
As the molecular weight of valproic acid is 144, the occurrence of substances 
with mass 142 is a strong indication for unsaturated metabolites. However, 
there is another important possibility. Linear fatty acids are predominantly 
metabolised by 0-oxidation. ω-Oxidation and (cj-l)-oxidation occur also and 
these pathways are even more important in the case of branched-chain fatty 
acids (Preiss and Bloch 1964, Schreiber 1974). Kuhara and Matsumoto (1974) 
were able to prove the ω-oxidation of valproic acid in rats. Beside 2-propyl-
glutaric acid, the existence of the intermediate 5-hydroxy-valproic acid was 
also plausible. This compound and other hydroxylated fatty acids tend to form 
lactones. The lactones of all monohydroxylated valproic acid metabolites will 
have a molecular weight of 142. Even when the hydroxy-metabolites occur as 
free acids in vivo, they will be transformed into the corresponding lactones by 
the usual extraction procedure at acidic pH. Therefore 3-OH, 4-OH and 5-OH 
valproic acid lactones may be identical to the metabolites found. The 3-OH de­
rivative is somewhat less likely to form a lactone, as /Mactones are usually not 
very stable. However, the existence of the unsaturated compounds is not im­
probable. The first step in the oxidation processes mentioned before, is thought 
to proceed by dehydrogenation, leading to unsaturated intermediates, which 
are in turn hydrated. Consequently also, three mono-unsaturated derivatives 
of valproic acid may play a role as metabolites. The situation becomes more 
complex asseverai of the proposed substances may occur as stereoisomers. Iso­
mers may have different physico-chemical properties and then will be detected 
separately. Three of the possible metabolites with molecular weight 142 were 
synthetised (appendix 2): δ-valprolactone (5-OH-valproic acid lactone), γ-val-
prolactone (the 4-OH isomer) and 2-propyl-3-pentenoic acid (/3,7-unsaturated 
valproic acid). Their structural formulas are shown on the next page. 
4.7 Assay methods 
As for valproic acid itself, gas liquid chromatography is the most appropriate 
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analytical technique for these compounds. However, the metabolite concen­
trations are much lower and detection sensitivity becomes a limiting factor. 
Because of the volatility of the compounds to be analysed only minor enrich­
ment is possible. To overcome these difficulties, advantage was taken of the 
common molecular weight, by use of the highly specific and sensitive single ion 
detection possibility of the mass spectrometer. The main M.W. + 1 peak of the 
valproic acid 
cyclo heptane 
carboxylic acid 
1-val pro lactone 
chemical ionisation 
methane 3 0 0 eV 
single ion 
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160° 170° 180° 190° 
Figure 4.4 
Quantitative analysis of valproic acid and two metabolites in plasma by means 
of coupled gas liquid chromatography ¡mass spectrometry. Single ion chroma-
togram of a calibration sample, containing 100 ßg/ml sodium valproate, 10 
ßg/ml 2-propyl-3-pentenoic acid and 1 ßg/ml y-valprolactone. Cycloheptane 
carboxylic acid is the internal standard. 
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Figure 4.5 
Calibration curves o f valproic acid and two metabolites, analysed by the GLC/ 
mass spectrometry method. Because of the diverging concentrations the curves 
are shown on a log-log scale. 
chemical ionisation mass spectrum was chosen for this purpose. At the same 
time the smaller M.W. - 1 peak of valproic acid itself was measured, enabling 
simultaneous determination of the parent drug at a lower sensitivity. The rou-
tine extraction procedure for the GLC assay method for valproic acid, as it has 
been modified by Vree et al. (1976), appeared to be suited for this assay. The 
internal standard cyclohexane carboxylic acid was replaced by cycloheptane 
carboxylic acid, which has a molecular weight of 142. Programming of GC oven 
temperature was introduced to sharpen the GLC peaks by shortening retention 
times. The assay appeared to be applicable also for the analysis of plasma sam-
ples. A representative chromatogram and standard curves are shown in fig. 4.4 
and fig. 4.5. Detection limits are 0.5 mg/l for valproic acid, 0.2 mg/l for 2-pro-
pyl-3-pentenoic acid and 0.02 mg/l for7-valprolactone. The difference in sen-
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sitivity between the latter compounds is partially explained by the difference 
in retention times, causing sharper peaks for the lactone. Moreover both com­
pounds do react in different ways with the methane ions. 
δ-Valprolactone is not included in the present assay. Under the applied 
conditions separation from valproic acid is insufficient for this purpose. On the 
other hand, δ-valprolactone does not interfere with the quantitation of valproic 
acid at usual concentration ratios. 
4.8 Occurrence of metabolites 
Using the assay technique described here, metabolites I, II and III could be 
analysed in plasma and urine of several species and in monkey brain. Primary 
estimations were based on the assumption of correspondence with the synthesis 
products with similar GLC retention times. Metabolite I was found in every 
sample. Concentrations in plasma were usually around 1 per cent of the val­
proic acid concentrations or below. In urine amounts of metabolite I up to 10 
per cent of total valproate were found. Metabolite II was not detected in plasma. 
Because of separation problems and the lack of pure substance, quantitation 
in urine was difficult. However, concentrations were not likely to su φ ass 10 
per cent of the valproate concentrations. Nevertheless care should be taken 
of this substance, as it will contribute to valproate concentrations determined 
in routine practice. Metabolite III appeared to be the main metabolite in the 
dog, where it was present in plasma and in urine. The substance was found 
only in some species of monkey, as will be shown below. It appeared to be 
present in significant amounts in plasma of patients treated with valproic acid. 
In monkey brain, especially metabolite I was found. In three autoradiogra­
phy experiments, described in the previous chapter, brain concentrations of 
about 10 дg/g wet brain tissue were found despite large differences in valproic 
acid concentrations. In the brain of the pregnant squirrel monkey, infused for 
4 hours with l-l^c-valproic acid, this substance accounted for about 35 per 
cent of total brain radioactivity. After 9 hours infusion of 3-1 ^ C valproic acid 
to a marmoset or squirrel monkey only about 5 per cent of total radioactivity 
Figure 4.6 
Mass spectra of the three metabolites of valproic acid, which -were detected in 
urine by GLC (fig. 4.3j. Spectra were obtained by electron ionisation at 70 eV 
and 110 °C. The spectra appear to be identical to those of the synthetic pro­
ducts y-valprolactone, δ-valprolactone and 2-propyl-3-pentenoic acid (see ap­
pendix 2, fig. A.2 and A.3). 
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appeared to represent metabolite I. Perhaps the high concentrations of valproic 
acid, in the latter experiments, have inhibited proportionate metabolism. 
To confirm the identity of the three metabolites, mass spectra were com­
pared with those of the synthetic products: metabolite I and II from patient 
urine, metabolite HI from dog urine (fig. 4.6). Metabolite I and 7-valprolactone 
have the same retention times and identical mass spectra. They therefore may 
be considered identical. For similar reasons metabolite II appears to be δ-val-
prolactone. The peak retention times of metabolite HI and 2-propyl-3-pente-
noic acid appeared to differ consistently by about 10 seconds even at low GLC 
oven temperatures. Nevertheless the mass spectra correspond very well. The 
possibility of stereoisomerism should be considered. The cis-and trans-confi­
guration may be equally present in the synthetic product while one may pre­
dominate in the product formed/'« vivo. For the time being the substances will 
be considered identical. Recently also Kuhara et al. (1978) obtained indications 
for the existence of an unsaturated metabolite in patient plasma. However, 
they have not clarified its structure. 
4.9 Metabolites in dog urine and plasma 
Isotope dilution experiments in the dog have suggested considerable accumu­
lation of valproic acid metabolites in plasma (fig. 4.1). For that reason, a dog 
was given a constant rate infusion of valproic acid, and plasma and urine samples 
were analysed for the three metabolites. Phénobarbital appears to induce 
valproic acid metabolism to a considerable degree (Vree et al. 1977b). As car-
bamazepine is an even more potent enzyme inducing agent, the animal had 
been pretreated with this drug for three weeks (see also chapter 5). In plasma 
only metabolite III was found. After 4 hours of infusion its concentration was 
almost equal to that of valproic acid (fig. 4.7). The experiment was not conti-
nued long enough to estimate the elimination rate of this substance. In urine 
metabolite III was again found in considerable amounts while only traces of 
metabolite I and II could be detected. Like valproic acid itself, the major part 
Figure 4.7 
Plasma concentrations and urinary excretion of valproic acid and a metabolite, 
which is considered identical to 2-propyl-3-pentenoic acid, in a dog, during 
and after a constant rate i.v. infusion of sodium valproate for 4 hours. The 
dog had been treated with valproic acid and carbamazepine for 3 weeks. Note 
the important accumulation of the metabolite in plasma and its relatively 
small urinary excretion. The urinary excretion rate of the free compounds 
and their glucuronide conjugates is shown. For further explanation see text. 
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of the metabolite was excreted as its glucuronic acid conjugate Until three 
hours after discontinuation of the infusion, 50 per cent of the administered 
amount was recovered 39 per cent as valproic acid glucuromde, 7 per cent as 
free drug, 4 per cent as glucuromdated metabolite III and 0 5 per cent as the 
free metabolite For comprehensive interpretation of the results of this experi­
ment the kinetics of metabolite III will have to be studied by direct adminis­
tration to dogs It is plausible however that this substance may be responsible 
— at least partially - for the large half-life of plasma radioactivity found in the 
isotope dilution experiment mentioned before As metabolites I and II were 
not found in dog plasma and their amounts in urine appeared to be small com­
pared to those in human and monkey unne, it is preferred to do further expen-
ments in monkeys for reasons of better comparison with the metabolism in 
man 
4.10 Mass balance study in monkey 
Until now, no mass balance between administered valproic acid and excreted 
drug or metabolites has been reported in man or animal species Recovery of 
valproic acid and its glucuromde in urme accounts for 20-80 per cent of the 
dose However, Ferrandesand Eymard (1977) claimed to have found complete 
recovery in two dogs after hydrolysis of urine, collected over 4-5 days, almost 
100 per cent of the dose was recovered as unchanged drug In view of the me­
tabolism in dog described above it is unlikely that such high recoveries will be 
found consistently Balance studies employing 2-^C-labeled valproic acid have 
been carried out in rats (Kukino et al 1972) These data may not be directly 
applied to higher animals and to man Apart from some exceptions, metabolic 
pathways are identical in all mammals but large species differences exist in their 
quantitative contribution to total metabolism Therefore, a mass balance study 
in the macaca monkey has been performed 
After a single intravenous dose of labeled valproate, urinary and faecal excre-
Figure 4 8 
Excretion ofl4C-actmty after rapid ι ν injection of 1-^C and З-^С labeled 
valproic acid on two occasions in the same rhesus monkey The curved lines 
represent the course of total '^C-activity m plasma Far the greatest fraction 
of the dose is excreted via urine The figures refer to the cumulative excretion 
by a certain pathway as percentage of the dose Note the marked '^СС^ elim­
ination in the case of the carboxy-labeled drug Expiratory air could be 
measured for only 6-7 hours Faecal excretion may be neglected (cf table 
411) 
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Table 4.II Recovery of radioactivity in macaca monkey 
dose 
urine 
14C02 
faeces 
blood samples 
1-14C valproic acid 
81.2 μ α (=100%) 
69.9 μα/100.4ΗΓ 86.1% 
5.5 μΟΐ/7.251ΐΓ 6.8% 
0.13
Д
Сі/83.5 1іг 0.2% 
1.16 μ α 1.4% 
total 94.5% 
3-14c valproic acid 
92.0 μ α (=100%) 
84.4 μα/78.5 hr 91.7% 
0.17 μα/6 hr 0.2% 
0.17 μα/71 hr 0.2% 
1.55 μ α 1.7% 
total 93.8% 
tion was followed for 4 days. Radioactivity in expiratory air could be meas­
ured only for the first 6-7 hours. In order to elucidate the metabolic pathway 
leading to the formation of CCb.the experiment was carried out twice with 
an interval of one week, using l-'^C and З-'^С labeled valproic acid in turn. 
Almost 100 per cent of the radioactivity administered was recovered (fig. 4.8 
and table 4.II). 
The difference between CO2 formation in both experiments is striking. 
The higher value for the carboxy-labeled valproic acid appears to prove decar­
boxylation. The parallelism between the valproic acid plasma concentration 
and CO2 elimination curves suggests direct decarboxylation of the parent 
drug. Extrapolation of the excretion curve would result in total expiration of 
8 per cent of the administered radioactivity. Formation of labeled CO2 in the 
other experiment, had a slow onset. Some metabolic steps may be intermedi­
ate to this formation. In view of the place of the labeled carbon in the valproic 
acid molecule, a rather complete breakdown of this acid appears to take place. 
j3-Oxidation could be responsible. As indicated above, such a mechanism has 
been proposed by Matsumoto et al. (1976). 
Comparison of total radioactivity balance of both experiments reveals that the 
metabolite formed by decarboxylation was excreted, mainly at least, via urine. 
In the case of carboxy-labeled valproic acid a part of the radioactivity was 
eliminated rapidly as CC^.If a difference between both experiments is tobe 
found at all, then a larger retention of radioactivity in the body would be 
expected in the case of the side-chain-labeled drug. Surprisingly, the longest 
terminal half-life for plasma radioactivity was found after administration of 
the 1- C-label. Apparently the decarboxylated metabolite has not a very long 
half-life. The only explanation for the slowest elimination phase maybe found 
in incorporation of CO2 in the carbonate pool of the body, which has a slow 
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Figure 4.9 
Elimination of ^C-activity, valproic acid and two metabolites from plasma 
of a rhesus monkey after rapid i.v. injection of the 1-'*Сlabeled drug. Total 
radioactivity is converted into mg/l by division by the specific activity of val­
proic acid The valproic acid concentrations have been fitted to a tri-exponen-
tial function (thick line). From 2 hours after injection the y-valprolactone 
curve appears to parallel the valproic acid concentration. From the linear part 
of the curve of metabolite 3, considered identical to 2-propyl-3-pentenoic 
acid, a half-life of 7 hours is estimated. 
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turnover. Even after lOdays.some radioactivity was still found in urine. Faecal 
excretion appeared of no importance. In view of the high amounts of radio­
activity, which have been found in the intestines in previous autoradiography 
experiments, losses from the enteric cycling are small. CO2 expiration and 
urinary excretion beyond thf period of sampling may account for the 6 per 
cent missed. 
In blood valproic acid, γ-valprolactone and metabolite III were found. Con­
centration courses are given in figure 4.9. Valproic acid itself may be fitted to 
a tri-exponential curve: 
c^Ae-^+Be^+Ce-T1 
Values for the hybrid constants are obtained by the graphical method: 
A=110mg/1 α =3.466 hr-1 ( 1 ^ = 12 min) 
В = 150 mg/1 β = 0.408 hf 1 0 ^ = 102 min) 
C= 5 mg/1 у =0.0613 hr"1 ( t ^ = 113 hr) 
In most single dose experiments the last phase was overlooked because it be­
comes important only at the level of the detection limit of most GLC methods. 
Despite its ongoing formation, the elimination half-life of metabolite III may 
be estimated at, about, 7 hours. The γ-valprolactone curve appears to be par­
allel to that of the parent drug starting from 2 hours after administration. 
Therefore, this substance was more rapidly eliminated than valproic acid. This 
was also reflected in its low plasma concentrations, in comparison with a rela­
tively more important urinary excretion. Summation of plasma concentrations 
of valproic acid and both metabolites does not equal total plasma radioactivity, 
even in the experiment with the 3- С labeled compound. Therefore other 
metabolites must be present. 
The urinary excretion pattern is shown in figure 4.10. All three metabolites 
were present. After deglucuronidation, valproic acid accounted for 54 per cent 
of the dose. Contribution of the metabolites was small: γ-valprolactone 1.5 per 
cent, δ-valprolactone about 05 percent and metabolite III 0.3 percent of the 
administered dose. The two lactones occurred only in the unconjugated form 
while the unsaturated free acid (metabolite III) was partially glucuronidated. 
Still 10 percent of radioactivity was excreted into urine in another form. Even 
the decarboxylated product did not contribute to urinary activity in this case. 
For elucidation of the relative importance of the three metabolites, their inter­
relations and elimination will have to be studied by separate administration to 
the same animal. 
3-Oxo-valproic acid could be responsible for the remaining difference 
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between total radioactivity and known metabolites in urine. This substance 
has been proven to be a urinary metabolite of valproic acid in man (Gompertz 
et al. 1977). Schäfer and Lührs (1978) have analysed quantitatively urine 
samples from epileptic patients for several metabolites: the 3-oxo-derivative 
was sometimes present in greater amounts than valproic acid itself. However, 
they measured this substance in an indirect way by transformation into 
excretion rate (jug/min) 
20 40 60 80 100 hours 
Figure 4.10 
Excretion of total '^C-activity, valproic acid and three metabolites in urine 
of a rhesus monkey after rapid i.v. injection of 30 mg/kg 1-^C sodium val-
proate, corresponding to 10.3 ßCi/kg. The figures indicate the cumulative ex-
cretion as percentage of the dose. The curved line represents the radioactivity 
in plasma, converted into valproate concentration and expressed as Idg/ml. 
Note the small contribution of the three metabolites. 
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heptanone-3. It is possible that this substance is liberated under the chosen 
hydrolysis conditions from other conjugates or substances. They also found 
small amounts of 4-hydroxy and 5-hydroxy valproic acid, corresponding to 
the 7- and δ-lactones. The presence of these substances in rat urine had been 
indicated already by Matsumoto et al. (1976). However, the trimethylsilyl de­
rivatives of these compounds are very similar and interpretation without com­
parison with reference substances is open to question. Schäfer and Lührs (1978) 
on the other hand had synthetised several reference substances. 
4.11 Metabolites in patient plasma 
Screening of patient plasma samples revealed the presence of the same two 
metabolites that have been found in monkey plasma. Quantitative analysis in 
30 patients showed that concentrations varied widely: values between 0.30 
and 2.00 mg/1 were found for γ-valprolactone while metabolite III concentra­
tions ranged from 4.3-23 mg/1. Valproic acid concentrations in the same samples 
were between 20 and 125 mg/1. The correlation between metaboUte concen­
trations and valproic acid concentration is poor, as is the correlation with 
the dose of valproic acid per kilogram body weight. The variation appears to 
be somewhat less on valproate monotherapy. γ-Valprolactone concentrations 
averaged 1.5 ± 0.7 per cent and those of metabolite III 13.8 + 7.3 per cent of 
valproate plasma concentrations. Despite its remarkable concentrations in 
plasma metaboUte III has not been found before. This maybe attributed to the 
fact that this substance coincides with cyclohexane carboxylic acid, which is 
used as internal standard for the routine analysis of valproate plasma concen­
trations. Moreover, GLC peaks are small and broad under the analysis condi­
tions, chosen for routine purposes. There are indications that individual 
metabolite plasma concentrations fluctuate less than those of the parent 
compound. From 5 patients duplicate samples have been analysed, one taken 
before the morning intake and one a few hours later. Valproic acid concen­
trations differed by about 50 per cent, those of γ-valprolactone by 30 per cent, 
while an average difference of only 20 per cent was observed for metaboUte 
III. In correspondence with the results in dog and monkey the latter substance 
seems to have the longest half-life. 
This could be confirmed in two patients, where valproate treatment was stop­
ped abruptly. From blood samples taken on subsequent days, half-lives could 
be estimated in one case at 10 hours for valproic acid, 12.5 hours for γ-valpro­
lactone and 44 hours for metabolite III (fig. 4.11). This data refer to a boy of 
18 years who had been treated with valproic acid, phenytoin and carbamaze-
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Figure 4.11 
Elimination of valproic acid and two metabolites from plasma of a patient 
after discontinuation of chronic treatment. Note the slow elimination of 
metabolite 3 which is considered identical to 2-propyl-3-pentenoic acid. For 
further details see text. 
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pine for a long period. Valproic acid was replaced by clonazepam. 
In the second case, valproic acid monotherapy was stopped after 6 weeks and 
was replaced by phenytoin. Valproic acid half-life appeared to be 14hours, 18 
hours were found for7-valprolactoneand 22 hours for metabolite III (fig. 4.12). 
Especially in the second case the metabolites appear to follow first order elim­
ination perfectly. Valproic acid on the other hand could not be followed long 
enough to prove the existence of a slower terminal elimination phase as has 
been found in the monkey. However, the shape of the plasma concentration 
curves give indications that it will be the case. 
4.12 Conclusions 
In macaca monkey, valproic acid kinetics appear to fit a model, that is de­
scribed by the sum of three exponential terms. It is not unlikely that the same 
will hold for man. The slow terminal elimination phase points to the existence 
of a deep compartment, where the drug is slowly accumulated and released. 
The time course of valproic acid concentration in this compartment might par­
allel the therapeutic effects. In such a way the delayed onset of action and the 
observed carry-over effects could be explained. A factor 6.6 between the half-
life of the /3-phase, which is normally considered to represent total elimination 
of valproic acid, and that of the terminal phase, as it has been found in the 
monkey experiments, is quite realistic in this view. The results of the previous 
chapter correspond well with these findings. From the infusion experiments 
similar terminal half-lives were estimated; the first distribution phase may have 
been overlooked because of infrequent sampling. 
From the expiration of radioactive CO2 after administration of valproic acid, 
provided with а С label at different places in the molecule, it may be con­
cluded that part of the drug(± 8 per cent) is decarboxylated. On the metabolites 
formed, no information is available. The molecule also appears to undergo ex­
tensive breakdown but this process is much slower and appears to play a minor 
role quantitatively. Experiments with valproic acid, labeled in the carboxyl 
group, should be interpreted cautiously as the liberated carbon dioxide appears 
to be incorporated in the carbonate pool. Part of the radioactivity, found in vivo 
may not be related to true valproic acid and metabolite levels. After administra­
tion of labeled valproic acid to a macaca monkey almost 100 per cent of the 
dose could be recovered. Faecal excretion and breakdown to carbon dioxide and 
subsequent expiration, may be almost neglected. In urine, nearly the entire dose 
can be recovered as valproic acid itself or metabolites. A number of these meta­
bolites have been identified or are reported in the literature. A hypothetical 
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valproic acid metabolites in man 
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Figure 4 12 
Plasma concentrations of valproic acid and two metabolites on discontinu­
ation of subchromc treatment m an epileptic patient Both metabolites appear 
to follow first order elimination The valproic acid curve might suggest a mul­
tiple-exponential function 
151 
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Hypothetical scheme of metabolism for valproic acid. The compounds in a 
shaded area have been identified as metabolites in animals or man. The three 
metabolites, which were noticed in this chapter, are indicated by Roman 
figures. 
scheme of metabolism is shown in figure 4.13. 
Two metabolites of valproic acid are present in the plasma of epileptic patients 
and in laboratory animals. γ-Valprolactone is always present in blood and urine 
of all species tested. Based on circumstantial evidence the second metabolite is 
considered identical to 2-propyl-3-pentenoic acid. This substance is eliminated 
more slowly than valproic acid itself (/3-phase). In two patients half-lives of 22 
and 44 hours have been found. In urine, a third metabolite is encountered: 
δ-valprolactone. In macaca monkey, the sum of the three metaboUtes men­
tioned accounts for less than 3 percent of urinary excretion. Other metabolites 
are also likely to be present. 
7-Valprolactone deserves special attention as it has been found in monkey brain 
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tissue. On its pharmacological activity no information is available.However, as 
the metabolite appears to be eliminated even faster than the drug itself, it is 
improbable that this compound will be responsible for the lack of correlation 
between the plasma concentration of valproic acid and the therapeutic effect. 
The metabolite thought to be 2-propyl-3-pentenoic acid might be useful for 
monitoring purposes: due to its larger half-life, plasma concentrations fluctu-
ate less than those of valproic acid itself while concentrations between 5 and 
20 mg/1 enable routine GLC analysis. However, it remains to be investigated 
whether these concentrations are related to the therapeutic effect. 
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Chapter 5 
Interactions with valproic acid 
5.1 Introduction 
Indications for drug interactions were already obtained during pharmacologi-
cal screening of valproic acid. In animal experiments, the drug appeared to 
potentiate effects of several barbiturates and benzodiazepines, phenytoin, 
chloral hydrate and morphine (Lebreton et al. 1964,Isihtobietal. 1969,Shuto 
and Nishigaki 1970). However, these experiments did not offer explanations for 
the observed interactions. In comparison with other antiepileptic drugs valproic 
acid is present at high concentrations, especially when calculated on a molar 
basis. Competition with drugs given concomitantly for metabolising enzymes 
and for binding to plasma proteins or tissue constituents, is likely to occur. Dis-
placement from protein binding sites by other drugs may have significant con-
sequences for valproic acid itself, due to its high protein binding. 
On the other hand, valproic acid appears to lack the hepatic enzyme inducing 
properties shared by almost all antiepileptic drugs. Jordan et al. (1976) did 
not find a change of activity of cytochrome P-450 in rats after one week of 
treatment. In the same species, the drug had no influence on the paralysis 
time, brought about by injection of zoxazolamine. This test appears to be a 
sensitive indicator for induction by phénobarbital. Combined treatment with 
valproic acid and phénobarbital had the same effect as the latter drug on its 
own. The elimination rate of valproic acid after a single dose and after chronic 
treatment appears not to differ (Gugler et al. 1977, Levy et al. 1977a). This 
lack of auto-induction of metabolism is an additional indication that enzyme 
stimulation is unlikely. Opinions differ on possible inhibitory effects of the 
drug (Jordan et al. 1976, Flachs et al. 1977, Patsalos and Lascelles 1977b). 
Some interactions, which are relevant for antiepileptic drug therapy, will be 
discussed in detail. 
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5.2 Experimental methods 
Chemicals 
Sodium valproate, pure substance and tablets (Depakine , 300 mg) were 
obtained from Labaz, the Netherlands. _ 
Carbamazepine.pure substance and tablets (Tegretol , 200 mg) were obtained 
from Ciba-Geigy, the Netherlands. 
Valproic acid capsules (Propymal® direkt oplosbaar, 300 mg), experimental 
dosage form, were supplied by Chemische Industrie Katwijk, the Nether-
lands. 
Polyethylene glycole 400, salicylic acid and acetylsalicylic acid tablets, 500 mg 
(FNA) were obtained from Onderlinge Pharmaceutische Groothandel, 
Utrecht, the Netherlands. 
All other reagents were analytical grade and were obtained from Merck, Darm-
stadt, Germany. 
Patient clearance values 
All data from antiepileptic drug plasma concentration analyses, performed 
by the Laboratory of Clinical Pharmacy of the St. Radboud Hospital, Nijmegen, 
the Netherlands, during the last three years, were screened for patients with 
phénobarbital and valproic acid as sole medication. Patients involved in the 
clinical study described in chapter 7, were included. Relative clearance values 
were calculated according to equation (3) of chapter 2. The 128 cases found, 
were divided into 8 groups according to age (see table 5.1). For each group 
the average clearance ± standard deviation and the average age were calculated. 
Similar data were gathered for a group of 143 patients on phénobarbital mono-
therapy. 
From the same data those patients were selected, who were treated with 
phénobarbital and whose plasma concentrations had been analysed before and 
after addition or withdrawal of valproic acid. All other medication had to be 
kept unchanged. These requirements were met in 33 cases. Three patients with 
phénobarbital clearance values greater than 10 ml.hr"1 .kg"1 have been omitted 
from the results because the reliability of these data is doubtful. Data of 13 
patients of the study by Flachs et al. (1977) were added. Relative clearance 
values for phénobarbital were calculated, both with and without valproic acid. 
Out of the total number of patients 8 received no other drugs than the two al-
ready mentioned, 12 got Phenytoin in addition; 11 patients were treated with 
two or more antiepileptic drugs, besides phénobarbital and valproic acid. 
Carbamazepine 
A. A male beagle dog of 13.2 kg was given an intravenous infusion of 30 mg 
carbamazepine per hour during 5 hours. After 3 hours an intravenous in-
jection of 400 mg sodium valproate was given. Blood samples were taken 
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at intervals of 5-15 minutes as indicated in figure 5.4. Plasma was analysed 
for valproic acid by GLC according to Vree et al. (1976) and for carbama-
zepine by HPLC (Westenberg and de Zeeuw 1976). During the experiment 
the animal was kept under light anaesthesia by pentobarbital i.v. 
B. A male beagle dog of 11.2 kg was given a constant rate intravenous infusion 
of 90 mg sodium valproate per hour, during 5 hours. The dog was under 
light anaesthesia by inhalation of nitrous oxide, oxygen and halothane. 
Blood samples were taken at intervals of 10-15 minutes up to two hours 
after the end of the infusion. Urine samples were collected during the same 
period. Blood and urine were analysed for valproic acid and itsglucuronide, 
as indicated in chapter 4. After the control experiment the animal was treated 
with 1600 mg carbamazepine (Tegretol® tablets) orally two times a day 
for 3 weeks. This dosage was chosen to obtain maximal plasma concentra-
tions of 2-3 mg/1 after each dose. The infusion experiment was repeated 
after 1 week and 3 weeks of treatment, and 1 week after the last dose of 
carbamazepine. 
The total clearance was calculated from the infusion rate and the steady 
state plasma concentrations. The clearance values for free valproic acid and 
its glucuronide were calculated from the valproic acid steady state plasma 
concentration and the average urinary excretion rates for the free drug and 
the glucuronide at steady state (cf. Vree et al.. 1977b). 
C. A male beagle dog of 9.8 kg was given an intravenous infusion of valproic 
acid and carbamazepine during 4 hours. The infusion fluid consisted of 5.0 
mg of carbamazepine, 20 mg of sodium valproate, 400 mg of polyethylene 
glycole 400 and water per ml and was given at an infusion rate of 8.0 ml/hr. 
Blood samples were taken during 7 hours at regular intervals as indicated 
in figure 5.7. Plasma was analysed for valproic acid and for carbamazepine 
as indicated above. Urine fractions, collected during the entire experiment, 
were analysed for valproic acid and a metabolite (2-propyl-3-pentenoic 
acid) and their glucuronide-conjugates, as described in chapter 4. The ex-
periment was repeated after 3 weeks of treatment with 1200 mg carbama-
zepine (Tegretol® tablets) and 600 mg sodium valproate (Depakine®tab-
lets) orally two times daily. After each dose maximal plasma concentra-
tions of about 2 mg/1 carbamazepine and 150 mg/1 sodium valproate were 
reached. 
Ethanol 
A male volunteer (F.S., 69 kg) took 600 mg of valproic acid (2 soft gelatin 
capsules) orally, two hours after a standard breakfast. Blood samples were 
taken at regular intervals during 2 days as indicated in figure 5.8. Urine fractions 
were collected during the same period. The urinary pH was kept between 7.0 
and 8.0 by intake of 1 g of sodium bicarbonate every two hours. Plasma and 
urine samples were analysed for valproic acid and its glucuronide as indicated 
above. The experiment was repeated after one week. 90 Minutes after intake 
of the valproate, 400 ml rosé wine, containing 10.6 per cent of ethanol w/v, 
were taken, followed by 100 ml every hour for 12 hours. In order to keep the 
urinary pH greater than 7.0, intake of 1 gram of sodium bicarbonate per hour 
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was necessary. Ethanol concentrations were determined by means of GLC. 
Full blood was diluted with water containing propanol (internal standard) and 
injected on a column packed with Chromosorb 101, at 110oC. 
Salicylic acid 
Two volunteers took single oral doses of sodium valproate in combination 
with acetylsalicylic acid, in several dose ratios. Urine fractions were collected 
during two days. Urinary pH was kept between 4.8 and 5.5 by intake of 2 
grams of ammonium chloride every six hours. Urine was analysed for total 
valproate and total salicylate after alkaline hydrolysis. Further details and 
overall results have been reported earlier (Schobben et al. 1978). In the experi-
ment referred to here, one of these volunteers (P.G., 62 kg) took 900 mg of 
sodium valproate, with and without 2 grams of acetylsalicylic acid. 
A beagle dog of 13.5 kg was given an intravenous infusion of 122 mg sodium 
valproate per hour during 5 hours. After 3 hours an intravenous injection of 
783 mg of sodium salicylate was given. Blood samples were taken during 7 
hours at regular intervals as indicated in figure 5.10. Urine was collected during 
the same period. Plasma and urine samples were analysed for valproic acid and 
salicylic acid as indicated above. The experiment was repeated with an infusion 
of 103 mg sodium valproate per hour for 5.5 hours and 2 consecutive injections 
of sodium salicylate: 391 mg after 2 hours and 783 mg after 3.5 hours. Blood 
and urine samples have been obtained for 9 hours. 
5.3 Phénobarbital 
In many clinical trials with valproic acid, drowsiness was observed as a side 
effect. However, in almost all patients the drug was added to the existing 
therapy, frequently including phénobarbital (Matthes and Schmutterer 1971, 
Herbaut 1972). Generally, reduction of the dose of phénobarbital led to dis-
appearance of the complaints (Jeavons and Clark 1974, Barnes and Bower 
1975). In the results of their clinical study, Schäfer and Kettner (1974) men-
tioned a rise of plasma concentrations of barbiturates, which necessitated 
reduction of dose. Our first experience in three patients, who were treated 
with valproic acid in addition to phénobarbital and other drugs for a short 
period, showed a marked increase of phénobarbital plasma concentrations: in 
two patients an increase of 35 per cent and 65 per cent respectively was found 
after one week of combined treatment, in the third case the phénobarbital 
concentration was more than doubled after 18 days (Schobben et al. 1975). 
These observations have been confirmed in many studies since: Richens et al. 
(1976) reported an increase of phénobarbital steady state plasma concentra-
tions of 17-48 per cent in 7 patients. In 14 children, Taburet et al. (1976) 
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Table 5 Mnfluence ofvalproic acid on phénobarbital clearance inchronic treatment 
age group 
(years) 
1-5 
5-10 
10-15 
15-20 
20-30 
30-40 
40-50 
50 
total 
PHENOBARBITAL 
MONOTHERAPY 
η age relative clearance 
(years) (mlJir^.kg1) 
24 2.911.2 9.71+3.79 
16 7.111.2 7.73+3.23 
12 11.913.8 6.27+3.01 
25 18.211.1 5.27+2.55 
26 24.412.7 4.2812.02 
16 36.312.8 4.7911.48 
17 44.5+2.9 4.5911.37 
7 58.713.5 3.7111.08 
143 5.9813.22 
PHENOBARBITAL + 
VALPROIC ACID 
η age relative clearance 
(years) (mlJir^kg1) 
23 3.011.0 6.05+2.09 
18 7.011.0 4.2310.83 
7 11.712.1 4.1011.90 
22 18.411.6 3.1110.67 
19 25.7+2.6 3.9611.89 
19 34.812.7 4.0711.90 
13 43.9+2.2 3.2211.18 
7 57.915.6 3.4911.48 
128 4.2011.91 
DIFFER­
ENCE 
(Students 
t-test) 
ρ < 0.005 
ρ < 0.005 
n.s.* 
ρ < 0.005 
n.s. 
n.s. 
ρ < 0.005 
n.s. 
n.s. difference not significant 
observed an increase of phénobarbital levels by an average of 44 per cent. In 
86 children, treated with valproic acid and phénobarbital, the same workers 
found higher phénobarbital plasma concentrations than in children on similar 
doses of phénobarbital alone (average difference 30 per cent). Corresponding 
results are obtained here. In figure S.l and table 5.1 average phénobarbital 
clearance values of two comparable groups of patients are shown: 128 patients, 
treated with a combination of phénobarbital and valproic acid but no other 
drugs and 143 patients on phénobarbital monotherapy. The average clearance 
value is 30 per cent lower for the combined treatment. In children the differ-
ence may be somewhat larger. For 41 children below 10 years of age, the 
difference with the expected clearance values without comedication is over 
40 per cent. In figure 5.2, the effect of addition or withdrawal of valproic acid 
on the clearance of phénobarbital is shown for 43 individual cases. Most 
of these patients were treated with other drugs as well. A reduction of the 
phénobarbital clearance of 31 ± 14 per cent (average ± s.d.) is found. No 
influence of comedication or age could be detected from these data. However, 
data from only 4 children were included in this series. The dose of valproic 
acid does not appear to be important. In the dose range from 7 to 60 rngJcg"!. 
day'l, similar changes of phénobarbital clearance were found. 
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Figure 5.3 
Phénobarbital concentrations in plasma, brain and liver of rats after sub-
chronic treatment with only phénobarbital, or with a combination of this drug 
and sodium valproate. Time is indicated as hours after the last oral dose. Valproic 
acid appears to raise overall phénobarbital concentrations. The brain/plasma 
concentration ratio is almost unchanged, while the liver/plasma ratio appears 
to be increased (from Hulshof et al. 1977). 
The observed decrease of clearance may be caused by a lowered elimination 
rate, a smaller volume of distribution, or both. Elimination of phénobarbital 
from plasma, liver and brain after lOdaysofintermittenttreatmentwas studied 
in rats (Hulshof et al. 1977). Concurrent administration of valproic acid caused 
a marked increase of phénobarbital concentrations in plasma and tissues (fig. 
5.3). Liver concentrations appear to have been raised more than propor-
tionately. This does not suggest a decreased volume of distribution. Due to 
the long absorption phase half-lives cannot be accurately estimated. However, 
Figure 5.1 
Phénobarbital clearance values of 128 patients, treated with phénobarbital 
and valproic acid, in comparison to 143 patients on phénobarbital mono-
therapy. Data of table 5.1. For each age group the average relative clearance 
value and the standard deviation are indicated. Note the lower clearance 
values for the combined treatment, especially in children. 
Figure 5.2 
Relative clearance values of phénobarbital in 43 patients before and after ad-
dition or withdrawal of valproic acid therapy. Both values are highly corre-
lated. Valproic acid lowers the clearance of phénobarbital by 31 ± 14% . 
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a decreased elimination rate is obvious. This has been confirmed by Loiseau 
et al. (1978) in epileptic patients. Phénobarbital half-lives were determined by 
frequent sampling during an interruption of phénobarbital treatment for several 
days. In 13 patients the phénobarbital half-life was increased by 20-79 per cent 
(average 39 per cent) during combined treatment with valproic acid. Plasma 
concentrations during phénobarbital treatment had changed less, but it may 
be that a steady state had not been reached in the combined treatment period. 
In one patient, Flachs et al. (1977) found evidence of an impairment of the 
metabolism of phénobarbital by valproic acid: after addition of valproic acid 
to the chronic phénobarbital treatment of this patient, the relative amounts 
of the metabolite p-hydroxy-phenobarbital, excreted into urine, appeared to 
decrease. 
On the other hand, phénobarbital influences valproic acid kinetics. Due to 
the fluctuating plasma levels this will hardly be detected in clinical practice. 
However, animal experiments clearly demonstrate the increase of clearance of 
valproic acid. In rats, significantly lower plasma concentrations were reached 
after pretreatment with phénobarbital (Taburet et al. 1976, Hulshof et al. 
1977). Vree et al. (1977b) reported a doubled clearance of valproic acid in two 
dogs after 2 weeks of treatment with phénobarbital (cf. fig. 5.6). This change 
was accompanied by a reduction of the elimination half-life by 50 per cent. 
As the excretion of the free drug and its glucuronide into urine did not change, 
an induction of the oxidative metabolism was held responsible for the increase 
of total clearance. Also in man, induction of valproic acid metabolism by 
phénobarbital is likely to occur. Some of the differences of half-life between 
healthy volunteers and epileptic patients, as reported by Richens et al. (1976) 
and Perucca et al. (1978b), may be explained this way. 
Figure 5 4 
Treatment record from the clinical study, described in chapter 7. Patient A R. 
(female, 23 years) suffered from generalised tomc-clomc seizures (black tri-
angles), psychomotor seizures (broken line) and clustered myoclonic seizures 
(each vertical line represents a series of myoclonies). Her type of epilepsy 
could not be classified with certainty. Note the marked effect of valproic acid 
on the frequency of myoclonic seizures On discontinuation of valproic acid 
(august 1976) the carbamazepine plasma concentration appeared to rise mark-
edly, while the decrease of the phénobarbital concentration was less than 
had been expected Possibly indirect interactions are responsible for this ob-
servation 
163 
On the interaction between primidone and valproic acid less consistent data 
are available. Gram et al. (1977) measured only phénobarbital plasma concen-
trations of patients on primidone therapy. As for phénobarbital itself, they had 
to reduce primidone doses by an average of 30 per cent in order to maintain 
constant plasma concentrations. Windorfer and Sauer (1977) observed a marked 
increase of primidone concentrations, several days after addition of valproic 
acid, but this effect was transient. Perhaps the metabolism of primidone is 
impaired initially, but the enzyme induction caused by the increased plasma 
concentrations of phénobarbital and of the drug itself compensate for this 
effect. 
г influence of valproic acid on carbamazepine in Beagle dog 
- plasmacene ug ml 
' 130 mg kg"1 
Figure 5.5 
Lack of effect of an i.v. in/ection of sodium valproate on the plasma concen­
tration of carbamazepine in a beagle dog, attained by a constant rate i.v. infu­
sion. Elimination half-lives of both drugs are in the normal range. 
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S.4 Carbamazepine 
Carbamazepine has strong enzyme inducing properties. Therefore, the elim-
ination of valproic acid will be enhanced, as will be shown below. On the other 
hand, valproic acid appears not to influence carbamazepine kinetics. Gram et 
al. (1977) found no change of carbamazepine steady state concentrations in 
14 patients after addition of valproic acid. However, in clinical practice low 
carbamazepine clearance values are often found in patients, treated with car-
bamazepine and valproic acid. An extraordinary case of reputed interaction is 
shown in figure 5.4. The interaction between both drugs was investigated in 
animal experiments. In a dog valproic acid appeared to have no influence on 
the plasma concentration of carbamazepine, attained by constant rate infusion 
(fig. 5.5). The hypothesis that valproic acid might limit the enzyme induction 
induction of valproic acid clearance in dog by phénobarbital and carbamazepine-
clearance 
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200 m l / m m 
І2Й 
200 
~ / 
120 mg 
phenobaibttal 
2 к dally 
dog 26 0 kg 
glucuronide* 
T ' I l ree»i 
1 6 0 0 mg 
carbamazepine 
2 χ daily 
dog 112 kg 
J t ^ 
k glucuronide A 
^ metabolite Э • 
•Г.1 tree · 
Figure 5.6 
Change of clearance of valproic acid in a dog caused by subchronic treatment 
with carbamazepine, in comparison with induction by phénobarbital as observ-
ed by Vree et al. (1977b). The clearance is estimated on several occasions by 
constant rate infusion of valproic acid and analysis of plasma and urine for 
valproic acid and its glucuronide, during and after infusion. Metabolite 3 was 
measured in urine, for the carbamazepine treatment only. For further expla-
nation see text. 
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by carbamazepine, was tested by an experiment, in which dogs were treated 
with carbamazepine alone or in combination with valproic acid for three 
weeks. Carbamazepine caused a significant increase of valproic acid clearance 
after one week (fig 5.6). In contrast with the induction by phénobarbital, the 
excretion of the glucuronide of valproic acid increased markedly. Excretion 
of one of the metabolites of valproic acid (2-propyl-3-pentenoic acid, see 
chapter 4) also appeared to be multiplied. An accurate quantitative assay for 
this substance had not yet been developed. One week after discontinuation of 
carbamazepine the clearance had fallen to the ρ re treatment value. Combined 
treatment with carbamazepine and valproic acid for three weeks in another 
dog gave no indications forimpaired induction. On the contrary, the clearance 
of valproic acid was even more markedly increased (fig. 5.7). The reason for 
interaction of carbamazepine and valproic acid in dog-
after 3 weeks of 
treatment 
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Figure 5.7 
Plasma concentrations during and after 4 hours of constant rate i.v. infusion 
of 16.3 mg.kg'1.hr'1 sodium valproate and 4.08 mg.kg'1 .hr'1 carbamazepine 
in a beagle dog. After 3 weeks of regular treatment with both drugs the ex­
periment was repeated. Note the marked decrease of steady state concen­
trations. The half-life of valproic acid is reduced to 20% of the original value, 
that of carbamazepine to 32% . 
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the observed differences has not yet been estabUshed. Apart from individual 
differences, the phenomena could be explained by a direct effect of carbama-
zepine on valproic acid kinetics or a quickly reversible enzyme induction. In 
the case of combined carbamazepine and valproic acid treatment, both drugs 
were given simultaneously for estimation of clearance. In the other experiment, 
the last dose of carbamazepine had been given 18 hours before. After each 
oral dose of carbamazepine and/or valproic acid maximal plasma concentrations 
were reached quickly, but the drugs could not longer be detected in blood a 
few hours later. 
Although the reported phenomena have not been fully elucidated, impairment 
of the enzyme induction of carbamazepine by valproic acid is not likely. The low 
clearance values of carbamazepine in patients with valproic acid comedication 
therefore will have to be ascribed to the absence of other, inducing drugs such 
as phénobarbital and phenytoin, rather than to the influence of valproic acid. 
5.5 Ethanol 
On the analogy of their studies on interaction between 4-hydroxy-butyric 
acid and ethanol, Vree and van der Kleijn (1977a) searched for interaction 
between valproic acid and ethanol. This phenomenon was found in dogs and 
monkeys, although no interaction was observed unless a certain dose level for 
valproic acid was reached. Above a dose of 90 mg/kg in the dog and 45 mg/kg 
in the rhesus monkey, the elimination of both compounds was mutually in-
hibited. Information on this interaction in man is lacking. In view of the dis-
cussion on social use of alcohol by epileptic patients, it would be useful to 
know whether similar effects occur in man at the usual doses of the drug and 
ethanol. Such information would also be of interest in relation to the use of 
valproic acid during abrupt withdrawal of alcohol in addicts, in order to prevent 
withdrawal seizures (Bastie 1970). 
As experiments with epileptic patients, designed to solve this problem, easily 
raise ethical and medical objections, a preliminary single-dose experiment was 
performed in a volunteer. The elimination of valproic acid was monitored on 
two occasions after intake of 600 mg valproic acid. The second time an ethanol 
blood level was maintained above 0.5 0loo w/v from 2 to 12 hours after drug 
intake. Plasma half-lives did not differ, as also the area under the plasma con-
centration curve and the urinary excretion of valproic acid itself and its glucu-
ronide (fig. 5.8). Also the elimination of ethanol appeared not to be signifi-
cantly impaired. A previous single dose of ethanol followed by frequent blood 
sampling had revealed a maximal metabolic rate of 8 g per hour for thisvolun-
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teer. After intake of valproic acid, intake of 10 g ethanol per hour caused a 
stabile ethanol blood level for about 7 hours. From these results it was con­
cluded that combination of the usual doses of valproic acid and ethanol are 
not likely to cause serious interference with elimination in man. Therefore, 
experiments on patients were abandoned. 
influence of ethanol on elimination of ЭІрГОІС acid -
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Figure 5.8 
Plasma concentration of valproic acid in a volunteer after intake of 600 mg of 
the free acid, with and without subsequent intake of wine to produce a con-
centration of ethanol in blood over 0.5°/oo from 2-12 hours after drug intake. 
The difference of the valproic acid curves is not considered of importance. 
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5.6 Phenytoin 
After addition of valproic acid to phenytoin therapy, decreased, increased 
and unchanged plasma concentrations of the latter drug have been found 
(Richens et al. 1976, Wilderet al. 1978). Bardy et al. (1976) reported a marked 
increase of phenytoin plasma concentrations in 8 patients after withdrawal of 
valproic acid. As has been discussed already in chapter 2, displacement from 
plasma proteins, in combination with the capacity-limited elimination of 
phenytoin, might explain both increased and decreased total plasma concen-
trations. Significant displacement of phenytoin from proteins has been clearly 
demonstrated in vitro (Jordan et al. 1976, Patsalos and Lascelles 1977). The 
latter authors also demonstrated increased brain/plasma concentration ratios 
of phenytoin in rats, when phenytoin and valproic acid were simultaneously 
administered. Similar results were obtained after acute and subchronic admin-
istration. 
In man, transient effects have been observed by Windorfer and Sauer (1977). 
During the first two weeks of combined treatment the phenytoin plasma con-
centrations were markedly higher than usual, and this was accompanied by 
toxic effects. Later, phenytoin concentrations fell below the level expected 
for monotherapy. This sequence of changes is compatible with almost all ob-
servations reported, and may be explained by displacement from protein 
binding sites. Impairment of phenytoin metabolism appears not to occur as 
Mattson et al. (1978) found an increase of HPPH-excretion into urine under 
valproate comedication. The latter authors also measured protein binding in 
vivo. Despite the marked reduction of total plasma concentrations, the con-
centration of the free fraction of phenytoin appeared to remain almost un-
changed. 
Some case reports described a marked reduction of seizure frequency on with-
drawal of phenytoin in patients treated with a combination of phenytoin and 
valproic acid (Barnes and Bower 1975, Coulthard 1975). Several explanations 
have been suggested for this, including a rise of valproic acid concentrations, 
which has been demonstrated in one patient. Therefore, phenytoin appears to 
raise the clearance of valproic acid.In vitro studies shoyed only limited effects 
of normal concentrations of phenytoin on valproic acid protein binding 
(Taburet and van der Kleijn 1977, Patel and Levy 1979). 
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5.7 Salicylic acid 
Salicylates have a marked influence on the protein binding of several drugs. 
F o r phenyto in, a doubling of the free fraction was reported (Lunde et al. 
1970). Potratz and Schulz (1976) reported the displacement of valproic acid 
by acetylsalicylic acid in vitro. Binding of valproic acid to human plasma was 
decreased from 85 per cent to 60 per cent at a salicylic acid concentrat ion of 
4 0 0 mg/1 (Schobben et al. 1978). After a single dose of valproic acid to volun-
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Figure 5.9 
Urinary excretion rate of valproic acid, including conjugates, in a volunteer 
(P.G.) after intake of 900 mg of sodium valproate alone (solid line) and in 
combination with 2 grams of acetylsalicylic acid (dotted line). The smooth 
curves represent the cumulative excretion. Total valproate excretion is in­
creased from 20 to 54% of the administered dose. 
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teers the excretion of the drug into urine appeared to increase by concomitant 
administration of acetylsalicylic acid (fig. 5.9). The percentage excreted 
appeared to be related to the dose of acetylsalicylic acid (Schobben et al. 
1978). Decreased protein binding may explain these observations, as it had 
been demonstrated previously that the fraction of a dose of valproic acid ex-
creted into urine, appears to rise with increasing doses of the drug (Vree and 
van der Kleijn 1977b). Salicylic acid, which is the main metabolite of acetyl-
salicylic acid in plasma, is largely held responsible for the displacement. 
The effect of salicylic acid on the plasma concentration of valproic acid was 
studied in dogs. At a steady state of valproic acid, achieved by constant rate 
-influence of salicylic acid on valproic acid in dog — 
plasma cone m g / l 
Figure 5.10 
Influence of i.v. injection of different doses of salicylic acid on the steady 
state concentration of valproic acid in a dog, achievea by constant rate i.v. in-
fusion of the latter drug. Note the rapid fall of total (bound and free) valpro-
ate plasma concentrations and the gradual return to the previous steady state 
value. The dip appears to depend on the dose of salicylic acid. A second injec-
tion of salicylic acid after a short interval has almost no influence. These ob-
servations are compatible with displacement of valproic acid from protein 
binding sites. The open circles represent salicylate plasma concentrations. 
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infusion, an intravenous injection of salicylic acid caused a dip of the plateau 
of total valproic acid plasma concentrations, which was dependent on the dose 
of salicylic acid (fig. 5.10). In order to prove the mechanism of interaction, 
the experiment will have to be repeated including quantitation of the concen-
tration of unbound valproic acid. The curves shown, correspond to the theor-
etical course, but from the present experiments it is not clear whether the 
elimination rate has changed accordingly (Shand et al. 1975). Conversely, 
valproic acid appears to influence the kinetics of salicylates: in the volunteer 
studies with acetylsalicylic acid and valproic acid the total excretion of salicylic 
acid and its glucuronides appeared to decrease with increasing valproic acid/ 
acetylsalicylic acid dose ratios (Schobben et al. 1978). 
5.8 Conclusions 
Valproic acid appears not to have enzyme inducing properties, nor does it 
influence induction by carbamazepine. Influence on the enzyme induction by 
phénobarbital was denied already by Jordan et al. (1976). 
The reduction of phénobarbital clearance by valproic acid appears to be one 
of the most marked interactions between antiepileptic drugs.. Reduction of 
the dosage of phénobarbital by 30 per cent, when valproic acid is added to 
the treatment, would be a sensible standard procedure. In children the effect 
may even be greater. In animal studies, the pharmacokinetics of carbamazepine 
appear not to be influenced by valproic acid. Valproic acid decreases protein 
binding of phenytoin. Apart from the risk of toxic effects immediately follow-
ing the addition of valproic acid, it is not clear whether correction of pheny-
toin dosage is necessary. Although total plasma concentrations of phenytoin 
are generally lowered, the level of the unbound fraction may be little changed. 
Steady state concentrations of other antiepileptic drugs appear to be little 
influenced by valproic acid (Gram et al. 1977). However, in animal experi-
ments, subeffective doses of valproic acid appeared to decrease the effective 
doses of several antiepileptic drugs (Isihtobi 1969). Perhaps interactions at 
the pharmacodynamic level do occur. 
Usual doses of salicylates appear to decrease protein binding of valproic acid 
to a considerable degree. In single dose studies the excretion of valproic acid 
appears to be enhanced during salicylate treatment. Total valproate plasma 
concentrations are lowered, but the influence on the concentrations of the 
unbound drug in vivo has not been determined yet. The influence of salicylate 
treatment on the kinetics and effects of valproic acid deserves further attention. 
Whether valproic acid and ethanol show similar interactions in man, as have 
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been found in dog and monkey, remains unknown. However, at usual dose levels 
of both compounds, no serious interference of elimination is to be expected. 
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Chapter 6 
Bioavailability of phenytoin after oral administration 
6.1 Introduction 
In patients, treated with phenytoin, plasma concentrations appear to be 
almost impossible to predict. This chapter is dedicated to the question whether 
bioavailability problems contribute to the wide variability of clearance values. 
Based on dissolution characteristics, a preparation is searched for, which is less 
likely to cause such problems. 
Indications for bioavailability problems 
It is a common experience of many laboratories, involved in routine moni­
toring of antiepileptic drug plasma concentrations, that extremely low pheny­
toin concentrations are found frequently. In view of the non-linear kinetics 
of phenytoin, elimination is relatively rapid at low dosages. In the Western 
European continent, 3 χ 50 mg phenytoin daily is a common dose in adults 
and very low plasma concentrations are to be expected (Guelen and van der 
Kleijn 1978). Poor patient compliance appears to be the explanation for a great 
number of cases with unexpectedly low plasma concentrations (Kutt et al. 
1966, Haerer and Grace 1969, Lund et al. 1971, Lund 1973, Booker 1975). 
However, under controlled intake of normal dosages these low figures are also 
encountered, especially in children. Even when the upper part of the normal 
distribution of elimination rates and the influence of age are taken into account, 
sufficient cases are left in which poor bioavailability appears to be the only 
explanation. 
Since the question of bioavailability and of therapeutic equivalence of 
different products of the same drug has received attention, phenytoin has 
been suspect in this regard (Martin 1969). The committee on drug product 
selection of the Academy of General Practice of Pharmacy and the Academy 
of Pharmaceutical Sciences (1973) has attributed high risk of therapeutic in­
equivalence to phenytoin. A warning example was the widespread appearance 
of phenytoin intoxication in Australia when the excipient in one brand of 
phenytoin sodium capsules was changed (Bochner et al. 1972). Beside bio-
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availability differences between various preparations, which will be discussed 
in detail below, some individual cases of malabsorption have been reported in 
literature. Kutt et al. (1966) described a case, in which phenytoin plasma con-
centrations and urinary output of the main metabolite, (para-hydroxy-phenyl) 
-phenyl-hydantoin (HPPH), remained unexpectedly low, despite controlled 
drug intake. When oral intake was replaced by intravenous administration at 
the same dosage schedule, plasma concentrations rose to toxic values. However, 
absorption of many other drugs in this patient was normal. Also Borofsky et 
al. (1973) reported one case of poor phenytoin absorption. Consequently not 
only differences between preparations, but also large interindividual variation 
must be taken into account. 
Design of bioavailability studies 
During recent years, numerous studies on the bioavailability of phenytoin 
preparations have been undertaken. In most studies, a large single dose (300-
600 mg) of several preparations was given to a number of volunteers in a cross-
over design and plasma concentrations were followed over 3 to 5 days. Usually 
Epanutin capsules (Parke-Davis) containing 100 mg phenytoin sodium were 
used as reference product (Lund 1974b, Alván et al. 1975, Smith and Kinkel 
1976).Others used a suspension of microcrystalline phenytoin acid or a solution 
of the drug (Albert et al. 1974b, Pentikainen et al. 1975). 
Gugler et al. (1976) compared oral and intravenous administration. In addi-
tion to the area under the plasma concentration curve (AUC), which was the 
vital parameter in the studies mentioned before, they also measured urinary 
output of the main metabolite, HPPH, in the first 48 hours. With one exception 
the bioavailability of the oral dose was larger when based on HPPH output 
than according to the AUC ratios. In fact the AUC method for bioavailability 
calculations is only applicable for drugs with first order elimination (Martis 
and Levy 1973). Although deviations from linear kinetics are hardly detectable 
at the plasma concentrations, which are reached in these experiments, the AUC 
is already significantly influenced. Jusko et al.(1976) compareda 300mgdose 
by intravenous injection and as phenytoin sodium capsules orally. Following 
the AUC method they found an average bioavailability of 87 percent. Starting 
from the same experimental data an average value of 98 per cent was obtained 
by calculations derived for non-linear kinetics. As elimination of phenytoin is 
largely confined to the HPPH-pathway, measurement of total urinary HPPH is 
a better measure for bioavailability than the area under the plasma concentra-
tion curve. It may be clear that higher values are to be expected. 
Another alternative for bioavailability studies is the chronic treatment 
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Situation. In view of the saturable elimination, small differences in bioavail-
ability may have profound influence on steady state concentrations. Therefore, 
cross-over studies in a steady state situation will overestimate bioavailability dif-
ferences both when steady state concentrations and the areas under the curve 
over one dosage interval are used for its estimation (Tsuchiya and Levy 1972). 
However, because oral phenytoin is used almost exclusively in chronic treatment 
this method appears to be preferable to judge therapeutic equivalency. Another 
argument to test bioavailability in normal therapeutic conditions is the 
influence of food intake. In all single-dose experiments, oral phenytoin was 
taken after an overnight fast and no meal was taken during the first hours after 
intake. As will be described later food may significantly alter phenytoin ab-
sorption. In several studies with patients on chronic phenytoin therapy, replace-
ment of preparations has been carried out under control of plasma concentra-
tions. 
Dissolution of phenytoin preparations 
The bioavailability problems may be greatly attributed to the poor solubility 
of phenytoin. The drug is a weak acid with a pK. value of 8.3 (Pippengeret al. 
1978). For that reason phenytoin will occur largely in its acid form at pH 
values found in the body, irrespective of the form of administration. At pH 7, 
and room temperature, the solubility of the drug in water is only 14 mg/1. Due 
to these properties, dissolution of the drug from its dosage form might be the 
limiting factor in gastrointestinal resorption. This was confirmed by the studies 
of van Rees and Noach (1973) on absorption of suspensions of phenytoin 
from the rat jejunum. 
Already since 1938, attempts have been made to explain differences in 
plasma concentration by different dissolution characteristics (Marshall et al. 
1938). From around 1960, dissolution tests have been used for the comparison 
of pharmaceutical preparations of the same drug (Nelson 1957, Levy and 
Hayes 1960). The first study on phenytoin was published by Martin et al. 
(1968). They found a rough correlation between in vitro and in vivo results 
and they insisted on improvement of the in vitro tests. Johansen and Wiese 
(1970) examined the influence of phenytoin particle size, tablet compression 
and other technological variables on the dissolution rate of phenytoin tablets. 
Most of these factors had a clear influence on the in vitro dissolution rate but 
for the absorption in vivo only the particle size appeared to be important. 
Neuvonen et al. (1975) found a very good correlation (0.92) between in vivo 
and in vitro results. They carried out a cross-over study with 6 preparations of 
phenytoin acid in 6 volunteers. The AUG after a 600 mg dose was compared 
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to the amount dissolved after 30 minutes in a buffer solution of pH 9. Again 
the phenytoin particle size appeared to be an important factor. 
Finholt and Solvang ( 1968) have stressed the use of a dissolution medium with 
the surface tension of gastric juice, especially for hydrophobic substances. 
They have evaluated this approach also for phenytoin (Finholt et al. 1972). 
Unfortunately, they tested only a solution of the sodium salt in their in vivo 
studies and a suspension of the powdered substance in the dissolution experi-
ments. 
Phenytoin acid versus sodium salt 
Phenytoin is available for oral administration as tablets or capsules of the free 
acid or of its sodium or calcium salt and as a suspension of the acid. Already 
Dill et al. (1956) had compared the sodium salt and the free acid in some vol-
unteers. The acid appeared to be absorbed more slowly. Lund(1974b) observed 
a significant increase in fasting steady state plasma concentrations of patients on 
chronic phenytoin therapy, when Swedish phenytoin acid tablets (Difhydan , 
Leo) were replaced by the same dose of sodium phenytoin (Epanutin cap-
sules, Parke-Davis). This led to side effects in several patients. However, a large 
particle preparation of phenytoin acid was used here. A comparable increase 
in plasma concentrations could be observed after replacement by a preparation 
of the free acid with a smaller particle size(Alván et al. 1975).Tammisto et al. 
(1976) compared 4 preparations of phenytoin acid with Epanutin capsules. 
All phenytoin acid preparations appeared to yield higher plasma concentrations 
than the capsules of the sodium salt, with one exception: the same brand of 
tablets used by Lund (1974b)before, which gave the lowest concentrations. It 
may be concluded, that the initial supposition that phenytoin sodium is always 
better absorbed than the free acid, has not held. Preparations of the acid with 
a large particle size are likely to be absorbed poorly. 
Regarding the dissolution of the drug from its dosage form, the use of pheny-
toin sodium preparations introduces an additional complication. During gastric 
passage the amount of the salt which contacts the gastric juice, will usually be 
transformed into the less soluble acid. Therefore the initial disintegration of a 
tablet or capsule in acidic medium may profoundly influence the dissolution in 
the intestinal fluid. Such influences had already been observed for warfarin 
(O'Reilly et al. 1966). Concerning phenytoin, Arnold et al. (1970) found an 
extraordinary delay of dissolution after acid pretreatment for a rapidly dis-
integrating capsule. With another preparation whose contents appeared to be 
firmly aggregated after dissolution of the gelatine envelope, the dissolution 
rate was hardly influenced. Surprisingly, the first capsule was absorbed most 
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rapidly in some volunteers. In patients, chronically treated withphenytoin,no 
significant differences were found at all. 
In the Netherlands, one brand of phenytoin sodium tablets is used almost 
exclusively for oral administration (Diphantoine , Chemische Industrie 
Katwijk). These tablets are available in several strengths: 25, 50,75 and 100 
mg. Bioavailability studies on this preparation have not been published until 
now. For that reason dissolution studies have been carried out. As has been 
indicated before, part of the sodium salt will usually be transformed into 
phenytoin acid during gastric passage. However, as the gastric juice in a resting 
stomach may be almost neutral, this will not always take place (Kuna 1964). 
To simulate both possibilities, dissolution rates have been determined at pH 9 
directly and after pretreatment with acid. Arbitrarily 30 minutes in 0.1 N 
hydrochloric acid containing 0.02 per cent polysorbate 80 was chosen for this 
purpose. As reference products, Epanutin® capsules (Parke-Davis) and tablets 
containing microcrystalline phenytoin acid (Fenantoin®, ACO, Sweden) have 
been used. Results of dissolution studies are compared with some preliminary 
data from in vivo studies. 
Phenytoin calcium 
Phenytoin calcium has found little application. This compound had been in-
cluded in the Dutch Pharmacopoeia Ed. VI and a prescription for preparation 
of tablets is currently available (Tabulae phenytoini calcici FNA). Also until 
1976 in Germany, tablets were marketed containing the calcium salt 
(Phenhydan®, Desitin). In 1968, a widespread outbreak of phenytoin intoxi-
cation occurred in Australia after a change of formula in a brand of phenytoin 
sodium tablets. The increased phenytoin bioavailability responsible for this 
effect was attributed to the change of excipient from calcium sulphate to 
lactose (Bochner et al. 1972). In view of this event, low bioavailability for 
phenytoin calcium preparations would not be surprising. Indeed, Rambeck et 
al. (1977) found higher plasma concentrations when calcium salt tablets were 
replaced by phenytoin acid. Calcium salt tablets (FNA) have been incorporated 
in the present study. 
Phenytoin-3-(a-amino)-valeric acid 
Because of the poor solubility of phenytoin some attention is paid to a more 
soluble derivative: phenytoin-3-(o¡-amino)-valeric acid. Its structure is given in 
fig. 6.1. Although this substance has already been marketed for more than 30 
years as an antiepileptic drug (Neo-Citrullamon ), data on its bioavailability 
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Figure 6 1 
Structural formula of phenytoin-3-a-ammo valeric acid 
and metabohsm are entirely lacking Because of its amphoteric character, ex­
traction from aqueous samples is difficult Recently, immunoassay and reversed 
phase liquid chromatography have enabled its analysis The drug appears to (я) 
react with the antibody in the EMIT -phenytoin assay Dissolution studies 
and single-dose experiments in dogs and a human volunteer were carried out 
Bioavailability of different dosage strengths 
An interesting observation was made by Manson et al (1975) Comparison 
of 100 mg capsules and tablets revealed that the capsules gave higher blood 
levels. In another group of patients the 30 mg forms of both preparations were 
compared with the unexpected result that the tablets were superior here This 
would imply that therapeutic equivalency studies are necessary not only to 
compare different preparations changes of drug dosage including change of 
preparation strength are far more frequent than changes of brand Therefore, 
proof of relative therapeutic equivalence of different strengths of the same 
preparation is urgently needed Inequivalency m this respect would be especial­
ly hazardous for drugs with non-linear kinetics such as phenytoin Moreover, 
if 4 χ 25 mg is not equal to 1 χ 100 mg all dosage calculations would be 
worthless and many efforts for optimal individual adjustment are condemned 
to fail 
6.2 Experimental methods 
Dissolution tests 
Dissolution tests were carried out according to a modification of the rotating 
basket method of the United States Pharmacopoeia Ed XVIII An Erweka dis-
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solution apparatus was equipped with nylon baskets Motor speed was 50 ro­
tations per minute The dissolution fluid was kept a t 3 7 0 ± 0 5 o C 
Dissolution media 
A 450 ml of borate buffer pH 9 0 (3 093 g of bone acid, 0 852 g of sodium 
hydroxide and 3 728 g of potassium chloride per liter) and 450 ml of water 
В 400 ml of 0 1 N hydrochloric acid for the first 30 minutes After that pe­
riod a sample was taken The basket was removed from the fluid, and under 
continuous stirring 40 ml of 1 0 N sodium hydroxide, 10 ml of water and 
450 ml of borate buffer pH 9 0 were added The basket was brought back 
into the fluid and the test was continued 
С 900 ml of 0 1 N hydrochloric acid 
D 900 ml of phosphate buffer pH 7 5 (6 80 g of potassium biphosphate and 
1 65 g of sodium hydroxide per liter) 
E, F and G identical to А, В and D to which 1 ml 9% polysorbate 80 was ad­
ded 
2 0 ml samples were taken at about 20 mm from the fluid surface by means 
of pipettes with a glasswool filter tip Samples were taken after 30 mmutes of 
pretreatment with 0 1 N hydrochloric acid and otherwise at 5, 15, 30 and 60 
minutes, 2, 4 and 6 (or 3, 5 and 7) hours In many cases a last sample was 
taken after 24 hours 
Initially Phenytoin was determined by GLC with on column methylation 
(Barrett 1971) In the later series, samples were analysed by HPLC without 
pretreatment 100 ді samples were injected on a column, 10 cm χ 4 6 mm in­
ternal diameter, packed with Lichrosorb RP 18, particle size ΙΟμπι (obtained 
from Chrompack, Middelburg, the Netherlands) The column was eluted with 
0 0667 M potassium biphosphate, water and methanol mixed m the ratio 2 1 2, 
at a flow rate of 2 0 ml/mm Detection was effected by UV absorption at 249 
nm. Both analysis methods yielded identical results Phenytoin-3-(oi-ammo)-
valenc acid was detected at 220 nm For each sample time, the amount dissol­
ved has been calculated as a percentage of the declared content of tablet or 
capsule All treatments have been carried out in triplicate, at least For each 
sample time the results are indicated as average value ± standard deviation, or, 
in the case of 3 observations, with the average, the lowest and the highest value 
Preparations 
® 
- Diphantoine tablets 100 mg (Chemische Industrie Katwijk, the Nether­
lands) containing Phenytoin sodium, charge numbers 142130, 144352, 
144385, 144508 
- Diphantoine tablets 50 mg, charge number 144512 
- Diphantoine tablets 25 mg, charge numbers 144419,144539 
- Epanutin capsules 100 mg (Parke-Davis, Belgium) containing phenytoin 
sodium, charge number 77L01 
- Lehydan capsules 100 mg (Leo, Sweden) containmg microcrystalline 
Phenytoin acid, charge number A3311 
- Fenantoin®tablets 100 mg (ACO, Sweden) containmg microcrystalline Phe­
nytoin acid, charge number Fl 17 
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- Tabulae Phenytoini calcici 100 mg (FNΑ-Formulary of the Dutch Pharma­
cists), manufactured by the pharmacy of the Maria Hospital, Tilburg, the 
Netherlands 
- Neo-Citrul]amon®tablets (Sildmedica, Germany) containing 50 mg pheny-
toin-3-(oi-amino)-valeric acid 
In vivo studies on Phenytoin 
With intervals of one week a healthy volunteer (F.S., male, 68 kg) took single 
doses of Phenytoin. One Diphantoine® tablet (charge number 144385) was 
taken at three occasions with differences in food intake: 
A. after an overnight fast and no food intake until 4 hours after drug adminis­
tration, 
B. with a fat breakfast consisting of bread with fried ham and eggs and a glass 
of milk, 
C. with a light breakfast consisting of 2 rusks with marmalade without butter 
and a cup of tea. 
One Fenantoin® tablet containing 100 mg Phenytoin acid was taken at two 
occasions under conditions A and B. One tablet containing 100 mg Phenytoin 
calcium was taken without food intake (condition A). Blood samples were 
taken at 1, 2, 4, 7, 13, 16 and 25 hours after intake. Plasma was kept frozen 
until analysis in one run by the EMIT®-technique. For each dose the area 
under the plasma concentration curve has been calculated according to the 
trapezoidal rule. Urine samples were collected during 72 hours after drug in­
take. Samples were analysed for HPPH by GLC following the flash methylation 
technique (Barfett 1971), after treatment with 75000 units of ^-glucuronidase 
(Sigma) for 1 ml of urine, incubated at pH 5 and 37°C during 16 hours. Total 
HPPH excretion and excretion rates for each sample interval have been calcu­
lated. 
In one patient (M.A., female, 68 kg) Fenantoin® 100 mg 3 times daily was 
substituted for Diphantoine® 100 mg (charge number 144508) 3 times daily. 
Dosage of other medication, including carbamazepine and phénobarbital, was 
kept constant. At day 18 and 26, and on two occasions before substitution, 
Phenytoin plasma concentrations were determined 3 hours after the morning 
dose. From steady state plasma concentrations at other dosages of Phenytoin, 
with the same comedication, the К
т
 value for this patient had been calcula­
ted at 3.7 mg/1 Phenytoin sodium. 
In vivo experiments with phenytoin-3-(0L-amino)-valeric acid 
Dog: 
10 mg/kg phenytoin-3-(a-amino)-valeric acid (obtained from Südmedica, 
Germany) in aqueous solution was administered by rapid intravenous injection 
to a male beagle dog, kept under light anaesthesia by pentobarbital i.v. and 
subsequent inhalation of nitrous oxide. Heparinised blood samples were taken 
at regular intervals up to 7 hours after injection as indicated in figure 6.9. Urine 
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samples were collected during the same period by means of a bladder catheter 
Urine production was stimulated by i.v. infusion of 5% glucose. 
Man 
One healthy volunteer (F.S., male, 69 kg) took several dosages of phenytoin-
34a-ammo)-valeric acid on different occasions 1,2,4 and 8 Neo-Citrullamon® 
tablets corresponding to 50, 100, 200 and 400 mg of the drug. Blood samples 
have been taken at 15, 30, 60 and 90 minutes and at 2, 3, 5 and 8 hours after 
intake. Urine fractions have been collected during 60 hours. 
Analysis 
Plasma and urine samples were analysed by EMIT® and by HPLC The EMIT®-
phenytom assay was carried out following the standard procedure, except the 
use of plasma and urine calibrators spiked with phenytom-3-(a-ammo)-valeric 
acid. Several blank urine samples have been checked for interference. 
For HPLC analysis, 100 μΐ plasma was mixed with 0.4 ml of 0.33 M perchlor­
ic acid. After centnfugation 100 μΐ of the supernatant was injected m the 
HPLC system. 25 μΐ of each unne sample were diluted with 0.5 ml of the elu-
tion solvent (0.0667 M potassium biphosphate, water and methanol 2 1 2) 
and 100 μΐ of this dilution was injected. HPLC conditions were the same as 
described for the dissolution tests. 
Dog urine samples have also been treated with ^-glucuronidase before HPLC 
analysis. Plasma and urine samples have been screened by GLC for Phenytoin 
and HPPH, both directly and after deglucuromdation. 
6.3 Results of dissolution tests 
Influence of dissolution medium 
Phenytoin appears to dissolve slowly from the Dutch tablet preparation under 
study. In a buffer of pH 9 total dissolution was reached in about 5 hours (fig. 
6.2A). Addition of a surfactant increased the dissolution rate. In this dissolution 
medium, 2 charges of the same brand of tablets showed significant differences 
(fig. 6.2B). It was found that the formulation of the tablets had been changed 
in the middle of 1973' the excipients lactose and potato starch had been re­
placed by maize starch and colloidal silicon dioxide while binding by hydroxy-
ethylmethylcellulose and water was replaced by polyvinylpyrrolidone Also, 
in 1975, water replaced methylenechlonde as the granulating agent. While this 
change in tablet composition had little influence on the dissolution pattern in 
pure buffer, significant differences were found in all other media tested. Pre­
treatment with 0.1 N hydrochloric acid during 30 minutes significantly reduced 
the dissolution rate of the old tablets while those prepared according to the 
new prescription showed an almost unchanged pattern (fig. 6.2C). Surprisingly, 
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% dissolved formulation 1973 
Figure 6.2 
Dissolution of Phenytoin from Diphantoine® 100 mg tablets in several dis-
solution media: a borate buffer pH 9 with or without 0.02% polysorbate 80, 
both directly and after pretreatment with 0.1 N hydrochloric acid for 30 min. 
For each sample moment the amount dissolved is calculated as percentage of 
the declared tablet content. Average values ± standard deviation are indicated. 
In the case of only three determinations the highest and the lowest value are 
shown. Two formulations of the same brand were tested: an asterisk indicates 
a significant difference. 
addition of polysorbate 80 to the acidic fluid completely reversed the picture 
(fìg. 6.2D). Even after 7 hours only about 50 per cent of the drug content 
appeared to have dissolved from the new tablets. Explanation of these obser-
vation appears to be difficult but possibly the penetration of the acidic pre-
treatment fluid into the new tablets is rather limited in the absence of a 
surfactant. The dissolution rate of the phenytoin acid, which has been formed 
during pretreatment, largely depends on particle size and aggregation. An 
almost intact tablet coated with a layer of phenytoin acid will dissolve only 
with grfeat difficulty. This view is supported by the observation that the new 
184 
Figure 6.3 
Influence of acid pretreatment on dissolution of Phenytoin from several prep-
arations: tablets and capsules of both the sodium salt and micro cry stalline 
Phenytoin acid. The dissolution pattern is only slightly influenced in the case 
of capsules. Surprisingly acid pretreatment appears to enhance the dissolution 
rate of the Phenytoin acid preparations. Asterisks indicate significant differ-
ences. 
tablets maintain their shape for a long period at pH 9, after pretreatment with 
acid and surfactant, while old tablets disintegrate more rapidly. 
Comparison of different preparations 
An ideal preparation has to show a constant rate and extent of absorption 
under varying circumstances. Transfering this requirement to dissolution studies 
would mean that a constant dissolution pattern, almost independent of dissol-
ution medium or physical circumstances, is considered to be ideal, as the risk 
of strongly varying dissolution rates in vivo is then small. When the dissolution 
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is slow, the bioavailability is likely to be less constant, due to variation of the 
gastrointestinal passage. In order to compare the phenytoin sodium tablets 
tested before, with some alternative preparations, dissolution tests have been 
carried out with and without acid pretreatment, a surfactant added in both 
cases. The phenytoin sodium capsules (Epanutin®) appeared to dissolve rela­
tively rapidly in both circumstances, although acid pretreatment is likely to 
impede total dissolution (fig. 6.3B). Surprisingly phenytoin acid preparations 
dissolved significantly faster after acid pretreatment. Again the difference 
between both treatments was smaller for capsules (fig. 6.3C and 6.3D). 
Disintegration and deaggregation of tablet contents appear to play an important 
role. These processes are influenced not only by the solubility of the drug it­
self but also by the type of binder and disintegration agent, whose activities 
may also be pH-dependent. 
Similar differences in dissolution rate between sodium salt and free acid have 
been observed by O'Reilly et al. (1966) for warfarin tablets. The dissolution 
from the tablet of warfarin acid at pH 7.4 was greatly increased by acid pre-
treatment. As most tablets will pass an acidic stomach fluid in clinical practice, 
it is likely that for such tablets, only dissolution tests including acid pretreat­
ment will provide data which may correlate with the in vivo absorption rate. 
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Figure 6.4 
Differences among batches of the same phenytoin sodium preparation, in the 
dissolution test including low surface tension and pretreatment with diluted 
acid. 
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A comparison of the dissolution patterns of several batches of the phenytoin 
sodium tablets in the test with surfactant and acid pretreatment is given in 
figure 6.4. All batches had been prepared according to the new formulation, but 
in the 100 mg tablets with the slowest dissolution rate, an organic granulating 
agent was used. The latter batch did not reach 100 per cent dissolution even 
after 24 hours. Other batches of 100 mg or 50 mg tablets that have been tested 
showed smaller differences, reaching about 70 per cent dissolution in 2 hours 
and 90 per cent after 6 hours. 
Choice of preparation 
If the differences observed here are relevant for absorption in vivo, replace-
ment of this brand of phenytoin sodium tablets by another preparation would 
be desirable. Dissolution patterns of some alternative preparations under iden-
Figure 6.5 
Dissolution patterns of five preparations of phenytoin in a buffer pH 9 after 
pretreatment with 0.1 N hydrochloric acid. Polysorbate 80 was added to 
lower the surface tension of the dissolution fluid. The calcium salt prepara-
tion shows a poor dissolution. The drug appears to dissolve only slowly from 
the sodium salt tablets (Diphantoine®) in this test. 
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tical circumstances are given in figure 6.5. Dissolution of phenytoin calcium 
tablets was extremely poor. After 24 hours about 30 per cent of the phenytoin 
content appeared to have dissolved. If the same pattom would occur in vivo, 
it is questionable whether the amount of drug that dissolves during the last 
part of the 24 hours would still contribute to total absorption. Tablets and 
capsules of the microcrystalline phenytoin acid and the Epanutin® capsules 
containing the sodium salt appeared to dissolve quickly.lt is likely that dissol-
ution at this rate is less susceptible to interferences than may be the case for 
the phenytoin sodium tablets. For economic reasons,'tablets maybe preferred 
to capsules. So tablets containing phenytoin acid in a microcrystalline form 
appear to be the formulation of choice. 
In vivo experiments will have to show whether the results obtained in vitro 
have therapeutic consequences. In view of the capacity-limited kinetics of 
phenytoin small changes in bioavailability may have large consequences in 
clinical practice. 
6.4 In vivo bioavailability studies 
Preliminary experiments 
In one volunteer, the absorption of phenytoin was studied from tablets con-
taining the sodium salt, the calcium salt and the free acid. The tablets were 
taken on an empty stomach or with a defined breakfast. Windorfer et al. (1978) 
found considerable differences in plasma concentrations after intake of a single 
dose of phenytoin tablets (5 mg/kg), depending on the type of food taken 
concomitantly. They compared a fat breakfast with a light one, or no food at 
all. In the present case, differences in absorption following intake with different 
meals are detectable but they are much less pronounced (fig. 6.6). Peak plasma 
concentrations were reached quickly without food intake. With breakfast, peak 
concentrations are observed later. The delay is more pronounced in the case 
of the fat breakfast. In the last case, plasma concentrations appear to be higher 
than after intake without food, both for the sodium salt and the free acid. 
Facilitation of dissolution by bile salts is supposed to explain these differences. 
The less dramatic effect of food intake in comparison with the study of 
Windorfer et al. (1978) may be caused by the lower dose (1.45 versus 5 mg/kg) 
and by the use of different preparations. The two tablet forms, used in the 
former study, most likely contained phenytoin acid with a larger particle size 
than is the case in the present experiments. In the study referred to, both prep-
arations gave different results already. It is easy to understand that solubilising 
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agents will have a greater influence in the case of lower solubility. 
Not only plasma concentrations of phenytoin but also urinary HPPH excretion 
were measured (fig. 6.7). After phenytoin acid intake the highest values were 
found. In table 6.1. total HPPH excretion as percentage of dose (corrected for 
molecular weight) is compared to the area under the plasma concentration 
curve for each experiment. 
Phenytoin calcium appears to be absorbed very slowly and incomplete. As 
far as may be concluded from this single experiment the phenytoin acid prep-
aration seems to have a higher bioavailability than the sodium salt tablets. 
This result would correspond with the in vitro data. In comparison with other 
studies, the amount of HPPH found in urine after intake of the phenytoin acid 
tablets is remarkably high. Usually 60-80 per cent of the daily dose is found 
in a 24-hour urine specimen of patients on chronic treatment (Wilder et al. 
1972, Borofsky et al. 1973). After a single dose about the same values have 
been found over a wide dose range (Jusko 1976). However, Smith and Kinkel 
(1976) reported over 90 per cent recovery in two out of 11 volunteers after a 
J subject F S 
/ single dose 100 mg tablet 
without food 
light breakfast 
fat breakfast 
calcium salt 
20 24 hours after 
intake 
Figure 6.6 
Phenytoin plasma concentrations in a male volunteer after intake of single 
doses of 100 mg tablets of phenytoin sodium (Diphantoine®), phenytoin cal-
cium and microcrystalline phenytoin acid fFenantoin®) on an empty stomach, 
with a light or with a fat breakfast. Resorption of the calcium salt tablet is ex-
tremely slow. Food intake appears to lower the speed of resorption but to in-
crease its extent. See also table 6.1. 
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Figure 6. 7 
Urinary excretion of (para-hydroxy-phenylj-phenyl-hydantoin in a volunteer 
after a single dose of 100 mg phenytoin free acid, sodium or calcium salt on an 
empty stomach. The total excretion is indicated as percentage of the dose (cf. 
fig. 6.6 and table 6.1). 
Table 6.1 Influence of breakfast on the absorption of different tablet prepara-
tions of phenytoin in one volunteer. 
prepa-
ration 
sodium 
salt 
acid 
calcium 
salt 
tablet content 
phenytoin acid 
mg 
92 
100 
93 
1 
break-
fast 
no 
light 
fat 
no 
fat 
no 
AUC 24 hours 
mg.hr. Γ 1 
12.3 
15.0 
15.8 
15.1 
17.8 
3.9 
HPPH excretion 
in 72 hours 
mg 
76.2 
71.5 
83.2 
106.4 
103.7 
26.7 
per cent 
of dose 
78 
73 
85 
100 
97 
27 
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single dose of 250 mg. AU reported doses are higher than those used in the 
present experiment. Houghton and Richens (1974) found an inverse relation-
ship between steady state phenytoin plasma concentrations and urinary HPPH/ 
Phenytoin ratio. Their data suggest that below plasma concentrations of 5 mg/1 
maximal HPPH recoveries can be expected. At the low dosages used here the 
elimination of phenytoin may not be capacity-limited. In that case, the AUC 
method and the HPPH recovery should yield comparable results. 
Recommended experiments 
The preliminary results obtained here will have to be confirmed before any 
definitive conclusion can be drawn. Comparison between the tablets with 
phenytoin sodium and those with the free acid is recommended. As has been 
argued before, the best way to judge bioavailability differences for phenytoin 
preparations would be a cross-over study in chronically treated patients. In one 
patient the usual phenytoin sodium tablets have already been replaced by the 
acid preparation for a period of 4 weeks. At a constant dosage of a 100 mg 
tablet 3 times daily plasma concentrations rose from 6.0 ± 0.5 mg/1 to 7.2 
and 8.0 mg/1 after 3 and 4 weeks respectively. This rise was to be expected 
merely because of the dose increment from 300 mg phenytoin sodium to 300 
mg phenytoin acid, corresponding with 326 mg of sodium salt. 
The in vitro results stress the fact that dissolution of phenytoin sodium tablets 
can be easily influenced by various factors indicating that in some patients, or in 
special circumstances in others, absorption difficulties may be expected. There-
fore, a large-scale cross-over study is recommended, especially including those 
patients with unexpectedly low phenytoin concentrations on their usual 
phenytoin dosage form. 
6.5 Phenytoin-3-(a-amino)-valeric acid 
Due to the amphoteric nature of the amino acid which has been coupled to 
phenytoin, this substance readily dissolves at several pH conditions (fig. 6.8). 
Even at pH 7.5,when the molecule is uncharged, the 50 mgNeo-Citrullamon® 
tablets appeared to dissolve almost completely within 4 hours. For this reason, 
absorption problems are unlikely to occur. 
The supposition that the drug would undergo N-dealkylation to form pheny-
toin could not be verified. After oral administration to man or after intravenous 
injection in the dog, no phenytoin or HPPH could be detected in blood or urine. 
After i.v. injection of 10 mg/kg in a dog, blood and urine concentrations were 
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dissolution of phenytoin-3-a-amino-valeric acid 
% DISSOLVED-
Fìgure 6.8 ®, Dissolution of phenytoin-3-a-amìno-valeric acid from Neo-Citrullamon^tab 
lets at several pH conditions. The drug appears to dissolve readily. 
Figure 6.9 
Plasma concentrations and urinary excretion of phenytoin-3-a-amino-valeric 
acid in a dog after rapid i.v. injection of 10 mg/kg. The unchanged drug was 
quantitated by HPLC. Plasma and urine were also analysed by the EMIT®-
assay for phenytoin. The antibody used in this assay crossreacts with pheny-
toin-3-a-amino-valeric acid and one or more of its, unknown, metabolites. 
Therefore higher concentrations are found by this method. The absolute con-
centrations may deviate as the degree of cross-reactivity for these substances 
is not known. 
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followed. Analyses were carried out by a specific HPLC method and by the 
EMIT®-assay for phenytoin. Phenytoin -3 -(α -amino)-valeric acid appeared to 
crossreact with the antibody of the latter assay for 30-70 per cent on molar 
basis, depending on the reagent batch. Significantly higher concentrations were 
•phenytoin-3-<i -amino-valeric acid in man 
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Figure 6.10 
Urinary excretion of phenytoin-3-a-amino-valeric acid after a single oral dose 
of 400 mg to a volunteer. Only small amounts of the unchanged drug are 
found by the HPLC method (2.5% of the dose). Note the larger amounts 
found as EMIT-equivalentS, representing the unchanged drug and one or more 
metabolites (no absolute concentrations). 
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found in the immunoassay, hereby demonstrating the formation of one or 
more metabolites with a longer biological half-life (fig. 6.9). These substances 
could not be detected by the chromatographic assay method and their structure 
remains to be solved. In urine, 70 percent of the i.v. dose was recovered as the 
unchanged compound. 
After single oral doses of 50-400 mg to a volunteer, and in a patient, chroni-
cally treated with 400 mg daily, no drug or metabolites could be detected in 
plasma by any of the assay methods. In urine, both metabolites and the un-
changed drug were present. After intake of 400 mg, the urinary recovery of 
the unchanged drug was only 2.5 per cent (fig. 6.10). Rapid metabolism of 
phenytoin-3-(a-amino)-valeric acid is the most obvious explanation for the 
observations in man and dog. Not all metabolites are detected by either assay 
method. It is not improbable that the original drug is reformed in kidney or 
urine. As dose increment studies in the dog did not reveal non-linear kinetics, 
this compound would have several advantages above phenytoin, provided the 
pharmacological spectrum is almost identical. 
6.6 Conclusions 
Due to the non-linear kinetics of phenytoin, small bioavailability differences 
may have important consequences for therapy. Ideally, the drug should be 
formulated in such a way that it will give a constant bioavailability under 
varying conditions. This requirement is more likely to be fulfilled when the 
preparation shows similar and high dissolution rates under several circumstances. 
Dissolution tests with the phenytoin sodium tablets, commonly used in 
the Netherlands, show a marked influence of pretreatment with 0.1 N acid. 
Gastric pH therefore may influence the rate and extent of absorption of these 
tablets. Transformation of the sodium salt of phenytoin -into the less soluble 
acid is important in this respect. However, bioavailability of phenytoin acid 
preparations does not need to be poorer than that of the sodium salt, certainly 
when a microcrystalline grade of the acid is used. 
In the present study, standard dissolution conditions include pretreatment 
with 0.1 N hydrochloric acid to which a surfactant is added to approach gastric 
fluid surface activity. The tested phenytoin sodium tablets dissolved only slowly. 
Such a slow process is very susceptible of interferences. Significant differences 
between some batches have been found. Tablets with microcrystalline pheny-
toin acid appeared to dissolve quickly. Capsules containing the sodium salt or 
the acid both showed a similar dissolution pattern. Rapid initial disintegration 
may explain the difference with the sodium salt tablets. Dissolution of pheny-
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loin calcium tablets was poor. 
Preliminary in vivo experiments yielded corresponding results. Bioavailability 
of the microcrystalline phenytoin acid tablets seems to be slightly superior to 
that of the sodium salt preparation. Phenytoin calcium is poorly absorbed and 
its use should be stopped. Food intake appears to influence the degree of 
resorption of phenytoin: fatty meals enhance absorption. 
As the dissolution of phenytoin acid preparations appears to be more constant 
under different conditions a large-scale comparison of the phenytoin sodium 
tablets and the microcrystalline acid preparation appears to be desirable. It 
should preferentially include patients, in whom indications for malabsorption 
are present. 
Phenytoin-3-(a-amino)-valeric acid deserves further attention as a possible 
alternative for phenytoin. The drug has better dissolution characteristics. 
Moreover, indications have been obtained that it does not show non-linear 
kinetics; a property which severely complicates therapy with phenytoin. 
However, it needs to be demonstrated whether the drug shows therapeutic 
effectiveness, comparable to that of phenytoin. The drug is not metabolised 
to form phenytoin. Before the substance can be applied on a large scale also 
its metabolism will have to be elucidated and the effective substance will have 
to be identified. 
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part three 
therapeutics 

Chapter 7 
Multidisciplinary approach to the treatment of epilepsy 
7.1 Introduction 
The knowledge on pharmacokinetics and pharmacodynamics of the antiepi-
leptic drugs, which has been reviewed and extended in the previous parts, was 
applied in clinical practice. During a pilot study with a limited number of 
patients a treatment protocol and evaluation methods have been developed and 
further adjusted. In a follow-up study a larger group of patients was treated 
according to this protocol. The results are evaluated, in order to judge the ef­
fectiveness of the chosen approach. 
Thanks to the evaluation of each medication step, the study yields a large 
amount of useful, individual data on effective plasma concentrations, drug inter­
actions and withdrawal phenomena, which are discussed in chapters 8 to 10. 
Usefulness of antiepileptic drug plasma concentrations 
During the last 10 years, the analysis of antiepileptic drugs in body fluids has 
found increasing application in the treatment of epilepsy. This technique has 
proven its usefulness in cases of lack of effect despite normal or even high 
dosages and on suspicion of toxicity (Eadie and Tyrer 1974, Решу 1974). 
Whether routine monitoring of drug concentrations leads to improved treat­
ment of epileptic patients is still open to discussion (Kutt and Решу 1974). 
Green et al. (1973) compared the results of treatment in a group of patients 
before plasma concentration determinations had become available with the 
new situation. The adjustment of plasma concentrations appeared to result in 
a significant reduction of seizures. Reynolds (1975) designed a prospective 
study with a corresponding approach: two matched groups of patients were 
treated in a similar way, but for one group only, the results of antiepileptic 
drug determinations were available to the medical attendant. No definite con­
clusions in favour of routine analysis of antiepileptic drug plasma concentra­
tions can be drawn yet. 
Adjustment of dosages in order to obtain plama concentrations within the 
'therapeutic range' does not necessarily lead to improved control of epilepsy 
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and to prevention of side effects. Nevertheless, in some studies this method 
has brought substantial seizure control (Sherwin et al. 1973). As has been 
demonstrated in chapter 2, individual therapeutic concentrations may vary 
widely. 
Several studies have been performed with the aim to correlate antiepileptic 
drug levels and therapeutic or side effects (Woodbury et al. 1972, Richens 
1976; see also chapter 2). Such studies may be designed in several manners: 
Schneider (1975) treated a group of patients with a fixed dose of carbamazepi-
ne as additional drug. He tried to correlate the improvement of seizure control 
with carbamazepine steady state concentrations. This approach has the disad-
vantage that interindividual differences may confuse the results unless large 
groups are compared. Ideally, individual plasma concentration/response rela-
tions should be investigated. The study by Lund (1974a) was a good start in 
this direction. A group of patients was treated with phenytoin during three 
years, each year at a higher level. The average number of major seizures ap-
peared to decrease from year to year. Later on, individual concentration/effect 
curves have been presented (Lund and Alván 1975). In principle such results 
might be obtained from each patient, whose drug dosage is increased step by 
step until the desired control of seizures is reached. Generally, periods between 
two medication changes are too short to detect small differences in seizure 
frequency. A large time scale is desirable for scientific purposes but is not al-
ways clinically justified. An example of a change of medication, too shortly 
after the previous one, and its consequences for the patient, are shown in 
figure 7.1. On the other hand, for each patient who benefits from a certain 
drug, it must be possible to determine the plasma concentration level associ-
ated with a marked clinical improvement, for instance a 50 per cent reduction 
of seizure frequency. Knowledge on the distribution of these individual values 
in a sufficient number of patients adds to the value of plasma concentration 
analysis. 
Figure 7.1 
Treatment record of patient K.T. (female, 26 years) suffering from epilepsy 
with psychomotor seizures. Three variables are recorded graphically : drug dos-
ages (lower part), plasma concentrations (upper part) and seizure frequency 
(median part). The number of seizures per half month is shown. Due to the 
short interval between the increment of the dose of valproate and the start of 
carbamazepine treatment (March/April 1977), it was not certain which change 
was responsible for the disappearance of seizures. An attempt to withdraw 
carbamazepine led to some tonic-clonic seizures (black columns), which were 
unusual for this patient. 
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Routine monitoring of antiepileptic drug levels has significantly increased 
knowledge on the pharmacokinetic properties of these drugs. Probably this 
knowledge has attributed to the improvement of epilepsy treatment to a 
higher extent than the analyses themselves (Penry 1974). However, proper 
use of this know-how is only possible when it is incorporated in a broader ap-
proach of the treatment of the patient. The usefulness of antiepileptic drug 
determinations including expert interpretation, therefore has to be assessed in 
a comprehensive treatment study. 
Polypharmacy 
The widespread occurrence of polypharmacy in epilepsy adds to the compli-
cation of the situation. Changes in clinical picture can only be attributed to 
one drug, when it does not influence other drugs given concomitantly or when 
such interactions are anticipated. When the plasma concentrations of all drugs 
except one have remained or are kept constant, the effect is attributed to the 
variable one. Interactions on distribution, on metabolism or at the pharmaco-
dynamic level are often overlooked. As there is no scientific proof for the 
necessity of the combination of several antiepileptic drugs, reduction of the 
variety of drugs should be tried (Reynolds et al. 1976). At the same time this 
offers the opportunity to detect possible effectiveness of the plasma concen-
trations of the drugs to be withdrawn. Often plasma concentrations are found, 
that are well below the generally accepted 'therapeutic range'. 
Shorvon et al. (1978) treated a group of previously untreated patients with 
only one drug. They were able to reach complete control of seizures in 74-85 
per cent of the patients. The authors estimate that this figure would have been 
below 60 per cent without determinationof plasma concentrations. Addition 
of a second drug in cases· of incomplete control did not result in a significant 
reduction of seizure frequency. Existing multiple drug treatment appears to 
be difficult to reverse in clinical practice and therefore Reynolds et al. (1976) 
advocate monotherapy for new epileptic patients. 
Judgement of results of treatment 
Most studies on the efficacy of epilepsy treatment in the past used the clinical 
seizure frequency and/or qualitative interpretation of the EEG as sole para-
meters for the effect. Indeed, monitoring of epileptic seizures by clinical ob-
servation is considered the first requisite for judgement of the effects of treat-
ment. 
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In most studies described in the previous section, the patient serves as his 
own reference. This approach is based on the assumption that no or unchanged 
treatment would have resulted in equal seizure frequency. Although periodic 
changes in the pattern of clinical symptoms are not uncommon in epilepsy, 
this assumption can be used, provided that patients with active pathological 
processes and children are excluded, and the baseline period is chosen care-
fully and is long enough (Johnson et al 1959). 
Whereas electroencephalography is a powerful tool in diagnosis of epilepsies, 
its use for quantitative purposes is limited. Often no correlation is found 
between clinical improvement or deterioration and results from visual inspec-
tion of routine EEG recordings. Perhaps prolonged registration or computer 
analysis of the EEG will improve this correlation Application of these 
methods is still limited to research centers. Epilepsy treatment may be as com-
prehensive as to include synchronous 24-hour registration of the EEG and of 
clinical manifestations by video-recording, frequent sampling of blood for 
analysis of drugs and biogeneous substances and extensive psychometric tes-
ting. Such a program will be supervised by a team of skilled epileptologists, 
experts in several disciplines who are intensively concerned with epilepsy This 
approach will have a limited application, mainly concerning the extreme re-
fractory cases A way of treatment which works in practice, has to depend on 
techniques that are generally available EEG recording and the measurement 
of plasma concentrations of antiepileptic drugs may be considered to belong 
to this category. 
Behavioural and functional changes 
Side effects of antiepileptic drug treatment are not uncommon and they also 
have to be involved in the judgement of treatment results. Not only negative 
effects such as drowsiness and ataxia, but also improvement of vigilance, work 
or school performance and behaviour have been observed (Knäuel and Gruter 
1967, Ishibashietal. 1970, Stores 1975). The latter phenomena are sometimes 
considered to be intrinsic effects of drugs like caibamazepine and valproic acid 
but they may also be secondary to improvement of epileps^ control. On the 
other hand rigorous suppression of epileptic discharges may also provoque 
serious behavioural problems (Wolf 1976). 
Objective and reproducible measurement of such effects is difficult. More-
over the choice of characteristic criteria is a problem in itself. Literature data 
stress these difficulties. Numerous psychometric tests and evaluations have 
been performed to discover differences between several antiepileptic drugs or 
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different dosages or plasma concentrations of the same drug (Hutt et al. 1968, 
Marjerrison et al. 1968, Stephens et al. 1974, Diehl and Werner 1975, Trimble 
1977). Similar studies have been undertaken in order to compare epileptic pa-
tients and healthy volunteers or non-epileptic patients. The low number of 
significant differences is striking. Heijbel and Bohman (1975) found almost 
no differences between epileptic children and their healthy class-fellows con-
cerning intelligence, behaviour and school adjustment. Only in a test for visu-
motoric coordination the epileptic children had lower scores. On the other 
hand KlfWe and Matthews (1966) found differences in a large number of tests 
between adult epileptics and controls. By means of a behaviour rating scale 
Cereghino et al. (1974) were able to demonstrate differences between three 
anticpileptic drugs. In a group of chronically treated patients Dodrill (1975) 
found differences in several tests between patients with phenytoin plasma 
concentrations above and below 30 mg/1. Performance of tests with motoric 
components appeared to be especially impaired. However, most patients with 
low performance also showed clinical signs of intoxication. In a controlled 
trial on sodium valproate Sommerbeck et al. (1977) tried to find evidence for 
the supposed psychotropic effect of the drug. They found only a few signifi-
cant test differences. However, these pointed in the opposite direction, as 
psychomotor activity and speed tended to decrease on valproic acid. It may 
be concluded from the data reviewed, that differences in behaviour or perform-
ance caused by changes in antiepileptic therapy are difficult to demonstrate. 
Best results have been obtained with behaviour rating scales and with psycho-
metric tests with predominantly pure motor or psychomotor components. 
Treatment of institutionalised patients 
Environmental factors have a marked influence on the epileptic manifesta-
tions in many patients. Adjustment of epilepsy treatment therefore will have 
to take place in normal circumstances for the patient. Short-term admission 
into a hospital does not fulfil this requirement. Outpatient treatment is pre-
ferred but much information on clinical symptoms is missed as the acquisition 
depends on the subjective impression of the patient himself or on the observa-
tion of his fellow-men, who have generally not been trained for this purpose. 
However, information on seizure frequency appears to be markedly improved 
by the introduction of a seizure calendar (Hommes 1979). From many patients 
reliable data can be obtained, which may be used as a guide for therapy. 
Treatment in an epilepsy center or other institutions for a prolonged period 
may both provide environmental stability and professional observation facil-
ities. On the other hand institutionalisation involves several drawbacks for the 
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patient. For that reason, it is only indicated for the adjustment of difficult 
cases, after the outpatient treatment has appeared to be unsuccessful. Patients, 
who are institutionalised for other reasons, can be treated in the same way. All 
staff members who have to do with the patient will be involved in permanent 
registration of clinical events. Participation of several disciplines in the treat-
ment is desirable. 
Multidisciplinary treatment 
Cooperation of several disciplines in the treatment of epileptic patients has 
occasionally been reported. Cereghino and Cole (1971) evaluated several pro-
jects in which clinics offered a multidisciplinar approach to epileptic patients. 
The staff of these clinics consisted of a physician, psychologist, social worker, 
public health nurse, vocational counseler, EEG technologist and secretaries. 
This approach turned out to be very effective. For institutionalised patients 
the presence of several disciplines in the institution does not automatically 
imply a coordinated multidisciplinar approach. Recently O'Neill et al. (1977) 
reported the improved control of epilepsy after the appointment of a nurse-
specialist in epilepsy, who coordinated patient care, provided instructions and 
information and organised the supervision on patient units. Patients were seen 
weekly by the neurologist and a systematic evaluation was introduced. 
In the working groups mentioned before no experts in physical sciences have 
been incorporated. Probably the first report on a working group with clinical 
pharmacologists is of Italian origin (Milano Collaborative Group 1977). Four 
pharmacologists, one chemist, one social worker and eight neurologists from 
several institutions met monthly and discussed general problems, and 60 'dif-
ficult' patients as single cases. Preliminary results indicated a reduction of the 
number of antiepileptic drugs per patient, and a decreased frequency of seiz-
ures and side effects. 
7.2 Objectives 
The main objective of the present project is to develop a treatment policy 
for epileptic patients using generally accessible means, by gathering the knowl-
edge of several disciplines. 
The approach is evaluated by an attempt to reach optimal treatment in a 
group of institutionalised mentally retarded epileptic patients, by intensive 
collaboration of physicians, the attendants of the patients and a pharmacist. 
Optimal treatment is defined as an optimum between minimal frequency of 
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epileptic seizures of the lowest possible severity, the best possible functioning 
of the patient in his environment and his well-being. Moreover a minimal num-
ber of drugs should be used. All requirements are related to what can be real-
ised under the actual circumstances. 
As methods to measure several of these parameters, are not ready to hand, 
attention to the development of such techniques had to be included within 
the project. 
In order to judge the necessity of the intensive accompaniment in this inves-
tigation, some of the results will be compared with a project in another insti-
tution, set up with similar objectives. The applied techniques are almost 
identical but the accompaniment is less intensive and less strictly regulated. 
The design and the results of this project will be given separately. 
The mental handicap of the patients and the disorders, that occur in addi-
tion, offer special problems for treatment: diagnosis of epilepsy and the re-
liable registration of seizures are seriously hampered. The detection of slight 
side effects requires special efforts. As the types of epilepsy, whose seizures 
are difficult to control, occur frequently in institutionalised patients, the 
treatment of this group may be considered a hard test case. 
7.3 Design of the project 
General outline 
The project is carried out in an institution for mentally retarded people, Huize 
Boldershof, Druten, the Netherlands. The institution takes care of about 600 
patients of all ages with a moderate to severe mental handicap. Due to the 
policy of admission in the past about 90 per cent of the patients are women. 
Additional handicaps occur frequently: cerebral palsy, epilepsy, chorea, atetho-
sis etc. About 25 percent of the patients were treated with antiepileptic drugs 
or were suspect of having epilepsy because of clinical phenomena. In the first 
phase of the project the team started treatment of 37 patients who had frequent 
or grave seizures, or were treated with a combination of several antiepileptic 
drugs. Initially these patients have been treated according to the modem prin-
ciples of epilepsy treatment, taking into account recent neurological and phar-
macological findings but without strict rules. Further literature search and 
growing experience enabled the development of a strategy for treatment, which 
was laid down in a strict protocol. In the second phase of the project 98 
patients were treated according to this protocol. At the same time treatment 
of the first group was brought into agreement with the same rules as far as 
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possible. Three years of experience with the first group and the results in the 
second group after IVi years will be reported here. 
The team 
The team consisted of the medical staff and two psychologists of the insti-
tute, and two external consulents, a neurologist and a pharmacist. A secretary 
was added to the team to keep minutes of the meetings and to assist in organ-
isation. The medical staff consisted of five general practitioners charged with 
the medical care for different departments of the institute. The team met for 
one afternoon a week. 
Policy was discussed in fully attended meetings. All other meetings were at-
tended by the neurologist, pharmacist, secretary and those members of the 
medical staff, whose patients were discussed. Sometimes attendants or nurses, 
charged with supervision of the patients discussed, and the psychologists in-
volved were invited to join the discussion. Every patient was discussed by the 
team at regular intervals. For the first group the average frequency was once 
in 6 weeks. Acute problems were discussed weekly. All decisions concerning 
changes of therapy, recording of EEG, blood sampling, etc. were taken by 
consensus of the team. 
— The practitioners kept frequent contact with the patients and their atten-
dants. They brought information on seizures, side effects and particularities 
to the team, and returned information and instructions to the patient-units. 
They prescribed all drugs and treated emergency cases, often after consulta-
tion of the neurologist or pharmacist, and reported this to the team. 
— The neurologist judged all EEG recordings and performed neurological ex-
aminations when necessary. 
— The pharmacist (the author) performed plasma concentration analyses and 
interpreted the results. Moreover, he functioned as coordinator. He kept 
record of all relevant information of each patient in a central documenta-
tion system: seizures, antiepileptic drug dosages and plasma concentrations, 
team decisions, EEG results and particulars. 
— The psychologists supervised and partially executed behavioural scores and 
psychometric tests. 
Patients 
Initially group I consisted of 29 patients but was expanded to 37 within 6 
months. There were 28 females and 9 males. Of this group 27 patients had 
more than 5, usually grave, seizures a month. The remaining 10 patients were 
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all treated with a combination of 3 or 4 antiepileptic drugs. The whole group 
consisted of 22 adults, 5 were adolescents and there were 10 children below 
10 years (average age ± standard deviation: 24 ± 15 years). Based on the avail-
able data the team made a preliminary classification of the individual types of 
epilepsy, but for several patients these diagnoses had tobe reconsidered during 
the period of the investigations. Increased information by improved observa-
tion and reporting, and changes of type of seizures as a result of medication 
adjustments were the main reasons. 
Diagnosis of epilepsy in this population of mentally retarded patients is bur-
dened with special difficulties: 
— In general the patients are not able to describe their experiences during or 
preceding the epileptic seizure. The presence and the type of an aura may 
be very helpful in diagnosis. 
— Interpretation of EEG tracings is difficult because the background pattern 
is often irregular and movement artefacts occur frequently. 
— Moreover, epileptic seizures are not always recognised clinically because 
they have to be distinguished from spastic, choreo-atethotic and other ab-
normal movements and from several types of behavioural disorders. 
— The degree of consciousness is often difficult to estimate and it may already 
fluctuate at a low level in seriously retarded patients. 
Types of epilepsy, classified according to the prevailing type of seizures, are 
given in table 7.1. The large group of epilepsies with secondarily generalising 
partial seizures does not enclose only cases with a demonstrated focal onset 
of epileptic discharges in the EEG. Also patients with generalised tonic-clonic 
Table 7.1 Types of epilepsy in 37 patients (group I) 
epilepsy with 
simple partial seizures 
psychomotor seizures 
partial seizures, secondarily generalising 
infantile spasms 
Lennox syndrome 
myoclonic epilepsy 
atypical absences 
primarily generalised tonic-clonic seizures 
unclassifiable 
no diagnosis of epilepsy 
preliminary 
diagnosis 
1 
5 
14 
2 
3 
3 
2 
3 
3 
1? 
later 
diagnosis 
-
4 
19 
-
5 
-
— 
— 
8 
1! 
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seizures and complex minor seizures, with an EEG showing paroxysmal dis­
charges of varying localisation and an underlying serious diffuse brain damage 
have been attributed to this group. The patient, who is diagnosed as having no 
epilepsy, is no longer treated with antiepileptic drugs. No history of seizures 
is known in this case. 
The second phase of the project concerned all patients of the institution, 
who were treated with antiepileptic drugs, not included in the first phase, and 
those who recently showed clinical signs suspect for epilepsy. Patients who 
were treated with antiepileptic drugs for cerebral palsy, behavioural disturb­
ances or anxiety were not included. The group consisted of 6 male and 92 fe­
male patients. There were 10 children between 5 and 10 years of age, 9 ado­
lescents and 79 adults (average age ± s.d.: 29 ± 14 years). The group has been 
increased by 15 patients because of admission of new patients treated with 
antiepileptic drugs, or the occurrence of the first possible signs of epilepsy 
among other patients of the institute. Data presented here are confined to the 
former 98 patients. During a first round of meetings of the team, patients were 
selected for participation in the project and a preliminary treatment policy 
was fixed: 
A. search for better treatment, 
B. reduction of medication, 
С observation whether treatment is necessary, 
D. already optimal treatment. 
After registration of seizures for several months and collection of other data, 
each patient was discussed extensively. Diagnosis was fixed as far as possible 
and the treatment policy was translated into concrete measures. Types of epi­
lepsy of this group of patients are shown in table 7.II. 
From the first group of 37 patients one died during the course óf the project 
of an illness, not related to his epilepsy. A second patient, whose epileptic 
seizures had been satisfactory controlled, was transferred to another institution. 
Their data have been omitted from the results shown below. 
In the second group of 98 patients the recording of seizures was clearly un-
reliable in two patients: several clinical phenomena had not been recognised 
as epileptic seizures during the first part of the registration period. Only data 
for the 96 remaining patients will be given. 
Techniques 
Registration of seizures 
Before initiation of the project, all attendants of the patients involved received 
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Table 7.II Types of epilepsy in 98 patients (group II) 
epilepsy with 
simple partial seizures 
psychomotor seizures 
partial seizures, secondarily generalising 
Lennox syndrome 
myoclonic epilepsy 
petit mal absences 
atypical absences 
primarily generalised tonic-clonic seizures 
tonic seizures 
unclassifiable 
no diagnosis of epilepsy 
1 
16 
27 
4 
1 
1 
1 
7 
1 
19 
20 
a specific instruction. After an explanation on the aims and methods of the 
project they were told how to discriminate several types of epileptic seizures. 
This was illustrated by means of a video program showing several epileptic 
seizures, that was made available by the Interfacultary Working Group on 
Education in Neurology and obtained from the Foundation Film and Science 
(SFW, Utrecht, the Netherlands). The forms to be used were explained. 
Seizures were continuously scored on the form shown in fig. 7.2. A score 
had to indicate time of the day, type and duration of the seizure. Details and 
particular circumstances were also indicated. Initially forms for a week were 
used, later on they were replaced by forms covering a month. At the beginning 
of the study and in cases of abnormal seizures or changes of type, seizures 
were described by means of the questionaire shown in fig. 7.3. All completed 
forms — also blank ones — are immediately sent to the practitioner in charge. 
Electroencephalography 
During sessions of 30 minutes, 16-channel routine EEG records were made, 
Figure 7.2 
Form for the registration of epileptic seizures. Each seizure has to be recorded 
in the appropriate time period of the day by the code for type and duration, 
indicated at the bottom of the form. Special features of the seizure, particular 
circumstances, side effects, etc. are indicated on the right side of the form. 
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ÜLSCRIPTION OF A CHARACTERISTC EPILEÍ-TIC SEIZURE 
CIRCUHSTAVCES, UNDER WHICH THF 
SEIZURES PREDOMINANTLY OCCUR 
At a tixed time of the day1 
After awakening'' 
During bathing or dressing^ 
On emotion"5 
On efforts'5 
In connection with meals? 
Related to menses? 
Other circumstances 
SITUATION IMMEDIATELY PRECEDIN 
OR AT THE ONSET OF THE SEIZURL 
Do you foresee the seizure^ 
How and how long before"5 
Does the patient feel the 
seizure coming alorg"5 
Agressive behaviour"5 
Change of mood"5 
Does twitching stdrt at a 
certain point of the body"5 
Does twitching spread"5 
Does the patient turn red*5 
Does the patient turn pale"5 
Other particulars 
THE SLIZURF ITSELF 
Does the patient loose 
consciousness' 
Do you see tonic spasin(s)'' 
Are there clonic spasms'5 
Tn which order do the spasms 
occ jr-5 
Only on one side of the body"5 
does the patient fall"5 
Is there т^игу"5 
Only forwards nodding of the 
head and arms'» 
' cannot be indicated/not rel 
YES NO •> DESCRIPTION AND PARTICULARS 
overnight/in the morning/ 
in the afternoon/in the evening 
before/dunnp/after 
G 
How do you know that"5 
How? 
Hhere* 
Where"5 
Hnuf Innp? 
WTIPT-P-Ï 
WKprP? 
corsciojs/unronsr.in.is X 
V Τ D 
evant к croSbS which is incorrect 
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Moveirents or sounds of smack ing 
swallowing,sniffing.snoring' 
Does the head turn"5 
Do the eyes ΐυτη1 
Staring еуеь1' 
Irregular breathing' 
Does the patient turn blue 0 
Actions without sense, 
automatisms0 
Incontinence' 
Is there contact with the 
patient during the attack^ 
Other particulars 
SITUATION AT THE END OF OR 
AFTER THE SEIZURE 
Does twitching continue 
somewhere'' 
Directly normal after 
the seizure9 
Does the patient fall asleep' 
Drowsy' 
Headache' 
Other particulars 
Duration of the whole seizure 
This seizure is scored on t"he 
registration forms as 
Frequency of seizures 
YES NO ' DESCRIPTION AND PARTICULARS 
In what direction' 
In what direction' 
Wh*™' 
For how lone' 
г
o·
,
 no* lo-p' 
sec/mir 
GM/PS/A/H/O x 
per day/week/month/year 
GIVE A SHORT DCSCRIPTIOH 01 THE SEIZURE USING YOUR OWW TERKS 
Are the seizures always identical0 yes/no If not, complete a new fom 
Form completed by 
Date 
Figure 7.3 
Questionaire for the description of epileptic seizures. For each type of seizures 
of an individual patient a characteristic seizure must be described. The atten­
dants of the patients had been instructed on the precise meaning of each ques­
tion. 
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including provocation of epileptic discharges by photostimulation and, when-
ever possible, by hyperventilation. During the first year 2-4 records were made 
for each patient. 
Antiepileptic drug plasma concentrations 
Blood was taken at 11 o'clock ± 15 minutes. Usually the morning drug intake 
was at 8 o'clock consistently, in some cases at 7 o'clock.Phénobarbital, Pheny-
toin and primidone were determined by the EMIT -method, sodium valproate 
and ethosuximide by GLCand carbamazepine, diazepam and nitrazepam were 
determined by HPLC. Clonazepam analyses by means of GLC with electron 
capture detection were performed by Drs. H. Knop, Department of Clinical 
Pharmacy, St. Annadal Hospital, Maastricht, the Netherlands (Knop et al. 
1975). During the first year an average of 5 samples per patient was analysed. 
Behavioural scores 
Behaviour was judged by means of the HELO-rating scale, developed at 
's Яеегеп Ζ,οο-Lozenoord (Ermelo, the Netherlands). The scale describes 
behaviour and personality of a mentally retarded person by means of 47 ad­
jectives, whose validity for the patient was scored between 0 and 10 by the 
attendants of the patient in a session guided by a psychologist (Kraijer 1978). 
For judgement the items are summed to form 6 clusters: attitude towards 
work, positivity, dominance, demand for attention, agression and fear. Scoring 
was performed twice in the starting situation and once a year subsequently. 
Treatment protocol 
Initially the first group of patients was treated without a strict protocol. 
Medication was reduced by withdrawal of drugs that were given at a low level. 
During the next stage an attempt was made to achieve improved epilepsy 
control by dose increments of the remaining drugs, provided that this could 
be tolerated without disturbing side effects and excessively high plasma con­
centrations. If this approach did not succeed one of the antiepileptic drugs 
was replaced by another. The second group was treated according to strict 
rules from the onset. The protocol is given below. 
Starting conditions 
Before the first change of treatment the following requirements had to be 
met: 
1. instruction of attendants, 
2. registration of seizures during at least 3 months at a constant therapy - for 
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low seizure frequencies the data of the last 4-10 seizures should be known, 
3. description of all registered seizure types, 
4. review of disease history, 
5. review of EEC's, 
6. review of medication history, 
7. recent score of behaviour and psychometric tests, 
8. identical testing of non-epileptic patients with comparable handicaps living 
in the same group, 
9. recent analysis of antiepileptic drug plasma concentrations, 
10. description or recording of individual characteristics which might be influ-
enced. 
During the first extensive discussion on a patient, where the attendants and 
psychologists involved also were present, the team judged whether sufficient 
data had been gathered. Diagnosis was established and a plan for treatment 
for future months was designed. Later on these plans and the actual outcome 
have been compared. 
Choice of drugs 
The antiepileptic drugs of choice for the treatment of several types of epilepsy 
are indicated in table 7.HI. Whenever possible high dosages (see table 7.IV) 
are lowered and the number of antiepileptic drugs given simultaneously is re-
duced to 2 or less, prior to an increase of dosage or the addition of a new drug. 
Table 7.III Drugs of choice for several types of epilepsy 
TYPE OF EPILEPSY 
primarily gen. ton.clon. seizures 
petit mal absences 1 
atypical absences j 
myoclonic epilepsy 
Lennox syndrome 
infantile spasms 
simple partial seizures 
psychomotor seizures 1 
partial seizures, sec. generalising 
status epilepticus 
serious repetitive seizures 
DRUGS OF CHOICE 
1. valproic acid 2. phénobarbital 
1. valproic acid 2. ethosuximide 
1. valproic acid 2. clonazepam 
1. valproic acid 2. carbamazepine 
or clonazepam 
1. nitrazepam 2. ACTH 
1. phenytoin 2. carbamazepine 
1. carbamazepine 2. phenytoin or 
valproic acid 
1. diazepam i.v. 2. phenytoin i.v. 
or by rectal 
solution 
215 
In cases of more than 4 severe seizures per month reduction is postponed. 
Dose increments or addition of another drug are carried out in the following 
order as far as applicable: 
1. dose increment of drug of first choice, 
2. dose increment of drug of second choice, 
3. addition of drug of first choice, 
4. addition of drug of second choice. 
If a drug has no clear effect at maximal dosages it is subsequently withdrawn. 
Dosage 
In order to give comparable doses in individual cases dosage calculations are 
based on the theoretical attainment of fixed plasma concentrations. For this 
purpose relative clearance values with correction for age and comedication are 
used (Guelen and van der Kleijn 1978). Later on dose increments are based 
on measured plasma concentrations and the appropriate correction formulae. 
Directions for the use of plasma concentrations are given in table 7.IV. Dosages 
are increased stepwise, corresponding to a plasma concentration shift of one 
level, until the desired therapeutic effect or persisting side effects occur, or 
until the maximal plasma concentration is reached. Changes of dosage may be 
spread over smaller increments but a full step is to be completed within two 
weeks. In cases of disturbing initial side effects deviations from this rule are 
allowed. Intervals between two increment steps depend on seizure frequency 
but are at least 6 weeks apart. Slight side effects are tolerated for 3 weeks, 
Table 7.IV Guidelines for antiepileptic drug plasma concentrations (mg/I) 
sodium valproate 
phénobarbital 
carbamazepine 
Phenytoin sodium 
clonazepam 
ethosuximide 
primidone 
level I 
< 30 
< 10 
< 2 
< 3 
< 0.010 
< 25 
< 4 
level II 
50 
20 
4 
7 
0.020 
40 
7 
level I is considered not to be effective 
— drug will be withdrawn or dose will be ir 
level II target concentration for initial dosage 
level III should be tried if level 11 is not effective 
level IV maximal concentrations - higher levels wil 
level III 
80 
35 
8 
12 
0.040 
70 
10 
icreased 
1 be decreased 
level IV 
140 
50 
12 
20 
0.060 
100 
15 
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serious ones for one week. 
Antiepileptic drugs are not given to previously untreated patients unless 
they have experienced three seizures, for which no immediate cause can be 
found. Some minor seizures per year with little risk for injuries are not treated 
with drugs unless on special request. Patients are treated with a single antiepi-
leptic drug for a limited period of time. If no significant improvement is achie-
ved, treatment is withdrawn subsequently. The same procedure is sometimes 
followed when paroxysmal phenomena cannot be diagnosed as epileptic for 
sure. 
Reduction of medication 
Dose reductions are carried out stepwise in the same manner with step-inter-
vals of at least two weeks. For complete reduction also dosage at level I is in-
corporated. For reduction or withdrawal, drugs are chosen in the following 
order: 
1. drugs not mentioned in table 7.IV, 
2. drugs not indicated for the particular type of epilepsy (table 7.III), 
3. drugs of second choice, 
4. drug of first choice. 
In cases of equivalent alternatives low dosages are withdrawn first. Withdrawal 
effects are tolerated for 6 weeks if not too serious. When extra seizures continue 
over 6 weeks the previous dose of the drug is prescribed again. When it may 
be expected that the remaining medication is effective on its own, a dose in-
crement may be tried first. Withdrawal of primidone is effected by replacement 
by phénobarbital in such a way, that the phénobarbital plasma concentration 
does not change. Phénobarbital is then reduced in a second phase (fig. 7.7). 
Complete withdrawal of antiepileptic drugs is considered in cases of freedom 
from seizures for more than 4 years and in cases of rare occasional seizures. 
Particular circumstances 
In cases of intercurrent disease, accident, transfer to another department etc. 
treatment is kept unchanged until the clinical picture has been stabilised again. 
Deviations from the rules mentioned above are allowed in cases of status epi-
lepticus and drug intoxications, and when seizure frequency is increased by 
over 100 per cent for more than a week without immediate cause. As far as 
possible emergency situations are treated symptomatically or in such a way 
that the treatment policy is not abandoned. 
Plasma concentrations 
Antiepileptic drug plasma concentration determinations are performed under 
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constant therapy for at least three weeks, especially in the following cases: 
1. antiepileptic drug treatment in the starting situation, 
2. when medication change appears to be successful, 
3. before giving a drug at its highest dose level, 
4. at maximal dosage, 
5. after complete withdrawal of a drug (and others are left), 
6. carbamazepine at each dose level, 
7. phenytoin at least at two dose levels, 
8. in case of toxic effects. 
7.4 Drug consumption pattern 
Quantitative aspects 
An important result of the project is a reduction of drug consumption, both 
regarding the number of drugs per patient taken simultaneously and the variety 
of antiepileptic drugs, that is used for the whole population. The onset of this 
effect had a delay time of about 6 months. For the first phase of the project 
this period represents the acquaintance period of the team and the time needed 
for the first cautious attempts to reduce medication. The number of drugs per 
patient in the first group is shown in table 7.V. 
Table 7.V Number of antiepileptic drugs per patient (group I, 35 patients) 
date 
NONE 
1 drug 
2 drugs 
3 drugs 
4 drugs 
Average number of drugs 
per patient: 
- total group 
- treated patients only 
number of patients 
01-01--76 01-01-77 01-01-78 01-01-79 
1 
11 
17 
6 
2.80 
(2.80) 
4 
20 
10 
1 
2.22 
(2.22) 
1 
1 
24 
8 
1 
2.20 
(2.26) 
2 
2 
20 
10 
1 
2.17 
(2.30) 
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After the initial sharp decrease further reduction in this group of difficult 
patients appears hardly possible. The final number is expected to stabilise 
around an average of 2.0 antiepileptic drugs per patient. 
In the second group of patients similar results have been obtained. Although 
reduction of medication has been carried out more energetically, the same lag 
of 6 months is observed before results became apparent. The first round of 
meetings to extensively discuss all patients was very time consuming and may 
be held responsible. This period also includes the baseline registration. The 
course of drug treatment in the second group of patients is shown in table 7 .VI. 
Table 7.VI Number of antiepileptic drugs per patient (group II, 96 patients) 
date 
NONE 
1 drug 
2 drugs 
3 drugs 
4 drugs 
Average number of drugs 
per patient: 
— total group 
- treated patients only 
number of patients 
01-07-77 01-01-78 01-07-78 01-01-79 
12 
39 
36 
8 
1 
1.45 
(1.58) 
12 
38 
36 
9 
1 
1.47 
(1.60) 
22 
43 
19 
12 
122 
(1.50) 
21 
44 
26 
5 
1.16 
(1.48) 
Twelve patients have been included in the study to evaluate whether it would 
be necessary to start antiepileptic treatment. Seven of them receive drug treat-
ment now. On the other hand 16 patients who have been treated with one or 
two antiepileptic drugs for years have become free from drugs without recur-
rence of seizures. As the average follow-up period since complete withdrawal 
is over one year their chance to keep free from epileptic seizures at least for 
several years may be estimated at about 90 per cent (Juul-Jensen 1968). 
Qualitative aspects 
The reduction of the number of drugs, given individually, is accompanied by 
a clear simplification of the number of drugs in current use. Figures for both 
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Table 7.VII Medication pattern in 35 patients (group I) 
date 
phénobarbital 
valproic acid 
Phenytoin 
carbamazepine 
clonazepam 
primidone 
diazepam 
ethosuximide 
nitrazepam 
sulthiame 
01-01-76 
30 
25 
10 
5 
5 
4 
9 
5 
4 
1 
86% 
72% 
29% 
14% 
14% 
11% 
26% 
14% 
11% 
3% 
number of patients 
01-01-77 
28 
18 
10 
15 
4 
1 
2 
— 
— 
-
01-01-78 
15 
20 
14 
25 
2 
1 
— 
— 
— 
-
01-01-79 
12 
21 
14 
24 
3 
2 
— 
— 
_ 
-
34% 
60% 
40% 
69% 
9% 
6% 
-
_ 
_ 
-
Table 7.VIII Medication pattern in 96 patients (group II) 
date 
phénobarbital 
valproic acid 
Phenytoin 
carbamazepine 
clonazepam 
primidone 
diazepam 
ethosuximide 
nitrazepam 
01-07-77 
52 
43 
13 
8 
6 
3 
6 
7 
1 
number of patients 
01-01-78 01-07-78 
50 
47 
13 
11 
6 
3 
6 
5 
-
28 
42 
19 
19 
5 
1 
3 
1 
-
01-01-79 
26 
41 
14 
21 
3 
2 
4 
-
-
parts of the study correspond very well as may be seen from tables 7.VII and 
7.VIII. 
The most striking phenomenon is that almost all patients can be treated with 
only four drugs: phénobarbital, valproic acid, phenytoin and carbamazepine. 
Only 12 per cent of all patients are treated with other drugs. At the onset of 
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the study this number was 31 per cent. From the remaining drugs clonazepam 
is of great value in some difficult cases but all other antiepileptic drugs seem 
to be dispensable in the present treatment of this group of patients. 
Concerning separate drugs the share of valproic acid and phenytoin has re-
mained almost constant while phénobarbital is withdrawn in a great number 
of patients and the use of carbamazepine has increased significantly. This is 
not surprising when the large number of patients with partial epilepsies is con-
sidered. Phénobarbital is thought to have little value in this type of epilepsy 
while carbamazepine is the drug of choice. By clinical tradition phénobarbital 
is known to be associated with withdrawal problems. Experience in 60 patients 
will be discussed in chapter 9. 
Dosages and plasma concentrations 
In order to maintain or to improve control of epilepsy the reduction of the 
number of antiepileptic drugs has been accompanied by an increase of the 
average dosages of the remaining drugs. For the first group of 35 patients the 
average daily dose per kilogram body weight has been calculated for the most 
important drugs (table 7.IX). With the exception of phénobarbital average 
dosages indeed have increased. As has already been suggested in chapter 2, 
lower doses of phénobarbital than applied usually, might be effective as well. 
Moreover the drug is often combined with sodium valproate in the observed 
Table 7.IX Dosage of antiepileptic drugs in 35 patients (group 1) 
date 
phénobarbital 
sodium valproate 
phenytoin sodium 
carbamazepine 
daily dose ± standard deviation (mg/kg) 
01-01-76 01-01-77 01-01-78 01-01-79 
2.53 ± 1.44 
(n=30) 
24.9 ±9.4 
(n=25) 
5.07 ±2.40 
(n=10) 
8.8 ±2.7 
(n= 5) 
235 ± 0.93 
(n=28) 
28.1 ±8.9 
(n=18) 
5.97 ±1.76 
(n=10) 
18.6 ±7.0 
(n=15) 
223 ± 1.09 
(n=15) 
29.7 ±10.1 
(n=20) 
5.61 ± 1.73 
(n=14) 
18.9 ± 8.9 
(n=25) 
1.94 ± 1.31 
(n=12) 
30.7 ±10.1 
(n=21) 
5.41 ± 0.90 
(n=14) 
21.5 ±11.3 
(n=24) 
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patients and the increase of the concentration of phénobarbital as a result of 
interaction urges to lower doses. Plasma concentrations which have been found 
at the given doses are shown in table 7X. 
Table 7X Plasma concentrations of antiepileptic drugs in 35 patients (group I) 
date 
phénobarbital 
Phenytoin sodium 
caibamazepine 
plasma concentration (mg/1) 
01-01-76 01-01-77 01-01-78 01-01-79 
30.5 ±13.1 
(ii=33) 
7.8+ 6.9 
(n=10) 
2.8 ± 0.7 
(n= 5) 
31.6+11.1 
(n=29) 
13.3+ 5.1 
(n=10) 
5.8+ 2.1 
(n=15) 
26.7+ 7.7 
(n=15) 
8.6 ± 3.7 
(n=14) 
6.5 ± 2.1 
(n=25) 
24.6 ±12.6 
(n=12) 
11.8 ± 4.5 
(n=14) 
6.6+ 2.4 
(n=24) 
Concentrations of valproic acid have deliberately been omitted. Due to the 
large fluctuations the available figures do not well reflect average drug levels. 
For phénobarbital and carbamazepine average dosages and plasma concentra-
tions correlate well. The lack of correlation in the case of phenytoin may be 
partly attributed to the non-linear kinetics of this drug. The reduction of the 
standard deviation for phenytoin plasma concentrations might reflect improved 
individual dosage. However, the applied dosages per kilogram body weight also 
appear to vary less. 
Figure 7.4 
Course of the total number of seizures in 35 patients (group I) over 2Vi years. 
The patients have been divided into two groups according to the average seiz-
ure frequency. For the majority of patients the overall seizure frequency ap-
pears not to have changed. Also the share of major seizures has kept constant. 
In the 9 patients with very frequent seizures the seizure frequency appeared 
to increase for the first year. Only since then the treatment efforts appear to 
have had some effect. Almost 50% of the total number of seizures can be 
ascribed to one patient (G.R.j. 
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7.5 Treatment results 
Seizure pattern 
Validity of the seizure scores 
Registration of the epileptic seizures has been performed by all attendants 
of the patients with great devotion. Nevertheless the method is subject to 
several drawbacks. Not all patients have been supervised for 24 hours a day. 
Many seizures are not easily recognised .especially in the group of patients with 
diverging motoric and mental disturbances. Also in some patients simulated 
seizures have been reported. These objections are partly met by the principle 
that every patient serves as his own reference. In addition it is supposed that 
the ratio between the reported and the actual number of seizures has remained 
constant in the course of the project. This supposition is not correct but it 
can only influence the results in a negative way. The fact is, that the 'quality 
of observation' has improved during the project, not only by increasing at-
tention and experience of the observers but also by the insistence of the team 
and explication on the spot. In several patients epileptic phenomena have not 
been recognised as such in the first registration periods. Also periodic transfer-
ring of staff members will have influenced the registration of seizures, especial-
ly concerning the scoring of seizure type. 
A second supposition is that unchanged policy would have resulted in an un-
changed seizure frequency. In view of the types of epilepsy and the underlying 
brain defects in the major part of the patients, spontaneous reduction of seiz-
ures is not likely. Only in the few cases of juvenile epilepsy such as infantile 
spasms and Lennox syndrome with very frequent attacks, a transition to other 
types of seizures with a lower frequency might be expected. Taking these fac-
tors into consideration a reduced or even an unchanged seizure frequency may 
be explained in favor of the chosen approach. 
Total number of seizures 
The course of the total seizure number for all patients of the first group is 
Figure 7.5 
Treatment record of patient L.E. (female, 45 years) suffering from a partial, 
secondarily generalising epilepsy. Note the change of seizure pattern on change 
of medication. Phenytoin caused a shift from generalised tonic-clonic seizures 
¡black triangles) and isolated psychomotor seizures (broken line) to clustered 
psychomotor seizures (vertical lines, the length of the line indicates the num-
ber of seizures in one series). The latter seizures almost disappeared when so-
dium valproate was added. 
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given in figure 7.4. Because patients with frequent seizures seriously dominate 
the picture, the group has been divided according to the average number of 
seizures. Again in both frequency groups the most serious cases will dominate, 
because they generally show the highest number of seizures. The total number 
of seizures of the 26 patients in the low frequency group appears to have 
little changed (fig. 7.4A). In several patients the first improvement was a 
decrease of seizure severity. However, this was accompanied by an increased 
seizure frequency (see fig. 7.5). This phenomenon may be explained in terms 
of suppression of the generalisation of discharges from the epileptic focus, 
whose strength has not been impaired yet. Also in order to count such changes, 
major seizures have been indicated separately. This number is obtained by 
summation of all seizures indicated as 'GM' (Grand Mai) on the registration 
forms. Experience shows that not only pure generalised tonic-clonic seizures 
sum of 
seizures/month 
400., 
total number of seizures in 96 patients 
Boldershof II 
300 
200 
100 
6 patients 
>10 seizures/month 
90 patients 
<10 seizures/month 
Jul 
1977 
sep han mrt may jul 
1978 
sep 
Figure 7.6 
Course of the total number of seizures in the patients of group II, treated ac-
cording to the strict protocol. Patients are divided into two groups according 
to the average seizure frequency. In both groups the total number of seizures 
tends to decline. 
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but also various severe seizures of the tonic or clonic type have been scored as 
such. The share of these major seizures appears not to have changed for the 
whole group. However, in individual cases separate scoring of majorand minor 
seizures often yielded important information, which was missed when only 
the total seizure frequency was observed. In the 9 patients with very frequent 
seizures, vigorous efforts of the team were not successful for the first year, but 
they appear to have had an effect on the number of seizures since (fig. 7.4B). 
For the group of 96 patients, treated according to the strict protocol in the 
second phase of the project, seizure frequency appears to change more clearly 
(fig. 7.6). After about one year, a marked reduction is observed for the total 
number of seizures of 90 patients. The number of seizures of the remaining 6 
patients with more than 10 seizures a month also tends downwards. 
Individual seizure frequencies 
For individual calculations the average seizure frequency during 3 periods 
has been compared. For the first group of 35 patients the initial 5-8 months 
of the registration period are considered as a baseline period. This is not com-
pletely correct as the first medication changes for a number of patients had 
taken place already in this period. Based on previous observation data 10 
patients had more frequent seizures during the 4 to 6 months preceding the 
formal registration. Four patients had a lower frequency, of whom two showed 
a progressive number of seizures, which also continued later (fig. 7,4B). The 
seizure frequency in other patients had remained constant. With only a few 
exceptions no changes in treatment had taken place during this pre-study 
period. Being aware of this restriction seizure frequencies of a second and 
third period, each 12 months, were compared to that in the 'baseline' period 
for each patient. Results are given in table 7, XI. In general for the whole group 
no clear change of seizure frequency may be concluded. 
Individual data from the second group of patients are compared for three 
consecutive periods of 6 months. Here the first period may be considered as a 
real baseline situation. Medication had not been changed during some preceding 
months. In 13 patients the first medication change took place during the 5 
or 6 month of registration. In two patients this led to a decreased number 
of seizures in the last month of this period. Comparison of average seizure 
frequencies per month for the periods mentioned are given in table 7.XII. 
From these data it may be concluded that 22 patients (23 per cent) experienced 
a marked reduction of seizure frequency. In 61 patients no change was obvious. 
An important fraction of this group, had no seizures at all or only during a 
limited period. In the case where a drug was withdrawn but had to be given 
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Table 7.XI Change of seizure frequency in 35 patients during three years 
no seizures 
over 7 5% reduction 
50-75% reduction 
25-50% reduction 
unchanged (± 25%) 
25-50% increase 
over 50% increase 
1977 versus 1976 
2 patients 
2 
6 
4 
10 
2 
8 
1978 versus 1976 
2 patients* 
3 
7 
4 
11 
1 
7 
* all antiepilectic drug treatment withdrawn 
Table 7.XII Change of seizure frequency in 96 patients over 18 months 
Change of seizure frequency 
compared to first half year 
no seizures 
100% reduction 
over 50% reduction 
unchanged (± 50%) 
over 50% increase 
second half year 
22 patients 
4 
9 
47 
14 
third half year 
22 patients 
13 
9 
39 
.
 1 3 
The unchanged group also includes the following cases: 
— only seizures during withdrawal attempt 8 
— 3 or less seizures during whole period 6 
— less than 8 seizures during whole period, and differences between 
the 6-month periods of only 1 seizure 12 
back later, the individual patients had the following number of seizures: 1 (2x), 
2 (2x), 3 (2x), 4 and 8. Seizure frequency appeared to increase in 13 patients; 
in 4 of them a significant improvement was achieved during the last months 
of the registration period reported here. In judging the results it should also 
be taken into account that a short period of exacerbation of seizures may 
seriously influence the individual results, especially for patients with relatively 
few seizures. In those cases an increase of seizure frequency by hundreds of 
per cents is not unusual, while the overall picture even may be improved. For 
the group of patients as a whole an important reduction of seizures is demon-
strated. 
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Electroencephalography 
Apart from its contribution to diagnosis the EEG was used as an aid to judge 
progress of treatment in cases where clinical observation did not give much 
information. Drug withdrawal in patients, who were free from seizures but who 
had shown epileptic EEG disturbances, was controlled by EEG at some stages 
during withdrawal. Deterioration of the EEG led to a still more cautious with-
drawal procedure and prompt re-administration of the drug at the first seizure 
that might occur. The EEG was also used to distinguish ictal confusional states 
or absence status from sedation, and to control the influence of medication 
changes on such conditions. 
Analysis of plasma concentrations 
The need for these analyses appeared to decrease in the course of the project. 
For the 35 patients of the first group an average of 4.7 samples per individual 
has been analysed during the first year, 4.0 in the second and 2.3 samples in 
the third year of the project. During the last year 200 blood samples have been 
analysed for the whole group of 108 patients, who received antiepileptic drug 
treatment. In these samples 430 single drug determinations have been per-
formed. Sampling was most frequent in difficult cases but in general the demand 
for analyses was more frequent for patients, treated with phenytoin. The 
average difference of sampling frequency, compared to patients not on pheny-
toin therapy, was one sample a year. The reason for this need is that phenytoin 
concentrations can be predicted less accurate, due to the non-linear kinetics 
of the drug and its high susceptibility for interactions. 
Behaviour 
Although in some patients marked improvement of consciousness or of 
behaviour has been reported from subjective impressions, this effect cannot 
be confirmed for all patients. Lack of observation staff prevented regular re-
testing, necessary for such judgement. In subjectively improved cases, the 
behaviour rating scale did indicate some positive score differences. Because of 
lack of data the consistent change of these items could not be confirmed. The 
problem whether reduction of medication has a positive influence on the per-
formance and behaviour of the patients, cannot be solved for this group of 
patients. 
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Overall treatment judgement 
Attempts to improve therapy were continued until the team judged that the 
best possible treatment had been reached. One of the crucial parameters was 
the seizure frequency, which had to be minimal, related to disease history and 
reactions on the tested therapies. In some cases a slightly higher frequency 
than could be attained was prefened,because of drug side effects or prolonged 
periods of increasingly troublesome behaviour preceding the few seizures left. 
As far as possible drugs, which seemed not to contribute to the attained degree 
of seizure control, were withdrawn before the team was finally satisfied. The 
progress that was made by the team and the rate at which success was obtained 
can be derived from table 7. XIII. It must be concluded that the attainment of 
Table 7.XIII Progress of treatment of 35 patients (group I) 
date 
permanently difficult 
search for improvement 
provisionally satisfying 
further reduction 
finally adjusted 
— 
number of patients 
01-01-76 01-01-77 01-01-78 01-01-79 
35 
1 
28 
4 
2 
8 
9 
13 
2 
3 
6 
6 
9 
6 
8 
an optimal treatment takes much time. Even after three yeará the attainable 
optimum does not seem to be reached yet. Much time had to be taken for 
evaluation of treatment changes. If the team could have spent all available time 
on this group of 35 difficult patients a maximum of 6 months might have been 
saved. In the second group of patients, results have been obtained much faster. 
This is due not only to the relative large number of patients whose epilepsy 
was easier to control, but also to the strict protocol that was used from the 
outset and the experience of over one year of team treatment. In table 7.XIV 
the results in the 96 patients are arranged according to the initial plan for 
treatment, that had been designed during the first discussion on a patient. It 
can be concluded now whether these judgements were correct. 
From the 96 patients 68 have already reached the final adjustment within V/i 
years. The use of antiepileptic drugs in this group is limited: 40 patients are 
treated with one and 9 with two of these drugs; the remaining patients get no 
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Table 7.ХГ Progress of treatment of 96 patients (group It) 
INITIAL PLAN 
search for better treatment (38 pat.) 
reduction of medication (35 pat.) 
is treatment necessary? (11 pat.) 
well treated already (12 pat.) 
SITUATION AFTER 1Й YEARS 
14 finally adjusted 
4 further reduction of medication 
17 search going on 
3 treatment withdrawn - 1 succeeded 
2 given back 
13 all medication withdrawn 
5 part of medication withdrawn 
9 medication given back 
1 reduction going on 
4 left unchanged 
3 search for better treatment 
— 2 already adjusted 
6 treated — 4 already adjusted 
4 left untreated 
1 further observation 
6 left unchanged 
4 treatment withdrawn - 1 succeeded 
3 given back 
1 reduction of medication 
1 search for better treatment 
drug treatment. An attempt to withdraw all medication has been undertaken 
in 26 patients but this was successful in only 15 cases. This is the main reason 
for the difference between the original treatment plans and the final outcome. 
Initially, it was thought that only 12 patients got an optimal treatment. Retro­
spectively, it must be recognised that this was the case in 28 patients. The 
initially designed policy appeared to be correct in 74 cases, incorrect in 22 
cases. 
7.6 Comparison with an alternative team project 
The results described above are compared to those of a project in another 
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institution for mentally retarded patients. Within this project the treatment 
of a group of patients with severe epilepsy is accompanied by a multidisci-
plinary team of a slightly deviating composition. Some of the used techniques 
are identical. The main difference with the previously described project is that 
the accompaniment is less intensive and less strictly regulated. 
Study design 
The project is carried out in the institution Maria Roepaan (Ottersum, the 
Netherlands). This institution takes care of approximately 700 mentally handi-
capped patients. Patient care is based more firmly on the medical model than 
in Huize Boldershof mentioned before. Medical treatment is usually provided 
for by five general practitioners. For the accompaniment of the most 'difficult' 
epileptic patients a multidisciplinary team has been formed. The team consists 
of the physicians of the institute, a neurologist, a retail pharmacist, a 'pharma-
cokineticist' and an EEG technician, who is also secretary of the group. The 
team meets bimonthly to discuss and plan antiepileptic drug treatment of a 
group of 30 patients. 
This group had been selected from all epileptic patients of the institute by 
some members of the team. The composition of the patient group is varying: 
once a patient has reached a satisfactory treatment, he is replaced by another 
severe case. During 2 years 40 patients have been discussed in the team. In this 
group were 10 children of all ages, 15 adolescents and 15 adults (average age 
17 years). Types of epilepsy have not been systematically classified. Seven 
patients have been taken out of the group because they did not present serious 
problems, 3 patients left the institute and 4 patients died. Results will be 
largely confined to a group of 20 patients, whose treatment has been supervised 
by the team for the full 2 years. 
Seizure frequency is scored by attendants of the patient using the same 
forms as in the project described previously (fig. 7.2). No special training in 
observation of epileptic patients has been given before. Plasma concentrations 
of antiepileptic drugs are measured at regular intervals on request of the team. 
Analyses are carried out in the Pharmacy and Clinical Laboratory Venray, the 
Netherlands. The policy of the team is comparable to that for the project de-
scribed before. However, several differences must be stressed: 
- For changes of medication no strict protocol is used. 
- The team only advises the responsible practitioner, who will decide on 
changes of treatment on his own authority. 
— Individual patients are discussed at an average frequency of once in 4 months. 
— No central documentation system exists, in which data on seizure frequency, 
drug dosages and plasma concentrations can be easily surveyed. 
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Medication and seizure pattern 
For comparison purposes, the results are handled in the same way as for the 
project described previously. Among the 40 patients, who were discussed by 
the epilepsy team, 20 have been supervised for 2 years until now. In view of 
the policy of shift of patients this already means that no satisfactory treatment 
Table 7.XV Number of antiepileptic drugs per patient (Maria Roepaan, 20 
patients) 
date 
1 drug 
2 drugs 
3 drugs 
4 drugs 
5 drugs 
Average number of 
drugs per patient 
number of patients 
01-01-77 01-01-78 01-01-79 
1 
7 
8 
3 
1 
2.80 
3 
6 
9 
2 
2.50 
5 
5 
5 
5* 
2.50 
* two patients temporarily have one extra drug during a replacement procedure. 
Table 7.XVI Medication pattern in 20 patients [Maria Roepaan) 
date 
phénobarbital 
valproic acid 
Phenytoin 
carbamazepine 
ethosuximide 
clonazepam 
diazepam 
nitrazepam 
01-01-77 
19 
6 
17 
8 
2 
1 
1 
2 
number of patients 
01-01-78 
18 
7 
15 
9 
— 
1 
-
-
01-01-79 
16 
7 
14 
9 
2 
1 
1 
-
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has yet been reached. The 7 patients who have been taken out of the group 
intentionally, may be considered to have improved. The group of 20 patients 
may be compared with the first group of the project described previously. 
However, the present group includes more young children. 
Medication changes have been performed more slowly than in the other 
project as may be seen from tables 7.XV and 7.XVI. 
It may be clear that the medication pattern has changed little until now. Most 
medication changes indeed involved increasing dosage of drugs, already being 
given, or a replacement of one drug by another. Plasma concentrations are 
usually raised to values in the accepted 'therapeutic ranges'. This has caused a 
reduction of seizure frequency in several patients, as may be concluded from 
table 7 .XVII. 
Table 7. XVII Change of seizure frequency in 20 patients (Maria Roepaan)* 
over 75% reduction 
50-75% reduction 
25-50% reduction 
unchanged (± 25%) 
25-50% increase 
over 50% increase 
1 
3 
9 
4 
1 
2 
* the average seizure frequency during the second year of the project is compared to 
that during the first year. 
The results seem to be better than that obtained in the previous project. This 
is stressed by the fact that the average seizure frequency for the 20 patients 
has decreased from 32 seizures per month in the first year to 18 seizures per 
month in the second year. Before conclusions can be drawn, some remarks 
must be made: the first year of the project is not a real baseline period, as 
attempts to improve treatment were undertaken directly from the outset. 
Several patients showed a marked reduction of seizures because of the disap-
pearance of very frequent minor attacks. The frequency of more serious seizures 
appears to have changed little until now. In this study drugs have been with-
drawn in only a few cases and medication changes were not as frequent as in 
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the previous project. These actions are known to be associated with periods 
of increased seizure frequency. This may explain the rather prosperous course 
of seizure frequency in the present study until now. 
7.7 Conclusions 
Medication and seizure pattern 
Although the clinical project described here is still in progress the results up 
to now are encouraging. It is questionable whether merely the marked reduction 
and simplification of drug treatment will justify all the effort applied. Un-
fortunately, the improvement of behaviour, consciousness or abilities, which 
has been experienced in individual patients, could not be evaluated systema-
tically. The contribution to the patients well-being is even more difficult to 
estimate. 
Monotherapy appears to give sufficient control of epilepsy in 43 per cent of 
all patients, who need drug treatment, and 14 per cent of the patients is 
finally adjusted on a combination of two antiepileptic drugs. For the majority 
of the remaining group optimal treatment probably will require two drugs. 
In 13 cases (12 per cent of the patients) a third drug appears to be necessary 
for the time being. However, attempts for improvement have not been 
abandoned yet in these cases. These results contrast with the opinion that 
hospitalised patients often need more than two antiepileptic drugs (Easton 
1972). Acoording to Grant (1976) 20 per cent of epileptic patients cannot 
be satisfactorily controlled on two drugs. In previously untreated patients on 
the other hand monotherapy can be succesful in 90 per cent of the patients 
(Shorvon et al. 1978). The severity and the long duration of epilepsy in the 
patients studied here will be responsible for the difference. An additive 
explanation may be that polypharmacy, once it has been established, is 
difficult to reverse (Reynolds et al. 1976). 
Despite the problems associated with withdrawal of antiepileptic drugs 
complete discontinuation of treatment has been achieved in 18 patients, who 
had been treated with one to three of these drugs for njany years. In the group 
of patients, who are still treated, the average number of drugs for individual 
treatment has been reduced by 15 per cent until now. From the large amount 
of available antiepileptic drugs, only a limited number seems to be necessary. 
Five drugs appear to be sufficient for 93 per cent of the patients under treat-
ment: valproic acid, carbamazepine, phénobarbital, phenytoin and clonazepam. 
Large experience has been gathered in the use of these drugs. This adds to 
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improve their further application. 
Despite the reduction of medication, the average seizure frequency has not 
increased. A reduction of seizures in many patients predominates the general 
outcome. As the types of epilepsy found in the studied population are often 
difficult to treat, this result is the more striking. Therefore the approach of 
epilepsy treatment, that has been chosen for this project, appears to be effec-
tive. The onset of improvements takes much time however. A less systematic 
policy probably would have been successful in a shorter period in several 
cases, but it would have taken more time in the difficult cases. Most attempts 
would have to be repeated completely. A major advantage of the chosen 
approach is that it can be easily applied in other institutions. For that purpose, 
the protocol may be partly improved and adapted. 
Design of treatment 
Comparison of the two projects, in which the treatment of a comparable 
group of patients with severe epilepsy is accompanied by a multidisciplinary 
team, yields interesting results. More frequent team meetings and a more strict 
treatment policy appear to accelerate simplification of the medication. To 
control the treatment process a meeting of the team every two weeks appears 
to be a minimum for the first two years. However, the more energetic approach 
might fall behind concerning reduction of seizure frequency. Follow-up 
registration of seizures will be necessary to judge whether the final seizure fre-
quencies on a stabilised treatment will differ. Substantial elements of the 
treatment policy will be summarised: Reliable continuous registration of 
seizures is a crucial condition, as has been stressed by many authors before 
(Penfield and Jasper 1954, Sjöqvist and Bertilsson 1973). The registration 
forms appeared to be useful. The necessity to record time, type and duration 
of each seizure stimulates prompt and thereby accurate scoring. 
Periodical meetings with the attendants of a patient appeared to be very 
valuable to stimulate attentive observation and to receive optimal information. 
Figure 7.7 
Graphical treatment record of patient J.N. (female, 40 years), whose type of 
epilepsy could not be definitely established. The increase of dosage of sodium 
valproate (Sept. 1977) and the introduction of carbamazepine appears to have 
caused a reduction of seizures, at least temporarily. Note the replacement of 
primidone by phénobarbital and the subsequent gradual withdrawal of this 
drug. 
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Their participation in the discussion may influence team decisions. Informa-
tion on particular circumstances, for instance fear of the patient for certain 
medication changes, may lead to postponement or change of treatment plans. 
Another key element is a careful, centralised administration of all informa-
tion about the individual patient. The lack of such a system in one of the de-
scribed projects was felt to decrease the efficiency of the meetings of the team 
and to hinder a well-founded choice of treatment in some cases. Graphical re-
cording of drug dosages, plasma concentrations and seizures, updated from 
week to week, was an indispensible aid in decision making on treatment 
changes (fig. 7.7). Such reviews also have found useful application in the treat-
ment strategy of Kienast et al. (1976). Not all collected information appeared 
to be useful. Medication history lost significance as the results of medication 
changes in the past were often not clearly documented and maximum dosages 
had seldom been tried. Anamnestic data often were so vague that· their use for 
diagnostic purposes was doubtful. 
With growing knowledge and experience antiepileptic drug plasma concen-
tration analyses became less frequently necessary but could not be missed. 
For expert interpretation one of the members of the team must be familiar 
with the pharmacology and pharmacokinetics of the drugs concerned. Expe-
rience with pitfalls in the analytical techniques is advantageous. 
EEG interpretation will also gain in significance when combined with clinical 
and pharmacological information. It should be done by an expert who is a full 
member of the team. Series of EEG recordings often appeared to be helpful 
for the proof of an epileptic focus. In such cases the observed disturbances 
could only raise suspicion for epilepsy, when they occurred in a single EEG. 
Aside from the practitioners, in charge of patient care, a member of the team 
will have to guard treatment policy and evaluation periods. In view of the im-
portant role of the attendants of the patient it might be sensible to incorporate 
a representative of this group in the team. 
According to Penry (1974) expert adaptation of knowledge on pharmacoki-
netics and of plasma concentration analyses may improve patient care in more 
than one third of the patients and will increase the number of patients whose 
seizures are completely controlled, by over 10 percent. The present study may 
suggest that this will only be possible when other provisions are optimally used 
in addition. The results obtained in the project reported here are due to the 
combined efforts of many dedicated colleagues of several disciplines. 
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Chapter 8 
Effective drugs and plasma concentrations 
8.1 Introduction 
As has been shown in chapter 2, individual effective plasma concentrations 
may vary considerably. Knowledge on the distribution of individual values will 
be very useful for correct dosing of the drugs and will add to the value of the 
analysis of plasma concentrations. In the clinical study, that is described in the 
previous chapter, seizures were registered continuously and plasma concentra-
tions of antiepileptic drugs were analysed frequently for each individual pa-
tient. Therefore the influence of each change of medication on the clinical pic-
ture and the plasma concentrations could be estimated.Provided that the plasma 
concentration of only one drug was changed at a time, a marked reduction of 
seizure frequency may be associated with the attainment of a certain plasma 
concentration in an individual case. 
8.2 Treatment of data 
The individual effective concentrations reported here are based on a reduc-
tion of the number of seizures by 50 per cent or more. Two consecutive periods 
of 4 months are compared, before and after addition, withdrawal, replace-
ment or change of dosage of the drug in question. Sometimes, one or two 
months are omitted in between, because of gradual dose increments or with-
drawal effects. The plasma concentrations of all other drugs have been left or 
are kept constant; however, lower concentrations in the improved period are 
allowed. The seizure frequency within a period of 4 months has to be rather 
uniform. Although the total number of seizures may not have changed much, 
the change of medication is also considered effective, when the number of 
major seizures is decreased by more than 50 per cent. When a patient has not 
experienced seizures for more than a year, recurrence of seizures during a shor-
ter period than 4 months is considered to prove the efficacy of the previous 
treatment: two or more separate seizures beyond the withdrawal period are 
sufficient. 
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The definition of effective concentration given here is fulfilled in 69 cases of 
change of medication in 53 patients altogether. In most other cases the change 
of seizure frequency was less than 50 per cent or the medication was not kept 
constant for 4 months. In tables 8.I-8.V individual effective concentrations are 
indicated. If the improvement was achieved by a dose increment, the plasma 
concentration at the lower dose is indicated as subtherapeutic. Plasma concen-
trations are averaged for the blood samples taken during a 4 month period. 
Antiepileptic drugs given simultaneously, and their plasma concentrations dur-
ing the improved 4 month period are also indicated. With exception of val-
proic acid, too few cases of monotherapy are included to be able to compare 
effective concentrations with and without concomitant drugs. 
8.3 Individual effective plasma concentrations 
Phénobarbital 
For phénobarbital (table 8.1) it must be considered that in a large number of 
patients the drug had been given for many years already. Most of the indicated 
effective plasma concentrations are the initial levels in patients in whom with-
drawal of phénobarbital was associated with an increase of seizure frequency 
which was sustained for several months and then reduced again by renewed 
treatment with phénobarbital or by another drug. The reported concentrations 
for 20 patients correspond reasonably well with the 'therapeutic range' from 
several literature sources (see chapter 2). In many cases however, lower con-
centrations may be equally effective. In 7 patients effective concentrations are 
between 12 and 18 mg/1. Moreover a definite proof that 20 mg/1 is not suffi-
cient has only been given for 2 patients. The group reported here is too small 
to discover factors which may influence the effective concentration. 
Carbamazepine 
Effective plasma concentrations for carbamazepine appear to fluctuate be-
tween 4 and 10 mg/1 (table 8.II). These values correspond to those reported 
elsewhere (see chapter 2). Again the plasma concentrations may be an overes-
timation of what is sufficient to improve control of epilepsy. This point deser-
ves special attention in the case of carbamazepine because plasma concentra-
tions tend to decrease with time due to auto-induction. Almost all presented 
values have been determined during the first 4 months of treatment with car-
bamazepine. However, it did not appear necessary in all cases to increase the 
240 
Table 8 I Individual effective concentrations of phénobarbital 
patients 
initials (age) 
RA (43) 
AD (27) 
ED (40) 
SD (47) 
LE (45) 
RE (21) 
WG (23) 
AH (15) 
RH (44) 
TH ( 8) 
NK (41) 
NL (47) 
RR (25) 
JT (25) 
[CV (43) 
ICV (43) 
EV (24) 
KV (12) 
LV (42) 
LW (21) 
MW (31) 
type of epilepsy 
part sec gen 
part sec gen 
part sec gen 
part sec gen 
part sec gen 
part sec gen 
part sec gen 
part sec gen 
part sec gen 
Lennox syndr 
part sec gen 
unclassif 
pnm gen ton clon 
part sec gen 
unclassif 
unclassif 
psychomotor 
Lennox syndr 
unclassif 
unclassif 
part sec gen 
20 pat 
plasma cone 
(mg/1) 
subther 
_ 
19 
7 
-
21 
-
16 
-
12 
10 
-
-
-
-
-
26 
-
13 
-
-
-
7 - 2 6 
The penultimate column shows th< 
month penod versus 4 months at th< 
column indicates the comedication, t 
the 
effect 
12 
25 
20 
20 
39 
29 
42 
25 
38 
18 
37 
20 
13 
33 
29 
38 
14 
36 
16 
14 
17 
12 42 
seizures 
/4 months 
4 0 
6 0 
6* 3* 
20 0 
3 0 
250 16 
133 54 
comedication 
(plasma cone mg/l) 
_ 
VPA (79) 
PHT(15) 
PHT(13 5) 
PHT(10),CBZ(7 3) 
VPA (110), CBZ (5 2) 
CBZ (3 9) 
2 4 м 0 M I PHT(11),CBZ(6 5) 
25 12 ι VPA (110) 
33 1 CBZ (3 2) 
15 1 
+ 0 
+ 0 
54 27 
10 1 
5 2 
8 0 
143 58 
+ 0 
69 2 
20 4 
. 
CBZ (6 0), VPA (75) 
VPA (45) 
VPA (53) 
CBZ(4 0),PHT(8) 
VPA (80) 
-
VPA (65) 
CZP (0 010) 
-
VPA (48) 
CBZ (6 3) 
: total number of seizures m the worse 4-
; effective plasma concentration The last 
he figures between parentheses represent 
»verage plasma concentrations during the improved period Further expia-
nation is given in the text 
CBZ = carbamazepine 
CZP = clonazepam 
DZP = diazepam 
ESM = ethosuximide 
PB = phénobarbital 
FHT = phenytoin 
PRM = primidone 
VPA = valproic acid 
M only major seizures 
* seizures over 6 months 
- drug not given 
+ recurrence of seizures 
on withdrawal after prolonged 
freedom from seizures 
Table 8.II Individual effective concentrations of carbamazepme 
patients 
initials (age) 
MB ( 7) 
AD (27) 
MD (19) 
SD (47) 
LE (45) 
WG (23) 
AH (15) 
LH (23) 
LH (27) 
RH (44) 
MJ ( 9) 
NL (47) 
NL (35) 
MS (44) 
KT (27) 
PT (47) 
JW (22) 
17 pat 
type of epilepsy 
part sec gen. 
part sec gen. 
part sec gen 
part sec gen 
part sec gen 
part sec gen 
part sec gen 
part sec gen 
part sec gen 
psychomotor 
part sec gen 
unclassif. 
part sec gen 
psychomotor 
psychomotor 
part sec gen. 
part sec gen. 
plasma cone (mg/1) 
subther effect 
3 0 
3.8 
3 0-3 8 
5 8 
9 5 
4 3 
6 4 
9 6 
3 9 
7 8 
7 3 
7 2 
61 
51 
6 2 
7 2 
4 0 
4 7 
7 8 
6 7 
3 9-9 5 
seizures 
/4 months 
52 0 
6 0 
38 13 
20 2 
4 1 
119 54 
133 54 
12 6 
3 0 
22 7 
40 6 
+ 0 
42 8 
38 4 
17 0 
6 1 
45 20 
comedication 
(plasma cone mg/1) 
PB (21) 
VPA (80) 
VPA (95) 
PHT (11 4) 
PB (36), VPA (60) 
PB (42) 
PB (27), PHT (14) 
PB (28) 
VPA (ПО) 
PHT (16) 
VPA (100) 
PB (40) 
PHT (22), PB (25) 
VPA (75) 
VPA (71) 
VPA (77) 
For explanation, see table 8 I 
dose later in order to maintain the same degree of control. 
Valproic acid 
For valproic acid not only plasma concentrations but also daily dosages have 
been indicated (table 8.III). Due to the large fluctuations of the plasma con­
centration, the dose per kilogram body weight is considered a better measure 
for the average amount of drug in the body than the actual plasma concentra­
tion. In the majority of cases, therapeutic efficacy is associated with daily dos­
ages between 20 and 30 mg/kg sodium valproate, given in three doses. Effec­
tive doses appear to be slightly higher in combinations with other antiepilep-
tic drugs. This may correlate with the higher clearance values, averaged 16.5 
ml.hr"1 .kg"1 compared to 11.7 ml.hr1 .kg"1 for valproate monotherapy. In 
both cases the same range of plasma concentrations is found. A much higher 
clearance was found in a child of 3 years. This also may explain the high dose 
of 50 mg/kg daily. 
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Table 8.Ill Individual effective dosages and plasma concentrations of sodium valproate 
patients 
initials (age) 
AB (32) 
LB (38) 
MB (33) 
LE (45) 
RE (21) 
AH (15) 
JH (28) 
LH (23) 
TH (44) 
AL (22) 
JN (41) 
AR (24) 
WS (31) 
MT (39) 
KV ( 3) 
LW (21) 
TW (42) 
17 pat 
type of epilepsy 
part sec gen 
psychomotor 
part ¿ее gen 
part sec gen 
part sec gen 
prim gen ton clon 
myoclon 
part sec gen 
unclassif 
unclassif 
unclassif 
unclassif 
prim gen .ton .clon 
psychomotor 
Lennox syndr 
unclassif 
unclassif 
seizures 
/4 months 
5 0 e 
13 0 
19 9 
364 76 
250 15 
4 1 
77 6 
15 5 
+ 0 
+ 0 
33 9 
123 58 
7« з 
18 0 
818 147 
69 21 
+ 0 
doseOngJcg'1 day 1 ) 
subther effect 
19 6 
9 5 
18 8 
16 4 
9 519 6 
25 0 
19 6 
23 8 
22 0 
39 1 
26 1 
20 0 
18 0 
143 
16 4 
28 1 
28 1 
17 0 
17 0 
50 0 
2 7 3 
170 
14 3-50 0 
plasmacene (mg/1) 
subther effect 
61 
33 
53 
4 8 " 
33-61 
110 
55 
51 
50 
98 
80 
36 
58 
58 
62 
85 
94 
63 
47 
60 
90 
50 
36-110 
comedication 
(plasmacene mg/1) 
PHT (13 5) 
CBZ (4 1) 
CBZ (117) 
PB (29) 
PHT (13 8) 
PRM (9 3) 
PB (33) 
PB (21) 
PHT (12) 
PB (26) 
CBZ ( 4 3 ) 
PB (30) 
CBZ (8 1) 
CBZ (3 8) 
CBZ (6 5) 
seizures over one year 
For explanation, see table 8 I. 
Table 8.IV Individual effective concentrations of Phenytoin sodium 
patients 
initials (age) 
MC (35) 
ED (40) 
MJ ( 8) 
TJ (18) 
NK (38) 
MM (19) 
GR ( 8) 
JT (25) 
CV (53) 
JW (22) 
10 pat. 
type of epilepsy 
part.sec.gen. 
part.sec.gen. 
part.sec.gen. 
part.sec.gen. 
part.sec.gen. 
unclassif. 
part.sec.gen. 
part.sec.gen. 
part.sec.gen. 
part.sec.gen. 
plasma cone, (mg/1) 
subther. effect. 
2.9 
16 
1.5 
1.5-16 
4.9 
15.5 
37 
5.1 
2.0 
6.0 
5.8 
19 
7.5 
6.2 
2.0 - 37 
1 
seizures ; comedication 
/4 months ¡ (plasma cone, mg/1) 
14: 3 
11 : 1 
49 : 11 
21 : 5 
7 : 0 
41 : 1 4 м 
4 0 · 1 
53 :20 
1 4 : 0 
2 0 : 8 M 
PB (30) 
PB (43) 
PB (35) 
PB (27), VPA (55) 
PB (29), VPA (60) 
VPA (57) 
PB (40), VPA (70) 
CBZ (4.9), VPA (95) 
For explanation, see table 8.1. 
Phenytoin 
Effective phenytoin plasma concentrations appear to vary widely among in­
dividual patients (table 8.IV). Extremes found in the present study are 2.0 and 
37 mg/1. In the latter case only a subtherapeutic level of 16 mg/1 is indicated 
but a long history of phenytoin treatment in this patient indicates that seizure-
free periods occuned only at plasma concentrations above 30 mg/1. These high 
levels were only periodically associated with ataxia and drowsiness. Nystagmus 
has never been observed. An attempt to reduce the risk for toxic effects by 
combination with carbamazepine led to the discovery of a case of clear syner­
gism of two antiepileptic drugs. At plasma concentrations of 16 mg/1 for phe­
nytoin and 5.1 mg/1 for carbamazepine seizure frequency was about the same 
as on the high phenytoin doses mentioned before. Carbamazepine alone was 
not responsible for this effect as further reduction of phenytoin caused a mar­
ked increase of seizures. 
It is clear from the wide scatter of effective plasma concentrations that it is 
almost impossible to indicate a 'therapeutic range' for phenytoin.Based on the 
present data 5 mg/l would perhaps be a better initial goal for therapeutic effect 
than the 10-20 mg/l range generally used (cf. chapter 2). As no reasons for 
the great variation of individual sensitivity to phenytoin are known, a gradual 
increase of dose is indicated, guided by the clinical response. 
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Table 8.V Individual effective concentrations of clonazepam 
patients 
initials (age) 
JK ( 3) 
MK (13) 
MZ (12) 
type of epilepsy 
Lennox syndr. 
part.sec.gen. 
part.sec.gen. 
plasma cone, (mg/1) 
subther. effect. 
-
0.021 
0.025 
0.015 
seizures 
/4 months 
400 : 0 
850:418 
17: 6M 
comedication 
(plasma cone, mg/1) 
CBZ (8.3) 
VPA(51),PHT(7.0) 
VPA(85),PHT(4.5) 
Clonazepam 
According to table 8.V three patients did benefit from treatment with clona-
zepam at plasma concentrations, which are low compared to literature data on 
effective concentrations (Dreifuss et al. 1975). 
8.4 Individual effective dru¡£ and types of epilepsy 
As the efficacy of several drugs has been clearly demonstrated here in individ-
ual cases, it seems worthwhile to evaluate the relation of efficacy with the 
type of epilepsy in this group of patients. Cases of definite ineffectiveness of 
certain drugs in individual cases are added for this purpose. A drug is consider-
ed ineffective when no difference of seizure frequency is observed between 
periods without the drug in question and a period where the plasma concen-
tration of the drug exceeds a certain level: for phénobarbital 30 mg/1, carba-
mazepine 10 mg/1, phenytoin 15 mg/1, ethosuximide 80 mg/1 and clonazepam 
50 ng/ml. For sodium valproate 30 mg/kg daily is used instead of a plasma 
concentration limit. The result is shown in table 8.VI. Patients, whose type of 
epilepsy could not be classified, have been omitted from this table. 
In general this table fits into the existing classification of antiepileptic drugs 
(chapter 1). However, the role of phénobarbital in cases with partial seizures 
and the Lennox syndrome is remarkable. An example of the efficacy of phé-
nobarbital in a patient with the Lennox syndrome is shown in figure 8.1. Per-
haps the long-term use of phénobarbital has developed a drug dependency in 
several patients. It is generally accepted that phénobarbital withdrawal may 
be accompanied by a few generalised tonic-clonic seizures, temporally related 
to the withdrawal period. On long-term consequences no information is avail-
able. As the patients with partial, secondary generalising epilepsies form a 
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Table 8.VI Type of epilepsy and efficacy of antiepileptic drugs 
part .sec .gen. 
(n = 32) 
psychomotor 
(n = 9) 
Lennox syndr. 
(n = 6) 
prim.gen.ton.clon. 
(n = 3) 
myoclon. 
( n = l ) 
atypical absences 
( n = l ) 
PB 
12 + 
7 -
1 + 
2 + 
1 + 
VPA 
5 + 
2 -
2 + 
1 -
1 + 
2 + 
1 + 
CBZ 
13 + 
3 -
3 + 
2 -
1 -
PHT 
14 + 
3 -
1 -
2 -
CZP 
2 + 
1 -
1 + 
1 -
ESM 
1 -
1 + 
η the number of cases of a certain type of epilepsy included in this table 
+ the number of patients, in whom the drug was effective 
- the number of patients, in whom the drug was ineffective 
rather heterogeneous group in the present case, it was thought to be interes­
ting to search for factors related with the efficacy of phénobarbital. Compari-
son of the 12 patients, in whom phénobarbital was effective and the 7 in whom 
Figure 8.1 
Treatment record of patient Т.Н. (male, shown from the age of 5) suffering 
from the Lennox syndrome. Seizures are discriminated between generalised 
tonic-clonic seizures and myoclonic jerks. Drowsiness is roughly scored by the 
attendants of the patient. It is indicated per half month as the number of days 
the patient was predominantly drowsy. Gradual reduction of phénobarbital 
led to a significant increase of drowsiness. The EEG showed continuous epi-
leptic discharges in these periods. Note the strong dose-dependent interaction 
between nitrazepam and Phenytoin (June -Dec. 1976). 
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it was not revealed almost no differences. Only the average age in the pheno-
barbital-responding group was higher, 33 ± 11 years compared to 19 ± 9 years 
in the other 7 patients. Indications for a rather diffuse, serious brain damage 
were somewhat more frequent in the refractory group. The EEG background 
pattern was seriously disturbed in most of the patients of this group. Other 
factors such as seizure frequency, the share of generalised seizures and the oc-
currence of clustered seizures do not differ between the two groups. The same 
holds for the localisation of maximal discharges and the influence of photo-
stimulation on the EEG phenomena. After several years of freedom from seiz-
ures the risk of recurrence after discontinuation of treatment is greater with in-
creasing age, and therefore the age difference found here, is probably impor-
tant (Juul-Jensen 1964, Holowach et al. 1972). 
8.5 Conclusions 
The efficacy of drugs in several types of epilepsy in the population studied 
here, corresponds to the literature data, reviewed in chapter 1. The share of 
phénobarbital clearly diminishes but the drug cannot be abandoned. Inseverai 
cases of partial secondarily generalised epilepsy and the Lennox syndrome, the 
drug was of indispensable value. Therefore it seems sensible for the time being 
to consider phénobarbital as a drug of second choice for these types of epilep-
sy in populations comparable to the present one. 
Table 8.VII Estimation of plasma concentration goals 
phénobarbital 
Phenytoin sodium 
carbamazepine 
sodium valproate 
EC20(mg/l) 
15 
6 
4 
50* 
EC50 (mg/1) 
20 
11 
6 
80* 
EC20, EC50 plasma concentration, at which a therapeutic effect is observed in 20%, and 
50% respectively, of the patients. 
* depends on moment of sampling: by preference 15 mg.kg"'.day"' and 25 mg.kg'l.day"* 
respectively. 
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From the data described here and those reviewed in chapter 2, an estimation 
was made of the plasma concentrations that would be effective in 20 and 50 
per cent of the patients respectively (EC20 and EC50). The results are shown 
in table 8.VII. These concentrations may be used for dosage calculations, as 
will be indicated in chapter 10. 
In the present work no further attempts have been undertaken to explain the 
variability of effective plasma concentrations. For this purpose the group of 
patients, whose data were available, is too small and too heterogeneous. 
For some drugs, the individual effective plasma concentrations, that are found 
here, correspond well to those reported by others. This is the case for carba-
mazepine for instance. The reported values for phénobarbital suggest that 20 
mg/1 may be sufficient in many patients. Effective concentrations of Pheny-
toin vary so widely among individuals, that their use as a guide in therapy is 
questionable. However, in view of the non-linear kinetics of the drug, control 
of plasma concentration at some dose levels is a useful procedure. Sodium val-
proate treatment may be entirely based on body weight: 20-30 mg/kg daily is 
effective in most patients. 
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Chapter 9 
Withdrawal of antiepileptic drugs 
9.1 Introduction 
It is generally known that antiepileptic drugs should be withdrawn gradually 
in order to avoid aggravation of seizures. Abrupt withdrawal of antiepileptic 
drugs is the most common cause of status epilepticus (Dreyer 1969, Browne 
1978). Phénobarbital is notorious for its Vithdrawal-seizures', massive gen-
eralised tonic-clonic seizures that occur only during or shortly after withdrawal 
of the drug. However, this knowledge is merely based on traditions as litera-
ture on this topic is extremely scarce. 
The occurrence of withdrawal seizures is not limited only to antiepileptic 
drugs. Similar phenomena have been described on withdrawal of ethanol and 
short-acting barbiturates after chronic use of high dosages. Clinical and experi-
mental studies with respect to the latter compounds have been published 
(Bastie 1970, Wilder and Essig 1970, Littleton 1975). 
In studies on withdrawal of antiepileptic drugs after freedom from seizures 
for several years about 50 per cent of all recurrences appear to occur during the 
withdrawal period or the first months afterwards (Juul-Jensen 1968,Holowach 
et al. 1972, Janz and Sommer-Burkhardt 1976). Only the complete number of 
recurrences has been correlated with several factors such as withdrawal rate, 
type of epilepsy, age, EEG phenomena etc. In the studies mentioned, no cor-
relation between recurrence and the drug in question has been investigated. 
Here the clinical problems will be reported, which occured during or after 
withdrawal of antiepileptic drugs, in the study described in chapter 7. The 
results will be given in relation to the drug that was withdrawn. The presence 
of gross neurological deficits, mental retardation, temporal lobe epilepsy and 
a long history of seizures is known to bear a bad pfognosis with respect to 
recurrence of seizures (Zenker et al. 1957, Juul-Jensen 1964). Therefore, the 
complete withdrawal of antiepileptic drugs in the present population of insti-
tutionalised, mentally retarded patients, has only a small chance of success. 
Recurrence of seizures at long-term is not included in the present results, as 
the follow-up period is between one and two years in nearly all patients. 
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9.2 Withdrawal difficulties 
Unusual clinical events during reduction of dosage up to some months after 
the last dose of a drug are considered to be due to withdrawal unless other 
causes can be indicated. The frequency of withdrawal problems in the com-
plete group of 135 patients is shown in table 9.1. Cases, in which the dose of 
Table 9.1 Problems on withdrawal of antiepileptic drugs 
drug 
phénobarbital 
valproic acid 
carbamazepine 
Phenytoin 
clonazepam 
ethosuximide 
withdrawn 
60 
30 
10 
15 
14 
8 
number of patients 
problems 
16 
2 
3 
-
3 
-
drug retaken 
11 
11 
2 
-
1 
1 
the drug had to be reincreased before complete withdrawal had been achieved, 
are included; they are counted in all three columns of the table. A drug is con-
sidered to be retaken, even when this occurs after an interval on one year. 
Problems associated with the drug withdrawal have not been seen for Pheny-
toin and ethosuximide. However, the latter drug was restored in one patient, 
because of better clinical control. 
Valproic acid 
Valproic acid treatment has been restarted in 11 patients: 
- In two of them this had to be done shortly after discontinuation. 
In the first patient a psychomotor status was observed one day after the 
last dose of sodium valproate, the dosage being reduced already during 5 
weeks. The patient had been free from seizures for several years, the last two 
years on valproate monotherapy. After re-administration no further prob-
lems have been encountered. 
The other patient, treated with phenytoin, carbamazepine and sodium 
valproate, had psychomotor and generalised tonic-clonic seizures. During 
and after withdrawal of valproate the patient experienced several unusual 
series of major seizures. 
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— In 7 cases the drug was restored after a period of 4-12 months because an 
increase of seizure frequency could be recognised retrospectively. 
— Finally in two patients the drug was retaken after a short period. In one of 
these patients, who had been free from seizures for several years, a deteriora-
tion of the EEG and a single seizure led to renewed treatment, one month 
after withdrawal. The other patient had probably experienced some noctur-
nal seizures during gradual withdrawal. After a major daytime seizure a few 
days after the last dose, treatment was immediately restored. 
Carbamazepine 
After discontinuation of carbamazepine, problems have been met with in 
three patients. However, they cannot all be definitely held for withdrawal phe-
nomena, as these patients had shown similar difficulties in other circumstances. 
— One patient experienced a psychomotor status, 5 days after the last dose of 
carbamazepine. 
— In another case, 5 major seizures occurred on the fourth day after complete 
withdrawal. Phenytoin was started quickly and no further problems were 
observed. 
— In the third case carbamazepine withdrawal caused a marked increase of ma-
jor seizures, which was suppressed directly on re-administration of the drug. 
— The latter case is shown in figure 7.1. The relatively low frequency of major 
seizures in other periods raises suspicion of carbamazepine withdrawal seiz-
ures, comparable to those known for phénobarbital by tradition. 
Gomzepam 
Discontinuation of clonazepam had serious consequences in three out of 14 
patients. 
— In a patient with secondarily generalised tonic-clonic seizures, treated with 
phénobarbital, valproic acid and a low dose of clonazepam (3 mg daily), the 
latter drug was withdrawn gradually over 3 weeks. Seizure frequency during 
this period was significantly raised and on the penultimate day of treatment, 
a major status epilepticus occurred. The status was terminated with diaze-
pam. With the exception of an abnormal series of seizures two weeks later, 
no further problems were encountered. 
— In a patient with the Lennox syndrome, withdrawal of clonazepam over 5 
weeks was followed by frequent massive myoclonies, which gradually dis-
appeared over 4 weeks. The patient was treated with phénobarbital in addi-
tion and carbamazepine treatment was initiated during the withdrawal 
period. 
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— However, the most curious effect was seen in a female of 50 years of age, 
treated with 4 mg clonazepam daily for 5 years. Seizures had not been ob-
served . Clonazepam was reduced to 2 mg daily for half a year without prob-
lems. The plasma concentration was 14 ng/ml. Clonazepam was withdrawn 
in 2 steps over 3 weeks. Five days after the last dose the patient became ex-
tremely excited. This developed into a severe psychosis, which maintained 
despite treatment with haloperidol up to 6 mg daily. After 2 months 2 mg 
clonazepam daily was reinstituted. The patient fell asleep for 3 days and 
awoke completely normal again. Haloperidol was withdrawn without diffi-
culties. 
In addition to the cases described above discontinuation of clonazepam led to 
increased seizures in two patients and a marked deterioration of cerebral palsy 
in one. 
Serious withdrawal effects of clonazepam have been described earlier 
(Edwards 1974). Their frequency argues against the use of clonazepam as a 
drug of first choice. Many benzodiazepines are notorious forwithdrawal prob-
lems after long-term treatment, sometimes in the form of epileptic seizures 
(Hollister et al. 1961, Rifkin et al. 1976).However, in the present study diazepam 
was discontinued in 11 patients without problems and only one out of five pa-
tients, in whom nitrazepam treatment was withdrawn, may have experienced 
some extra major seizures. 
Phénobarbital 
After chronic intoxication with short-acting barbiturates withdrawal seizures 
are common. According to Wikler and Essig (1970) all barbiturates may develop 
a similar dependency. However, literature data on phénobarbital withdrawal 
are scarce. In the present study the drug is withdrawn in 60 patients. In 33 
cases this was not accompanied by any difficulty: 15 patients did not ex-
perience seizures during the whole observation period, while the seizure fre-
quency kept constant in the remaining 18 cases. 
In a further group of 11 patients, it was apparent after several months that 
the seizure frequency had increased since the withdrawal. In 6 of these cases 
the drug was reinstituted after 3-10 months. 
The 16 problem cases left, are shown in table 9.II. They are divided into 
three groups: 
A. Seven patients experienced 'classical withdrawal seizures' (table 9.II, upper 
part). These seizures were of the primarily generalised tonic-clonic type and 
occurred only during withdrawal of phénobarbital or within 6 weeks after 
the last dose. Three of these patients had been free from seizures for years. 
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Table 9.II Phénobarbital withdrawal problems 
patients 
initials 
(age) 
RA (43) 
LB (18) 
MB (53) 
AD (57) 
ED (40) 
DR (18) 
LW (42) 
HA ( 7 ) 
RD(31) 
SD (47) 
AH (15) 
RH (43) 
AR (23) 
RR (25) 
RW (12) 
GR ( 9 ) 
type of 
epilepsy 
part.sec. 
gen. 
part.sec. 
gen. 
psychomot. 
part .sec. 
gen. 
part sec 
gen 
unclassif. 
unclasaf. 
part.sec. 
gen. 
part.sec. 
gen. 
part.sec. 
gen. 
part sec 
gen. 
psychomot. 
unclassif. 
pnm.gen. 
ton.don. 
unclassif. 
part .sec. 
gen 
seizure 
frequency31 
-
14/month 
6/year 
5/year 
4/year 
(50% major) 
-
~ 
5/month 
(20% major) 
10/year 
8/year 
(25% major) 
15/month 
3/month 
22/month 
(10% major) 
2/year 
3/month 
initial 
PB level 
mg/l 
12 
29 
32 
14 
29 
18 
18 
29 
20 
20 
25 
39 
30 
13 
23 
28 
duration of 
withdrawal 
(weeks) 
2 
13 
27 
0 
43 
3 
3 
2 
7 
8 
4 
18 
12 
0 
4 
3 
corned 
-
PHT 
CBZ 
VPA 
VPA 
PHT 
CBZ 
VPA 
PHT 
CBZ 
VPA 
PHT 
DZP 
PHT 
CBZ 
VPA 
CBZ 
VPA 
-
VPA 
events 
3 major seizures m 
6 weeks 
5 major seizures in 
5 weeks 
1 major seizure after 
3 weeks 
2 major seizures after 
3 weeks 
9 major seizures within 
2 weeks 
4 major seizures m 
5 weeks 
4 major seizures in 
3 weeks 
confusional state after 
3 weeks 
status of adversive 
spasms 
20 seizures in 2 months 
24 major seizures in 2 
months 
doubled seizure 
frequency 
doubled frequency of 
major seizures 
6 seizures in 8 weeks 
psychomotor status 
psychomotor status 
x
 average frequency of seizures before withdrawal of phénobarbital The oc-
currence of major seizures is indicated as percentage of the total frequency. 
In other cases only minor seizures have been reported 
time period between the fint reduction of dosage and the ultimate dose of 
phénobarbital. A period of 0 weeks indicates abrupt withdrawal 
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Three other patients only had minor seizures normally but now 1-5 major 
seizures occurred. The last patient did experience sporadic generalised tonic-
clonic seizures, but at the lowest phénobarbital dose, he had 9 seizures in 
2 weeks. After these seizures, the clinical picture returned to normal with-
out intervention. 
When this group of patients was compared with the other 53, in whom 
phénobarbital was withdrawn, no differences regarding seizure frequency, 
type of epilepsy, phénobarbital maintenance dose and comedication were 
found. The occurrence of withdrawal seizures in only one of the patients 
who already had major seizures seems to be a favourable exception, but 
a few extra seizures may have been overlooked. Other antiepileptic drugs 
appear not to prevent these seizures, as patients treated with valproic acid, 
carbamazepine or phenytoin and those without other drugs are'represented 
in proportion. The ineffectiveness of valproic acid is remarkable in this 
respect, as the drug has shown to be effective in the prevention of seizures 
on abstinence of ethanol in alcoholists (Bastie 1970). Experimental studies 
on withdrawal of barbiturates and ethanol showed similar effectiveness 
of compounds, which are able to prevent decrease of brain GAB A concen-
trations (Essig 1968, Littleton 1975). 
Also the rate of withdrawal appears tobe of little significance for the occur-
rence of "withdrawal seizures': both patients in whom the drug was stopped 
abruptly and those in whom a stepwise decrease of dosage was performed 
over 10 months were included.The only difference that was found concerned 
the age of the patients: average 39 years in comparison with 26 years for all 
60 patients. Based on actual blood samples or estimated from previously 
obtained data the plasma concentrations at the moment of the first with-
drawal seizure have been estimated: all seizures appear to have occurred at 
phénobarbital concentrations below 10 mg/1. In 3 patients (RA, ED and DR) 
the withdrawal seizures have been followed by one or two major seizures 3 
months to 1 year later. Before withdrawal of phénobarbital two of these 
patients had not experienced this type of seizure for several years, and one 
only on rare occasions. 
B. Other serious problems have been encountered in 8 patients (table 9.II, se-
cond part). As phénobarbital has been re-administered or another drug has 
been added within 2 months after complete withdrawal it cannot be jud-
ged whether the clinical deterioration was only transient. Three patients 
experienced a type of status epilepticus: 
— a confusional state 3 weeks after discontinuation of phénobarbital, which 
was treated with valproic acid. 
- a psychomotor status 3 days after the last dose of phénobarbital; the 
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drug was restored. 
- a status of adversive spasms which lasted almost 48 hours. There was only 
a short-lasting effect of intravenous diazepam or phenytoin. Parenteral 
phénobarbital appeared to be effective and oral treatment was restored. 
The phénobarbital plasma concentration appeared to have decreased 
to 7 mg/1 at the onset of the status. After the termination of the status 
the plasma concentration appeared to have raised to 14 mg/1. 
The remaining 5 patients experienced a marked increase of frequency of 
seizures, predominantly of the tonic-clonic type. 
In contrast to the group of classical withdrawal seizures the duration of 
drug withdrawal may have played a role here. In 6 out of the 8 patients 
phénobarbital was completely withdrawn within 2 months. No other differ-
ences with the patients, who experienced no withdrawal difficulties, could 
be found. 
C, In one patient a short-lasting psychomotor status occurred (table 9.II, last 
part). In this case no short-term change of medication appeared to be necess-
ary. 
9.3 Conclusions 
Antiepileptic drug withdrawal may bring about serious problems. Concerning 
the difficulties, directly related to the withdrawal period, the drug which is 
withdrawn appears to be of importance. Based on the present data problems 
appear to be infrequent on discontinuation of phenytoin, ethosuximide and 
valproic acid. Attention should be paid to possible withdrawal effects of car-
bamazepine. As one of the theories on phénobarbital withdrawal phenomena 
is based on the enzyme inducing properties of this drug, carbamazepine might 
show similar problems. In some patients difficulties have been met, that are 
suspicious in this respect. 
Withdrawal of phénobarbital or clonazepam on the other, hand is often ac-
companied by serious epileptic phenomena. Of the 60 patients, in whom 
phénobarbital was withdrawn, only 33 did not show any negative consequences. 
In 19 patients phénobarbital was given back or other drug treatment had to 
be increased. In only 5 patients the problems were exclusively Umited to a few 
'classical' withdrawal seizures. These results throw serious doubt upon our 
policy to abide withdrawal effects for 6 weeks if this can be tolerated, and are 
in favour of re-administration o f phénobarbital at the first unusual event. The 
occurrence of the notorious withdrawal seizures appears to be independent of 
the rate of withdrawal and comedication. Other unwanted consequences may 
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be less frequent when phénobarbital is withdrawn slowly. 
As antiepileptic drug treatment is not to be continued necessarily for life 
long, the problems to be expected on withdrawal should be considered in the 
choice of therapy. Therefore, the obtained results argue against the use of 
phénobarbital and clonazepam as drugs of first choice. 
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Chapter 10 
Handling of individual pharmacokinetic data 
10.1 Use of plasma concentration determinations 
Plasma concentration analyses of antiepileptic drugs and the study of their 
pharmacokinetic properties are meant as an aid in the therapy of epileptic 
patients. Although the plasma concentrations, that are needed to achieve a 
therapeutic effect, differ widely among individual patients, they appear to be 
a better guide for therapeutic aims than drug dosage. Proper application may 
increase the probability to reach the desired therapeutic effect and the speed 
at which this effect is attained. 
Ideally, pharmacokinetic knowledge should be able to explain and to predict 
the relation between the dose and the resulting plasma concentration. There-
fore , when sufficient knowledge has been gathered, plasma concentration analy-
ses would almost become superfluous, in cases of reliable information on drug 
intake and other relevant parameters. As long as this ideal situation has not 
been reached, analyses will be useful in many cases. The results of these analy-
ses will have to match the needs of the physician; at the same time they have 
to increase the knowledge of pharmacokinetics of the drugs in question. Infor-
mation on clinical effects should be added whenever possible. 
In clinical practice an evaluation of plasma concentrations is most frequently 
used to solve one or more of the following questions: 
1. does the patient take the prescribed medication? 
2. is an unexpectedly low plasma concentration value the reason for the lack 
of effect? 
3. is it justified to increase the dose any more? 
4. can the clinical suspicion of intoxication be confirmed? 
5. is there possibly a problem with the pharmaceutical formulation? 
As the individual effective and toxic concentrations significantly differ among 
individuals, drug plasma concentrations on their own will only permit a reliable 
answer to one of these questions in cases of exceptional values. Results of the 
analyses in combination with clinical data more often yield useful information. 
To overcome individual differences, each patient should serve as his own 
reference. Therefore, repeated plasma concentration analyses of a single patient 
are indicated. This involves the problem of storage and recall of previous data, 
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which will be discussed later. At the same time, such an accumulation of data 
might be suited for statistical evaluation, which may refine or increase the 
accuracy of basic pharmacokinetic and clinical parameters. 
10.2 Variation of clearance values 
Treatment of data 
From the data sources, that have been described in chapter 5, patients were 
selected, whose plasma concentrations were analysed before and after addition 
or withdrawal of the drug in question. The change of clearance was correlated 
with the plasma concentration of the affecting or of the affected drug, the 
clearance value of the latter drug, the age of the patient and the presence of 
certain other drugs. Correlation co-efficients are calculated by linear regres-
sion analysis. The most relevant results are shown in table 10.1. 
V m a x and km values for Phenytoin kinetics in individual patients have been 
calculated according to Ludden et al. (1976) by linear regression of the dosage 
of the drug (mg.kg"vday"') and the quotient of this value and the plasma 
concentration. The data had to meet the following requirements: 
1. a constant comedication, 
2. at least 3 plasma concentrations at different dose levels, 
3. a correlation co-efficient over 0.90, 
4. no significant change of the resulting values, when any single plasma con-
centration point was omitted. 
In this way 16 sets of parameters were obtained. Data were completed with 
15 cases from Mawer et al. (1974), 10 from Garretson and Jusko (1975), 5 
from Richens (1975) and 7 from Guelen and van der Kleijn (1977). All data 
were converted to Phenytoin sodium. Average values of km and Vmax were 
calculated for the whole group, and for subgroups, classified according to age, 
sex and comedication. 
Reduction of variation 
Judgements on patient compliance by means of the determination of plasma 
concentrations, require reliable statistical data on dose/plasma concentration 
ratios. A suited form of this ratio is the relative clearance, for which sufficient 
data are available (Guelen and van der Kleijn 1978). However, random average 
clearance values show a marked variation: standard deviations of around 50 
per cent are not unusual. When only monotherapy of the drug in question is 
concerned, the variation co-efficient appears to be reduced to about 30 per 
cent, depending on the drug. This accuracy would still be not enough for 
statements on poor compliance in the majority of cases. Calculation of a 
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maintenance dose based on these figures would give a probability of 50 per 
cent to reach a plasma concentration within 20 per cent of the intended value. 
It is questionable whether this result is better than by dosage based on clinical 
experience. However, when the influence of age is taken into account, the 
clearance values can be predicted more accurately: standard deviations of 
about 15 per cent have been obtained by Guelen and van der Kleijn (1978). 
This accuracy is sufficient for dosage calculations and for judgement of patient 
compliance. 
Interactions 
Unfortunately most epileptic patients are treated with a combination of 
several antiepileptic drugs. This markedly increases the variation of clearance 
of any drug involved. For a defined combination of antiepileptic drugs the 
average clearance values have a variation co-efficient of about 40 per cent. This 
figure can be reduced when corrections for age are incorporated. However, 
the situation may become more complex when the influence of comedication 
on itself is age-dependent, as has been put forward for valproic acid and phéno-
barbital (chapter 5). On the other hand, the influence of valproic acid on the 
kinetics of phénobarbital is a rather simple example, as the dose of valproic 
acid apparently plays no important role. In the case of metabolic enzyme in-
ducing drugs the effect may depend on the dose of the inducing agent and the 
degree of induction, that already exists. An impression of the importance of 
individual interaction effects and some possible sources of the variation can 
be obtained from table 10.1. 
Although the number of data is too small to draw definite conclusions, yet 
some interesting trends can be noticed. The influence of diazepam on phéno-
barbital kinetics appears to depend on the dose or the resulting plasma con-
centration of diazepam. A clear example of the reversed effect of nitrazepam 
on the clearance of phenytoin is shown in fig. 8.1. The influence of phéno-
barbital on carbamazepine kinetics also suggests a dose-dependent relationship. 
Maximal increase of the clearance of carbamazepine is observed at phénobarb-
ital plasma concentrations between 20 and 30 mg/1. Besides additive enzyme 
induction both drugs may compete for metabolism. Perhaps the latter phenom-
enon only becomes important at higher phénobarbital concentrations. 
In three of the indicated interactions the clearance of the affected drug seems 
to be of importance: when clearance is high already, additional increase is less 
likely. Statistical analysis of a great number of cases will have to confirm the 
suggested relations. This approach is likely to discover other similar correlations 
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Table ЮЛ Individual drug interactions 
affected drug 
phénobarbital 
Phenytoin 
carbamazepine 
affecting drug 
valproic acid 
Phenytoin 
diazepam 
phénobarbital 
valproic acid 
phénobarbital 
Phenytoin 
correction factor 
for the clearance 
(mean ± s.d.) (n) 
0.69 ±0.14* 43 
0.97 ± 0.32 20 
1.25 ±0.28 5 
0.78 ± 0.63 12 
0.70 ± 0.24* 7 
1.69 ±0.30* 11 
1.26 ±0.43 12 
possible correlations 
more important at lower 
ages (chapter 5) 
depending on plasma 
cone, of affecting drug 
(r=0.95) 
depending on clearance of 
affected drug (r =-0.70) 
depending on clearance of 
affected drug (r =-0.84) 
depending on concentra-
tion of affecting drug 
(maximum between 20 
and 30 mg/1) 
depending on clearance of 
affected drug (r =-0.69) 
Average clearance values of the affected drug for η patients after addition of 
the affecting drug. Clearance before addition is taken 1.0. Correlation co-ef­
ficients are obtained by linear regression of the correction factor and the para­
meter, stated in the last column. 
* means a significant change (p < 0.05). 
and will lead to more accurate prediction of individual clearance values. 
Complications by non-linearity 
Phenytoin and carbamazepine offer special problems as their clearance values 
are variable, even at a constant comedication (Levy and Lane 1978). The 
clearance of phenytoin is dependent on the plasma concentration of the drug, 
because of the capacity-limited metabolism. Two constants, k
m
 and V
m a x
, 
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replace the single clearance parameter in equations defining the relation 
between dose and plasma concentration (chapter 2). While the clearance value 
can be derived from a single plasma concentration, more data are needed to 
define k m and V j ^ ^ . For that reason statistical data on these parameters are 
still lacking. Average values from 53 cases are shown in table 10.11. 
Table 10.11 km and Vmax values for Phenytoin sodium in epileptic patients 
selection 
total 
monotherapy only 
children below 10 years 
females only 
monotherapy in adults 
number of patients 
53 
17 
15 
23 
10 
(m£/l) 
5.58 + 3.80 
6.39 ±5.51 
6.01 ± 3.40 
5.11+2.92 
4.92 ±2.01 
v m a x 
(mgJcg-i.day1) 
7.74 ± 2.43 
8.10 ±2.72 
8.30 ±3.61 
8.36 ±2.15 
7.71 ±1.16 
Although no significant differences have been found until now, some para-
meters might be of importance. Children appear to have somewhat higher 
values for both parameters. Combination with other drugs, most frequently 
phénobarbital or primidone, tends to lower values. In general, female patients 
show slightly lower k_ values and higher V^,^ values than males. All sub-
III l l ld-X. 
divisions of the present material showed similar influences of age, sex and 
comedication. As has also been found in the statistical analysis of clearance 
values, km and V m a x appear to show the lowest variation for the group of 
adult patients on phenytoin monotherapy. Analysis of a larger number of 
patient data will be necessary to obtain reliable values for the pharmacokin-
etic parameters of phenytoin and to quantitate the effects of age, sex and 
various comedications on these values. 
Carbamazepine shows time-dependent kinetics, due to the important in-
duction of its own rate of metabolism. When this process would only depend 
on time, a kinetic model including auto-induction could be practicable. Such 
a model has been proposed by Pitlick et al. (1976). However, the degree of 
induction also appears to depend on the dosage of the drug (see fig. 2.5) and 
it may even be attenuated by concomitant administration of other enzyme 
inducing drugs (Levy and Lane 1978). Therefore plasma concentrations of 
carbamazepine probably are the most difficult ones to predict. Attempts to 
provide statistically reliable values for the clearance of carbamazepine should 
take into account the period since the last change of dosage, the dose level, 
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the age of the patient and the plasma concentrations of concomitantly admin-
istered drugs. Conversily, the latter concentrations will probably depend on 
the degree of induction by carbamazepine. 
10.3 Individual applications 
Statistical data on clearance values are not only very helpful in the calculation 
of initial dosages, but are also important in the judgement of plasma concen-
trations, once they have been determined. When the clearance values which 
are found in an individual case, do not fit into the normal distribution, an 
explanation should be searched for, previous to dose corrections based on 
these results. Poor patient compliance or a wrong sampling moment are the 
most common causes for deviating clearance values. Many other factors will 
influence the plasma concentration and therefore the clearance value (van der 
Kleijn et al. 1975, Cuelen and van der Kleijn 1978). Drug dosage, based on 
unreliable plasma concentration data, may cause serious problems. 
The most reliable, and therefore the safest way to treat epilepsy appears to 
make use of a single drug whenever possible. For addition or potentiation of 
antiepileptic effects at the pharmacodynamic level only sporadic indications 
have been obtained (Sherwin et al. 1976, chapter 8). The combination of anti-
epileptic drugs in order to summate therapeutic effects without risk of side 
effects cannot be justified at the time being. 
The most uniform way of dosing is obtained,when the dose is calculated from 
the desired plasma concentration, the average relative clearance value corrected 
for the age of the patient, and his body weight. As initial goal a plasma con-
centration may be chosen, at which for instance 20 per cent of the patients 
will show a therapeutic effect. A next stage might be the median effective 
concentration. An estimation of these values has been given in table 8.VH. 
Concerning therapies with a combination of several antiepileptic drugs, a 
reduction of the number of drugs should be taken into consideration. As has 
been shown in the previous chapter, this is possible without deterioration of 
the clinical picture. The choice of drugs to be withdrawn largely depends on 
the type of epilepsy and the history of the disease. Pharmacokinetic knowl-
edge or plasma concentrations may be helpful to determine which drugs 
probably will contribute to the clinical effect and which will not. A second 
application is the maintenance of constant levels of drugs to be continued 
by anticipation or by correction afterwards. When these precautions have not 
been taken, loss of control of epilepsy will almost invariably be attributed to 
the drug, that is withdrawn. In many cases this will lead to unnecessary con-
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tinuation of polypharmacy. Accurate quantitative information on drug inter-
actions is still lacking in most cases. Therefore, simplification of medication 
often needs analysis of plasma concentrations before and after withdrawal of 
a drug. 
10.4 Storage of individual data 
As has been pointed out before, storage of plasma concentration data is 
necessary for optimal accompaniment of individual therapies and for statistical 
analysis. Storage of copies of all request forms in a systematic order has several 
disadvantages. A clear survey of all information on a patient is not ready at 
hand. Updating and search for data takes much time. Statistical analysis of 
data is almost impossible. The only advantage of the system is the almost un-
limited information capacity. 
Many laboratories use a system with patient-cards. The most relevant data 
for each blood sample are transcribed on these cards. Especially in the case of 
a limited number of patients this method appears to function satisfactorily, 
although any statistical analysis requires much hand-work. The amount of 
information that can be dealt with, usually is limited to one line on the patient-
card. 
Computerised database systems become increasingly popular for storage of 
widely varying types and amounts of data. Such a system is perfectly suited 
to fulfil the information needs described above. Database systems are commer-
cially accessible. Input and output of data can be executed on a terminal, 
connected by telephone. Both surveys of individual patient data and statistical 
analysis of all data, that have been put into the system, can be easily performed 
in this way. Patient data can be better protected than by the classical systems. 
The database is only accessible to authorised operators. 
Two years of experience with a database system have proven its usefulness 
for individual monitoring. The Composit-77 (Comshye, London) database 
system is used. In a first experimental stage we stored data of about 200 
outpatients over 3 years. This number of data is not yet enough to detect 
factors influencing clearance values by statistical analysis. 
Patients are identified by name and date of birth. For each patient the follow-
ing data are added: sex, body weight, length, code for institute or department, 
and first date of information. Body weight, length and institution can be 
easily changed on any occasion. Further information is stored per date of 
the month, for instance the date of blood sampling. This information may 
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select patient by patient 
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name + date of birth 
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of the patient 
input of medication and 
plasma concentration data 
drug (phenytoin), date of sample, 
dose per time, dosage interval 
(100 mg 3 times daily), plasma 
concentration 
contracted input of 
medication data 
automatic calculation 
of clearance 
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Figure 10.1 
Example of the database system. Input of the plasma concentration analysis 
results and the subsequent output of all stored data of a (fictive) patient. To 
show the difference between input and output the typed characters have been 
underlined. 
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include drug dosages and plasma concentrations, biochemical parameters, 
and data on clinical effects. Medication input consists of: drug code, sample 
date, dose, dosage interval and plasma concentration. Relative clearance per 
kilogram body weight and per square meter body surface are automatically 
calculated and printed, and are stored with the previous data. Also drugs, 
whose concentrations are not analysed, are stored in a similar fashion. At any 
moment a survey of all data of an individual patient or a wanted selection can 
be printed out (see fig. 10.1). For statistical analysis all data except the name 
of the patient are available. The search can be directed on any stored item, 
for instance age, drug, dosage, plasma concentration, clearance or combinations 
of these. 
The input and recall of data is easy and requires no experience with automated 
systems. The costs of the system are modest and can be justified already by 
the gain in time and ease in individual monitoring. The additional possibilities 
for statistical analysis render the system invaluable, especially when the amount 
of data would be markedly enlarged by participation of several laboratories. 
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Appendix 1 
Synthesis of 3- ^C-valproic acid 
Introduction 
After administration of ^C-labeled valproic acid to laboratory animals, 
expiration of ^ С С ^ has been demonstrated (Eymard et al. 1971, Kukino et 
al. 1972). These studies made use of valproic acid, labeled in the carboxy-group. 
In order to clarify the mechanism of formation of the labeled carbon dioxide, 
and to detect the metabolites left after possible decarboxylation, an attempt 
was undertaken to obtain the drug with a ^ C label at another position in the 
molecule. 
Several synthetic pathways for the preparation of valproic acid have been 
described in the last century. Burton (1881) prepared the compound via the 
acetoacetic ester synthesis starting from àcetoacetate and propylbromide. 
The formed ethylester of dipropyl-acetoacetic acid was hydrolysed to form 
valproic acid. In most other syntheses esters of dipropylmalonic acid were the 
intermediate product, which yielded valproic acid by hydrolysis and subsequent 
decarboxylation (Fürth 1888, Oberreit 1896). The intermediate esters were 
obtained via the malonic ester synthesis: the carbanion of diethyl or dimethyl 
malonate reacts with a propyl halide. 
1-^C-valproic acid has been prepared by a reaction of heptyl lithium or the 
corresponding Grignard reagent with labeled carbon dioxide (Eymard et al. 
1971). Also, 2-^C-valproic acid has been prepared (Merits 1977). In the 
present synthesis, side-chain-labeled valproic acid is prepared according to the 
malonic ester+synthesis. The starting product was mono-propyl-malonic acid 
dimethylester, whose carbanion was formed by the reaction with sodium 
methoxide. In order to bind all radioactivity, an excess of the carbanion 
was allowed to react with the labeled propylbromide. The conversion was 
completed by a second reaction, using an excess of unlabeled propylbromide. 
Before the main synthesis, the reaction was carried out several times without 
radioactive label and with small amounts of '4ç.pr0pyibromide consecutively. 
In order to obtain an end product of sufficient specific activity, the method 
was transformed to micro-scale. The procedure was adapted to ensure minimal 
loss of radioactivity. The most important adaptations were: 
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1. The main reaction step was carried out at room temperature in a closed 
system, which was initially kept at low pressure. The reaction appeared to 
be nearly complete in 24 hours. 
2. This enabled simplification of the glass apparatus, as in the main reaction 
step a reflux condenser was not necessary any longer. 
3. The labeled propylbromide was thoroughly mixed with unlabeled fluid 
before the reaction took place: the carbanion solution was concentrated 
and frozen, unlabeled propylbromide and methanol were added and cooled. 
The supernatant fluid acted as a cold trap to retain the labeled propylbro­
mide, which was expelled from the capsule by gentle heat at low pressure. 
4. Distillation of excess methanol was replaced by evaporation at room tem­
perature and atmospheric pressure. This greatly reduced the contaminated 
glass surface. 
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5. Washing of inorganic salts was accelerated by the use of diluted acid at room 
temperature instead of refluxing with concentrated hydrochloric acid. All 
bromide had to be washed out thoroughly before heating with sulphuric 
acid. 
6. Control of each hydrolysis step by means of GLC prevented the application 
of temperatures higherthan necessary, at which carbonisation of the product 
easily takes place. 
Materials and methods 
Chemicals 
n-(l-14c)-propylbromide, 6.9 mCi/mmole (batch 9) was obtained from the 
Radiochemical Center, Amersham, England. 
n-propyl-malonic acid dimethylester, containing 15 % diprppyl-malonic acid 
dimethylester, and sodium methoxide 30 % in methanol were kindly 
supplied by Chemische Industrie Katwijk, Katwijk, the Netherlands. 
All other reagents were analytical grade and were obtained from Merck, Darm­
stadt, Germany. 
Experimental procedure 
In a 2 ml flask, 522 mg of n-propyl-malonic acid dimethylester 85 % and 334 
mg of sodium methoxide 30 % were refluxed at 100 0C for 15 minutes. The 
flask was placed in a desiccator charged with concentrated sulphuric acid 
at atmospheric pressure for one night in order to remove excess methanol. 
The flask was provided with an adapter with an inner tube almost touching 
the contents of the flask and the side tube ending in a vacuum stopcock (fig. 
A.l). The flask was cooled to -80 "С. 75 ці of n-propylbromide and 200 μΐ 
of methanol were added. A sealed capsule with a claimed content of 5 mCi 
n-(l-^c)-propylbromide was mounted in the adapter. In this way, it was 
connected to the inner tube, which now ended below the liquid surface. The 
system was evacuated to 0.3 mmHg and the stopcock closed.The capsule seal 
was broken by means of a stirrer magnet, which had been brought into the 
system previously. The contents of the capsule were distilled downwards by 
means of an electric hairdryer. The reaction mixture was left at room tempera­
ture and low pressure for two days. By means of the hairdryer the flask and 
the capsule were heated alternately for one hour. The flask was cooled to -80 "С 
and atmospheric pressure was admitted cautiously. After renewed heating of 
the capsule the system was disconnected. Capsule and adapter were rinsed with 
0.8 ml of methanol. Also 200 μΐ of sodium methoxide 30 % were added 
to the reaction flask. It was connected with a high efficiency reflux condenser. 
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magnetic stirrers — 
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carbanion 
Figure A. 1 
Synthesis of З-^C-valproìc acid. Glassware assembly for the main reaction 
step. 
The condenser outlet was connected to a set of wash bottles containing a 
solution of potassium hydroxide in methanol. The reaction mixture was re-
fluxed for 15 minutes at 75 0C. After vigorous cooling 300 μ\ of propylbromide 
were added. The mixture was left at room temperature for one night. The 
reaction was completed by heating at 75 0C for 1 hour. To evaporate excess 
methanol the flask was placed in a desiccator with sulphuric acid for one night. 
Before completely opening the desiccator fresh air was sucked through via 
several active carbon filters. The first filter was continuously monitored by a 
Geiger-Müller probe. Approximately 40 μ€ί had passed or were retained in 
this filter. 
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The contents of the reaction flask were washed once with 5 N hydrochloric 
acid to remove excess of alkali, twice with 0.1 N hydrochloric acid to eliminate 
bromide and twice with 12 N sulphuric acid. The acid layer was removed each 
time. To hydrolyse the intermediate product the organic phase was refluxed 
with sulphuric acid of increasing strengths consecutively: 1 hour with 1 ml of 
12 N sulphuric acid at 120 0C,two times 1Й hours with 1 ml of 45 % sulphuric 
acid at 130 0C and seven times 1Й hours with 1 ml of 50 % sulphuric acid 
at 137 0C. After each hydrolysis step the acid fraction was renewed and 
small samples were taken from the organic phase. Samples were analysed by 
GLC on a 5 % FFAP column at 110-140 "С (for further conditions, see 
chapter 4). After the first hour of heating with 12 N sulphuric acid the 
organic phase consisted of 92 % dipropylmalonic acid dimethylester and 8 % of 
monopropylmalonic acid dimethylester (starting product). Heating at 130 0C 
caused a complete transformation of the monopropylester into valeric acid; 
only 5 % hydrolysis of the dipropylester had taken place. Affer three periods 
of heating with 50 % sulphuric acid, 65 % was transformed into valproic acid, 
after six treatments 93 % appeared to be converted. 
The end product was washed with water and dissolved in 2 ml of 1 N sodium 
hydroxide. With hydrochloric acid the pH was brought at 7.75. The solution 
was filtered through a Millipore -0.22 jum membranefìlter. GLC analysis 
showed that the product was 97 % pure and contained 3 % valeric acid. Thin 
layer chromatography was carried out as described in chapter 4. Scanning 
revealed two radioactive peaks: one with Rf0.64, corresponding to valproic 
acid, the other at Rf 0.31. The radioactivity of the latter spot appeared to be 
9 % of the total amount. This unknown substance was removed by extraction 
with chloroform at pH 4.0 (sodium phosphate - citric acid buffer). The 
chloroform phase was re-extracted with 0.1 N sodium hydroxide solution. 
The solution was adjusted to pH 7.6 with 0.1 N hydrochloric acid. The yield 
of the main fraction was 105 mg sodium valproate, specific activity 1.30 mCi/ 
mmole, in 11.5 ml. Chemical purity (GLC) was 98 % (2 % valeric acid), radio-
chemical purity (TLC) better than 99.5 %. By extraction of washing fluids and 
rinsing of glass apparatus a second fraction of almost 300 μ ο was regained. 
Comments 
Due to the micro-scale work relatively great losses at every step are inevitable. 
A total yield of 40 % of the theoretical amount is considered satisfactory. 
The same holds for the specific activity, which is 76 % of the expected value. 
The radiochemical impurity, accounting for 9 % of the total radioactivity, 
275 
but less than 1 % of the chemical composition, could be removed by simple 
extraction. This compound had not been observed in the end products of 
syntheses with smaller amounts of labeled propylbromide. Its identity has 
not been clarified. In view of the high specific activity its formation may be 
due to an impurity of the C-propylbromide, formed during storage, although 
the substance was kept at -20 0C. The avoidance of distillation steps prevented 
much loss of radioactivity. However, concentrated sulphuric acid appeared 
not to be a suitable drying agent as very volatile compounds appeared to have 
been formed when the intermediate product was kept overnight in a desiccator 
loaded with this agent. Reactions at the surface of the sulphuric acid are 
thought responsible for this finding. 
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Appendix 2 
Synthesis of possible valproic acid metabolites 
Introduction 
As has been pointed out in chapter 4, several metaboUtes of valproic acid have 
a common molecular weight of 142. In order to prove the identity of these 
compounds several reference substances were synthetised. Mono-unsaturated 
derivatives of valproic acid and lactones of mono-hydroxy derivatives might 
be identical to the unknown substances. The malonic ester synthesis and the 
Reformatski reaction were used as synthetic pathways. 
Materials and methods 
Chemicals 
npropyl-malonic acid dimethylester, containing 15% dipropyl-malonic acid 
dimethylester, and sodium methoxide 30% in methanol were kindly 
supplied by Chemische Industrie Katwijk, Katwijk, the Netherlands. 
n-propyl-malonic acid diethylester was obtained from Pfalz and Bauer, 
Stanford, Conn., USA. 
sodium ethoxideand allylbromide were obtained from Aldrich-Europe,Beerse, 
Belgium. 
All other reagents were analytical grade and were obtained from Merck, Darm-
stadt, Germany. 
2-A llyl-valeric acid 
4.9 g of n-propyl-malonic acid diethylester and 10 ml of sodium ethoxide 
20% w/v in ethanol were refluxed for 15 minutes. After cooling, 3.6 g 
of allylbromide was added and refluxing was continued for 2.5 hours. Frac-
tional distillation at 15 mm Hg yielded a main fraction at 77-78 0C. GLC 
analysis showed a single peak. The fluid decolourised bromine water. The 
organic fluid was washed with 10 ml of 25% hydrochloric acid and three times 
with 0.1 N acid. Subsequently it was refluxed with 10 ml of 12 N sulphuric acid 
for 1 hour, after replacement of the acid by 40% sulphuric acid again 
refluxed for 1 hour and finally 5 hours with 45% sulphuric acid. GLC 
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analysis revealed that over 90% of the intermediate product had been 
hydrolysed. The product was dissolved in chloroform and filtered. The 
organic solution was extracted with 40 ml of 0.25 N sodium hydroxide in 5 
steps. The combined alkaline phases were acidified and extracted with chloro­
form. After renewed back and forth extraction the solvent was evaporated. 
Mass spectrometry revealed that the substance had a molecular weight (M.W.) 
of 142. It did not bind bromine. 
δ-Valprolactone 
Part of this synthesis, which is almost identical to the previous one, was carried 
out by Chemische Industrie Katwijk. n-Propyl-malonic acid dimethylester 
was refluxed with sodium methoxide in methanol. 3-Bromo-propanol-l was 
added gradually. The reaction was completed by further refluxing. After puri­
fication by water/ether extraction the organic fluid was distilled. Fractions up 
to 103 0C at 16 mmHg did not contain the wanted intermediate product. The 
residue was hydrolysed with 15% hydrochloric acid. On distillation a 
fraction was obtained between 140 and 188 0C at 14 mm Hg, which appeared 
to contain a substance of molecular weight 142 (GC/MS). This fraction and 
the distillation residue had the appearance of a heavy syrup. Hydrolysis by 
strong acid or alkali and subsequent chloroform extraction of both fractions 
yielded solutions containing valeric acid and the end product. 
y- Valprolactorte 
This substance was synthetised according to the procedure of Blaise and 
Bagard (1907). All steps were controlled by GC/MS. 40 g of granulated zinc 
and 100 g of dry benzene were placed in a 500 ml round-bottomed flask, pro­
vided with a reflux condenser and a dropping funnel. In the latter a mixture 
of 110 g of 2-bromo-valeric acid ethylester and 35 g of propanol was brought. 
One third of this mixture was brought at once into the reaction flask. The 
reaction was started by gentle heating and maintained by cooling and gradual 
addition of reagents. After complete addition, the mixture was refluxed for 
30 minutes. Under cooling 100 ml of water and 100 ml of 4 N sulphuric acid 
were added gradually. The organic layer was washed with 100 ml of 4 N 
sulphuric acid, 50 ml of 25% ammonia solution and 50 ml of 1 N sulphuric 
acid in tum. Distillation gave a main fraction of 60 g at 110-116 0C 
and 10 mmHg. GC/MS showed two adjacent peaks with molecular weight 188 
(stereoisomers). 50 g of this product was placed in a dropping funnel and was 
added to a mixture of 20 g of phosphorus pentoxide and 85 ml of dry benzene 
over 1 hour. The mixture was refluxed during 2 hours. The black crust that 
had been formed was dissolved in 100 ml of water as far as possible and this 
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solution was extracted with 50 ml of benzene. The combined benzene fractions 
were concentrated and distilled. A first fraction of 17 g distilled at 85-95 0C 
and 14 mm Hg. GC/MS showed a double peak with a molecular weight of 170. 
The second fraction up to 115 0C at 14 mmHg largely consisted of a substance 
with molecular weight 142. The first fraction was refluxed with 100ml of 1 N 
sodium hydroxide solution for 40 hours. The alkaline solution was acidified 
cautiously with 30 ml of 4 N hydrochloric acid and was extracted with 50 ml 
of chloroform in three fractions. Distillation of the organic phase gave a main 
fraction between 95 and 105 0C at 10 mm Hg. This substance was identical to 
the second fraction of the previous distillation. The combined yield was 20 g. 
For further purification 10 g was dissolved in 1 N sodium hydroxide solution. 
The clear solution was extracted with chloroform. After evaporation of the 
organic solvent the first synthesis product was obtained: 6 g of 2-propyl-3-
pentenoic acid. The remaining part of the intermediate product was refluxed 
with 50% sulphuric acid during 5 hours. Another substance with molecular 
weight 142 but a shorter GLC retention time was formed. After 5 hours 
80% had been converted. The product was washed with 1 N sodium 
hydroxide solution. The yield was 5 g. 
Results 
2-Allyl-valeric acid 
The first attempt, meant to synthétise 2-allyl-valeric acid, which substance 
differs from valproic acid by a terminal double bond, did not yield the intended 
substance, but the product appeared to be identical to metabolite I (fig. 4.3). 
According to the malonic ester synthesis, allyl-propyl-malonic acid diethylester 
had been obtained from allylbromide and propylmalonic acid diethylester. 
This could be confirmed by GC/MS. Hydrolysis and consecutive decarboxyl-
ation of the intermediate product could be accomplished only by heating with 
40% sulphuric acid at about 130 0C. The product obtained showed a 
molecular weight of 142 but appeared to lack a double bond as it did not react 
with bromine. Under the conditions for hydrolysis, the desired product had 
formed a lactone directly by internal addition. In view of the stability of the 
intermediate carbonium ¡on, it is probable that γ-valprolactone has been ob­
tained (see reaction equation on page 280). However, the formation of the 
δ-lactone cannot be ruled out. 
b-Valprolactone 
The synthesis of the δ-valprolactone was carried out in an analogous manner. 
Treatment of the intermediate product, (3-OH-propyl)-propyl-malonic acid 
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dimethylester, with 50 % sulphuric acid led to a substance with the desired 
molecular weight and a GLC retention time equal to metabolite II (fig. 4.3). Its 
mass spectrum is given in fig. A.2. Fractions of the synthesis product were very 
viscous and did not show the expected peak on GLC chromatograms unless 
they were heated with strong alkali or acid. Probably, polymerisation of the 
hydroxy acid has taken place. For that reason attempts to obtain the pure end 
product were abandoned and the obtained solution was used as such. Valeric 
acid was obtained as a byproduct from hydrolysis of the starting product. 
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mass spectrum of δ-valprolactone 
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Figure Α.2 
Mass spectrum of the synthetised b-valprolactone, obtained by electron ion­
isation at 70 e V and 110°C (cf. fig. 4.6). 
y-Valprolactone and 2-propyl-3-pentenoic acid 
7-Valprolactone was obtained by synthesis in four steps, following the pro­
cedure of Blaise and Bagard (1907). After addition of 2-bromo-valeric acid 
ethylester to propanal in the presence of zinc according to the Reformatsky 
reaction and subsequent gentle hydrolysis the ethylester of2-OH-valproic acid 
was obtained. This substance was dehydrated bymeans of phosphorus pentoxide 
to form the ethylester of 0,7-unsaturated valproic acid. This ester was hydro-
lysed with diluted alkali. Partial hydrolysis was already achieved in the previous 
step. The unsaturated valproic acid, 2-propyl-3-pentenoic acid, which was ob­
tained in this way, has a molecular weight of 142 and has a GLC retention time 
very close to metabolite III (fig. 4.3). Heating of this substance with 50 % 
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sulphuric acid resulted in another compound with the same molecular weight, 
but with a retention time equal to metabolite I. The latter compound appeared 
to be identical to the product of the first synthesis, and consequently repre­
sents the γ-valprolactone. 
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2-propyl-3-peiitenoate M W. 142 y-valproJactone M.W. 142 
According to Blaise and Bagard ( 1 9 0 7 ) dehydration of 3-OH valproic acid 
ethyl ester gives only the β,γ-unsaturated compound and not the α,/3-isomer. 
This corresponds to our results, as only the ^^-unsaturated valproic acid will 
give the γ-lactone. α,/З- and ^^-unsaturated fatty acids tend to interconvert 
by migration of the double bond, but in the case of α-substituted carboxylic 
acids this appears to be less probable. 
To distinguish both potential metabolites obtained by the latter synthesis, 
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Figure А.З 
Mass spectra of the synthesis products y-välprolactone and 2-propyl-3-pente-
noic acid. Spectra are obtained by chemical ionisation with methane as reac-
tant gas at low ion source temperature, and by electron ionisation. For expla-
nation see text {cf. fig. 6.4). 
mass spectra of these compounds have been made under several conditions. 
Spectra obtained with chemical ionisation using methane as reactant gas at 
low ion source temperature are shown in figure A.3A. As could be expected 
the unsaturated compound with its free carboxyl group is decarboxylated more 
easily (M.W. — 45 ->• m7e 97) while the lactone shows a greater tendency to 
formdimers (2 χ M.W. + 1 -*• m+/e 285). Electron ionisation spectra are shown 
in fig. A.3B. While dealkylation predominates in the case of the lactone 
(— methyl -» m+/e = 126, — propyl -* m7e = 100) loss of carboxyl again is 
found in most mass fragments of the free acid (— carboxyl -* m7e = 97, 
— (carboxyl + propyl) ->• m7e = 55). 
Almost all intermediate synthesis products yielded double GLC peaks. Mass 
spectra of both fractions were almost identical. This may indicate that racemic 
mixtures of stereoisomers have been made. Under the chosen analysis condi­
tions, only single peaks were obtained from the end products 2-propyl-3-pen-
tenoic acid and γ-valprolactone. 
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Summary 
This thesis describes studies on the pharmacokinetics and pharmacodynamics 
of antiepileptic drugs, mainly based on clinical problems. Conversily, the ap-
plication of the gathered knowledge in clinical practice is also investigated. 
This thesis is divided into three main parts: 
— The first part gives some relevant characteristics of the disease and of the 
drugs, used in its treatment. 
— The second part describes studies on some special pharmacokinetic topics, 
concerning valproic acid and phenytoin. 
— The third part is mainly dedicated to a clinical study, set up in order to ap-
ply the gathered knowledge and to judge the effectiveness of this approach. 
Part one: Introduction 
After a historical introduction chapter 1 mainly deals with classification of 
the epilepsies. Several classification systems are compared. The significance of 
the classification for the choice of therapy and the estimation of prognosis is 
discussed. Only 18 types of epilepsy will have to be distinguished for these 
purposes. Literature review of the recommendations on first choice treatment 
of the various types of epilepsy reveals that nearly all epilepsies can be treated 
with a limited number of antiepileptic drugs: carbamazepine, phenytoin and 
valproic acid. 
Chapter 2 reviews some characteristics of the antiepileptic drugs. There ap-
pears to be some relation between the activities of the drugs in several experi-
mental models of epilepsy and the efficacy in certain types of human epilepsy. 
Valproic acid and carbamazepine appear to fit well in the scheme, designed 
before these drugs became available. A number of possible mechanisms of ac-
tion of the antiepileptic drugs are indicated. One or a limited number of pri-
mary sites of action may be compatible with the various observations and hy-
potheses. A comprehensive synthesis could not be found yet. In addition to 
the chromatographic methods such as GLC and HPLC, widely used for the 
routine analysis of antiepileptic drug plasma concentrations, an immunological 
technique becomes increasingly popular. Some advantages and disadvantages 
of the EMIT®-assay are briefly discussed. 
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Of the most important antiepileptic drugs data on relevant characteristics are 
reviewed, including pharmacokinetics, metabolism, routes of administration 
and bioavailability, and the relation between plasma concentration and thera-
peutic and side-effects. Appropriate drug dosage would not longer be a problem, 
when clearance values and effective plasma concentrations could be predicted 
in a reliable manner. Unfortunately the available data vary too widely for this 
purpose. On effective plasma concentrations of phénobarbital almost no well 
controlled data are available. In 80 per cent of the patients individual effective 
plasma concentrations of phenytoin between 5 and 25 mg/1 are to be expected. 
Non-linear kinetics further complicate the handling of this drug. For valproic 
acid no direct temporary relationship between plasma concentration and 
therapeutic effect could be found. On the other hand, in single-dose animal 
experiments a direct relation between log concentration and the pharma-
cological effect could be demonstrated. However, in animal experiments 
also carry-over effects have been noticed. The lack of direct relation may be 
explained in three different ways: 
1) the drug has an indirect action, via biochemical processes, 
2) the drug is active by itself, but it only slowly accumulates at the site of ac-
tion, 
3) a metabolite, which gradually accumulates, is responsible for the effect. 
For the first hypothesis no evidence is available. The latter two possibilities 
are investigated in part two. 
In view of the proposed mechanisms of action of valproic acid it is not 
clear whether it is necessary to avoid the large fluctuations of plasma 
concentration at the usual dosage regimens. Sustained release preparations 
of the drug, developed to ensure more stable plasma concentrations, are 
compared. 
Part two: Pharmacokinetics 
Chapter 3 describes the distribution of valproic acid, which is studied mainly 
by autoradiography. Whole body distribution is rapid. In monkeys the brain 
distribution pattern appears to change with increasing infusion time. The long-
term infusion experiments show that the pharmacokinetics follow a bi-expo-
nential function with a slow second phase. This phase may be related to the 
gradual development of brain distribution. Only after prolonged infusion, 
contrasts in several brain areas become perceptible. This accumulation is attrib-
uted to valproic acid itself. Still longer-lasting experiments are needed to vis-
ualise the ultimate steady state distribution pattern. Accumulation in the ol-
factory bulb is observed in mouse and monkey and appears to be specific for 
286 
valproic acid. It may be related to the marked role of GABA in this structure. 
In chapter 4 the metabolism of valproic acid is investigated. Screening of 
urine of patients and animals treated with this drug reveals three metabolites 
with a molecular weight of 142. They are considered to be identical to the 
following compounds, which were obtained by synthesis (appendix 2): γ-val-
prolactone, δ-valprolactone and 2-propyl-3-pentenoic acid. 7-Valprolactone is 
found in urine and plasma of several species; it is also found in monkey brain 
tissue. The unsaturated metabolite is found in human plasma in important 
concentrations. This substance appears to have a longer half-life than valproic 
acid itself. 
Comparison of the elimination of 3-"C valproic acid, obtained by synthesis 
(appendix 1), with its Г ^ С isomer in monkey, demonstrates that decarboxyl­
ation is one of the metabolic pathways of the drug. The remaining part is al­
most entirely excreted via urine. The three metabolites mentioned above only 
represent a small fraction of the urinary elimination. These metabolites are 
unlikely to contribute to the delayed therapeutic effect of valproic acid. A 
hypothetical metabolic scheme is presented. 
Chapter 5 gives some experimental data on interactions of valproic acid with 
other drugs. Influence of valproic acid on the kinetics of carbamazepine is not 
found. Salicylate treatment may drastically change valproic acid kinetics. At 
usual doses valproic acid and ethanol appear not to show serious interference 
of elimination. 
Influence of valproic acid on phénobarbital clearance in chronically treated 
patients appears to be rather consistent. Reduction of the phénobarbital dose 
by 30 per cent when valproic acid is added would be a sensible procedure. In 
children the effect may even be greater. 
Chapter 6 describes dissolution studies on phenytoin preparations. The tablet 
preparation of the sodium salt, commonly used in the Netherlands, is com-
pared to some alternative preparations, including tablets of microcrystalline 
phenytoin acid and capsules. Although dissolution in a pH 9 buffer is generally 
satisfactory, large differences are found after pretreatment with acid, even be-
tween preparations of .the same brand. It is desirable to control the bio-equiv-
alence of charges of the same preparation and different strengths of the same 
brand. Dissolution of the tested phenytoin calcium tablets is poor. Results of 
preliminary in vivo experiments correspond with in vitro dissolution tests, in-
cluding pretreatment with 0.1 N acid containing a surfactant. Tablets of the 
microcrystalline acid may be preferable to phenytoin salts, as their dissolution 
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pattern is less easily influenced. Large-scale comparison with this preparation 
in patients is recommended. Some attention is paid to a phenytoin derivative 
with good dissolution properties: phenytoin-3-(a-ammo)-valeric acid, which 
substance is marketed as antiepileptic drug. Elucidation of the metabolism of 
this compound is needed, before application on larger scale can be considered. 
Part three: Therapeutics 
Chapter 7 describes the accompaniment of the treatment of a group of insti-
tutionalised, mentally retarded epileptics by a multidisciplinary team and the 
results of this approach. During a pilot study including 37 'difficult' patients 
treatment and evaluation methods were developed. A second group of 98 
patients are being treated according to a strict protocol. Epileptic seizures, 
medication, antiepileptic drug plasma concentrations, behaviour and EEG are 
recorded. The approach turnes out to be effective: drug treatment has been 
markedly reduced and simplified. Moreover, many patients experienced a re-
duction of seizures. Due to the evaluation of each change of the treatment, 
the procedure takes much time. However, it gives the best chances for lasting 
optimal treatment in individual cases and at the same time much useful infor-
mation is obtained. Comparison with another team project emphasises the im-
portance of some key elements of the treatment design, such as a strict medi-
cation policy, regular contact with the attendants of the patient, a carefully 
updated central administration of all information and graphical recording of 
drug dosages, plasma concentrations and seizures. 
Chapter 8 gives the plasma concentrations of antiepileptic drugs, that ap-
peared to be effective in individual patients, included in the clinical study of 
the previous chapter. Values for some drugs correspond well to those reported 
in literature. Individual effective concentrations for phenytoin appear to vary 
widely. For valproic acid dosage may be entirely based on body weight. By 
combination of the results of this study with literature data, an attempt is 
undertaken to indicate a statistical probability of the effectiveness of a certain 
plasma concentration in an individual patient. Evaluation of the efficacy of 
an antiepileptic drug in individual patients and their types of epilepsy revéales 
a remarkable role of phénobarbital in some cases of partial epilepsy and the 
Lennox syndrome. 
During the clinical study described above, antiepileptic drug treatment was 
markedly reduced in many cases. Chapter 9 reviews the problems associated 
with drug withdrawal. As to difficulties, directly related to the withdrawal 
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period, the drug that is withdrawn appears to be of importance. In the case 
of discontinuation of phenytoin, ethosuximide and valproic acid problems 
were infrequent. However, withdrawal of phénobarbital or clonazepam was 
often accompanied by serious epileptic phenomena. Phénobarbital was with-
drawn in 60 cases. In only five the problems were exclusively limited to a few 
'classical' withdrawal seizures. Other problems were met in 23 patiens. 
Chapter 10 describes the application of pharmacokinetic data in individual 
cases. Some ways are indicated to reach a more accurate prediction of individ-
ual clearance values. The importance of more individual data on drug inter-
actions and non-linear kinetics is emphasised. Storage of individual plasma 
concentration data in a computerised database is suited both for individual 
monitoring and for statistical analysis. 
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Therapeutic implications 
In this thesis information has been accumulated, which supports the view 
that rational reduction and simplification of antiepileptic drug treatment 
leads to improvement of the treatment of epilepsy. Because the natural 
course of many types of epilepsy is not very propitious and prognosis in 
individual cases is difficult to estimate, treatment over prolonged periods 
is often necessary. Drug treatment is indicated as long as the medical and 
social consequences of the occurrence of seizures outweigh the side effects 
and risks of long-term use of antiepileptic drugs. 
The pathophysiological mechanisms of the epilepsies and the mechanisms 
of action of the antiepileptic drugs have not been elucidated yet. Therefore, 
choice of drugs is merely arbitrary. However, literature data based on large 
clinical experience indicate drugs of preference for various types of epilepsy. 
Essentially only eight types of epilepsy have to be distinguished for this 
purpose. The number of drugs of choice is even more limited: carbamazepine, 
Phenytoin and valproic acid. Thorough knowledge of the properties of these 
drugs appears to enable adequate treatment of most patients. In the remaining 
cases phénobarbital, ethosuximide, clonazepam or nitrazepam may lead to 
improved control of epilepsy. 
Single drug treatment should be pursued as far as possible. The combination 
of antiepileptic drugs in order to summate therapeutic effects without risk of 
side effects cannot be scientifically justified at the time being. An additional 
argument is that long-term polypharmacy appears to be difficult to reverse. 
However, under controlled conditions a reduction of antiepileptic drug 
treatment of many patients on long-term therapy can be achieved. Care 
should be taken of the possible occurrence of withdrawal phenomena; but 
even then the hurried restoration of the previous treatment is not necessary 
in most cases. Withdrawal problems are relatively frequent in the case of 
discontinuation of treatment with phénobarbital or clonazepam. This may 
argue against their use as drugs of first choice. Valproic acid is an antie-
pileptic drug with some specific properties. Due to the short half-life a steady 
state situation is reached rapidly after onset of treatment, but plasma 
concentrations show large fluctuations over the day. These fluctuations can 
be effectively reduced by the use of some preparations with sustained release. 
However, it is unclear whether this is necessary. Until now no direct temporary 
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relationship between plasma concentration and effect has been demonstrated. 
A gruadual accumulation of the drug at the site of action is the most plausible 
explanation at the time being. The therapeutic effect is often observed only 
after some weeks of treatment. The dose per kilogram body weight is 
considered a more reliable parameter for the amount of drug in the body 
and for the effect than a single plasma concentration. The strong influence 
of valproic acid on the kinetics of phénobarbital has to be anticipated by a 
reduction of the dose of the latter drug by 30 per cent when valproic acid 
is added. 
The appropriate dosing of phenytoin, which is already difficult because 
of the non-linear kinetics of the drug, appear to be complicated in addition 
by bioavailability problems. The rate and extent of dissolution of preparations 
of the sodium salt is variable, depending on several circumstances. The free 
acid in a microcrystalline form shows a more constant in vitro release. It is 
likely that this will result in a more constant bioavailability in vivo. The 
moment of intake of the drug in relation to meals and the composition of 
food appear to influence the extent of absorption. Therefore, intake at 
fixed times is strongly recommended. The phenytoin calcium preparation, 
which is available in the Netherlands, should not be used any longer because 
of poor bioavailability. 
Only little experimental work on carbamazepine has been performed within 
the scope of the reported investigations. The time-dependant kinetics appear 
to offer problems in the clinical application of the drug. Efforts to 
describe the increase of the clearance value, caused by enzyme induction, 
were not entirely sucessful until now. 
Treatment of epilepsy has to be based on a reliable registration of clinical 
seizures. A seizure calendar may significantly improve information from the 
patient or his attendants. Optimal treatment should be searched in a 
systematic way; therefore it is desirable to use a strict protocol concerning 
choice of drugs, dosages, evaluation techniques etc. Periods for evaluation 
of the effects of a change of treatment will have to be long enough. The 
actual period depends on the frequency and spreading of seizures, but in 
normal cases 6 weeks are thought to be a minimum. As the treatment of 
epilepsy is usually continued for long periods, it is worthwile, to have patience 
for such periods. 
Analysis of plasma concentrations of antiepileptic drugs can be helpful 
to solve specific problems. However, pharmacokinetic knowledge may reduce 
the necessity for these analyses and may significantly contribute to the 
improvement of treatment of epilepsy. Without comprehensive monitoring, 
plasma concentration analyses are of limited value. Individual effective 
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concentrations vary widely and a "therapeutic range" can only be indicated 
in terms of probability. For instance, the plasma concentration at which 
Phenytoin will be effective in 20 per cent of patients is estimated at 6 mg/1. 
The corresponding value for phénobarbital is 15 mg/1. Both values are well 
below the usually recommended levels. These concentrations may be used 
as initial goals for treatment. A uniform way of dosing is obtained when 
dosage calculations are based on these values and average clearance values, 
corrected for age and concomitantly administered drugs. To improve the 
statistical accuracy of effective concentrations and clearance values, data of 
many patients have to be pooled. This is easily done when the results of 
plasma concentration analyses are put into a computerised database system. 
Such a system can produce historical surveys of individual data for monitoring 
purposes, while, on the other hand, the whole number of stored data can be 
used for statistical analysis in order to improve the basic parameters. 
For individual patients graphical recording of some relevant parameters 
is considered very valuable. Survey of drag dosages, plasma concentrations 
and frequency of seizures, discriminated between different types, is suited 
for evaluation of treatment results, estimation of individual effective 
concentrations and detection of interactions. 
This study indicates that the treatment of epilepsy benefits from the co-oper-
ation of several disciplines in a well designed approach. A protocol for such a 
way of treatment is included. 
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Samenvatting 
De behandeling van epilepsie is de laatste jaren aanzienlijk verbeterd. Naast 
het beschikbaar komen van enkele nieuwe geneesmiddelen en een groeiende 
aandacht voor de psycho-sociale gevolgen van epilepsie en haar behandeling 
heeft vooral de toegenomen kennis van de farmacokinetiek van de anti-epilep-
tica hiertoe bijgedragen. Van deze kennis wordt evenwel nog niet tenvoUe ge-
profiteerd. In dit proefschrift is een studie gemaakt van de toepassing van de 
farmacokinetische en farmacodynamische kennis in de klinische praktijk. 
Daarnaast is getracht enige leemten in onze farmacokinetische kennis aan te 
vullen. De bestudeerde onderwerpen zijn voornamelijk geënt op klinische 
vraagstellingen. 
Dit proefschrift bestaat uit drie delen: 
- Het eerste deel beschrijft een aantal kenmerken van de epilepsieè'n en de 
anti-epileptica. 
- Het tweede deel omvat onderzoekingen aangaande enkele specifieke farma-
cokinetische vraagstukken met betrekking tot valproïnezuur en fenytoine. 
- Het derde deel is hoofdzakelijk gewijd aan een klinische studie, waarin de 
verzamelde kennis wordt toegepast en deze benadering vervolgens wordt ge-
ëvalueerd. 
Deel één: inleiding 
Hoofdstuk 1 begint met een historische inleiding. De rest van het hoofdstuk 
is voornamelijk gewijd aan de klassificatie van de diverse soorten epilepsie. 
Enkele klassiñcatiesystemen worden met elkaar vergeleken. Ruime aandacht 
wordt geschonken aan de betekenis van de klassificatie voor de keuze van de 
therapie, terwijl ook de consequenties voor de prognose worden toegelicht. 
Volgens de huidige stand van de wetenschap lijkt een indeling in meer dan 18 
typen epilepsie met betrekking tot de consequenties niet nodig. Voor de keu-
ze van de medicatie lijkt een indeling in 8 typen reeds voldoende. Een litera-
tuuroverzicht van de aanbevolen medicatie bij diverse typen epilepsie leidt tot 
de conclusie dat bijna alle epilepsievormen in eerste instantie behandeld kun-
nen worden met een zeer beperkt aantal geneesmiddelen: carbamazepine, fe-
nytoine en valproïnezuur. Aan deze drie middelen, en fenobarbital — nog 
steeds het meest gebruikte anti-epilepticum - , wordt in de rest van het proef-
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schrift extra aandacht besteed. 
Hoofdstuk 2 beschrijft een aantal eigenschappen van de anti-epileptica. Er 
blijkt enig verband te bestaan tussen de anticonvulsieve activiteit van de anti-
epileptica in verscheidene experimentele epilepsie-modellen en de werkzaam-
heid bij bepaalde vormen van epilepsie bij de mens. De voorspellende waarde 
is evenwel nog beperkt, zolang niet meer inzicht is verkregen in de pathofysio-
logie van epilepsie en de werkingsmechanismen van de anti-epileptica. Achter-
eenvolgens wordt een aantal eigenschappen van de belangrijkste anti-epileptica 
beschreven, waaronder de fanmacokinetiek, het metabolisme, toedieningswij-
zen, biologische beschikbaarheid en het verband tussen de plasmaconcentratie 
en het therapeutisch effect of de bijwerkingen. Effectieve plasmaconcentraties 
kunnen per patiënt sterk verschillen: voor fenytoïne bijvoorbeeld variëren de 
effectieve concentraties tussen 5 en 25 mg/l bij 80% van de patiënten. Een 
juiste toepassing van dit geneesmiddel wordt bovendien bemoeilijkt door de 
niet-lineaire farmacokinetiek. Voor valpro'mezuur kon geen direct verband 
tussen de plasmaconcentratie en het therapeutisch effect worden vastgesteld. 
Ondanks het snel bereiken van een farmacokinetisch evenwicht na de aanvang 
van de behandeling, wordt een therapeutisch effect vaak pas na enkele weken 
waargenomen. Voor dit verschijnsel worden drie mogelijke verklaringen ge-
noemd: 
1) Het geneesmiddel werkt indirect door ingrijpen in een biochemisch proces, 
waarvan de gevolgen pas op langere termijn optreden. 
2) Het geneesmiddel is zelf actief, maar het accumuleert slechts geleidelijk op 
de plaats van werking. 
3) Het effect wordt veroorzaakt door een metaboliet, die zich langzaam op-
hoopt. 
Er zijn nog geen aanwijzingen gevonden die de eerste hypothese ondersteu-
nen. De twee overige mogelijkheden worden onderzocht in deel twee van dit 
proefschrift. 
De sterke fluctuaties van de plasmaconcentratie, die optreden bij de gebrui-
kelijke doseringsschema's van valproïnezuur, kunnen aanzienlijk worden be-
perkt door gebruik te maken van preparaten met vertraagde afgifte. Het is 
evenwel de vraag of dit noodzakelijk is met het oog op de hierboven gesugge-
reerde werkingsmechanismen. 
Deel twee: farmacokinetiek 
Hoofdstuk 3 is gewijd aan de distributie van valproïnezuur. Zowel de verde-
ling over het gehele lichaam als de regionale hersenverdeling is zichtbaar ge-
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maakt door middel van autoradiografie. Het verdelingspatroon in de hersenen 
van apen bleek te veranderen naarmate het geneesmiddel langer werd geïnfun-
deerd. Tevens bleek het aanvankelijk gehanteerde open één-compartiments 
model niet langer bruikbaar te zijn. Toevoeging van een tweede, trage fase 
bleek nodig om het waargenomen verloop van de plasmaconcentratie te be-
schrijven. Wellicht loopt de geleidelijke ontwikkeling van de verdeling in de 
hersenen parallel aan deze fase. De plaatselijke stapeling in de kleine en grote 
hersenen wordt toegeschreven aan valproïnezuur zelf. Daarnaast werd zowel 
bij de muis als bij de aap een aanzienlijke ophoping in de bulbus olfactorius 
geconstateerd. Dit zou verband kunnen houden met de belangrijke functie van 
gamma-aminoboterzuur in dit gebied. 
Hoofdstuk 4 behandelt het metabolisme van valproïnezuur. Uit onderzoek 
van urine van patiënten en proefdieren bleek, dat er drie metabolieten van val-
proïnezuur voorkomen met een gemeenschappelijk molecuulgewicht van 142. 
Deze stoffen werden vergeleken met producten, verkregen via synthese (ap-
pendix 2). Een van deze stoffen, γ-valprolacton, werd zowel in urine als in 
bloed van diverse species aangetroffen, alsook in de hersenen van apen. Het 
laat optreden van het therapeutisch effect kan waarschijnlijk niet aan deze 
stof worden toegeschreven, gezien de snelle eliminatie. Een andere metaboliet, 
waarschijnlijk identiek aan β,γ-onverzadigd valproïnezuur, werd in aanzien-
lijke concentraties in plasma van patiënten aangetroffen. Deze stof blijkt een 
langere halfwaardetijd te hebben dan valproïnezuur zelf. 
Bij een aap werd de uitscheiding van de radioactiviteit gemeten na toedie-
ning van gemerkt valproïnezuur. Het geneesmiddel met ^ c in de carboxyl-
groep werd vergeleken met de verbinding met het radio-actieve atoom in de 
zijketen. Deze laatste stof werd voor dit doel gesynthetiseerd (appendix 1). 
Het verschil tussen de hoeveelheden uitgeademd radioactief koolzuur was aan-
zienlijk. Hiermee is decarboxylering als metabole weg bewezen. Nagenoeg alle 
resterende radio-activiteit werd in de urine teruggevonden. De drie hierboven 
beschreven metabolieten vormden slechts een kleine fractie van de totale uit-
scheiding. 
Hoofdstuk 5 besteedt aandacht aan interacties van valproïnezuur met andere 
geneesmiddelen. Valproïnezuur heeft een sterke invloed op de klaring van fe-
nobarbital. Bij chronisch behandelde patiënten blijkt de mate van interactie 
vrij constant te zijn. Het is daarom aan te bevelen de dosering van fenobarbital 
met 30% te reduceren, wanneer valproïnezuur aan de medicatie wordt toege-
voegd. Bij kinderen kan het effect nog groter zijn. In dierexperimenten kan 
geen invloed van valproïnezuur op de farmacokinetiek van carbamazepine 
worden vastgesteld; omgekeerd werd de halfwaardetijd van valproïnezuur on-
der invloed van carbamazepine aanzienlijk verkort. Salicylzuur heeft een ster-
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ke invloed op de kinetiek van valproïnezuur, voornamelijk door verdringing 
van plasma-eiwitten. Bij een vrijwilliger kon geen wederzijdse beïnvloeding 
van de eliminatie van valproïnezuur en ethanol, in gebruikelijke concentraties, 
worden vastgesteld. 
Hoofdstuk 6 beschrijft dissolutie-experimenten met enkele fenytoïne-prepa-
raten. Hoewel de in Nederland algemeen gebruikte tabletten van het natrium-
zout in een buffer van pH 9 voldoende oplossen, werd de afgifte van het ge-
neesmiddel door voorbehandeling met zuur aanzienlijk belemmerd. Er werden 
verschillen gevonden tussen diverse sterktes van hetzelfde merk en zelfs tussen 
diverse charges van hetzelfde preparaat. Gekozen werd voor een dissolutietest 
mét voorbehandeling met 0.1 N zoutzuur gedurende 30 minuten. Aan het 
zuur werd polysorbaat toegevoegd teneinde de oppervlaktespanning van maag-
sap te benaderen. In deze test gaven tabletten met microkristallijn fenytoïne-
zuur goede resultaten. De dissolutie van tabletten met fenytoïnecalcium was 
slecht. 
Voorlopige experimenten in vivo leverden resultaten, die correspondeerden 
met de bovengenoemde dissolutie tests. De tabletten met het fenytoine-zuur 
verdienen wellicht de voorkeur. Een vergelijkende studie op grote schaal is 
hiertoe geïndiceerd. 
Tevens is enige aandacht geschonken aan een derivaat van fenytoïne met uit-
stekende dissolutie-eigenschappen, welke stof eveneens als anti-epilepticum 
verkrijgbaar is: fenytoine-3-a-amino-valeriaanzuur. Deze verbinding wordt 
niet tot fenytoïne gemetaboliseerd. Gebruik van dit middel op grotere schaal 
vereist opheldering van het metabolisme. 
Deel drie: (farmacotherapie 
Hoofdstuk 7 beschrijft een klinische studie, waarin de behandeling van een 
groep geestelijk gehandicapte epileptici, opgenomen in een zwakzinnigeninsti-
tuut, begeleid wordt door een multidisciplinair team: de artsen en enkele psy-
chologen van het instituut, een secretaresse en twee externe deskundigen, een 
neuroloog en een apotheker. Gedurende een verkennende studie werden 37 
probleemgevallen behandeld, waarbij een behandelingsstrategie en evaluatie-
methoden werden ontwikkeld. 
Vervolgens werd een tweede groep van 98 patiënten volgens een vast proto-
col behandeld. Diverse variabelen werden geregistreerd: epileptische aanval-
len, medicatie, plasmaconcentraties van anti-epileptica, gedrag en EEG. De be-
nadering bleek effectief. Een van de meest opvallende resultaten is een aan-
zienlijke reductie en vereenvoudiging van de medicatie. Bij veel patiënten ver-
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minderde het aantal aanvallen. De gevolgde procedure kost veel tijd in ver-
band met het evalueren van elke verandering in de behandeling of omstandig-
heden. Toch lijkt dit de aangewezen weg om een optimale instelling van de 
epilepsie te bereiken. Bovendien levert deze werkwijze een schat van nuttige 
informatie op. 
Vergelijking met de team-behandeling van een vergelijkbare groep patiënten 
volgens een afwijkend model, onderstreept het belang van enkele elementen 
uit de opzet van deze studie: een strict beleid ten aanzien van de keuze van 
medicatie en dosering, frequente bijeenkomsten van het behandelings-team, 
regelmatig contact met de begeleiders van de patiënt en een zorgvuldig bijge-
houden, centrale administratie van alle informatie per patiënt. Grafische weer-
gave van doseringen, plasmaconcentraties en aanvalsfrequenties bleek van on-
schatbare waarde voor de evaluatie van de individuele therapieën, het vaststel-
len van effectieve concentraties en het signaleren van interacties. 
Hoofdstuk 8 geeft een overzicht van de effectieve concentraties van enkele 
anti-epileptica in individuele patiënten uit de bovengenoemde studie. Voor 
een aantal geneesmiddelen corresponderen de gevonden waarden met de gege-
vens uit de literatuur. De individuele effectieve concentraties van fenytoïne 
blijken zeer sterk uiteen te lopen. Voor valproïnezuur wordt de voorkeur ge-
geven aan doseringen per kilogram lichaamsgewicht, aangezien deze minstens 
even goed overeenkwamen met het therapeutisch effect als de plasmaconcen-
traties. Met behulp van de verkregen waarden, in combinatie met literatuurge-
gevens, werd getracht de kansverdeling van effectieve concentraties in een gro-
te groep patiënten aan te duiden. 
Wanneer de effectief gebleken geneesmiddelen in verband werden gebracht 
met het type epilepsie van de betreffende patiënten, was de betekenis van 
fenobarbital bij een aantal patiënten met partiële epilepsieën en met het 
Lennox syndroom opmerkelijk. 
Hoofdstuk 9 beschrijft de problemen, die zich voordeden bij het verminde-
ren van de medicatie van de patiënten in de bovengenoemde studie. Met be-
trekking tot moeilijkheden in de onttrekkingsperiode bleek het geneesmiddel, 
dat werd onttrokken, van belang. Bij fenytoïne, ethosuximide en valproïne-
zuur deden zich weinig problemen voor. Het beëindigen van de behandeling 
met fenobarbital of clonazepam daarentegen ging herhaaldelijk gepaard met 
ernstige epileptische verschijnselen. Fenobarbital werd onttrokken bij 60 pa-
tiënten. In 32 gevallen verliep dit zonder enige complicatie. Wat de overige 28 
betreft: slechts bij 5 patiënten bleven de moeilijkheden beperkt tot enkele 
'klassieke' onttrekkingsinsulten. Gelijktijdige behandeling met andere anti-epi-
leptica lijkt dergelijke moeilijkheden niet te voorkomen. 
In hoofdstuk 10 wordt aangegeven hoe de beschikbare farmacokinetische 
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gegevens gebruikt kunnen worden voor de berekening van doseringen in indi-
viduele gevallen. Er wordt nadruk gelegd op de wenselijkheid meer individuele 
gegevens over geneesmiddelinteracties en de niet-lineaire kinetiek van feny-
toïne te verzamelen, teneinde individuele klaringen nauwkeuriger te kunnen 
voorspellen. Een aantal manieren om deze gegevens te verwerken wordt aan-
gegeven. Het opslaan van de resultaten van plasmaconcentratiebepalingen in 
een databank biedt diverse voordelen, zowel voor het begeleiden van indivi-
duele therapieën als voor statistische analyse van alle ingevoerde gegevens. 
Doordat plasmaconcentraties van anti-epileptica reeds geruime tijd worden 
bepaald, zijn voldoende basisgegevens beschikbaar voorde gevolgde werkwijze. 
Eenzelfde benadering is evenwel mogelijk voor vele chronische therapieën. 
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STELLINGEN 
1. Alvorens een therapie in te stellen, en in het bijzonder in het geval van 
een medicamenteuze therapie, dient men zich ervan te vergewissen of het 
beoogde effect wel meetbaar is. 
2. Bij de behandeling van epilepsie is een goede registratie van de klinische 
aanvallen en van de toediening van geneesmiddelen van meer belang dan 
het bepalen van plasmaconcentraties. 
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3. Een systematische aanpak van de behandeling van epilepsie in multidisci-
plinair verband verhoogt de kans op optimale resultaten en de snelheid 
waarmee deze worden bereikt. 
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